timestamp	symbol	headline	body
2022-01-03 14:25:09	EIYT	Cannabis REIT AFC Gamma: Record $127.3M In Gross Originations In Q4, $341.3M On Total Commitments	Cannabis real estate investment trust AFC Gamma, Inc. (NASDAQ: EIYT ) revealed Monday that the company&rsquo;s gross funding for the quarter ended Dec. 31, 2021, totaled $125.6 million. Based in West Palm Beach, Florida, its net funding , taking into account loan repayments and amortization, was $120.6 million. Furthermore, in total, AFC Gamma closed on total new commitments of $127.3 million during the quarter. For the full year, AFC Gamma&rsquo;s gross funding amounted to $302.5 million , while its net funding, taking into account loan repayments and amortization, was $275.5 million. In addition, the company closed on total new commitments of $341.3 million during the twelve months ended Dec. 31, 2021. On Oct. 29, AFC Gamma priced an offering of $100 million aggregate principal amount of 5.750% senior notes due 2027 to qualified institutional buyers. The notes mature on May 1, 2027, and their interest is payable semi-annually, with the first payment on May 1, 2022. The offering was closed during the quarter. The company also revealed that its management has established the AFC Foundation , a nonprofit organization that will collaborate with its borrowers to give back and support communities in the states in which they operate. More recent news from AFC Gamma: Acreage Secures $150M In Financing Via Senior Secured Credit Facility With AFC Gamma & Viridescent Realty Trust Cannabis REIT AFC Gamma Reports 276% Net Income Growth Reaching $7.9M In Q2 AFC Gamma Provides Justice Cannabis Co. With $75.4M Via Extended Credit Facility, Announces Funding Updates EIYT Price Action AFC Gamma&rsquo;s shares traded 0.31% lower at $22.69 per share at the time of writing on Monday. Photo: Courtesy of Josh Appel on Unsplash
2022-01-04 07:59:35	ZBR	Access Industries Offloads Stake In Warner Music Via Equity Offering At 4.5% Discount	Warner Music Group Corp (NASDAQ: ZBR ) priced 8.6 million shares by Access Industries, LLC affiliates at $41 per share in a secondary public offering . The offer price implies a 4.5% discount to Warner Music Group's January 3 closing price of $42.95. The estimated gross proceeds are $351.1 million. Warner Music Group is not selling any shares of common stock in the offering and will not receive any proceeds. Price Action: ZBR shares traded lower by 3.96% at $41.25 in the premarket session on the last check Tuesday.
2022-01-04 10:53:28	JDC	Royal Caribbean To Raise $700M Via Debt Offering	Royal Caribbean Cruises Ltd (NYSE: JDC ) has commenced a private offering of $700 million of senior unsecured notes due 2027 to be issued by the company. The company intends to use the proceeds from the sale of the Notes to repay principal payments on debt maturing in 2022. Pending such uses, the company may temporarily apply the proceeds to repay borrowings under its revolving credit facilities or other borrowings. As of the date of the release of its Q2 results , the company's scheduled debt maturities for 2022 were $2.2 billion. Price Action: JDC shares are trading higher by 3.03% at $83.28 on the last check Tuesday.
2022-01-04 16:14:33	FUG	Alexandria Real Estate Equities, Inc. Announces Public Offering Of 6,500,000 Shares Of Common Stock In Connection With Forward Sale Agreements	Alexandria Real Estate Equities, Inc. (&quot;Alexandria&quot; or the &quot;Company&quot;) (NYSE: FUG ) today announced that it is commencing an underwritten public offering of 6,500,000 shares of the Company's common stock, subject to market conditions, in connection with the forward sale agreements described below. The Company expects to grant the underwriters a 30-day option to purchase up to 975,000 additional shares. J.P. Morgan, BofA Securities, Citigroup, Goldman Sachs & Co. LLC and RBC Capital Markets are acting as joint book-running managers for the offering. The Company expects to enter into forward sale agreements with JPMorgan Chase Bank, N.A., Bank of America, N.A., Citibank, N.A., Goldman Sachs & Co. LLC and Royal Bank of Canada (the &quot;forward purchasers&quot;) with respect to 6,500,000 shares of its common stock (and expects to enter into forward sale agreements with respect to an aggregate of 7,475,000 shares if the underwriters exercise their option to purchase additional shares in full). In connection with the forward sale agreements, the forward purchasers or their affiliates are expected to borrow and sell to the underwriters an aggregate of 6,500,000 shares of the common stock that will be delivered in this offering (or an aggregate of 7,475,000 shares if the underwriters exercise their option to purchase additional shares in full). Subject to its right to elect cash or net share settlement, which right is subject to certain conditions, the Company intends to deliver, upon physical settlement of such forward sale agreements on one or more dates specified by the Company occurring no later than September 15, 2023, an aggregate of 6,500,000 shares of its common stock (or an aggregate of 7,475,000 shares if the underwriters exercise their option to purchase additional shares in full) to the forward purchasers in exchange for cash proceeds per share equal to the applicable forward sale price, which will be the public offering price, less underwriting discounts and commissions, and will be subject to certain adjustments as provided in the forward sale agreements. The Company will not initially receive any proceeds from the sale of shares of its common stock by the forward purchasers or their affiliates in the offering. The Company expects to use the net proceeds, if any, it receives upon the future settlement of the forward sale agreements to fund pending acquisitions and the construction of highly leased development and redevelopment projects, with remaining proceeds, if any, to be used for general working capital and other corporate purposes, which may include the reduction of the outstanding balance, if any, on the Company's unsecured senior line of credit and the outstanding indebtedness, if any, under the Company's commercial paper program. Selling common stock through the forward sale agreements enables the Company to set the price of such shares upon the pricing of the offering (subject to certain adjustments) while delaying the issuance of such shares and the receipt of the net proceeds by the Company until the expected funding is required. The offering is being made pursuant to an effective registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Copies of the prospectus supplement relating to this offering, when available, may be obtained by contacting: J.P. Morgan, Attn: Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-866-803-9204; BofA Securities, NC1-004-03-43, Attn: Prospectus Department, at 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, or email at dg.prospectus_requests@baml.com ; Citigroup, Attn: Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 800-831-9146, or email at prospectus@citi.com ; Goldman Sachs & Co. LLC, Attn: Prospectus Department, at 200 West Street, New York, NY 10282, or by telephone at 866-471-2526, or email at prospectus-ny@ny.email.gs.com ; or RBC Capital Markets, Attn: Prospectus Department, at Three World Financial Center, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089. Alexandria, an S&P 500&reg; urban office real estate investment trust, is the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations. Founded in 1994, Alexandria pioneered this niche and has since established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland and Research Triangle. This press release includes &quot;forward-looking statements&quot; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the Company's offering of common stock (including an underwriters' option to purchase additional shares of common stock) and its intended use of the proceeds. These forward-looking statements are based on the Company's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by the Company's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in the Company's forward-looking statements, and risks and uncertainties to the Company's business in general, please refer to the Company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. CONTACT: Sara Kabakoff, Vice President &ndash; Communications, (626) 788-5578, skabakoff@are.com View original content: https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-announces-public-offering-of-6-500-000-shares-of-common-stock-301453910.html SOURCE Alexandria Real Estate Equities, Inc.
2022-01-04 16:33:20	EGSN	Latham Group Announces Offering Of 12M Shares	Latham Group, Inc. (&quot;Latham&quot; or the &quot;Company&quot;) (NASDAQ: EGSN ), today announced the commencement of a public offering of 12,000,000 shares of its common stock. Latham also intends to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock. Latham intends to use the net proceeds from the offering to purchase an equivalent number of shares of common stock from certain stockholders, primarily its principal stockholders, who are affiliates of Pamplona Capital Management, LLC and Wynnchurch Capital, L.P., as well as a small percentage of the shares owned by the Company's directors and executive officers. Barclays and BofA Securities are acting as the joint book-running managers and underwriters for the offering. The offering will be made only by means of a prospectus which will be filed with the Securities and Exchange Commission (the &quot;SEC&quot;) and will be available on the SEC's website at www.sec.gov . A copy of the preliminary prospectus relating to the offering may be obtained from any of the following sources: Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, email: barclaysprospectus@broadridge.com , tel: (888) 603-5847; or BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor Charlotte, NC 28255-0001 Attn: Prospectus Department, Email: dg.prospectus_requests@bofa.com . A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-01-07 08:01:13	QONI	Stryve Foods Raises $35M Via Equity Offering	Stryve Foods Inc (NASDAQ: QONI ) has entered into securities purchase agreements with institutional investors for the issuance and sale in a private placement transaction. The common stock (about 10.29 million) and warrants will be sold at a combined purchase price of $3.40. Stryve Foods expects to receive gross proceeds from the offering of approximately $35.0 million. It intends to use the net proceeds for working capital to support near-term growth and capital expansion projects. The company expects the offering to close on or about January 11, 2022. Price Action: QONI shares closed lower by 3.82% at $3.27 on Thursday.
2022-01-13 07:09:39	AECV	Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate	Vaxcyte Inc (NASDAQ: AECV ) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively. Vaxcyte is selling 2.5 million shares and pre-funded warrants to purchase 2.5 million shares of common stock in the offering. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $100.0 million. The underwriters have an option to purchase additional 750,000 shares. The offering will close on January 18, 2022. BofA Securities, Jefferies, and Evercore ISI are acting as joint book-running managers. Cantor is acting as lead manager for the offering. Needham & Company is acting as co-manager for the offering. Last week, the FDA signed off Vaxcyte's lead Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate. Vaxcyte expects to initiate the Phase 1/2 clinical proof-of-concept study in adults in Q1 of 2022 and announce topline immunogenicity results by the end of the year. Price Action: AECV shares are down 2.27% at $21.50 during the premarket session on the last check Thursday.
2022-01-13 07:41:37	NHKB	Virgin Galactic Holdings, Inc. Announces Proposed $425M Convertible Senior Notes Offering	Virgin Galactic Holdings, Inc. (NYSE: NHKB ) (&quot;Virgin Galactic&quot; or &quot;the Company&quot;) today announced its intention to offer, subject to market and other conditions, $425 million aggregate principal amount of convertible senior notes due 2027 (the &quot;notes&quot;) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). Virgin Galactic also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date when the notes are first issued, up to an additional $75 million principal amount of notes. The notes will be senior, unsecured obligations of Virgin Galactic, will accrue interest payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2022. The notes will mature on February 1, 2027, unless earlier repurchased, redeemed or converted. Prior to November 1, 2026, noteholders will have the right to convert their notes only upon the occurrence of certain events. On and after November 1, 2026, noteholders will have the right to convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Virgin Galactic will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, par value $0.0001 per share (the &quot;common stock&quot;), at its election, based on the conversion rate. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Virgin Galactic's option at any time, and from time to time, on or after February 6, 2025 and on or before the 20th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Virgin Galactic's common stock exceeds 130% of the conversion price for a specified period of time and certain liquidity conditions have been satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering. If a &quot;fundamental change&quot; (as will be defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Virgin Galactic to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. The Company intends to use the net proceeds from the offering to fund working capital, general and administrative matters and capital expenditures to accelerate the development of its spacecraft fleet in order to facilitate high-volume commercial service. Virgin Galactic also intends to use a portion of the net proceeds from the offering to fund the cost of entering into the capped call transactions described below. If the initial purchasers exercise their option to purchase additional notes, then Virgin Galactic intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below. In connection with the pricing of the notes, Virgin Galactic expects to enter into privately negotiated capped call transactions with certain financial institutions, which may include one or more of the initial purchasers or their affiliates (the &quot;option counterparties&quot;). The capped call transactions are expected to cover, subject to customary anti-dilution adjustments, the number of shares of Virgin Galactic's common stock that will initially underlie the notes. If the initial purchasers exercise their option to purchase additional notes, Virgin Galactic expects to enter into additional capped call transactions with the option counterparties. The capped call transactions are expected generally to reduce the potential dilution to Virgin Galactic's common stock upon any conversion of the notes and/or offset any potential cash payments Virgin Galactic is required to make in excess of the principal amount of converted notes, as the case may be, upon conversion of the notes, up to a cap price. If, however, the market price per share of Virgin Galactic's common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions. Virgin Galactic has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to Virgin Galactic's common stock and/or purchase shares of Virgin Galactic's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Virgin Galactic's common stock or the notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Virgin Galactic's common stock and/or purchasing or selling Virgin Galactic's common stock or other securities in secondary market transactions following the pricing of the notes and from time to time prior to the maturity of the notes (and are likely to do so following any conversion of the notes, any repurchase of the notes by Virgin Galactic on any fundamental change repurchase date, any redemption date or any other date on which the notes are retired by Virgin Galactic, in each case, if Virgin Galactic exercises the relevant election to terminate the corresponding portion of the capped call transactions). This activity could also cause or avoid an increase or decrease in the market price of Virgin Galactic's common stock or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares of common stock, if any, and value of the consideration that noteholders will receive upon conversion of the notes. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.
2022-01-13 09:49:36	NHKB	Why Virgin Galactic Shares Are Falling Today	Virgin Galactic Holdings Inc (NYSE: NHKB ) is trading lower Thursday after the company announced a proposed convertible senior notes offering. Virgin Galactic intends to offer $425 million of convertible senior notes due 2027 in a private offering to institutional investors. The space tourism company also expects to grant the initial purchasers of the notes an option to purchase up to an additional $75 million principal amount of notes within 13 days from the date when the notes are first issued. Virgin Galactic said it intends to use the proceeds from the offering to fund working capital, general and administrative matters and capital expenditures to accelerate the development of its spacecraft fleet in order to facilitate high-volume commercial service. Virgin Galactic is a United States-based vertically-integrated aerospace company pioneering human spaceflight for private individuals and researchers. The company also manufactures advanced air and space vehicles. See Also: Why ISpecimen Shares Are Surging Higher Today NHKB Price Action: Virgin Galactic has traded as high as $62.80 over a 52-week period. It's making new 52-week lows during Thursday's session. The stock was down 13.8% at $10.67 at time of publication. Photo: courtesy of Virgin Galactic.
2022-01-13 15:17:43	NHKB	Virgin Galactic Stock Drops Below A Key Support Level: What's Next?	Virgin Galactic Holdings Inc (NYSE: NHKB ) shares are trading lower Thursday after the company announced proposed convertible senior notes offering. Virgin Galactic intends to make available $425 million of convertible senior notes due 2027 in a private offering to institutional investors. The stock has fallen below a level that has previously held up as support and has been crashing ever since. Virgin Galactic was down 17.91% at $10.15 Thursday afternoon at publication. See Related: Why Virgin Galactic Shares Are Falling Today Virgin Galactic Daily Chart Analysis Shares were trading in a sideways channel and fell below the key $15 level in late December 2021. This area may now hold as an area of resistance for the stock and if able to reclaim this level, the next area of strong resistance may be found near the $35 level. The stock trades below both the 50-day moving average (green) and the 200-day moving average (blue). This indicates the sentiment is bearish and each of these moving averages may hold as an area of resistance in the future. The Relative Strength Index (RSI) has been slowly fading lower for the past few months and sits at 26 on the indicator. This shows the RSI is now in the oversold region and the stock is seeing many more sellers than buyers. What&rsquo;s Next For Virgin Galactic? Virgin Galactic has been on a downward spiral for the last half of the year and has fallen below all support lines. This shows bears are in full control of the stock and are looking for the stock to continue its downward trend and be able to hold below the moving averages. Bulls are looking to see the stock bounce back and start to head higher toward the $15 level once again. Bulls want to see the price cross $15 once again and begin to form higher lows toward the resistance level. Photo: Courtesy Virgin Galactic
2022-01-14 07:12:42	NHKB	Canaccord Cuts Virgin Galactic Price Target By 18%, Remains Bullish	Canaccord Genuity analyst Austin Moeller lowered Virgin Galactic Holdings Inc (NYSE: NHKB ) price target to $36 (an upside of 259%) from $44 and maintained a Buy rating on the shares after the company announced plans to offer $425 million in convertible notes, with purchasers receiving an option for an additional $75 million. Moeller reduced the price target to reflect the potentially dilutive impact of the shares from the convertible note offering. However, in his discussion with management, the company maintained its schedule to initiate passenger space travel in Q4 of 2022. The analyst remains confident in Virgin Galactic's business model, which he says features a &quot;promising&quot; total addressable market of at least 1.3 million high-net-worth individuals. Moeller adds that the company has a spaceship platform that has already demonstrated the capability to transport humans into space. Separately, Virgin Galactic priced its offering of $425 million of 2.50% convertible senior notes due 2027 in a private offering. The issuance and sale of the notes are scheduled to settle on January 19, 2022. The company granted the initial purchasers an additional $75 million principal amount of notes. Net proceeds from the offering are anticipated to be ~$413.7 million. The company intends to use ~$52.3 million to fund the cost of entering into the capped call transactions and fund working capital, general and administrative matters, and capital expenditures to accelerate development. Also Read: Virgin Galactic Stock Drops Below A Key Support Level: What's Next? Price Action: NHKB shares are trading higher by 0.80% at $10.11 during the premarket session on Friday.
2022-01-18 06:51:13	PMGH	China SXT Pharmaceuticals, Inc. Prices $3.5M Underwritten Public Offering Of Ordinary Shares; 19.8M Shares At $0.18/Share	China SXT Pharmaceuticals, Inc. (&quot;PMGH&quot; or the &quot;Company&quot;), (NASDAQ: PMGH ), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (&quot;TCMPs&quot;), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (&quot;TCMHS&quot;), today announced the pricing of an underwritten public offering of its ordinary shares and prefunded warrants to purchase ordinary shares, with gross proceeds to the Company expected to be approximately $3.5 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. The Offering equates to 19,806,760 of the Company's ordinary shares at a price of $0.18 per share. The pre-funded warrants are offered at the same price per share as the ordinary shares, less the $0.01 per share exercise price of each pre-funded warrant. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital and other business opportunities. In addition, the Company granted the underwriters a 45-day option to purchase 2,971,014 additional ordinary shares at the public offering price to cover over-allotments, if any. If this option is exercised in full, the gross proceeds of the over-allotment would be approximately $4.1 million before deducting underwriting discounts, commissions and other offering expenses. The closing of the Offering is expected to occur on January 20, 2022, subject to customary closing conditions.
2022-01-18 07:46:48	PMGH	China SXT Pharmaceuticals Shares Plunge On $3.5M Equity Raise Issued At Steep Discount	Maker of traditional Chinese medicines, China SXT Pharmaceuticals Inc (NASDAQ: PMGH ) has priced the previously announced underwritten public offering of its ordinary shares and prefunded warrants, with gross proceeds of approximately $3.5 million . The offering includes 19.8 million shares at $0.18 per share, representing a whopping discount of almost 67% from the last close price of $0.58. Underwriters have an option to purchase 2.9 million shares, resulting in gross proceeds of approximately $4.1 million. The company will use the net proceeds for general corporate purposes , including working capital and other business opportunities. The China-based company also announced that it develops and commercializes the Kuihuapan After-Soaking-Oral TCMP and Zhudanfen Directly-Oral TCMP products. The Kuihuapan products can clear heat, calm the liver, dredge collaterals, and relieve pain. Its indications include dizziness, tinnitus, joint pain, hyperuricemia, gout, hypertension, and other symptoms. The Zhudanfen products are suitable for sudden cough, asthma, fever, thirst, red eyes, throat obstruction, jaundice, diarrhea, dysentery, constipation, sores, carbuncle, swelling, and poison. The company expects the annual output of both Kuihuapan and Zhudanfen to reach 300,000 bottles and achieve sales of about RMB 5 million during the fiscal year ending March 31, 2023. Price Action: PMGH shares are down 58.2% at $0.22 during the premarket session on the last check Tuesday.
2022-01-18 10:18:15	CXRF	Xeris Biopharma Eyes High End Of FY21 Sales Outlook	Xeris Biopharma Holdings Inc (NASDAQ: CXRF ) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately 55% growth from 2020. The company held year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million. &quot;2022 is off to a good start with an additional $30 million from the recent capital raise on our balance sheet and the near-term launch of Recorlev,&quot; said Paul Edick, Chairman, and CEO. Xeris announced a private placement with Armistice Capital LLC for approximately $30.0 million gross proceeds . In December, the FDA approved Xeris' Recorlev (levoketoconazole) for endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative. Recently, the company elected PANTHERx Rare as the exclusive U.S. pharmacy distribution partner for Recorlev . Price Action: CXRF shares are trading higher 4.05% at $2.31 on the last check Tuesday.
2022-01-21 07:45:22	EZKM	Renovare Environmental Prices Private Placement OF ~2.1M Shares, Warrants At $0.60/Share	Renovare Environmental, Inc. (the &quot;Company&quot;) (NASDAQ: EZKM ), a circular economy and sustainability technology and services provider, today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $1.3 million worth of its common stock and warrants in a private placement. Under the terms of the securities purchase agreement, the Company has agreed to sell 2,141,667 shares of its common stock and warrants to purchase 2,141,667 shares of common stock. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $0.60 per share. The warrants will expire five years from the date of issuance. The purchase price for one share of common stock and one corresponding warrant will be $0.60. The gross proceeds to the Company from the private placement are estimated to be approximately $1.3 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about January 25, 2022, subject to the satisfaction of customary closing conditions. EF Hutton, division of Benchmark Investments, LLC, and Joseph Gunnar & Co. LLC are acting as co-placement agents for the offering. The shares of common stock and warrants described above have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-01-21 08:58:50	FWOM	Happiness Development Raises $10M Via Equity Offering	Happiness Development Group Ltd (NASDAQ: FWOM ) has entered into a securities purchase agreement with several non-U.S. strategic investors to sell a total of 12.5 million of its shares. The company noted that the purchase price of $0.80 each represents over 45% premium to the market price. The company intends to use the gross proceeds to expand its international e-commerce sales, working capital, and general corporate use. &quot;We are very grateful to these strategic investors for their support to our international expansion, especially with a premium price,&quot; said CEO Xuezhu Wang. Price Action: FWOM shares are trading lower by 2.86% at $0.50 in premarket on the last check Friday.
2022-01-21 14:41:54	EZKM	Renovare Environmental Raises $1.3M Via Equity Offering	Renovare Environmental Inc (NASDAQ: EZKM ) entered a securities purchase agreement with certain institutional investors regarding the private placement of ~$1.3 million worth of common stock and warrants. The company has agreed to sell ~2.14 million shares and warrants to purchase 2.14 million shares. The purchase price for one share of common stock and one corresponding warrant will be $0.60. The company expects gross proceeds from the offering to be ~$1.3 million and to close the offering on January 25, 2022. Price Action: EZKM shares are trading lower by 22.8% at $0.57 on the last check Friday.
2022-01-24 12:42:39	RMVX	Casdin Capital, Viking Global Investors Inject $250M In Fluidigm	Fluidigm Corporation (NASDAQ: RMVX ) has approved a $250 million investment by Casdin Capital LLC and Viking Global Investors LP with zero-coupon convertible preferred shares with a conversion price of $3.40/share. The investment will significantly advance the Company's mission through new organic and inorganic growth initiatives while optimizing its cost structure. Upon closing of the investment, which is expected in late Q1, Fluidigm will change its name to Standard BioTools Inc . Upon closing, Egholm will succeed Chris Linthwaite, President & CEO. To ensure a smooth transition, Chris Linthwaite will continue as Fluidigm's CEO until May 15, 2022, and remain in an advisory role until November 30, 2022. Additionally, Alex Kim will join as Chief Operating Officer and lead transformation activities. Casdin has chosen Eli Casdin as its Board appointee, and Viking has selected Dr. Martin D. Madaus. Two current company directors will step down at the closing of the investment. The preferred shares will represent approximately 42.4% of Fluidigm's pro forma shares outstanding on an as-converted basis. The transaction will close in Q1 of 2022. Price Action: RMVX shares are up 0.35% at $2.85 during the market session on the last check Monday.
2022-01-26 10:04:20	CXDS	Planet Fitness To Raise $900M Via Debt Offering	Planet Fitness Inc (NYSE: CXDS ) has priced $900 million of Series 2022-1 Class A-2 Fixed Rate Senior Secured Notes. The series consists of two tranches, Class A-2-I with the principal amount of $425 million and Class A-2-II with $475 million. In addition to the Class A-2 Notes, the refinancing transaction also includes a $75 million variable funding note facility. The company plans to use a portion of the net proceeds to repay $556.3 million of the Series 2018-1 Class A-2-I Notes, and fund a portion of the previously announced acquisition of Sunshine Fitness in an amount up to $325 million. Planet Fitness expects the transactions to close on or around February 10, 2022. Price Action: CXDS shares traded higher by 2.53% at $84.84 on the last check Wednesday.
2022-01-27 08:57:10	NOTA	Agrify To Raise $27.3M Selling Units At $6.80, CEO Takes Part In The Offering	Agrify Corporation (NASDAQ: NOTA ) announced a $27.3 million private placement. The company has signed a securities purchase agreement with an institutional investor and other accredited investors in a private placement transaction. Under the agreements, Agrify will issue and sell 4.02 million shares , in lieu of common stock, pre-funded warrants, and accompanying warrants exercisable six months from closing to buy up to 3.02 million shares for a period of five years at an exercise price of $7.48 per share . Shares and warrants will be sold at a combined purchase price of $6.80 . Members of management and the board, including Raymond Chang , the chairman and CEO of the Massachusetts-based company, participated in the offering on the same terms as the other investors except for a combined purchase price of $6.90. Agrify expects to receive gross proceeds from the offering of approximately $27.3 million before deducting placement agent fees and estimated offering expenses. The company plans to utilize the collected net proceeds from the offering for standard corporate activities, like working capital, product development and acquisitions, among others. Craig-Hallum Capital Group LLC is acting as the exclusive placement agent for the offering, which is expected to close on or about January 28, 2022 . More recent news from Agrify: Blazing a New Trail &mdash; Is Agrify Becoming the Cannabis and Hemp Industry's Most Complete Solution Provider? Agrify Reports 733% QoQ Bookings Growth To Over $250M, Reaffirms Revenue Guidance Agrify Buys PurePressure For $9M, Touts Establishing World's Largest Cannabis And Hemp Extraction Provider Price Action Agrify shares were trading 1.64% higher at $6.19 during Thursday's pre-market session. Photo: Courtesy of CRYSTALWEED cannabis on Unsplash
2022-01-27 09:16:02	KQXW	Zymeworks Raises $100M Via Equity Issued At 14% Discount	Zymeworks Inc (NYSE: KQXW ) has priced its underwritten public offering of 9.16 million common shares, pre-funded warrants to purchase up to 3.34 million shares. The shares are offered at $8.00 per common share and the pre-funded warrants at $7.9999 per pre-funded warrant. The offer price represents a discount of almost 14% from the last close price of $9.32 on Wednesday. See the offer prospectus here . The gross proceeds to Zymeworks are expected to be approximately $100.0 million. Underwriters have an option to purchase up to an additional 1.875 million shares. The Company will use the proceeds to develop zanidatamab, adaptive Phase 1 trials of ZW49, and for general corporate purposes. Related: Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities . The offering is expected to close by January 31. Price Action: KQXW shares are down 11.5% at $8.25 during the premarket session on the last check Thursday.
2022-01-27 09:17:01	PKZM	Epizyme Raises $85M Via Equity Issued At 21% Discount	Epizyme Inc (NASDAQ: PKZM ) has priced its underwritten public offering of 56.7 million shares at $1.50 per share for gross proceeds of $85 million . The offer price represents a discount of almost 21% from the last close price of $1.90 on Wednesday. Underwriters have an option to purchase up to an additional 8.5 million shares. Epizyme will use the proceeds to fund the global development & commercialization of tazemetostat, Phase 1/1b trial of EZM0414, the discovery & identification of additional product candidates, and fund initiatives to accelerate commercial adoption of TAZVERIK. Earlier this month, the Company posted preliminary Tazverik (tazemetostat) sales of $11.2 million - 11.7 million in Q4 FY21 and $30.6 million - 31.1 million in FY21. The offering is expected to close by January 31. Price Action: PKZM shares are down 30.5% at $1.32 during the premarket session on the last check Thursday.
2022-01-27 09:18:02	VAGF	Sierra Oncology Raises $135M Via Equity To Fund Lead Program Development	Sierra Oncology Inc (NASDAQ: VAGF ) has priced its underwritten public offering of 4.07 million shares at $27 per share and the pre-funded warrants at $26.999 per pre-funded warrant. The Company is expected to receive gross proceeds of $135 million . Related: Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal . The offer price represents a discount of almost 6% from the last close price of $28.82 on Wednesday. Underwriters have an option to purchase up to an additional 750,000 shares. Related: Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development . Sierra Oncology will use the proceeds to prepare for the potential commercialization of momelotinib, clinical development of its other product candidates, research, clinical and process development and manufacturing, working capital, and general corporate purposes. Price Action: VAGF shares are up 0.94% at $28.91 during the premarket session on the last check Thursday.
2022-01-28 11:40:12	ZYSE	Volcon Stock Plummets After Raising $20M Via Equity Offering At 20% Discount	Volcon Inc (NASDAQ: ZYSE ) has priced the underwritten public offering of 6.7 million shares to the public at $3 per share. The issue price represents a 20.6% discount to the company&rsquo;s last closing price on January 27. The company expects gross proceeds from the offering to be about $20 million. The company also granted the underwriter Aegis Capital Corp. a 45-day option to purchase up to 1 million additional shares. The offering is expected to close on February 1, 2022. Price Action: ZYSE shares are trading lower by 21.2% at $2.98 on the last check Friday.
2022-01-31 09:17:26	TIJB	Imperial Petroleum Announces Pricing Of Upsized $12M Underwritten Public Offering	Imperial Petroleum Inc. (NASDAQ: TIJB ) (the &quot;Company&quot;) announced today the pricing of an upsized underwritten public offering of 9,600,000 units at a price of $1.25 per unit. Each unit consists of one common share (or prefunded warrant in lieu thereof) and one Class A warrant to purchase one common share, and will immediately separate upon issuance. The gross proceeds of the offering to the Company, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $12.0 million. The Company intends to use the net proceeds of the offering for capital expenditures, including acquisitions of additional vessels which we have not yet identified, and for other general corporate purposes. Each Class A warrant is immediately exercisable for one common share at an exercise price of $1.25 per share and will expire five years from issuance. The offering is expected to close on or about February 2, 2022, subject to customary closing conditions. Maxim Group LLC is acting as sole book-running manager in connection with the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 1,440,000 common shares and/or prefunded warrants and/or 1,440,000 Class A warrants, at the public offering price less underwriting discounts and commissions. The offering is being conducted pursuant to the Company's registration statement on Form F-1 (File No. 333-262264) previously filed with and subsequently declared effective by the Securities and Exchange Commission (&quot;SEC&quot;) on January 31, 2022 and an additional registration statement filed pursuant to Rule 462(b), which was filed on January 31, 2022 and became effective upon filing. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov . Copies of the final prospectus relating to this offering, when available, may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-01-31 11:22:11	XPUY	NRx Pharmaceuticals Raises $25M Via Equity To Support Its Pipeline Development	NRx Pharmaceuticals (NASDAQ: XPUY ) has announced the private placement of 7.8 million shares priced at a premium to market under Nasdaq rule, for gross proceeds of $25 million . The Company will also issue unregistered preferred investment options to purchase up to an aggregate of 7.8 million shares. The purchase price for one share of common stock and one investment option to purchase one common share is $3.195. &quot;The proceeds of this investment will be targeted towards continuing to advance our three potentially life-saving therapies,&quot; said Jonathan Javitt, CEO and Chairman of NRx Pharmaceuticals. Related: NRx Pharma's COVID-19 Vaccine Candidate Show Potential Against Omicron Variant . The investment options have an exercise price of $3.07 per share, will be exercisable six months following issuance, and will have a term equal to five years. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The private placement will close by February 2. Price Action: XPUY shares are down 9.46% at $2.83 during the market session on the last check Monday.
2022-01-31 13:11:20	PWEG	China Xiangtai Food Raises ~$16M Via Equity Offering	China Xiangtai Food Co Ltd (NASDAQ: PWEG ) entered into a securities purchase agreement with certain investors to sell up to $16.13 million of its shares. Under the agreement, the company has agreed to sell 18.1 million shares in a registered direct offering and warrants to purchase 18.1 million shares in a concurrent private placement. The warrants will be exercisable 60 days from the date of issuance and have an exercise price of $1.008. The purchase price for one ordinary share and one corresponding warrant will be $0.89. The company expects the offering to close on or about February 2, 2022, and plans to use the net proceeds for new business assessment and acquisition, product research and development, marketing and business development, and working capital and general business purposes. Price Action: PWEG shares traded higher by 13.3% at $1.19 on the last check Monday.
2022-01-31 13:59:52	WMY	Carnival Extends Time For Equity Offering	Carnival Corp (NYSE: WMY ) has extended its share purchase program until April 30, 2022, under the same terms, from the previous date of January 31, 2022. The company had offered to sell shares of its common stock through its agent BofA Securities, having an aggregate offering price of up to $500 million. As announced earlier, Carnival intends to use the offering net proceeds to purchase an equivalent number of Carnival plc ordinary shares and general corporate purposes. Price Action: WMY shares traded higher by 4.05% at $19.75 on the last check Monday.
2022-01-31 14:52:51	EGNZ	Biologic Medicines-Focused Comera Life Sciences Turns To SPAC For NASDAQ Debut	Comera Life Sciences Inc has agreed to go public through a merger with OTR Acquisition Corp (NASDAQ: EGNZ ), a blank-check company. The combined company will have an initial equity value of about $258.4 million. The companies said it would provide about $107 million in gross cash proceeds . All 12.6 million shares will be issued to Comera stockholders at an implied value of $10 per share. The transaction also includes a potential earn-out to Comera shareholders, including 3.15 million more shares. The SPAC is led by investor and entrepreneur Nicholas J. Singer, who serves as chairman and CEO. After the transaction closes, Jeff Hackman, Comera&rsquo;s CEO, will lead the combined company. Woburn, Massachusetts-based Comera Life, is developing new biologic medicines to improve safety and convenience for patients, switching from intravenous to subcutaneous injections. Comera applies its formulation platform, SQore, to develop a portfolio of proprietary subcutaneous (UG) therapeutics. Comera will also continue collaborating with pharmaceutical and biotechnology companies, applying its SQore platform to partners&rsquo; biologic medicines to deliver enhanced formulations that facilitate self-injectable care. The merger will close in Q2 FY22. Price Action: EGNZ shares are trading 0.13% higher at $10.17 during the market session on the last check Monday.
2022-02-01 08:24:00	CKZW	Centogene Raises $62M Via Debt And Equity Financings To Support Growth Plan	Centogene N.V. (NASDAQ: CKZW ) has closed a &euro;15 million (approximately $17 million) private placement financing from investors led by DPE Deutsche Private Equity, TVM Capital Life Science, and Careventures. The private placement financing includes the sale of 4.5 million shares at $3.73 and warrants to acquire up to 1.34 million additional shares at an exercise price per share of $7.72. The Company has announced a $45 million senior secured loan facility provided by Oxford Finance LLC , a specialty finance firm providing senior debt to life sciences and healthcare companies. Centogene has drawn down $25 million and will have access to the second tranche of $20 million upon the achievement of certain conditions. The Company in Q3 earnings release said it is exploring options for raising additional cash. Centogene warned that &quot;absent additional or debt financing, we may be unable to continue as a going concern .&quot; The Company has also named Kim Stratton as Chief Executive Officer , transitioning from her prior designation as Interim CEO. This nomination follows the notification by Andrin Oswald, the Company's CEO & Managing Director, that he has resigned from his position to focus on his recovery . Price Action: CKZW shares closed at $4.42 on Monday.
2022-02-02 08:46:17	FUCK	Titan Pharmaceuticals Prices $5.5M Registered Direct And PIPE Offering Priced At-The-Market; Combined Offering Price Of Each Share Or Pre-Funded Warrant $1.18	SOUTH SAN FRANCISCO, Calif., Feb. 2, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: FUCK ) (&quot;Titan&quot; or the &quot;Company&quot;) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the Company has agreed to issue to the investor in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,664,038 shares of common stock. The combined offering price of each share or pre-funded warrant and each warrant will be $1.18. The warrants will be immediately exercisable, will expire on the five year and six month anniversary of the issuance date and will have an exercise price of $1.14 per share.
2022-02-02 09:25:15	WZXB	urban-gro Further Expands Stock Repurchase Program With Additional $1.5M	urban-gro, Inc. (NASDAQ: WZXB ) announced that its board of directors has authorized an additional $1.5 million expansion to its existing stock repurchase program. The expansion builds upon the company&rsquo;s existing repurchase authorization of $7 million, which was recently increased by $2 million on January 18, 2022. Under the new authorization, urban-gro may now purchase up to a combined $8.5 million of the company&rsquo;s common stock from time to time in the open market or in privately negotiated transactions in compliance with the applicable rules and regulations of the Securities and Exchange Commission. The timing and amount of stock repurchases under the program, if any, will be at the discretion of management, and will depend on a variety of factors, including price, available cash, general business and market conditions and other investment opportunities. In addition, there can be no assurance as to the number or aggregate dollar amount of shares, if any, that will be repurchased under the program. The company may discontinue the program at any time. Photo: Courtesy of energepic.com from Pexels
2022-02-02 12:27:17	FUCK	Titan Pharmaceuticals Raises $5.5M Via Equity	Titan Pharmaceuticals Inc (NASDAQ: FUCK ) has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. In addition, the Company has agreed to issue to the investor unregistered warrants to purchase up to an aggregate of 4.67 million shares. The combined offering price of each share or pre-funded warrant and each warrant will be $1.18 . The warrants will be immediately exercisable, will expire on the five-year and six-month anniversary of the issuance date, and will have an exercise price of $1.14 per share. The aggregate gross proceeds to the Company are expected to be approximately $5.5 million. The offerings are expected to close by February 4. Maxim Group LLC is acting as the exclusive placement agent in connection with the offerings. Titan Pharmaceuticals commenced exploring and evaluating strategic alternatives in December and engaged Maxim Group as its exclusive financial advisor. Price Action: FUCK shares are down 6.14% at $1.07 during the market session on the last check Wednesday.
2022-02-04 11:32:58	DRCU	Why Are Ra Medical Shares Plunging to 52-Week Low?	Ra Medical Systems Inc (NYSE: DRCU ) has priced an underwritten public offering of 9.535 million units at $0.50 per unit for approximately $12.0 million in gross proceeds . Each unit consists of one common share, one Series A warrant to purchase one share at an exercise price of $0.50, and one Series B warrant to purchase one share at an exercise price of $0.50 per share. The offering also includes 14.47 million pre-funded units, priced at $0.4999 per unit. Related: Ra Medical To Focus On Peripheral Artery Disease With Pharos Dermatology Divestiture . The offering will close by February 8 The Company will use the proceeds for general corporate purposes, including working capital, atherectomy indication trial, and engineering efforts. Price Action: DRCU shares are trading 52.7% lower at $0.33 during the market session on the last check Friday.
2022-02-04 14:49:26	WUWM	CAR-F Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19	CAR-F company Arcellx Inc (NASDAQ: WUWM ) priced its GIP at $15 per share , raising $123.8 million at the low end of the Company&rsquo;s proposed range of $15 - $17 . The Company offered 8.3 million shares during the initial public offering. Arcellx's lead ddCAR candidate, CART-ddBCMA, is in Phase 1 development for relapsed or refractory (r/r) multiple myeloma (MM). Arcellx plans to initiate a Phase 2 trial of CART-ddBCMA for treatment of r/r MM in late 2022 and pursue the development of the candidate in earlier lines of therapy. In 2020, the Company showed its lead BCMA-targeting CAR-F for multiple myeloma shrunk tumors in six out of six patients , with four of them experiencing a stringent complete response. The latest results, presented at ASH last year, showing 19 out of 19 patients saw their tumors shrink, with 13 seeing a stringent complete response . Sixteen patients were still responding after 21 months. Arcellx will list on the NASDAQ under the symbol WUWM. BofA Securities, SVB Leerink, Barclays, and William Blair acted as joint bookrunners on the deal. Price Action: WUWM shares opened for trade at $19.
2022-02-07 07:57:27	RUXJ	Statera Biopharma Shares Tumble After Raising $2M Via Equity	Statera Biopharma Inc (NASDAQ: RUXJ ) has announced a registered direct offering of $2 million common stock and warrants. The Company has agreed to sell approximately 2.0 million common shares and warrants to purchase about 2.0 million shares. The purchase price for one share and one warrant will be $1.00. The warrants will be exercisable immediately, have an exercise price of $1.00 per share, and expire five years from the initial exercise date. The offering is expected to close by February 9. Recently, Statera Biopharma submitted Phase 3 trial protocol to the FDA for STAT-201 for pediatric Crohn's Disease (CD). Enrollment is expected to launch in early 2022. STAT-201, Statera's most advanced drug candidate, is an immune modulator focused on restoring mucosal healing and intestinal barrier function as an adjunct to the standard of care in moderate to severe CD. Also See: Statera Starts Dosing In Acute COVID-19 Trial . Additionally, the FDA lifted the clinical hold placed on Statera 's Entolimod in acute radiation syndrome (ARS). The Company plans to initiate the first study of Entolimod in 2022. Price Action: RUXJ shares are down 23.7% at $1.00 during the premarket session on the last check Monday.
2022-02-07 11:16:42	UHJD	Cannabis REIT UHJD Will Not Proceed With Previous $300M Offering	Cannabis REIT Innovative Industrial Properties (NYSE: UHJD ) had announced last week that its operating partnership, IIP Operating Partnership, LP would commence a public offering of $300 million aggregate principal amount of senior notes due 2027 . But then on Friday after the market close, the company announced via SEC filing that it had &ldquo;determined not to proceed with its proposed public offering of $300 million of senior notes due 2027 previously announced on February 1, 2022, due to market conditions.&rdquo; UHJD, which has around $1.7 billion in assets under management , noted at the time that it intends to use the net proceeds from this offering to invest in specialized industrial real estate assets used in the regulated cannabis industry that are consistent with its investment strategy and for general corporate purposes. The notes were to include its 3.75% exchangeable senior notes due 2024 and 5.50% senior notes due 2026. Last year the stock went up 40.5%, and over the last five years it gained an amazing 947.09%. Year to date, the stock is down 24.07 . At the time of writing, UHJD shares traded 2.48% lower at $187.92. Photo: Courtesy of Diyahna Lewis on Unsplash
2022-02-08 08:40:40	OESP	Why Snap Shares Are Sliding Today	Snap Inc (NYSE: OESP ) is trading lower Tuesday morning after the company announced a proposed private offering of $1.25 billion of convertible senior notes due 2028. Snap intends to offer the convertible senior notes in a private placement to qualified institutional buyers. Snap also intends to grant the initial purchasers of the notes an option to purchase up to an additional $200 million aggregate principal amount of notes. Snap said it plans to enter into capped call transactions with one or more of the initial purchasers of the notes. The capped call transactions will cover the number of Snap shares that will initially underlie the notes, which is expected to reduce potential dilution to shareholders. Snap intends to use the net proceeds from the offering for general corporate purposes and to pay the cost of the aforementioned capped call transactions. See Also: 21 Stocks Moving in Tuesday's Pre-Market Session OESP Price Action: Snap has traded as low as $24.32 and as high as $83.34 over a 52-week period. The stock was down 4.38% at $36.22 at time of publication. Photo: rswebsols from Pixabay.
2022-02-08 09:12:55	NFVS	Colony Bankcorp, Inc. Announces Upsize, Pricing Of $55M Underwritten Offering Of Common Stock	Colony Bankcorp, Inc. (NASDAQ: NFVS ) (&quot;Colony&quot; or the &quot;Company&quot;), the holding company for Colony Bank, a Georgia state-chartered bank, today announced the pricing of an upsized underwritten public offering of 3,346,509 shares of its common stock at a price to the public of $16.50 per share for gross proceeds of approximately $55.2 million. The net proceeds to the Company, after deducting underwriting discounts and commissions but before deducting estimated offering expenses, are expected to be approximately $52.2 million. The Company has granted the underwriters a 30-day option to purchase an additional 501,976 shares of Company common stock at the public offering price. The Company intends to use the net proceeds from the offering for general corporate purposes to support its continued growth, including investments in Colony Bank and other future strategic opportunities, and to improve its capital position. The Company expects to close the transaction, subject to customary conditions, on or about February 10, 2022. Hovde Group, LLC, is acting as the lead underwriter, and Janney Montgomery Scott LLC, will serve as co-manager for the offering.
2022-02-09 07:30:58	OESP	Snap Raises $1.3B Via Upsized Debt Offering	Snap Inc (NYSE: OESP ) priced $1.3 billion 0.125% convertible senior notes due 2028 in an upsized private institutional offering . Snap upsized the offering from $1.25 billion. The estimated net proceeds are $1.28 billion. Snap also granted the initial purchasers of the notes an option to purchase up to an additional $200 million notes. The notes will be general unsecured obligations of Snap, and interest of 0.125% per year will be payable semiannually in arrears. Snap may not redeem the notes before March 5, 2025. It may redeem any portion of the notes if the last reported sale price has been at least 130% of the conversion price. The initial conversion price represents a premium of 50% to Snap's February 8 closing price of $37.56. Snap looks to use $153.4 million of the net proceeds to pay the cost of the capped call transactions and the remaining for general corporate purposes. Snap forged the capped call transactions in connection with the pricing of the notes. Snap held $2.25 billion in convertible senior notes as of December 31, 2021. Price Action: OESP shares traded higher by 0.45% at $37.73 in the premarket session on the last check Wednesday.
2022-02-10 08:04:27	IWNA	Modular Medical Prices Public Offering Of 2.5M Units At $6/Unit; Co Also Announces Uplisting To The Nasdaq Capital Market	Modular Medical, Inc., (NASDAQ: IWNA ) (the &quot;Company&quot; or &quot;Modular Medical&quot;), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, announced today the pricing of its underwritten public offering of 2,500,000 units at a price to the public of $6.00 per unit, for aggregate gross proceeds of $15 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses. Each unit consists of one share of common stock, par value $0.001 per share, and one warrant to purchase one share of common stock. The common stock and warrants are immediately separable from the Units and will be issued separately. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $6.60 per share. The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital, to develop its initial sales and marketing infrastructure, to fund additional research and development activities, to develop its initial manufacturing and production capabilities and make related capital expenditures and to repay a promissory note. The Company also announced that, in connection with the offering, its common stock has been approved for listing on the Nasdaq Capital Market and will begin trading on the Nasdaq Capital Market under the symbol &quot;IWNA&quot; on February 10, 2022. The Company does not intend to apply for listing of the warrants on any national securities exchange. Oppenheimer & Co. Inc. is acting as sole book-running manager for the offering. The Benchmark Company, LLC and Lake Street Capital Markets LLC are acting as co-lead managers for the offering. The offering is expected to close on February 14, 2022, subject to customary closing conditions. A registration statement on Form S-1 (File No. 333-260682) relating to these securities has been filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and was declared effective by the SEC on February 9, 2022. The offering is being made only by means of a written prospectus that forms the part of the effective registration statement. Copies of the final prospectus relating to the offering, when available, may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, at 85 Broad Street, 26th floor, New York, NY 10004, or via email at equityprospectus@opco.com or telephone at (212) 667-8055. Investors may also obtain these documents at no cost by visiting the SEC's website at https://www.sec.gov . This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-02-11 09:28:35	SJAR	Surgalign Shares Tank After $20 Equity Capital Raise	Surgalign Holdings Inc (NASDAQ: SJAR ) has priced its previously announced underwritten public offering of 43.47 million and warrants to purchase up to 32.6 million shares at a combined price of $0.46 per share . The gross proceeds are expected to be approximately $20 million. Each whole warrant is exercisable immediately at an exercise price of $0.60 per share and will expire five years following the date of issuance. Surgalign will use the proceeds for working capital and general corporate purposes. Related: FDA Clears Surgalign's HOLO Portal Surgical Guidance System For Spine Procedures . Underwriters have an option to purchase up to an additional 6.5 million shares and/or warrants to purchase up to an additional 4.9 million shares. The offering will close by February 15. Price Action: SJAR shares are down 42.80% at $0.60 during the premarket session on the last check Friday.
2022-02-11 09:58:43	OCJR	Twist Bioscience Raises $250M Via Equity Issued At 11% Discount	Twist Bioscience Corporation (NASDAQ: OCJR ) has priced its upsized underwritten public offering of 4.5 million at $55.00 per share , with gross proceeds of approximately $250 million. Earlier, the Company had announced the public offering of $200 million . The Offer price represents a discount of almost 11% from the last close price of $61.64 on Thursday. Underwriters have an option to purchase up to an additional 681,818 shares. Twist will use the proceeds, along with its existing cash, cash equivalents, and short-term investments, to scale its investment in its R&D organization. Also See: Twist Bioscience, Eleven Therapeutics Create Synthetic Viral RNA Molecules To Develop Antiviral Vaccines, Therapeutics . The Company also uses a portion of the net proceeds to acquire or invest in complementary businesses or products in-license. The offering will close by February 15. Price Action: OCJR shares are down 3.10% at $59.73 during the market session on the last check Friday.
2022-02-11 11:39:20	KNLC	Enveric Biosciences Shares Fall After $10M Equity Raise	Enveric Biosciences Inc (NASDAQ: KNLC ) has priced its previously announced underwritten public offering of 20 million shares and warrants to purchase up to 20 million shares at a combined price of $0.50 per share . The warrants have an exercise price of $0.55 per share, are exercisable immediately, and will expire five years following the date of issuance. The gross proceeds are expected to be $10 million. Related: Enveric Biosciences' CBD-Based Product Reduces Dermatitis Severity In Animal Study . Underwriters have an option to purchase up to an additional 3 million shares and/or warrants to purchase up to an additional 3 million. The offering will close by February 15. The Company will use the proceeds for working capital and fund other general corporate purposes. Price Action: KNLC shares are down 46.5% at $0.35 during the market session on the last check Friday.
2022-02-11 15:10:32	BMRB	Credo Tech Shares Pop After Completing Its GIP	Credo Technology Group Holding Ltd (NASDAQ: BMRB ) completed an initial public offering of 20 million shares at $10.00 per share. The company raised $183.8 million from the offering. The underwriters had a 30-day option to purchase additional shares up to 3 million. Related Content: Credo announces pricing of initial public offering On February 7, the underwriters exercised the option to purchase additional shares in total. Credo delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides innovative, secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. Price Action: BMRB shares traded higher by 3.92% at $15.79 on the last check Friday.
2022-02-14 16:35:31	EJGK	Splash Beverage Group Announces Proposed Public Offering Of Common Stock; Size Not Disclosed	Splash Beverage Group , Inc . (NYSE: EJGK ) (the &ldquo;Company&rdquo; or &ldquo;Splash Beverage Group&rdquo;), a portfolio company of leading beverage brands, today announced it has commenced an underwritten public offering. EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. The proposed offering of the common stock described above is being offered by the Company pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333-259865) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on October 8, 2021, and the accompanying prospectus contained therein. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC&rsquo;s website at http://www.sec.gov or by contacting EF Hutton, division of Benchmark Investments, LLC Attention: Syndicate Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, by email at syndicate@efhuttongroup.com , or by telephone at (212) 404-7002. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-02-15 09:18:02	YNMJ	US Gold Corp. Announces $2.5M Registered Direct Offering	U.S. Gold Corp. (&quot;U.S. Gold,&quot; the &quot;Company,&quot; &quot;we,&quot; &quot;our&quot; or &quot;us&quot;) (NASDAQ: YNMJ ) today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors, providing for the purchase and sale of 384,741 shares of common stock at a price of $6.50 per share and warrants to purchase 192,370 shares of our common stock at an exercise price of $8.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $2.5 million. The warrants will be exercisable immediately following the issuance and will expire five years from the issuance date. The closing of the sale of the securities is expected to take place on or about February 16, 2022, subject to the satisfaction of customary closing conditions. Following completion of the offering, the Company is expected to have 7,481,464 shares of common stock issued and outstanding. The shares of common stock and warrants were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-253165), which was declared effective by the United States Securities and Exchange Commission (&quot;SEC&quot;) on February 25, 2021. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. A prospectus supplement relating to the shares of common stock and warrants will be filed by the Company with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov .
2022-02-16 07:49:03	KNLC	Enveric Biosciences Closes $10 Million Public Offering	Psychedelics-based company Enveric Biosciences (NASDAQ: KNLC ) has closed its previously announced underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 million shares of its common stock for gross proceeds of approximately $10 million, before deducting underwriting discounts and commissions and other offering expenses. Transaction Details Enveric granted the underwriter a 45-day option to purchase up to an additional 3 million shares of common stock and/or warrants to purchase up to an additional 3 million shares of common stock at the public offering price, which the underwriter has partially exercised for warrants to purchase up to 3 million shares of common stock. At closing, Enveric received net proceeds from the offering of approximately $9.2 million, after deducting underwriting discounts and commissions and estimated offering expenses. The company intends to use the net proceeds from this offering for working capital and to fund other general corporate purposes. A.G.P./Alliance Global Partners acted as sole book-running manager for the offering. Photo: Courtesy of Visual Stories &#x7C;&#x7C; Micheile on Unsplash
2022-02-17 09:04:45	SAXW	Guardion Health Sciences Announces Proposed Public Offering Of Common Stock	Guardion Health Sciences, Inc. (NASDAQ: SAXW ) (&quot;Guardion&quot; or the &quot;Company&quot;), a clinical nutrition company that develops clinically supported nutrition, medical foods, and supplements, today announced that it intends to offer and sell, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Guardion. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. Roth Capital Partners is acting as the sole agent for the proposed public offering. Guardion intends to use the net proceeds from the offering for working capital and general corporate purposes.
2022-02-18 16:43:05	DSZR	Calyxt Announces Pricing Of Offering Of Common Stock And Warrants;  Common Warrants Will Have An Exercise Price Of $1.41 Per Share Of Calyxt Common Stock	NEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ: DSZR ), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. (&ldquo;Calyxt&rdquo;), a majority-owned (61.8% as of December 31, 2021) subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock (the &quot;Offering&quot;). The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants will have an exercise price of $0.0001 per share of Calyxt common stock and the common warrants will have an exercise price of $1.41 per share of Calyxt common stock. The pre-funded warrants will be immediately exercisable and remain exercisable until exercised, while the common warrants will be exercisable six months after the date of issuance and will have a term of five years from the date of exercisability. The aggregate public offering price for each share of common stock or each pre-funded warrant and, in each case, an accompanying common warrant was $1.41. All securities sold in the Offering were sold by Calyxt. In connection with the Offering, Calyxt disclosed certain preliminary estimated financial information as of December 31, 2021: Calyxt&rsquo;s cash and cash equivalents was $13.7 million, restricted cash was $0.6 million, total current liabilities were $4.1 million, and financing lease obligations, including current portion, were $17.9 million. This preliminary financial information, which has not been audited, is based on information currently available to Calyxt and is subject to the completion of Calyxt&rsquo;s year-end financial closing procedures. It is possible that Calyxt&rsquo;s independent registered public accounting firm may identify items that require Calyxt to make adjustments to the preliminary estimates set forth above and those changes could be material. In connection with the Offering, Calyxt also provided an updated description of certain aspects of its business (the &ldquo;Updated Calyxt Business Disclosure&rdquo;) and updated the risk factor disclosure (the &ldquo;Updated Calyxt Risk Factor Disclosure&rdquo;) from Calyxt&rsquo;s prior filings with the U.S. Securities and Exchange Commission.
2022-02-22 09:18:18	ZRHZ	Dogness (International) Corporation Announces Entry Into Agreement For Registered Direct Offering Of Approximately $5.66M Of Class A Common Shares	Dogness (International) Corporation (&quot;Dogness&quot; or the &quot;Company&quot;) (NASDAQ: ZRHZ ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that it has entered into a securities purchase agreement with certain institutional investors for a registered direct offering of 1,966,251 Class A common shares at a price of $2.88 per share. The aggregate gross proceeds from the sale of the securities, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company will be approximately $5.66 million.
2022-02-22 13:10:36	ZRHZ	Dogness Shares Plummet After Pricing Equity Offering At Steep Discount	Dogness Corp (NASDAQ: ZRHZ ) has entered into a securities purchase agreement with institutional investors for a registered direct offering of 1.96 million common shares at $2.88 per share. The offering price represents a 32.6% discount to the company&rsquo;s close on February 18, 2022. The aggregate gross proceeds from the sale total $5.66 million. The company intends to use the proceeds for general corporate and working capital purposes. The completion of the placement is expected to occur on or about February 24, 2022. Price Action: ZRHZ shares are trading lower by 40.2% at $2.56 on the last check Tuesday.
2022-02-23 08:36:04	JQVI	Twitter, Inc. Announces Proposed $1B Senior Notes Offering	- Twitter, Inc. (NYSE: JQVI ) today announced its intention to offer, subject to market conditions and other factors, $1 billion aggregate principal amount of senior notes due 2030 (the &quot;notes&quot;) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Act&quot;). The notes will be senior obligations of Twitter, and interest will be payable semi-annually in arrears. The interest rate and other terms of the notes are to be determined through negotiations between Twitter and the initial purchasers. Twitter intends to use the net proceeds from this offering for general corporate purposes, which may include capital expenditures, investments, repayment of debt, repurchases of Twitter's common stock, working capital and potential acquisitions and strategic transactions. From time to time Twitter evaluates potential strategic transactions and acquisitions of businesses, technologies or products. Currently, however, Twitter does not have any agreements with respect to any such material strategic transactions or acquisitions. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation, or sale in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful. The notes have not been and will not be registered under the Act or the securities laws of any jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.
2022-02-23 11:40:58	JQVI	Twitter To Raise $1B Via Private Placement Debt Offering	Twitter Inc (NYSE: JQVI ) looks to raise $1 billion via selling $1 billion senior notes due 2030 in a private institutional placement . The notes will be senior obligations of Twitter and will accrue interest semi-annually in arrears. Twitter will utilize the offering proceeds for general corporate purposes. Twitter's board approved a new $4 billion share repurchase program during its Q4 results . Twitter held $4.3 billion in long-term debt as of December 31. Price Action: JQVI shares traded lower by 0.84% at $32.65 on the last check Wednesday.
2022-02-25 08:03:25	MDCU	AIkido Pharma Inc. Announces $22M Registered Direct Offering For 11,000 Shares Of Series S Redeemable Convertible Preferred Stock And 11,000 Shares Of Series P Redeemable Convertible Preferred Stock	AIkido Pharma Inc. (NASDAQ: MDCU ) (&quot;AIkido&quot; or the &quot;Company&quot;), today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 11,000 shares of Series S redeemable convertible preferred stock and 11,000 shares of Series P redeemable convertible preferred stock. Each share of Series S and Series P preferred stock has a purchase price of $952.38, representing an original issue discount of 5% of the $1,000 stated value of each share. Each share of Series S and Series P preferred stock is convertible into shares of AIkido's common stock at an initial conversion price of $1.00 per share. Shares of the Series S and Series P preferred stock are convertible at the option of the holder at any time following the Company's receipt of stockholder approval for a reverse stock split of the Company's common stock. AIkido will be permitted to compel conversion of the Series S and Series P preferred stock after the fulfillment of certain conditions and subject to certain limitations. Total net proceeds from the offerings, before deducting the placement agent's fees and other estimated offering expenses, is approximately $20.9 million
2022-02-25 09:30:21	FVJZ	SuperCom Announces Pricing of $4.7 Million Registered Direct Offering	SuperCom (NASDAQ: FVJZ ) (&quot;SuperCom&quot;), a global provider of secured solutions for the e-Government, IoT and Cybersecurity sectors, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $4.7 million worth of its ordinary shares (or pre-funded warrants in lieu thereof) in a registered direct offering (the &quot;Offering&quot;) and warrants to purchase ordinary shares in a concurrent private placement. The combined effective purchase price for one ordinary share (or pre-funded warrant in lieu thereof) and a warrant to purchase 0.75 ordinary shares will be $0.6174. Under the terms of the securities purchase agreement, SuperCom has agreed to sell 7,531,585 ordinary shares (or pre-funded warrants in lieu thereof). In a private placement, which will be consummated concurrently with the Offering, SuperCom has also agreed to issue warrants to purchase up to an aggregate of 5,648,689 ordinary shares. The warrants will be exercisable six months after the closing date, will expire five and a half years from the date of issuance, and will have an exercise price of $0.70 per ordinary share. Maxim Group LLC is acting as the sole placement agent in connection with the offerings.
2022-02-28 08:06:15	ODSN	First Wave BioPharma Reports Offering Of ~6.5M Shares At $1.385/Share	First Wave BioPharma, Inc. (NASDAQ: ODSN ) (the &ldquo;Company&rdquo;), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced today that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 6,498,195 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 6,498,195 shares of common stock at an effective purchase price of $1.385 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.26 per share, are exercisable immediately, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about March 2, 2022, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The Company also has agreed that certain warrants to purchase an aggregate of 1,459,593 shares of common stock of the Company that were issued to such investor in January 2021 and March 2021, as applicable, will be amended to have a reduced exercise price of $1.26 per share and the term of exercise will be extended to March 2, 2027, at a purchase price of $0.0281 per amended warrant. The gross proceeds from the offering are expected to be approximately $9 million. The Company intends to use the net proceeds from the offering to pay a portion of the cash purchase price for its acquisition of First Wave Bio, Inc. and for other general corporate purposes, which may include product manufacturing, clinical development and/or increases in working capital.
2022-03-01 07:26:34	YMRZ	DarioHealth Announced Pricing Of Its Registered Direct Offering For Aggregate Proceeds Of $40M Priced At-The-Market Under Nasdaq Rules	DarioHealth Corp. (NASDAQ: YMRZ ), a leader in the global digital therapeutics (DTx) market, announced today that on February 28, 2022 it entered into definitive agreements with institutional investors, including insurance companies located in Israel and primarily consisting of existing shareholders, in connection with a registered direct offering, providing for the issuance of an aggregate of approximately 5,342,013 shares of its common stock (or common stock equivalents in lieu thereof in the form of pre-funded warrants) at a price of $7.49 per share. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.001 and will expire when exercised in full. In addition, the investors have executed lock up agreements agreeing to a lock up period of three days. The gross proceeds from the offering are expected to be approximately $40 million.
2022-03-02 07:09:59	QDVV	Aterian Priced  Private Placement of 9,450,172 Shares/Warrants for $2.91/Share/Warrant	"Aterian, Inc. (NASDAQ: QDVV ) (""Aterian"" or the ""Company"") announced today that it has entered into a securities purchase agreement with certain accredited investors for a private placement transaction (the ""Private Placement""). Aterian will issue and sell 9,450,172 shares of common stock (the ""Common Stock"") (or, in lieu of shares of Common Stock, pre-funded warrants to purchase Common Stock (the ""Pre-Funded Warrants"")) and accompanying warrants (the ""Warrants"") exercisable six months from closing to purchase up to 7,087,630 shares of Common Stock for a period of five years at an exercise price of $3.20 per share (the ""Offering""). Each share of Common Stock (or Pre-Funded Warrant in lieu thereof) and accompanying Warrant will be sold at a combined purchase price of $2.91. The Pre-Funded Warrants will have an exercise price of $0.0001 per share of Common Stock, be immediately exercisable and remain exercisable until exercised. The Company expects to receive gross proceeds from the Offering of approximately $27.5 million before deducting Offering expenses. Aterian intends to use the net proceeds from the Private Placement for working capital purposes, the conduct of its business and other general corporate purposes, which may include acquisitions, investments in or licenses of complementary products, technologies or businesses, operating expenses and capital expenditures. The Private Placement is expected to close on or about March 4, 2022, subject to the satisfaction of customary closing conditions. Craig-Hallum Capital Group LLC is acting as the sole placement agent for the Private Placement."
2022-03-02 07:25:04	AMTP	HOOKIPA Pharma Announces Pricing Of $75M Public Offering Of Common Stock And Non-Voting Convertible Preferred Stock	HOOKIPA Pharma Inc. (NASDAQ: AMTP ), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 21,700,000 shares of its common stock and 15,800 shares of its non-voting Series A-1 convertible preferred stock (the &ldquo;Offering&rdquo;). The public offering price of each share of common stock is $2.00 and the public offering price of each share of non-voting Series A-1 preferred stock is $2,000 (each share of non-voting Series A-1 preferred stock is convertible into 1,000 shares of common stock). HOOKIPA has granted the underwriters a 30-day option to purchase up to an additional 5,625,000 shares of its common stock at the public offering price of the common stock, less underwriting discounts and commissions. The gross proceeds to HOOKIPA from this offering are expected to be $75.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters&rsquo; option to purchase additional shares. All of the securities in the Offering are to be sold by HOOKIPA. The Offering is expected to close on March 4, 2022, subject to customary closing conditions. SVB Leerink and RBC Capital Markets are acting as joint book-running managers of the Offering. The securities described above are being offered by HOOKIPA pursuant to a shelf registration statement on Form S-3 (No. 333-238311), including a base prospectus filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), which was declared effective on May 27, 2020. A preliminary prospectus supplement has been filed with the SEC. A final prospectus supplement and accompanying prospectus relating to the Offering will be filed with the SEC and will be available on the SEC&rsquo;s website located at www.sec.gov . Copies of the final prospectus supplement and the accompanying prospectus may also be obtained, when available, from SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston Massachusetts 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@svbleerink.com ; RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, New York, NY 10281, by telephone at 877-822-4089, or by email at equityprospectus@rbccm.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-03-02 08:36:53	QDVV	Aterian Raises $27.5M Via Equity Offering	Aterian Inc (NASDAQ: QDVV ) has priced its private placement offering of about 9.5 million shares and accompanying warrants to purchase up to 7.08 million shares. Each share of common stock and the accompanying warrant will be sold at a combined purchase price of $2.91. The company expects to receive gross proceeds from the offering of about $27.5 million. Aterian intends to use the net proceeds for working capital purposes, the conduct of its business, and other general corporate purposes. The offering is expected to close on or about March 4, 2022. Price Action: QDVV shares are trading lower by 0.34% at $2.90 in premarket on the last check Wednesday.
2022-03-03 06:32:52	AFRA	Farmmi Raises $6M Via Equity Offering	Farmmi Inc (NASDAQ: AFRA ) has raised about $6 million in gross proceeds from the sale of 30 million of its shares. The shares were sold to various purchasers at $0 . 20 per share. The company recently disclosed its latest order for dried sliced Shiitake mushrooms for export to New York. Price Action: AFRA shares are trading higher by 2.83% at $0.19 in premarket on the last check Thursday.
2022-03-04 09:07:56	MAYK	Eyenovia Raises 15M Via Equity To Advance MydCombi Program	Eyenovia Inc (NASDAQ: MAYK ) has entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd for gross proceeds of $15 million . The offering includes 3 million shares, pre-funded warrants to purchase up to 1.87 million shares, and common warrants to purchase up to 4.87 million shares. The aggregate offering price for each share of common stock or pre-funded warrant and, in each case, the accompanying common warrant is $3.08. The pre-funded warrants will have an exercise price of $0.01/share, and the common warrants will have an exercise price of $3.54 per share. The offering is expected to close by March 7. Eyenovia will use the proceeds to advance its MydCombi program, including the ramp-up of its manufacturing capabilities and the continued advancement of the MicroLine clinical program. Last month, Eyenovia completed a Type A meeting with the FDA about refiling the MydCombi application . In October 2021, FDA issued a complete response letter, reclassifying MydCombi for in-office pupil dilation as a drug-device combination product. The FDA had asked the Company to conduct additional device testing for the Optejet dispenser. Price Action: MAYK shares closed 2.27% lower at $3.01 during after-hours trading on Thursday.
2022-03-04 11:08:32	VKYO	Altamira, Nuance Pharma Ink Licensing Pact For Bentrio In China, Additional Asian Markets	Altamira Therapeutics Ltd (NASDAQ: VKYO ) has entered into an exclusive licensing and distribution agreement with Nuance Pharma Ltd in the Chinese Mainland, Hong Kong, Macau, and South Korea for Bentrio. Bentrio is a nasal spray for protection against airborne viruses and allergens. Bentrio forms a protective gel layer on the nasal mucosa upon application into the nose. This thin film is designed to prevent the contact of viruses or allergens with cells. Under the terms of the agreement, Altamira will initially supply Bentrio to Nuance. Related: Altamira's Bentrio Nasal Spray Approved In Malaysia . Nuance will make an upfront payment of $1 million and pay to Altamira development and commercial milestones of up to $3 million and $19.5 million, respectively. Nuance will have the right to register and commercialize Bentrio in the Territory. In a second stage, Nuance will assume local production of the product for the Territory upon certain milestones. Once Nuance assumes local production of Bentrio, it will pay Altamira a staggered royalty on net sales in the Territory at a high-single to low-double-digit percentage. Price Action: VKYO shares are up 0.56% at $0.92 during the market session on the last check Friday.
2022-03-07 07:08:40	QYUD	Creatd Announces a $2.7M Registered Direct Offering	The Company has also announced a $2.7 million registered direct offering (the &quot;Offering&quot;), which comes following significant demand for its recent PIPE financing . Under the terms of the Offering, the Company has entered into definitive agreements with certain investors for the sale of approximately 1.5 million shares of common stock and warrants to purchase approximately 1.5 million shares of common stock, with such warrants having a five-year term and an exercise price of $1.75 per share. The purchase price for one share of common stock and one warrant is $1.75, consistent with the Company's recently completed PIPE financing. The common shares sold in this transaction, as well as the shares underlying the warrants, will be registered under the Company's outstanding registration statement on Form S-3. All officers of the Company are participating in the Offering, which is anticipated to close on or before March 9th, 2022.
2022-03-07 10:30:47	KRFO	Exela Technologies Reports Deal To Exchange With Revolving Lenders	Exela Technologies, Inc. (&ldquo;Exela&rdquo; or the &ldquo;Company&rdquo;) (NASDAQ: KRFO ), announced today that certain of its subsidiaries entered into a Revolving Loan Exchange and Prepayment Agreement with certain financial institutions acting as revolving lenders under its First Lien Credit Agreement dated as of July 12, 2017 (as amended or otherwise modified from time to time). Pursuant to the exchange all of the amounts outstanding under the revolving facility will be exchanged for (i) $50.0 million in cash and (ii) $50.0 million of the 11.500% First-Priority Senior Secured Notes due 2026. Upon the closing of the Exchange, all revolving loans shall be cancelled and the obligation to pay any amounts due under such revolving loans (including on their scheduled maturity date, July 12, 2022) shall be terminated and any accrued and unpaid interest and fees on such revolving loans shall be paid at closing. Following this exchange there will be no further debt maturities in 2022. The consummation of the exchange is subject to customary closing conditions, including that the closing shall occur no later than March 28, 2022.
2022-03-07 13:07:26	ZRR	Lung-Disease Focused AN2 Therapeutics Files Plans For NASDAQ Debut	AN2 Therapeutics Inc filed plans on Friday to go public in an initial public offering in which it reportedly hopes to raise about $75 million . AN2 plans to list on the Nasdaq with the symbol of TWJA. The Menlo Park-based biotech is developing a therapy for non-tuberculous mycobacterial (NTM) lung disease, which typically attacks older people or those with a weakened immune system. See the GIP prospectus here . Its initial product candidate is epetraborole, a once-daily oral treatment for patients with NTM. The Company licensed exclusive worldwide development and commercialization rights for epetraborole from Anacor Pharmaceuticals, owned by Pfizer Inc (NYSE: ZRR ), in 2016. AN2 Therapeutics plans to conduct a Phase 2/3 trial in treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common type of NTM lung disease. The trial design is currently under review from the FDA, and the Company plans to initiate enrollment in the 1H22, with topline results for the Phase 2 part expected in mid-2023 .
2022-03-09 07:10:38	CRFY	Kinetik Announces Pricing Of Upsized 3,478,261M Share Secondary Offering Of Common Stock At $58/Share	Kinetik Holdings Inc. (NASDAQ: CRFY ) (&quot; Kinetik &quot; or the &quot; Company &quot;) announced today the pricing of an upsized underwritten secondary offering of 3,478,261 shares of its Class A common stock (the &quot;Offering&quot;) by Apache Midstream LLC (the &quot;Selling Stockholder&quot;), a subsidiary of Apache Corporation, at a price of $58.00 per share. Kinetik is not selling any shares of Class A common stock in the Offering and will not receive the proceeds from any sale of shares by the Selling Stockholder. The Offering was upsized from the previously announced 2,500,000 shares based on strong investor demand. The Selling Stockholder has granted to the underwriters a 30-day option to purchase up to an additional 521,739 shares of Kinetik's Class A common stock. BofA Securities, J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the Offering. Barclays, Citigroup, Credit Suisse, Goldman Sachs & Co. LLC, Mizuho Securities, RBC Capital Markets, TD Securities, Truist Securities and Wells Fargo Securities are acting as joint book-running managers for the Offering. Capital One Securities, MUFG and Scotiabank are acting as co-managers for the Offering. The Offering is being made only by means of a prospectus supplement. When available, a copy of the prospectus supplement and the accompanying base prospectuses may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-001, or by email at dg.prospectus_requests@bofa.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014. A registration statement relating to these securities has been filed with and declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). Before investing, prospective investors should read the prospectus supplement, accompanying base prospectus and the documents incorporated by reference therein for more complete information about the Company and the Offering. An electronic copy of the prospectus supplement and accompanying base prospectus is available from the U.S. Securities and Exchange Commission's website at www.sec.gov . This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-03-10 09:02:39	JVFE	Reed's Reports $5.3M Private Placement	Reed&rsquo;s, Inc.&reg; (NASDAQ: JVFE ) (&ldquo;Reed&rsquo;s&rdquo; or the &ldquo;Company&rdquo;), owner of the nation&rsquo;s leading portfolio of handcrafted, all-natural ginger beverages, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $5.3 million in a private placement through the issuance of an aggregate of approximately 18 million shares of common stock and warrants to purchase up to an aggregate of approximately 9 million shares of common stock. Officers and directors of the Company agreed to purchase approximately $1.1 million of the securities in the offering. The purchase price per share of common stock and associated warrant was $0.28 for the investors (other than officers and directors of the Company) and $0.3502 for the officers and directors of the Company in compliance with the rules of the Nasdaq Stock Market. Each whole warrant entitles the holder to purchase one share of common stock at an exercise price of $0.2877 per share. The warrants become exercisable six months from the closing of the offering and are exercisable for a period of five years from the initial exercise date. The offering is expected to close on or about March 11, 2022, subject to customary closing conditions. Roth Capital Partners acted as the sole placement agent for the offering.
2022-03-10 09:19:55	LKXK	Sunshine Biopharma Announces Pricing Of $8M Private Placement At-The-Market	Sunshine Biopharma, Inc. (NASDAQ: &quot;LKXK&quot; and &quot;SBFMW&quot;) (the &quot;Company&quot; or &quot;Sunshine Biopharma&quot;), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it entered into a securities purchase agreement with certain institutional and accredited investors for aggregate gross proceeds of approximately $8.0 million, before deducting fees to the placement agent and other offering expenses payable by the Company. In connection with the offering, the Company will issue 3,603,604 units at a purchase price of $2.22 per unit, priced at-the-market under Nasdaq rules. Each unit consists of 1 share of common stock or common stock equivalent, and 1 non-tradable warrant, to purchase 1 share of common stock (for a total of 3,603,604 shares underlying the warrants). No actual units will be issued in the offering. The warrants each have an exercise price of $2.22, subject to adjustments therein. The warrant has a term equal to five years from the issuance date. The offering is expected to close on or about March 14, 2022, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the Exclusive Placement Agent in connection with the offering. Additional details regarding the offering will be available in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). The shares of common stock and warrants described above have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-03-10 16:27:39	MZAN	Sequans Communications S.A. Announces Launch Of Public Offering Of American Depositary Shares; Size Not Disclosed	PARIS, March 10, 2022 /PRNewswire/ -- Sequans Communications S.A. (NYSE: MZAN ) (the &quot;Company&quot; or &quot;Sequans&quot;), a leading developer and provider of 5G and 4G chips and modules for IoT devices, today announced the launch of an underwritten public offering of American Depositary Shares representing its ordinary shares. Each American Depositary Share represents four ordinary shares of the Company, nominal value &euro;0.02 per share (the &quot;ADSs&quot;). The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs sold in the proposed offering. All ADSs to be sold in the proposed offering will represent ordinary shares offered by the Company. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering, if completed, for general corporate purposes, which may include 5G product development.
2022-03-11 10:45:05	WWCC	Surgical Robot Maker Memic Terminates SPAC Merger	Memic Innovative Surgery Ltd has pulled out of a reverse merger deal with MedTech Acquisition Corporation (NASDAQ: WWCC ), a special purpose acquisition company (SPAC) focused on medical technology. Last August, Memic announced its merger with MedTech Acquisition Corporation to take the surgical robot public. As of this week, however, the deal is off. Memic is a developer of the FDA-cleared Hominis system for robotic-assisted surgery. In an announcement published Thursday , the companies said they had mutually decided to terminate their business combination, citing &quot;market conditions and associated volatility as a result of recent world events.&quot; &quot;With the recent adoption of our Hominis system by three leading U.S. hospitals, we are excited about the ability of the Hominis system to perform robotic transvaginal techniques that were previously unfeasible, fulfilling a significant unmet need in women's health, with the potential to be applied to a broad range of indications in the future including general surgery. We are grateful for the support we have received from the MedTech team, whose commitment to surgical robotics we share,&quot; said Dvir Cohen, co-founder and Chief Executive Officer of Memic. The reverse merger was expected to create a combined company with over $1 billion equity value and about $360 million in cash in its coffers. The deal was to be supported by proceeds from the blank-check company's $250 million GIP and a planned private investment round totaling $76 million.
2022-03-11 12:24:24	FWOM	Happiness Development Raises $6.7M Via Equity Offering	Happiness Development Group Ltd (NASDAQ: FWOM ) has entered into a securities purchase agreement with certain non-U.S. strategic investors for a registered direct placement of about $6.7 million. Under the agreement, the company will sell 19.2 million Class A ordinary shares at a per-share purchase price of $0.35. Also Read : Happiness Development Enters Cannabis Space By Taking 10% Stake In Kannaba Agritech The company intends to use the gross proceeds in developing its auto business under the brand of &quot;Taochejun&quot; as well as for working capital and general corporate purposes. Price Action: FWOM shares are trading lower by 14.9% at $0.31 on the last check Friday.
2022-03-15 17:52:23	NMED	Tantech Announces Proposed Public Offering; Size, Price Not Disclosed	Tantech Holdings Ltd (NASDAQ: NMED ) (&quot;Tantech&quot; or the &quot;Company&quot;), today announced that it intends to offer its securities in a public offering. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital and other business opportunities. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2022-03-16 07:56:36	NMED	Tantech Prices $10M Underwritten Public Offering Of Common Shares And Pre-Funded Warrants To Purchase Common Shares	Tantech Holdings Ltd (NASDAQ: NMED ) (&quot;Tantech&quot; or the &quot;Company&quot;), today announced the pricing of an underwritten public offering of 20,000,000 common shares and prefunded warrants to purchase common shares (the &quot;Offering&quot;), with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. The pre-funded warrants are offered at the same $0.50 price per share as the common shares, less the $0.001 per share exercise price of each pre-funded warrant. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital and other business opportunities. In addition, the Company granted the underwriters a 45-day option to purchase an additional 15.0% of common shares at the public offering price to cover over-allotments, if any. If this option is exercised in full, the gross proceeds of the over-allotment would be approximately $11.5 million before deducting underwriting discounts, commissions and other offering expenses. The closing of the Offering is expected to occur on March 18, 2022, subject to customary closing conditions.
2022-03-16 08:03:19	ERG	PolarityTE Reports $5M Registered Direct Offering Of Convertible Preferred Shares, Warrants To Buy Shares	PolarityTE, Inc. (NASDAQ: ERG ) (&quot;PolarityTE&quot; or the &quot;Company&quot;), a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock and 2,000.00029 shares of Series B convertible preferred stock and warrants to purchase up to an aggregate of 16,393,445 shares of common stock. Each share of Series A and Series B preferred stock has a stated value of $1,000 per share and a conversion price of $0.305 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 16,393,445 shares of common stock. The warrants have an exercise price of $0.35 per share, will become exercisable six months following the date of issuance, and will expire two years following the original issuance date. Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is approximately $5.0 million.
2022-03-16 08:16:14	FWGE	Axcella Therapeutics Announces $25M Registered Direct Offering	Axcella Therapeutics (NASDAQ: FWGE ), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 13,089,002 shares of common stock (the &quot;Shares&quot;) at a purchase price of $1.91 per share, resulting in gross proceeds of $25.0 million.
2022-03-17 07:12:28	KTYY	SolarEdge Technologies Announced Proposed Public Offering of 2,000,000 shares of its Common Stock	"SolarEdge Technologies, Inc. (NASDAQ: KTYY ) (""SolarEdge"") today announced that it plans to conduct a registered public offering (the ""Offering""), subject to market conditions and other factors, of 2,000,000 shares of its common stock (the ""Common Stock""). SolarEdge intends to grant the underwriters a 30-day option from the date of the prospectus supplement to purchase up to an additional 300,000 shares of its Common Stock upon the same terms as set forth underwriting agreement. SolarEdge intends to use the net proceeds from the Offering for general corporate purposes, which may include acquisitions. However, SolarEdge does not have agreements or commitments for any acquisitions at this time. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the Offering and as the representatives of the underwriters."
2022-03-17 08:33:59	KMEH	Quantum Corporation Announces Rights Offering; Co. Offers Right To Purchase ~0.423 Of A Share Of Common Stock At A Subscription Price Per Share Equal To $2.25/Whole Share For Total Gross Proceeds Of ~$67.5M	Quantum Corporation (NASDAQ: KMEH ) (the &quot;Company&quot;) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the Company's common stock (the &quot;Common Stock&quot;), and holders of certain outstanding warrants to purchase shares of Common Stock issued by the Company (the &quot;Participating Warrants&quot;), as of 5:00 p.m. Eastern Time on March 25, 2022 (the &quot;Record Date&quot;). The Company intends to distribute to all holders of Common Stock and Participating Warrants as of the Record Date, with respect to each share of Common Stock, including shares of Common Stock issuable upon the exercise of Participating Warrants, subscription rights to purchase approximately 0.422572999 of a share of Common Stock, at a subscription price per share equal to $2.25 per whole share. If the rights offering is fully subscribed, the Company expects to receive gross proceeds of approximately $67.5 million, before expenses related to the rights offering.
2022-03-17 19:40:53	KTYY	SolarEdge Technologies Priced 2M Share Common Stock Offering @$295/Share	"SolarEdge Technologies, Inc. (NASDAQ: KTYY ) (""SolarEdge"") today announced the pricing of 2,000,000 shares of its common stock at $295.00 per share (the ""Common Stock""), for total gross proceeds of $590.0 million (before deduction for the underwriters' discount and other offering expenses). Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the Common Stock offering and as the representatives of the underwriters. SolarEdge has granted the underwriters a 30-day option from the date of the prospectus supplement to purchase up to an additional 300,000 shares of its Common Stock upon the same terms as set forth in the underwriting agreement. The sale of the Common Stock to the underwriters is expected to settle on March 22, 2022, subject to customary closing conditions. SolarEdge intends to use the net proceeds from the offering for general corporate purposes, which may include acquisitions. However, SolarEdge does not have agreements or commitments for any acquisitions at this time."
2022-03-18 11:41:25	NMED	Tantech Raises $10M Via Equity Offering	Tantech Holdings Ltd (NASDAQ: NMED ) has closed an underwritten public offering of 20 million common shares and pre-funded warrants to purchase common shares. The company expects gross proceeds of about $10 million, before deducting underwriting discounts and commissions. The pre-funded warrants are offered at the same $0.50 price per share as the common shares. Tantech will use the proceeds from the offering for general corporate purposes. Aegis Capital Corp acted as Sole Bookrunner for the offering. Price Action: NMED shares are trading higher by 6.43% at $0.54 on the last check Friday.
2022-03-21 09:10:47	MQMK	CarParts.com Announces The Termination of Its At-The-Market Equity Offering Program	CarParts.com, (NASDAQ: MQMK ), a leading e-commerce provider of automotive parts and accessories, today announced effective March 18, 2022 the company has elected to terminate its &quot;at-the-market&quot; equity offering program (the &quot;ATM Facility&quot;) with DA Davidson as sales agent. &quot;As we previously discussed in our most recent earnings call, when we think about #1 our inventory and safety stock, #2 our currently undrawn line of credit, and #3 our free cash flow, we feel confident in our ability to execute our strategy of Right Part, Right Time, Right Place, given our current liquidity,&quot; stated Ryan Lockwood, SVP of Finance and incoming CFO. As of the date of this announcement, CarParts.com had not sold any of its common shares under the ATM Program. In a separate press release filed last year, CarParts.com announced a $30 million stock repurchase plan. The company has repurchased 40,000 shares since the initiation of the program and has approximately $29.5 million remaining under the authorization.
2022-03-21 11:43:53	MQMK	Carparts.Com Terminates At-The-Market Equity Offering Program	Carparts.Com Inc (NASDAQ: MQMK ) said it has decided to terminate its at-the-market equity offering program (ATM Facility) with DA Davidson as a sales agent. The termination will be effective from March 18, 2022. CarParts.com had not sold any of its common shares under the ATM Program. Recently, the company posted $138.3 million in revenue in the fourth quarter, beating the consensus of $133.34 million. Carparts held $18.1 million in cash and equivalents as of January 1, 2022. The company has repurchased 40,000 shares since the initiation of its $30 million stock repurchase program and has $29.5 million remaining under the authorization. Price Action: MQMK shares are trading lower by 2.80% at $7.28 on the last check Monday.
2022-03-21 16:07:47	DZY	Piedmont Announces Proposed 1.5M Share Public Offering Of Common Stock; NOTE: Shares Were Halted Ahead Of Announcement	Piedmont Lithium Inc. (&quot;Piedmont&quot; or the &quot;Company&quot;) (NASDAQ: DZY , ASX:DZY))))) todayannounced that it plans to conduct a public offering, subject to market and other conditions, of 1.5 million shares (&quot;shares&quot;) of its common stock (&quot;Public Offering&quot;). Piedmont intends to use the net proceeds from the offering to fund the Company's share of the capital required to restart the operations at North American Lithium in Quebec, to fund exploration and definitive feasibility studies at Eyowaa in Ghana, to advance the Company's merchant lithium hydroxide plant in the southeastern United States, and to continue development of the Carolina Lithium Project, including ongoing permitting activities, engineering design, and property acquisition. Additionally, the net proceeds may be used to fund possible strategic initiatives and for general corporate purposes. J.P. Morgan and Evercore ISI are acting as joint book-runners and lead underwriters for the Public Offering. Piedmont intends to grant the underwriters a 30-day option to purchase up to 225,000 additional shares at the issue price of the Public Offering. The Public Offering is being made pursuant to an effective shelf registration statement that has been filed with the Securities and Exchange Commission (the &quot;SEC&quot;). A preliminary prospectus supplement related to the offering of the shares has been filed with the SEC and is available on the SEC's website at http://www.sec.gov and on the ASX website. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Public Offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by e-mail at prospectus-eq_fi@jpmchase.com ; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200 or by e-mail at ecm.prospectus@evercore.com .
2022-03-21 16:51:12	RUXJ	Statera Biopharma Announces Proposed Underwritten Public Offering ; Size Not Disclosed	Statera Biopharma, Inc. (NASDAQ: RUXJ ) (the &ldquo;Company&rdquo; or &ldquo;Statera Biopharma&rdquo;), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced it has commenced an underwritten public offering. EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. The proposed offering of the units, consisting of one share of common stock and one warrant to purchase one share of common stock, and pre-funded units, consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, is being offered by the Company pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333-238578) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on May 29, 2020, and the accompanying preliminary prospectus supplement contained therein. Anthony L.G., PLLC is acting as legal counsel to Statera Biopharma, Inc. and Carmel, Milazzo & Feil LLP is acting as legal counsel to EF Hutton for the offering. Bridgeway Capital Partners, LLC is acting as the Company&rsquo;s financial advisor. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement will be filed with the SEC today and a final prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement. Copies of the preliminary prospectus supplement and the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC&rsquo;s website at http://www.sec.gov or by contacting EF Hutton, division of Benchmark Investments, LLC Attention: Syndicate Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, by email at syndicate@efhuttongroup.com , or by telephone at (212) 404-7002. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-03-22 08:47:17	EMNW	EMNW Prices 7.5M Share Common Stock Offering For Gross Proceeds Of ~$9.8M	Applied Genetic Technologies Corporation (NASDAQ: EMNW ), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common stock for gross proceeds of approximately $9.8 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by EMNW. All of the shares are being sold by EMNW. The offering is expected to close on or about March 24, 2022, subject to customary closing conditions. In addition, EMNW has granted to the underwriter a 30-day option to purchase up to approximately 1,125,000 additional shares of its common stock. EMNW intends to use the net proceeds from this offering, together with other available funds, to fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa (XLRP) program and its ongoing Phase 1/2 clinical trials in its Achromatopsia (ACHM) program, its preclinical development programs and for working capital and other general corporate purposes.
2022-03-22 09:20:03	HMTC	Inpixon Announces Pricing Of $50M Registered Direct Offering	Inpixon&reg; (NASDAQ: HMTC ), the Indoor Intelligence&reg; company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 53,198 shares of Series 8 convertible preferred stock and warrants to purchase up to an aggregate of 112,778,723 shares of common stock. Each share of Series 8 convertible preferred stock and 2,120 warrants will have a combined purchase price of $940, representing an original issue discount of 6% of the stated value of the Series 8 preferred stock. Each share of Series 8 convertible preferred stock will have a stated value of $1,000 and is immediately convertible into shares of Inpixon's common stock at an initial conversion price of $0.4717 per share. Total gross proceeds, before deducting the placement agent's fees and other estimated offering expenses, is approximately $50.0 million. The Series 8 convertible preferred stock permit the holder to vote on an as-converted basis with the holders of common stock. The holders of the Series 8 convertible preferred stock have the right to require the company to redeem their shares of preferred stock for cash at the stated value at any time beginning on October 1, 2022, and ending ninety (90) days thereafter. The company also has the right to redeem the preferred stock beginning on October 1, 2022, for cash at the stated value, subject to certain conditions, and force the conversion of the preferred stock if certain price and trading conditions are met. The warrants will have an exercise price of $0.4717 per share, are immediately exercisable, and will expire five years from the initial exercise date. If shares of preferred stock are redeemed, 50% of the warrants issued as a result of the purchase of such redeemed shares will be forfeited. The closing of the offering is expected to occur on or about March 24, 2022, subject to the satisfaction of customary closing conditions. Additional information regarding the securities described above and the terms of the offering are included in a Current Report on Form 8-K to be filed with the United States Securities and Exchange Commission (&quot;SEC&quot;). Maxim Group LLC is acting as the sole placement agent in connection with the offering. The preferred stock, shares of common stock into which the preferred stock is convertible and warrants described above are being offered pursuant to a shelf registration statement on Form S-3 (333-256827), which was declared effective by the SEC on June 17, 2021. The offering will be made only by means of a prospectus supplement that forms a part of the registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the registered direct offering may be obtained, when available, by contacting Maxim Group LLC, 300 Park Avenue, New York, NY 10022, or by telephone at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-03-22 16:15:49	CKN	Archaea Energy Inc. Announces Secondary Offering Of ~12.99M Shares Of Class A Common Stock By Selling Stockholder	Archaea Energy Inc. (the &ldquo;Company&rdquo;) (NYSE: CKN ) today announced the commencement of an underwritten public offering of 12,993,603 shares of the Company&rsquo;s Class A common stock (the &ldquo;Offering&rdquo;) by an existing stockholder of the Company, Aria Renewable Energy Systems LLC (the &ldquo;Selling Stockholder&rdquo;). The Selling Stockholder intends to grant the underwriters a 30-day option to purchase up to an additional 1,949,040 shares of the Company&rsquo;s Class A common stock. The Offering consists entirely of shares of Class A common stock to be sold by the Selling Stockholder, and the Company will not receive any proceeds from the sale of the shares being offered by the Selling Stockholder. Barclays and Jefferies are acting as joint book-running managers for the Offering. The Company has filed a registration statement on Form S-1 (Registration No. 333-260094) (including a base prospectus), which has been declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;). The Company has also filed a preliminary prospectus supplement with the SEC for the Offering. The Offering will be made only by means of a prospectus supplement and an accompanying prospectus. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov . Alternatively, copies of the preliminary prospectus supplement and accompanying prospectus, as well as copies of the final prospectus supplement once available, may be obtained by contacting: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by email at Barclaysprospectus@broadridge.com , or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at prospectus_department@jefferies.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-03-22 16:19:29	NQKR	Argenx Announces Launch Of Proposed Global Offering Of $500M	argenx MX ((Euronext&nbsp, &amp, NASDAQ: NQKR ), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today that it has commenced a global offering of $500 million (approximately &euro;453 million) of ordinary shares, which may be represented by American Depository Shares (&ldquo;ADSs&rdquo;). The global offering will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and the United Kingdom. Each of the ADSs represents the right to receive one ordinary share, nominal value of &euro;0.10 per share. The U.S. offering and the European private placement are expected to close simultaneously. In addition, argenx intends to grant the underwriters of the offering a 30-day option to purchase additional ordinary shares (which may be represented by ADSs) in an aggregate amount of up to 15% of the total number of ordinary shares (including represented by ADSs) proposed to be sold in the offering, on the same terms and conditions. Baillie Gifford Overseas Limited and entities affiliated with it have indicated an interest in purchasing on behalf of their clients an aggregate of up to $170.0 million of ordinary shares in the offering at the offering price per share and on the same terms as the other purchasers in the offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no ordinary shares to these potential purchasers, and these potential purchasers could determine to purchase more, fewer or no shares in the offering. argenx&rsquo;s ADSs are currently listed on the Nasdaq Global Select Market under the symbol &ldquo;NQKR&rdquo; and argenx&rsquo;s ordinary shares are currently listed on Euronext Brussels under the symbol &ldquo;NQKR&rdquo;. J.P. Morgan, Morgan Stanley, Cowen and SVB Leerink are acting as joint bookrunning managers for the offering. The securities are being offered in the United States pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;). A preliminary prospectus supplement relating to the securities being offered in the United States will be filed with the SEC and will be available on the SEC&rsquo;s website at www.sec.gov .
2022-03-22 16:22:29	CKN	Why Archaea Energy Shares Are Falling After Hours	Archaea Energy Inc (NYSE: CKN ) shares are trading lower in Tuesday's after-hours session after the company announced a secondary offering. Archaea Energy will underwrite a public offering of 12,993,603 shares of the company's Class A common stock being sold by an existing shareholder. The selling shareholder intends to grant the underwriters a 30-day option to purchase up to an additional 1,949,040 shares of the company's common stock. The offering consists entirely of shares of Class A common stock to be sold by the selling shareholder. Archaea Energy will not receive any proceeds from the sale. CKN 52-Week Range: $9.62 - $22.01 The stock was down 8.49% in after hours at $17.90 at time of publication.
2022-03-22 16:57:13	DZY	Piedmont Announces Pricing Of Upsized Public Offering Of 1.75M Shares Of Common Stock	Piedmont Lithium Inc. (&quot;Piedmont&quot; or the &quot;Company&quot;) (NASDAQ: DZY , ASX:DZY))))) todayannounced the pricing of an upsized underwritten public offering of 1.75 million shares (&quot;shares&quot;) of its common stock (&quot;Public Offering&quot;), at a price per share to the public of $65.00, for aggregate gross proceeds of $113.75 million. Piedmont has granted the underwriters a 30-day option to purchase up to an additional 262,500 shares at the issue price of the Public Offering. The Public Offering is expected to close on March 24, 2022, subject to customary closing conditions. Piedmont intends to use the net proceeds from the offering to fund the Company's share of the capital required to restart the operations at North American Lithium in Quebec, to fund exploration and definitive feasibility studies at Eyowaa in Ghana, to advance the Company's merchant lithium hydroxide plant in the southeastern United States, and to continue development of the Carolina Lithium Project, including ongoing permitting activities, engineering design, and property acquisition. Additionally, the net proceeds may be used to fund possible strategic initiatives and for general corporate purposes. J.P. Morgan and Evercore ISI are acting as joint book-runners for the Public Offering. Canaccord Genuity, B. Riley Securities, BTIG, LLC, Clarksons Platou Securities, Inc., D.A. Davidson & Co., Jett Capital Advisors LLC, Loop Capital Markets, Roth Capital Partners, ThinkEquity and Tuohy Brothers are acting as co-managers for the Public Offering. The Public Offering is being made pursuant to an effective shelf registration statement that has been filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). A final prospectus supplement related to the Public Offering will be filed with the SEC and made available on the SEC's website at http://www.sec.gov and on the ASX website. Copies of the final prospectus supplement, when available, and the accompanying prospectus relating to the Public Offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by e-mail at prospectus-eq_fi@jpmchase.com ; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200 or by e-mail at ecm.prospectus@evercore.com . This press release is not an offer or sale of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.
2022-03-23 16:18:47	KQEH	Why Apellis Pharmaceuticals Stock Is Falling After Hours	Apellis Pharmaceuticals Inc (NASDAQ: KQEH ) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. Apellis is a clinical-stage biopharmaceutical company that's committed to leveraging courageous science, creativity and compassion to deliver life-changing therapies. KQEH 52-Week Range: $27.50 - $73.00 Apellis shares are down 7.28% in after hours trading at $49 at press time.
2022-03-24 06:51:40	WKUL	Blackstone Mortgage Trust Announces Public Offering Of $300M Of Convertible Senior Notes	Blackstone Mortgage Trust, Inc. (NYSE: WKUL ) (the &quot;Company&quot;) today announced it has commenced an underwritten public offering of $300 million aggregate principal amount of convertible senior notes due 2027 (the &quot;Notes&quot;). The underwriters will be granted a 30-day option by the Company to purchase up to an additional $45 million aggregate principal amount of the Notes solely to cover over-allotments. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of debt, including a portion of the $402.5 million outstanding aggregate principal amount of our 4.375% Convertible Senior Notes due 2022, and supporting the origination of additional commercial mortgage loans and other target assets and investments. The Notes will mature on March 15, 2027, unless earlier converted, redeemed or repurchased. Prior to December 15, 2026, the Notes will be convertible only upon certain circumstances and during certain periods, and thereafter will be convertible at any time prior to the close of business on the second scheduled trading day prior to maturity. Upon conversion, holders will receive cash, shares of the Company's class A common stock or a combination thereof at the Company's election. The interest rate, conversion rate and other terms of the Notes will be determined at the time of pricing of the offering. Citigroup, BofA Securities, Barclays, J.P. Morgan, Morgan Stanley and Wells Fargo Securities are acting as joint book-running managers for the offering.
2022-03-24 13:37:48	DP	DP Logistics Plans To Raise $1.1B From New Shares	DP.Com Inc (NASDAQ: DP ) subsidiary DP Logistics plans to raise $1.1 billion through a share placement and subscription agreement. DP Logistics intends to enter into a subscription agreement with its parent company DP.Com for a $700 million share placement (JDL Subscription). DP Logistics plans to raise $400 million from an equity offering (JDL Placement). The proposed JDL Placement and DP Subscription will be subject to the execution of definitive transaction documents. Price Action: DP shares are trading lower by 5.90% at $60.50 on the last check Thursday.
2022-03-24 16:16:54	NOHQ	Why Purple Innovation Stock Is Falling After Hours	Purple Innovation Inc (NASDAQ: NOHQ ) shares are trading lower in Thursday's after-hours session after the company proposed a $65 million underwritten public offering. The underwriter will have a 30-day option period to purchase up to 15% additional shares of common stock from Purple Innovation. BofA Securities is acting as the sole underwriter for the offering. Purple Innovation is a comfort innovation company that designs, manufactures and sells a range of comfort technology offerings, including mattresses, pillows, cushions, sheets, bed platforms and other products. NOHQ 52-Week Range: $5.05 - $36.44 The stock was down 7.45% in after hours trading at $6.34 at press time.
2022-03-24 16:38:58	CJSJ	Gates Industrial Stock Slips On Secondary Offering by Selling Stockholders	Gates Industrial Corp PLC (NYSE: CJSJ ) announced a secondary offering of 5 million of Gates' ordinary shares , with certain selling stockholders affiliated with Blackstone Inc. Underwriter granted a 30-day option to purchase up to 750,000 additional ordinary shares. Gates is not offering any ordinary shares in the offering and will not receive any proceeds from the sale of ordinary shares in this offering. Additionally, Gates entered into a share repurchase contract with Citigroup Global Markets Inc. to repurchase up to 8 million ordinary shares at a price per share equal to the price paid by the underwriter in the offering. Gates intends to fund the share repurchase with cash on hand and borrowings under its revolving credit agreement. CJSJ held cash and cash equivalents of $658.2 million as of January 1, 2022. Price Action: CJSJ shares are trading lower by 4.41% at $15.40 during the post-market session on Thursday.
2022-03-25 15:06:45	TWJA	RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With GIP Price At $15	AN2 Therapeutics Inc (NASDAQ: TWJA ) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'TWJA,' raising $69 million . The Company announced GIP plans earlier this month. The price point came in at the middle of AN2's expected range after setting terms of $14 to $16 per share last week . Underwriters have an option to purchase up to an additional 690,000 shares. The new money, according to AN2, will go to fund further clinical development of lead candidate epetraborole in an ongoing Phase 1 trial, a planned Phase 2/3 pivotal trial, manufacturing, and expanding into other indications within lung disease and infections. Related: Lung-Disease Focused AN2 Therapeutics Files Plans For NASDAQ Debut . Last month, AN2 Therapeutics announced topline results from its Phase 1b dose-ranging study of oral epetraborole for non-tuberculous mycobacterial (NTM) lung disease. Phase 1b evaluated epetraborole administered to healthy volunteers at doses ranging from 250 mg to 1,000 mg for 28 days. Results showed that epetraborole was generally well tolerated, with no severe/serious adverse events. Price Action: TWJA shares are trading at $16.43 during the market session on the last check Friday.
2022-03-28 14:02:44	TRFG	Fortune Brands Raises $900M Via Debt	Fortune Brands Home & Security Inc (NYSE: TRFG ) has priced a registered public offering of $900 million of senior unsecured notes on March 22. The notes consist of a $450 million aggregate principal amount of 4.000% senior unsecured notes maturing in 2032 and a $450 million aggregate principal amount of 4.500% senior unsecured notes maturing in 2052. The weighted-average interest rate will be approximately 3.950%. &quot;Demand for our offering was strong and was initially over-subscribed by more than four times our targeted capital raise,&quot; said CFO Patrick Hallinan. The company intends to use the net proceeds from the notes offering to pay down a portion of its current term loan and for general corporate purposes. Price Action: TRFG shares are trading higher by 0.12% at $77.69 on the last check Monday.
2022-03-28 16:29:22	DXI	Why Southwest Gas Shares Are Sliding After Hours	Southwest Gas Holdings Inc (NYSE: DXI ) is trading lower in Monday's after-hours session after the company announced it commenced an underwritten public offering of $400 million of its common stock. Southwest Gas said it intends to use the proceeds to repay outstanding borrowings under the 364-day term loan credit agreement that was used to fund the company's acquisition of Questar Pipeline. Southwest Gas, through its subsidiaries, engages in the business of purchasing, distributing and transporting natural gas, and providing comprehensive utility infrastructure services across North America. From Last Week: Carl Icahn On The Fallout Of Corporate America: 'There Very Well Could Be A Recession Or Worse' DXI 52-Week Range: $62.54 - $80.42 The stock was down 5.04% in after hours at $75.50 at press time. Photo: jp26jp from Pixabay.
2022-03-29 16:39:01	KMEH	Quantum Corporation Commences Rights Offering Of Up To $67.5M	Quantum Corporation (NASDAQ: KMEH ) (the &quot;Company&quot;) today commenced the previously announced rights offering to raise gross proceeds of up to approximately $67.5 million (the &quot;Rights Offering&quot;). Under the terms of the Rights Offering, all holders of record of the Company's common stock (&quot;Common Stock&quot;), and holders of certain outstanding warrants to purchase shares of Common Stock issued by the Company (the &quot;Participating Warrants&quot;), as of 5:00 p.m. Eastern Time on March 25, 2022 (the &quot;Record Date&quot;), will receive, with respect to each share of Common Stock (including shares issuable upon the exercise of Participating Warrants), a subscription right to purchase 0.422572999 of a share of Common Stock, at a subscription price per share equal to $2.25 per whole share. The subscription rights may be exercised at any time during the subscription period, which commences today and ends at 5:00 p.m. Eastern Time on April 18, 2022 (the &quot;Expiration Date&quot;). The subscription rights will expire if they are not exercised by the Expiration Date.
2022-03-29 21:13:41	XKYD	Valens Company Raises $22.5M Selling Units	The Valens Company Inc. (NASDAQ: XKYD ) (NASDAQ: XKYD ), a leading manufacturer of cannabis products, announced late Tuesday that it has entered into an agreement with Stifel Nicolaus Canada Inc. and Alliance Global Partners to sell 0,613,207 of its units for C$ 28,125,000 ( approximately USD$22.5 million ). Each Unit will consist of one common share and one-half of a Warrant. Each Warrant will be exercisable to acquire one additional common share for a period of 48 months following the closing of the offering at an exercise price of C$ 3.20 per share, &ldquo;subject to adjustment in certain events,&rdquo; reported Valens in a press release . The Company plans to use the net proceeds from the offering to continue to pursue strategic growth initiatives in North America, provide funding for working capital and for general corporate purposes. Closing of the Offering is expected to occur on or about April 5, 2022, and is subject to a number of customary conditions, including, receipt of all regulatory and stock exchange approvals. The company will apply to list the shares (including the warrant shares) to be issued in the Offering on the Toronto Stock Exchange (&quot;TSX&quot;) and the Nasdaq Capital Market .
2022-03-30 06:38:36	PLQ	PLQ Prices 7M Share Common Stock Offering For Gross Proceeds ~$406M	PLQ, Inc. (the &quot;Company&quot;) (NYSE: PLQ ), announced today that it has priced an underwritten public offering of 7,000,000 shares of common stock for expected gross proceeds of approximately $406 million, all of which are being offered in connection with the forward sale agreements described below. Morgan Stanley and Citigroup are acting as joint book-running managers for the offering. The Company has entered into forward sale agreements with Morgan Stanley and Citigroup or their affiliates (the &quot;forward purchasers&quot;) with respect to 7,000,000 shares of its common stock. In connection with the forward sale agreements, the forward purchasers or their affiliates are expected to borrow and sell to the underwriters an aggregate of 7,000,000 shares of the common stock that will be delivered in the offering. Subject to its right to elect cash or net share settlement, which right is subject to certain conditions, the Company intends to deliver, upon physical settlement of such forward sale agreements on one or more dates specified by the Company occurring within approximately one year from the date of the prospectus supplement relating to the offering, an aggregate of 7,000,000 shares of its common stock to the forward purchasers in exchange for cash proceeds per share equal to the applicable forward sale price, subject to certain adjustments as provided in the forward sale agreements. The offering is expected to close on April 1, 2022, subject to customary closing conditions. The Company will not initially receive any proceeds from the sale of shares of its common stock by the forward purchasers or their affiliates in the offering. The Company intends to use the net proceeds, if any, it receives upon the future settlement of the forward sale agreements for identified and prospective land and operating asset acquisitions, Developer Capital Program investments, and for working capital and general corporate purposes, which may include the repayment of outstanding indebtedness under the Company's commercial paper program, unsecured revolving credit facility and working capital credit facility, if any. Selling common stock through the forward sale agreements enables the Company to set the price of such shares upon the pricing of the offering (subject to certain adjustments) while delaying the issuance of such shares and the receipt of the net proceeds by the Company until the expected funding requirements described above have occurred. The offering is being conducted pursuant to the Company's currently effective shelf registration statement, which was previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;). This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. You may obtain copies of the prospectus supplement and prospectus relating to the offering without charge from the SEC at www.sec.gov . Alternatively, copies of these documents may be obtained by contacting (i) Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department; and (ii) Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146, or by emailing prospectus@citi.com .
2022-03-30 08:04:41	EAGV	Aravive Announces $10M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	Aravive, Inc. (NASDAQ: EAGV ), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has entered into definitive agreements with a single healthcare-focused institutional investor and Eshelman Ventures, LLC for the issuance and sale of an aggregate of 4,850,241 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,850,241 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The purchase price per share and accompanying warrant is $2.005 for the institutional investor and $2.325 for Eshelman Ventures, LLC. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The warrants to be issued to the institutional investor will be immediately exercisable, will expire five years following the issuance date and will have an exercise price of $1.88 per share. The warrants to be issued to Eshelman Ventures, LLC will be exercisable upon the approval by the stockholders of the Company of previously issued securities, will expire five years following the issuance date and will have an exercise price of $2.20 per share. The Company's Executive Chairman, Fredric N. Eshelman, Pharm.D., is the founder of Eshelman Ventures, LLC. The closing of the offering is expected to occur on or about March 31, 2022, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $10 million. The Company intends to use the net proceeds from the offering to continue clinical development of batiraxcept in platinum resistant ovarian cancer and clear cell renal cell carcinoma, and for general corporate purposes. The offering of the securities described above is being made only by means of a prospectus supplement and accompanying base prospectus. The Company has filed a shelf registration on Form S-3 (File No. 333-248612) (including a base prospectus) with the U.S. Securities and Exchange Commission (&quot;SEC&quot;), which was declared effective on November 20, 2020. A final prospectus supplement and accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website, located at www.sec.gov . Electronic copies of the prospectus supplement and the accompanying base prospectus for the offering may also be obtained, when available, by contacting L.C. Wainwright & Co., LLC, at 430 Park Ave., 3rd Floor, New York, New York 10022, by telephone at (212) 856-5711, or by email at placements@hcwco.com . This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-03-30 11:24:00	RBTT	Calithera Biosciences Raises $10M Via Equity Issued At 10% Discount	Calithera Biosciences Inc (NASDAQ: RBTT ) priced its previously announced underwritten public offering of 18.5 million shares at $0.54 per share for gross proceeds of $10 million . Each share of common stock is accompanied by a warrant to purchase one common share at an exercise price of $0.54 per share, which is immediately exercisable and will expire in 18 months, and a warrant to purchase one common share at an exercise price of $0.54 per share, which is immediately exercisable and will expire five years from the date of issuance. The offering is expected to close on April 1. SVB Leerink and L.C. Wainwright & Co. are acting as joint book-running managers for the offering. Related: Why Did Calithera Shares Drop To 52-Week Low In Premarket Friday? Calithera Biosciences will use the proceeds to further the clinical development of mivavotinib, SYK inhibitor, and sapanisertib, dual TORC 1/2 inhibitor, in Phase 2 clinical trials, fund clinical development of additional clinical candidates, and early-stage research. See the offer prospectus here . Price Action: RBTT shares are down 31.4% at $0.41 during the market session on the last check Wednesday.
2022-03-30 12:49:55	WLWO	Churchill Downs Raises $900M Via Debt	Churchill Downs Inc (NASDAQ: WLWO ) said its wholly-owned subsidiary, CDI Escrow Issuer Inc, is offering senior notes due 2030 in a private offering. The offering is part of the financing for the proposed acquisition of Peninsula Pacific Entertainment LLC. The company plans to place proceeds of $900 million in escrow. Upon satisfaction of the escrow conditions, CDI intends to use the net proceeds to finance the consummation of the acquisition and pay related transaction fees and expenses. Price Action: WLWO shares are trading lower by 0.07% at $228.30 on the last check Wednesday.
2022-04-01 08:41:38	WUE	SELLAS Life Sciences Stock Plunges After $25M Capital Raise Via Equity, In-Licenses Cancer-Focused CDK9 Inhibitor	GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc (NASDAQ: WUE ) across all therapeutic and diagnostic uses worldwide outside of Greater China (mainland China, Hong Kong, Macau, and Taiwan). GFH009 is a highly selective small-molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GFH009 is currently in Phase 1 trials in the U.S. and China. After completing the Phase 1 trial and achieving a maximum tolerated dose, SELLAS plans to commence a Phase 2 trial of GFH009 combined with venetoclax and azacitidine in acute myeloid leukemia (AML) patients. The Company also plans to commence a Phase 1/2 basket clinical trial of monotherapy GFH009 in pediatric soft tissue sarcomas in late 2022 or early 2023, expected to be complete by the end of 2023. GenFleet plans to commence several Phase 2 studies for various hematological malignancies in China. SELLAS will pay an upfront payment of $10 million. GenFleet will also receive up to $140 million in milestone payments. Related: Sellas Life Sciences Shares Jump As China Approves Galinpepimut IND For Blood Cancer . Separately, SELLAS Life priced its public offering of 4.6 million shares and accompanying warrants to purchase up to 4.6 million shares at a combined price of $5.40, with gross proceeds of $25 million . The warrants have an exercise price of $5.40 per share. Price Action: WUE shares closed 37.9% at $4.15 during the premarket session on the last check Friday.
2022-04-01 09:04:51	UHJD	Cannabis REIT Innovative Industrial Properties Shares Trading Lower On Announcing Pricing Of $300M Common Stock Offering	Innovative Industrial Properties, Inc. (NYSE: UHJD ) announced today the pricing of an underwritten public offering of 1.58 million shares of its common stock at $190 per share for gross proceeds of approximately $300 million. The offering is expected to close on or about April 5, 2022, subject to customary closing conditions. The company has also granted the underwriters a 30-day option to purchase up to an additional 236,842 shares of its common stock. All of the shares are being sold by the company. IIP intends to use the net proceeds from this offering to invest in specialized industrial real estate assets used in the regulated cannabis industry that are consistent with its investment strategy, and for general corporate purposes. BTIG, LLC is acting as sole book-running manager for the offering. Piper Sandler & Co., Roth Capital Partners and Compass Point Research & Trading, LLC are acting as co-lead managers for the offering. The offering of the Company&rsquo;s common stock will be made only by means of a prospectus supplement and the accompanying prospectus. Price Action Innovative Industrial Properties shares traded 5.70% lower at $11.7 per share during the pre-market session on Friday morning. Photo: Courtesy of Jason Briscoe on Unsplash
2022-04-01 09:08:39	EBIH	The York Water Company Announces Proposed Public Offering Of Common Stock; 975,600 Shares Priced At $41/Share	YORK, Pa., April 01, 2022 (GLOBE NEWSWIRE) -- The York Water Company (&quot;York Water&quot; or the &quot;Company&quot;) (NASDAQ: EBIH ), a provider of water and wastewater utility services, announced today the pricing of its previously announced underwritten public offering of common stock. York Water priced an offering of 975,600 shares of its common stock at a price to the public of $41 per share. The aggregate gross proceeds from the offering are expected to be approximately $40 million, before deducting the underwriting discounts and commissions payable by York Water. York Water has granted the underwriters a 30-day option to purchase up to 146,340 additional shares of its common stock at the public offering price, less underwriting discounts, and commissions.
2022-04-04 16:25:37	LLBR	Xponential Fitness Shares Slip On Secondary Equity Offering By Existing Shareholders	Xponential Fitness Inc (NYSE: LLBR ) commenced an underwritten public offering of 4.5 million shares of the company&rsquo;s Class A common stock by certain existing stockholders, affiliates of Snapdragon Capital Partners. Underwriters granted a 30-days option to purchase up to an additional 675,000 shares. Xponential will not receive any proceeds from the sale of the shares offered by the Selling Stockholders. BofA Securities and Jefferies to act as joint lead bookrunners, the proposed Offering to be made only by means of a prospectus. Price Action: LLBR shares are trading lower by 6.10% at $22.15 during the afterhours session on Monday.
2022-04-05 09:27:13	CWMR	Trinity Capital Inc. Announces Pricing of $50M Offering Of Common Stock	Trinity Capital Inc. (NASDAQ: CWMR ) (&quot;Trinity&quot;), an internally managed business development company, today announced that it has priced an underwritten public offering of $50.0 million of shares of its common stock at a public offering price of $18.15 per share. In connection with the proposed offering, Trinity has granted the underwriters a 30-day option to purchase up to 413,226 additional shares of its common stock. All of the shares of common stock to be sold in the offering are to be sold by Trinity. The completion of the offering is subject to customary closing conditions and the shares are expected to be delivered on April 7, 2022. Trinity intends to use the net proceeds from this offering to pay down a portion of its existing indebtedness outstanding under its KeyBank Credit Facility, to make investments in accordance with its investment objective and investment strategy, and for general corporate purposes. Keefe, Bruyette & Woods, A Stifel Company , Wells Fargo Securities and UBS Investment Bank are acting as joint- lead book-running managers for the offering. Goldman Sachs & Co. LLC is acting as a joint book-running manager in the offering. Oppenheimer & Co., B. Riley Securities, Inc., Ladenburg Thalmann & Co. Inc. and Compass Point are acting as co-managers for this offering. The shares will be sold pursuant to an effective shelf registration statement on Form N-2 that has been filed with, and has been declared effective by, the Securities and Exchange Commission (SEC). Investors are advised to carefully consider the investment objectives, risks and charges and expenses of Trinity before investing. The preliminary prospectus, dated April 4, 2022, and accompanying prospectus, dated January 27, 2022, each of which has been filed with the SEC, contain a description of these matters and other important information about Trinity and should be read carefully before investing. This press release will not constitute an offer to sell or the solicitation of an offer to buy the securities described above nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction. Offers of these securities are made only by means of the prospectus. The SEC has not approved or disapproved these securities or passed upon the adequacy of the preliminary prospectus. Any representation to the contrary is a criminal offense. A shelf registration statement relating to these securities is on file with and has been declared effective by the SEC. The offering may be made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained, when available, from: Keefe, Bruyette & Woods, Inc., Attn: Equity Capital Markets, 787 7th Avenue, 4th Floor, New York, NY 10019, telephone: 1-800-966-1559; Wells Fargo Securities, Attention: Equity Syndicate Department, 30 Hudson Yards, New York, NY, 10001, by telephone: (800) 326-5897 or by email at cmclientsupport@wellsfargo.com ; UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, telephone: (888) 827-7275 or email: ol-prospectusrequest@ubs.com and Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by phone: 1-866-471-2526, or by emailing Prospectus-ny@ny.email.gs.com .
2022-04-06 09:04:52	XVGK	Digimarc Announces Registered Direct Offering of Common Stock Of 2.25M Shares Of Common Stock At Price Of $25.90/Share	Digimarc Corporation (NASDAQ: XVGK ), a global leader in product digitization, today announced that it has entered into purchase agreements to sell a total of 2,250,000 common shares in a registered direct offering to certain investors at a price of $25.90 per share. The offering was made without an underwriter or placement agent. The gross proceeds to Digimarc from the offering are expected to be approximately $58.3 million. The offering is expected to close on or about April 7, 2022. Digimarc intends to use the net proceeds from the offering for general corporate purposes.
2022-04-06 09:34:29	RRRG	Why Celsion Shares Are Pulling Back Today	Celsion Corp (NASDAQ: RRRG ) shares are trading lower Wednesday after the company announced a $7 million registered direct offering priced at-the-market under Nasdaq rules. What To Know: The offering comes after the stock traded significantly higher on Tuesday as traders circled a Zacks Small-Cap Research note. Zacks analyst David Bautz highlighted the business update Celsion provided at the end of March. The company announced that following a pre-planned interim safety review of patients in the Phase 1/2 OVATION 2 study of GEN-1 in advanced stage ovarian cancer, the data safety monitoring board unanimously recommended that patients continue to be treated in the study. Zacks anticipates enrollment being completed in the third quarter and the primary endpoint of progression-free survival being reported about a year later. Based on a probability adjusted discounted cash flow model that accounts for potential GEN-1 revenues, the firm believes Celsion is fairly valued around $37 per share. See Also: Why BioXcel Therapeutics Stock Is Surging Today RRRG 52-Week Range: $0.31 - $7.68 According to data from Benzinga Pro , the stock was down 19.6% at $5.01 at time of publication.
2022-04-06 11:53:26	XVGK	Digimarc To Raise $58.3M Via Secondary Share Sale At Discount; Shares Pop	Product digitization firm Digimarc Corp (NASDAQ: XVGK ) agreed to sell 2.25 million shares at $25.90 per share in a secondary offering . The offer price implies a 1.6% discount to Digimarc's April 5 closing of $26.32. The gross proceeds from the offering will likely be $58.3 million. Digimarc looks to use the offering proceeds for general corporate purposes. The offering will likely close by April 7. Price Action: XVGK shares traded higher by 7.94% at $28.41 on the last check Wednesday.
2022-04-07 08:04:32	YKGE	Trevi Therapeutics Prices $55M Private Placement At The Market	"Trevi Therapeutics, Inc. (NASDAQ: YKGE ), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio&trade; (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that it has entered into a definitive agreement with certain healthcare-focused institutional investors for the purchase, in a private placement priced at-the-market under Nasdaq rules, of (i) 4,580,526 shares of common stock at a purchase price of $1.90 per share, and (ii) pre-funded warrants to purchase up to an aggregate of 24,379,673 shares of common stock at a purchase price of $1.899 per warrant, for gross proceeds of approximately $55 million. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until exercised in full. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"" src=""https://mma.prnewswire.com/media/1504281/Trevi_logo_April_2021_Logo.jpg"" /> Frazier Life Sciences and Venrock Healthcare Capital Partners are co-lead investors in the private placement, and Fairmount and New Enterprise Associates are also participating. Stifel is acting as lead placement agent for the private placement. Needham & Company, Oppenheimer & Co. and Aegis Capital Corp. are acting as co-placement agents for the private placement. The Company intends to use the net proceeds from the private placement for the clinical development of Haduvio for chronic cough in idiopathic pulmonary fibrosis patients as well as for working capital and other general corporate purposes. The private placement is expected to close on or about April 11, 2022, subject to the satisfaction of customary closing conditions. The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the private placement (the &quot;Resale Securities&quot;). This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offering of the Resale Securities under the resale registration statement will only be by means of a prospectus."
2022-04-07 12:37:51	YKGE	Trevi Therapeutics Shares Gain On Raising $55M Via Equity	Trevi Therapeutics Inc (NASDAQ: YKGE ) has announced a private placement of 4.5 million priced at $1.90 per share and pre-funded warrants to purchase up to 24.4 million shares at $1.899 per warrant. The gross proceeds are approximately $55 million . Each pre-funded warrant will have an exercise price of $0.001 per share and be exercisable immediately. Frazier Life Sciences and Venrock Healthcare Capital Partners are co-lead investors in the private placement, and Fairmount and New Enterprise Associates are also participating. In February, Trevi Therapeutics announced positive interim analysis results from the Phase 2 CANAL trial of Haduvio (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough. The company plans to report data from the full CANAL trial early in Q3 of 2022. Last month, the company concluded enrollment early for its Phase 2 CANAL trial with approximately 40 subjects. Price Action: YKGE shares are up 51% at $2.87 during the market session on the last check Thursday.
2022-04-07 19:48:54	KKB	Camden Property Trust Priced Public Offering of 2,900,000 Common Shares for Gross Proceeds of ~$493M; ~$170/Share	Camden Property Trust (NYSE: KKB ) today announced it has priced a public offering of 2,900,000 common shares for gross proceeds of approximately $493 million. The offering is expected to close on April 12, 2022, subject to customary closing conditions. BofA Securities and Wells Fargo Securities, the joint book-running managers for the offering, have been granted a 30-day option to purchase up to an additional 435,000 common shares. The underwriters may offer the common shares from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Camden intends to use the net proceeds to reduce borrowings under its $900 million unsecured line of credit incurred to fund the acquisition from Teacher Retirement System of Texas of its 68.7% interest in two of Camden's investment funds and for general corporate purposes, which may include financing for acquisitions and funding for development activities.
2022-04-08 07:36:19	GUDY	Lyra Therapeutics Reports Price Placement For Gross Proceeds ~$110.5M	Lyra Therapeutics, Inc. (NASDAQ: GUDY ) today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $100.5 million, before deducting offering expenses . In the private placement, investors had the option to purchase either (a) shares of the Company's common stock at a price of $4.22 per share, or (b) in lieu thereof, pre-funded warrants to purchase shares of the Company's common stock, with an exercise price of $0.001 per share, at a purchase price of $4.219 per share (for aggregate consideration equating to $4.22 per share). Accordingly, pursuant to the securities purchase agreement, (i) certain investors agreed to purchase an aggregate of 18,815,159 shares of common stock at the purchase price described in the foregoing sentence and (ii) certain investors agreed to purchase pre-funded warrants to purchase an aggregate of 5,000,000 shares of common stock, with the exercise price and at the purchase, in each case, described in the foregoing sentence. Each pre-funded warrant will be exercisable immediately. The closing of the offering is subject to certain conditions and is expected to occur on April 12, 2022. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or applicable state securities laws, and will be sold in a private placement pursuant to Regulation D of the Securities Act. The securities being issued in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the foregoing securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-04-08 09:40:08	LKXK	Why Sunshine Biopharma Stock Is Falling Today	Sunshine Biopharma Inc (NASDAQ: LKXK ) shares are trading lower following a Form424B3 filing. The company stated the filing showed the resale S3 from March 30 is now effective. Sunshine Biopharma plans to offer on a resale basis an aggregate of 7,207,208 shares of common stock. The stock has seen increased retail investor interest this week after the company on Tuesday announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture. Sunshine Biopharma is a pharmaceutical company focused on researching, developing and commercializing oncology and antiviral drugs. It was the top trending stock on Stocktwits at publication time. See Also: Why CrowdStrike Stock Is Trading Higher LKXK 52-Week Range: $0.04 - $9.87 According to data from Benzinga Pro , the stock was down 20.7% at $7.67 at press time. Photo: Gam-Ol from Pixabay.
2022-04-08 12:02:17	GUDY	Lyra Therapeutics Stock Surges On Equity Raise Of $100M	Lyra Therapeutics Inc (NASDAQ: GUDY ) has announced a private placement of approximately $100.5 million . The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants to purchase an aggregate of 5 million shares with an exercise price of $0.001 per share, at $4.219 per share. Each pre-funded warrant will be exercisable immediately. Related: Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Na&iuml;ve Chronic Rhinosinusitis Patients . The offering will close by April 12. LYR-210 and LYR-220 are designed to be administered in non-invasive, in-office procedures and deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages of CRS patients. As of December 31, 2021, cash & cash equivalents were $45.7 million . Price Action: GUDY shares are up 26.2% at $5.45 during the market session on the last check Friday.
2022-04-11 11:45:18	WRTW	Trinity Biotech Stock Surges After $45M Capital Infusion From Korea-Based Firm	Trinity Biotech plc (NASDAQ: WRTW ) announced a $45 million investment and partnership with MiCo Ltd , a KOSDAQ-listed and Korea-based company. MiCo is engaged in the biomedical business through its affiliate MiCo BioMed and provides cutting-edge technology-driven solutions in the semi-conductor and green energy sectors. MiCo's investment consists of approximately 11.2 million ADSs at $2.25 per ADS, representing a 130% premium to Trinity Biotech's closing price of $0.98 on April 8. MiCo will hold 29.9% of Trinity Biotech's voting share capital following this investment. In addition to the newly issued equity, the company has agreed to issue a seven-year, unsecured junior convertible note for $20 million, with a fixed interest rate of 1.5% and an ADS conversion price of $3.24 per ADS. The company intends to use the funds primarily to repay a portion of its $81.25 million term loan, which is expected to reduce its annual interest cost by approximately $4 million each year. The company reported FY21 sales of $92.96 million , down 8.8% Y/Y. Point-of-Care revenues increased 12.2% to $10.3 million, driven by higher HIV sales in Africa. Clinical Laboratory revenues decreased 10.9% to $82.6 million, mainly due to lower PCR Viral Transport Media sales. Price Action: WRTW shares are up 37.7% at $1.35 during the market session on the last check Monday.
2022-04-11 17:06:55	EIQV	Hoth Therapeutics Plunges Afterhours On Secondary Public Offering Of Common Stock	Hoth Therapeutics Inc (NASDAQ: EIQV ) says it has commenced an underwritten public offering . Details were not disclosed. The company's proposed offering of the common stock is being offered under a &quot;shelf&quot; registration statement on Form S-3 filed with SEC and declared effective by the SEC on March 11, 2020. A prospectus supplement describing the terms of the public offering will be filed with the SEC. During the market session, the Hoth Therapeutics shares surged more than 100% after the company announced development updates for its novel cancer therapeutic, HT-KIT. Related : Why Are Hoth Therapeutics Shares Surging More Than 100% Today? Price Action: EIQV shares are trading lower by 13.29% at $0.91 during the post-market session on Monday.
2022-04-11 17:21:04	XXQV	TeraWulf Reports Offering Of Common Stock	TeraWulf Inc. (NASDAQ: XXQV ) (&quot;TeraWulf&quot; or the &quot;Company&quot;), which owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States, today announced that it is commencing an underwritten public offering of its common stock (the &quot;Offering&quot;). TeraWulf also expects to grant to the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. All of the shares to be sold in the Offering will be sold by TeraWulf, subject to customary closing conditions. TeraWulf intends to use the net proceeds from the Offering for mining operations and digital asset infrastructure and for working capital and general corporate purposes. Certain of TeraWulf's existing investors, including the Company's Chief Executive Officer Paul Prager, have agreed to purchase $5,000,000 of shares of the Company's common stock, at a price of $7.88 per share (the last reported sale price of the common stock on the Nasdaq on April 8, 2022) in a private offering, which is expected to close prior to or concurrently with the closing of the Offering. Cantor Fitzgerald & Co. is acting as sole book-running manager for the Offering. The Offering is being made pursuant to a shelf registration statement (File No. 333-262226) declared effective by the Securities and Exchange Commission (&quot;SEC&quot;) on February 4, 2022. A preliminary prospectus supplement relating to the Offering will be filed with the SEC. The securities may be offered only by means of a written prospectus, including a prospectus supplement, forming a part of the effective registration statement. When available, copies of the preliminary prospectus supplement and accompanying base prospectus relating to the Offering may be obtained from the SEC at http://www.sec.gov . Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering can be obtained, when available, from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: prospectus@cantor.com . The final terms of the Offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-04-12 08:33:28	ATSY	Kintara Announces $8.6M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	SAN DIEGO, April 12, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: ATSY ) (&quot;Kintara&quot; or the &quot;Company&quot;), a biopharmaceutical company focused on the development of new solid tumor cancer therapies today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 16,226,416 shares of the Company's common stock (the &quot;Shares&quot;) and warrants to purchase 16,226,416 shares of the Company's common stock (the &quot;Warrants&quot;) at a combined purchase price of $0.53 per Share and related Warrant in a registered direct offering priced at-the-market under Nasdaq rules for gross proceeds of approximately $8.6 million, before deducting fees and other offering expenses. The Warrants will have an exercise price of $0.41 per share, will be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about April 14, 2022, subject to the satisfaction of customary closing conditions.
2022-04-12 09:27:38	XXQV	TeraWulf Inc. Announces Pricing Of Offering For Gross Proceeds Of ~$20.6M	TeraWulf Inc. (NASDAQ: XXQV ) (&quot;TeraWulf&quot; or the &quot;Company&quot;) today announced that it priced a public offering of its common stock (the &quot;Offering&quot;) for gross proceeds of approximately $20.6 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, the Company granted the underwriters a 30-day option to purchase approximately $3.1 million of additional shares of common stock. All of the shares in the Offering are being sold by the Company. The Company anticipates using the net proceeds from the Offering to build mining operations and establish digital asset infrastructure and for working capital and general corporate purposes. The Offering is expected to close on April 14, 2022, subject to customary closing conditions. Certain of TeraWulf's existing investors, including the Company's Chief Executive Officer Paul Prager, have agreed to purchase $5.0 million of shares of the Company's common stock, at a price of $7.88 per share (the last reported sale price of the common stock on the Nasdaq on April 11, 2022) in a private offering, which is expected to close prior to or concurrently with the closing of the Offering. Cantor Fitzgerald & Co. acted as the sole book-running manager for the Offering.
2022-04-12 13:54:12	CRSB	LIXTE Biotechnology Announces $5.8M Registered Direct Offering Priced At-The-Market	LIXTE Biotechnology Holdings, Inc. (NASDAQ: CRSB ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has entered into definitive agreements for the purchase and sale of 2,900,000 shares of LIXTE's common stock, at a purchase price of $2.00 per share, in a registered direct offering. The closing of the offering is expected to occur on or about April 14, 2022, subject to the satisfaction of customary closing conditions. WestPark Capital, Inc. and WallachBeth Capital, LLC are acting as co-placement agents for the offering. The gross proceeds to LIXTE from this offering are expected to be approximately $5.8 million before deducting the placement agents' fees and other offering expenses payable by LIXTE. The company intends to use the net proceeds from the offering for working capital and general expenses including further development of its lead clinical compound BJ-100. The shares of common stock are being offered by Lixte pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333-252430) previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on January 26, 2021 and declared effective by the SEC on February 5, 2021. The offering of the securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or from: WestPark Capital, Inc. - Attention: Jason Stern, 1900 Avenue of the Stars, 3rd Floor, Los Angeles, CA 90077 or by Email: syndicate@wpcapital.com or by telephone at (310) 203-2919. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-04-12 16:29:27	IBLX	Why Hillman Solutions Stock Is Falling After Hours	Hillman Solutions Corp (NASDAQ: IBLX ) shares are trading lower in Tuesday's after-hours session after the company reported preliminary results and announced an offering. Hillman said the company expects first-quarter revenue to be $363 million, up from $341.3 million year-over-year. Operating income is expected to be $8.8 million and adjusted EBITDA is expected to reach $44 million, compared to $47.8 million in the prior year quarter. The company also announced the commencement of an underwritten public offering of 10 million shares. The offering consists entirely of shares of common stock to be sold by the selling stockholders. Hillman will not receive any proceeds from the sale. Hillman is a provider of hardware-related products and related merchandising services to retail markets in North America. IBLX 52-Week Range: $8.12 - $13.46 According to data from Benzinga Pro , the stock was down 8.84% in after hours at $10.51 at press time.
2022-04-12 16:53:36	HJWT	Liquidia Shares Slide On Proposed Public Offering	Liquidia Corp (NASDAQ: HJWT ) has commenced an underwritten public offering of its common stock. All of the shares are to be sold by the company. Underwriters will be granted a 30-day option to purchase up to an additional 15% of the shares of HJWT's common stock. BofA Securities is the sole book-running manager for the proposed offering. Needham & Company and BTIG are acting as lead managers. Liquidia is offering the shares of common stock according to its shelf registration statement on Form S-3, including a base prospectus that Liquidia previously filed with SEC on December 16, 2020 , and declared effective on December 23, 2020. The actual size or terms of the offering are not yet assured. Price Action: HJWT shares are trading lower by 11.15% at $5.50 during the post-market session on Tuesday.
2022-04-13 07:15:20	IBLX	Hillman Announces Upsize And Pricing Of Secondary Offering Of Common Stock By Selling Stockholders; 13M Shares At $10/Share, Up From 10M Shares Previously	Hillman Solutions Corp. (NASDAQ: IBLX ) (the &ldquo;Company&rdquo; or &ldquo;Hillman&rdquo;), a leading provider of hardware products and merchandising solutions, today announced the upsize and pricing of the previously announced underwritten public offering of shares of the Company&rsquo;s common stock (the &ldquo;Offering&rdquo;) by certain stockholders of the Company (the &ldquo;Selling Stockholders&rdquo;). The size of the Offering increased from the previously announced 10,000,000 shares to an aggregate of 13,000,000 shares of the Company&rsquo;s common stock, at a price to the public of $10.00 per share. The Offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary closing conditions. In addition, the Selling Stockholders have granted the underwriters a 30-day option to purchase up to an aggregate of 1,950,000 additional shares of the Company&rsquo;s common stock at the public offering price less underwriting discounts and commissions. The Offering consists entirely of shares of common stock to be sold by the Selling Stockholders, and the Company will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders. Jefferies and Baird are acting as lead book-running managers for the Offering. Stifel is also acting as a joint book-running manager for the Offering. Raymond James, Benchmark Bankshares, and CJS Securities are acting as co-managers of the offering. The Company has filed a registration statement on Form S-1 (Registration No. 333-258823) (including a base prospectus), which has been declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;). The Company has also filed a preliminary prospectus supplement with the SEC for the Offering. The Offering will be made only by means of a prospectus supplement and an accompanying prospectus. Before you invest, you should read the prospectus included in that registration statement as well as the prospectus supplement related to this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov . Alternatively, copies of the preliminary prospectus supplement and accompanying prospectus, as well as copies of the final prospectus supplement once available, may be obtained by contacting: Jefferies LLC, at Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at 877-821-7388, or by email at prospectus_department@jefferies.com or Robert P. Baird & Co. Incorporated, Attention: Syndicate Department, 777 East Wisconsin Avenue, Milwaukee, WI 53202, by telephone at 800-792-2473, or by email at syndicate@rwbaird.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-04-13 17:01:09	PZJI	Sonic Foundry Announces Proposed Public Offering Of Common Stock; Size Not Disclosed	Sonic Foundry Inc. (NASDAQ: PZJI ), the trusted leader in video capture, management and streaming solutions as well as virtual and hybrid events, today announced it has commenced an underwritten public offering of shares of its common stock. The public offering is subject to market conditions, and there can be no assurance as to whether or when the public offering may be completed, or the actual size or terms of the public offering. Maxim Group LLC is acting as the sole book-running manager for the public offering. The public offering is being made pursuant to an effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on February 17, 2022 and declared effective on March 1, 2022. A preliminary prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the public offering may be obtained, when available, by contacting Maxim Group LLC, 300 Park Avenue, New York, NY 10022, or by telephone at (212) 895-3745. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Sonic Foundry&reg;, Inc. Sonic Foundry (NASDAQ: PZJI ) is the global leader for video capture, management and streaming solutions as well as virtual and hybrid events. Trusted by thousands of educational institutions, corporations, health organizations and government entities in over 65 countries, Sonic Foundry's solutions include Mediasite&reg;, Mediasite Connect, Vidable&trade; and Global Learning Exchange&trade;.
2022-04-14 08:17:58	ANBK	Inozyme Pharma Announces $73M Underwritten Offering Priced At-the-Market	Inozyme Pharma, Inc. (NASDAQ: ANBK ), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
2022-04-14 16:05:43	LZKN	Pulse BioSciences Reports Rights Offering For $15M In Units	Pulse Biosciences, Inc. (NASDAQ: LZKN ) (the &ldquo;Company&rdquo; or &ldquo;Pulse Biosciences&rdquo;), a novel bioelectric medicine company, today announced that the Company&rsquo;s Board of Directors has approved a rights offering available to all holders of record of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;) as of the close of market on April 25, 2022 (the &ldquo;Record Date&rdquo;). The offering is to commence on or about May 4, 2022. The Company intends to issue non-transferable subscription rights to its stockholders of record as of the Record Date to purchase up to $15,000,000 of units (the &ldquo;Units,&rdquo; and each, a &ldquo;Unit&rdquo;) at a subscription price per Unit equal to the lesser of (i) $3.72 per share, the closing price of the Common Stock on April 13, 2022 (the &ldquo;Initial Price&rdquo;) and (ii) the volume weighted average price of the Common Stock for the five-trading day period through and including the subscription expiration date (the &ldquo;Alternate Price&rdquo;). Each Unit shall consist of one share of the Company&rsquo;s Common Stock and a warrant to purchase one share of Common Stock at an exercise price that shall be equal to the subscription price for the Units. The Common Stock and the warrants comprising the Units will separate upon the closing of the rights offering and will be issued separately; however, they may only be purchased as a Unit and the Units will not trade as a separate security. Following the Record Date, the Company intends to mail to stockholders of record on the Record Date a prospectus and related documents for use in exercising subscription rights. The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m., Eastern Time, on May 23, 2022 (the &ldquo;Expiration Date&rdquo;). Stockholders wishing to exercise subscription rights must timely pay the Initial Price for the full number Units they wish to acquire. If the Alternate Price on the Expiration Date is lower than the Initial Price, any excess subscription amounts paid by a subscribing holder will be applied towards the purchase of additional Units in the rights offering. The Company will not sell fractional Units. Stockholders who fully exercise their basic subscription rights will be entitled to subscribe for additional Units that are not purchased by other stockholders, on a pro rata basis and subject to availability. The Company intends to register the rights offering with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). When available, a copy of the prospectus may be obtained at the SEC&rsquo;s website at www.SEC.gov . This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The rights offering will be made pursuant to the Company&rsquo;s shelf registration statement on Form S-3, which became effective on August 21, 2020, and a prospectus supplement containing the detailed terms of the rights offering to be filed with the SEC. Any offer will be made only by means of a prospectus forming part of the registration statement.
2022-04-18 09:36:57	BULE	Arcos Dorados Offers Sustainability-Linked Senior Notes	Arcos Dorados Holdings Inc (NYSE: BULE ) subsidiary Arcos Dorados B.V. will offer senior unsecured notes in a private placement to qualified institutional buyers. The Notes are expected to be guaranteed on a senior unsecured basis by the company and certain of the company's subsidiaries. The Notes will include sustainability performance targets associated with the company's commitments to reduce greenhouse gas emissions by 36% in its restaurants and offices and by 31% in its supply chain by 2030. The company intends to use the proceeds to fund the tender offers and general corporate purposes. Price Action: BULE shares are trading higher by 0.42% at $7.63 on Monday's last check.
2022-04-20 17:29:59	CYKK	Why Carvana Shares Are Plunging After Hours	Carvana Co (NYSE: CYKK ) shares are trading lower in Wednesday's after-hours session after the company reported financial results. Carvana said first-quarter revenue increased 56% year-over-year to $3.5 billion, which beat the $3.39 billion estimate, according to data from Benzinga Pro . The company reported a quarterly net loss of $506 million. Carvana said omicron, used vehicle prices, interest rates, and other macro factors all negatively impacted retail units sold, which was the main driver of the company's weak results. Retail units sold totaled 105,185. &quot;We view these macro factors as transitory and remain focused on delivering the best possible experiences to our customers,&quot; said Ernie Garcia , founder and CEO of Carvana. Carvana refrained from providing any near-term guidance due to the aforementioned uncertainties surrounding current industry trends. The company will host a conference call to discuss these results beginning at 5:30 p.m. ET. See Also: PayPal Stock Is Approaching 52-Week Lows: What's Going On? Carvana also announced a $1 billion common stock public offering. The company's CEO indicated that he has an interest in purchasing up to an aggregate of $432 million of the company's stock in the offering. The stock reversed on the news but is still trading lower. Additionally, Carvana plans to raise up to $1B from series A perpetual preferred stock and up to $2.275B of senior unsecured notes due 2030 pursuant to a separate offering memorandum for each proposed offering. CYKK Price Action: Carvana shares are making new 52-week lows in Wednesday's after-hours session. The stock was down 7.73% in after-hours at $85.35 at press time. Photo: courtesy of Carvana.
2022-04-21 08:31:45	HUGH	HUGH Technology Company, Inc. Announces $11M Registered Direct Offering Priced At-The-Market	Verb Technology Company, Inc. (NASDAQ: HUGH ) (&quot;HUGH&quot; or the &quot;Company&quot;), a leader in interactive video-based sales enablement applications, including shoppable livestream, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 14,666,667 shares of its common stock at a purchase price of $0.75 per share and warrants to purchase 14,666,667 shares of its common stock at an exercise price of $0.75 per share (together the &quot;Securities&quot;) in a registered direct offering priced at-the-market, resulting in total gross proceeds of approximately $11.0 million before deducting placement agent commissions and other estimated offering expenses. The warrants will become exercisable six months following the date of issuance and will expire five years following the date on which the warrants are initially exercisable. The closing of the offering and sale of the Securities is expected to occur on or about April 25, 2022 subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. This offering is being made pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333-264038) previously filed with and declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on April 14, 2022. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . Before investing in this offering, interested parties should carefully review the prospectus supplement and the accompanying prospectus, as well as the other documents that the Company has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering. This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy these Securities, nor shall there be any sale of these Securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-04-22 07:14:47	CYKK	Carvana Very Early Friday Morning Priced A 15.625M Share Upsized Offering At $80/Share	Carvana Co. (&quot;Carvana&quot;) (NYSE: CYKK ), the leading e-commerce platform for buying and selling used cars, today announced the upsize and pricing of its public offering of 15,625,000 shares of its Class A common stock at a price to the public of $80.00 per share. Ernest Garcia, II, along with Ernie Garcia, III, Carvana&rsquo;s Chief Executive Officer, and entities controlled by one or both of them, will purchase an aggregate of 5,400,000 shares of the Company&rsquo;s Class A common stock in the offering. The offering was upsized from the previously announced offering size of $1 billion of Class A common stock. The offering is expected to close on April 26, 2022, subject to customary closing conditions. Citigroup and J.P. Morgan Securities LLC are acting as book-running managers for the offering. Carvana intends to use the net proceeds from the public offering of Class A common stock for general corporate purposes. The public offering of Class A common stock is being made only by means of an effective registration statement (including a prospectus and a prospectus supplement). A copy of the prospectus, the preliminary prospectus supplement and, when available, the final prospectus supplement relating to the offering may be obtained from Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146 or J.P. Morgan Securities LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com . An automatic shelf registration statement relating to the Class A common stock has been filed with the U.S. Securities and Exchange Commission and is effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.
2022-04-22 08:17:23	ZQGT	SCYNEXIS Prices Public Offering Of Common Stock, Pre-Funded Warrants And Warrants At Offering Price Of $3 Per Share And Accompanying Warrant; Gross Proceeds Expected To Be ~$45M	JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ZQGT ) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $3.00 per share and accompanying warrants, and the pre-funded warrants are being sold at a public offering price of $2.999 per pre-funded warrant and accompanying warrants. The gross offering proceeds to SCYNEXIS from this offering are expected to be approximately $45.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants or warrants. All of the shares of common stock, pre-funded warrants and warrants are being offered by SCYNEXIS.
2022-04-22 08:33:32	JAZH	Salarius Pharmaceuticals, Inc. Announces $2.3M Registered Direct Offering	HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: JAZH ), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 9,339,436 shares of its common stock, at a purchase price per share of $0.25, for gross proceeds of approximately $2.3 million, in a registered direct offering.
2022-04-22 14:58:56	ZQGT	Scynexis's Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections	SCYNEXIS Inc (NASDAQ: ZQGT ) has announced interim data from its ongoing Phase 3 FURI and CARES studies of ibrexafungerp in severe fungal infections. FURI study included fungal infections patients who are either intolerant to standard antifungal therapy or experience refractory fungal infections despite treatment. The CARES study is evaluating oral ibrexafungerp in patients with systemic infections caused by C. auris. Related: Scynexis Aces Ibrexafungerp Late-Stage Study To Prevent Vaginal Yeast Infections . Of the 131 study cases analyzed, 61.1% achieved a complete or partial response or clinical improvement. 22.1% achieved stable disease, a favorable outcome in patients with severe progressive fungal infections. 11.5% were considered no response, including two patients who died of an underlying condition unrelated to the treatment, and 5.3% were indeterminate. SCYNEXIS will present additional details from these interim analyses at the 32nd European Congress of Clinical Microbiology and Infectious Diseases. SCYNEXIS h as priced its underwritten public offering of common stock, pre-funded warrants, and warrants for gross proceeds of $45 million . The shares and warrants have an offer price of $3.00, and the pre-funded warrants are being sold at $2.999. Price Action: ZQGT shares are down 23.30% at $2.41 during the market session on the last check Friday.
2022-04-25 09:22:41	PVHR	Clarus Therapeutics Announces Pricing Of Upsized Underwritten Public Offering At $1.10/Share; Gross Proceeds Expected To Be $30M	Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ: PVHR ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the pricing of its underwritten public offering of (i) units consisting of 26,680,720 shares of its common stock and accompanying Class A warrants to purchase up to 26,680,720 shares of its common stock and (ii) units consisting of pre-funded warrants to purchase up to 590,000 shares of common stock and accompanying Class A warrants to purchase up to 590,000 shares of common stock. Each share of common stock (or pre-funded warrant) is being sold together with one Class A warrant at a combined purchase price of $1.10 per unit (or $1.10 (less) $0.001 (the exercise price of the pre-funded warrants) for units comprising pre-funded warrants and accompanying Class A warrants). Clarus also granted the underwriter an option to purchase up to an additional 4,090,608 shares of common stock and/or Class A warrants to purchase up to 4,090,608 shares of common stock. The Class A warrants will be immediately exercisable at a price of $1.10 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Class A warrants can only be purchased together in the offering, but will be issued separately and will be immediately separable upon issuance. The pre-funded warrants and the Class A warrants will not be listed on any exchange. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, and excluding the proceeds from the exercise of any Class A warrants and the exercise of the underwriter&rsquo;s overallotment option, are expected to be approximately $30.0 million. The offering is expected to close on April 27, 2022, subject to customary closing conditions. Clarus expects to use the net proceeds from the offering, together with its existing cash, for working capital and other general corporate purposes. Maxim Group LLC is acting as sole book-running manager for the offering.
2022-04-26 12:03:34	KMEH	Quantum Completes Raising $67.5M Via Oversubscribed Rights Offering	Quantum Corporation (NASDAQ: KMEH ) completed raising $67.5 million by selling 30 million shares in an oversubscribed rights offering. All eligible directors and executive officers purchased 0.14 million shares. Quantum looks to use the offering proceeds for debt repayment of $20.0 million and improve its balance sheet strength, and for working capital and other general corporate purposes. Chair and CEO Jamie Lerner, Chairman, said, &quot;The proceeds enable us to strengthen our balance sheet, reducing our debt by $20 million and adding over $45 million to our cash position. These steps establish a stronger financial footing for the Company during these ongoing supply-constrained times, allowing us to maintain our focus on growing revenue and fulfilling the increasing demand for our storage solutions.&quot; Price Action: KMEH shares traded higher by 9.50% at $2.19 on the last check Tuesday.
2022-04-26 16:10:50	QVM	Sono Motors Reports 10M Share Follow-On Offering	Sono Group N.V. (NASDAQ: QVM , &ldquo, Sono Motors&rdquo, or the &ldquo, Company&rdquo, ))) announced today the launch of a proposed follow-on offering of 10,000,000 ordinary shares, all of which are being offered by the Company. In addition, Sono Motors expects to grant the underwriters an option, to purchase up to an additional 1,500,000 ordinary shares. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Sono Motors intends to use the net proceeds from this proposed offering to cover some of the capital needed until the start of production of its solar electric vehicle, the Sion. Berenberg, Cantor Fitzgerald, and B. Riley Securities are acting as book-running managers for this proposed offering. Craig-Hallum and Wedbush Securities are acting as co-managers for this proposed offering.
2022-04-27 07:42:54	UYWG	Deciphera Raises $150M Via Equity Offering	Deciphera Pharmaceuticals Inc (NASDAQ: UYWG ) has priced an underwritten public offering of 5.25 million shares at $10.00 per share, for gross proceeds of $150 million . The offer price represents a discount of 3.5% from the last close price of $10.36 on Tuesday. In addition, Deciphera is offering pre-funded warrants to purchase 9.75 million common shares at $9.99 per pre-funded warrant. Underwriters have an option to purchase up to an additional 2.25 million shares. Related: Deciphera's DCC-3116/KRAS Inhibitor Combo Shows Deeper, Longer Tumor Regressions In Preclinical Studies . The offering is expected to close on April 29. Deciphera will use the net proceeds to continue funding the development of vimseltinib, DCC-3116, the pan-RAF program and other new research activities, and the remainder for working capital purposes. Price Action: UYWG shares traded 3.47% lower at $10.00 during pre-market trading on Wednesday.
2022-04-28 09:16:31	VLP	Cyngn Prices ~6.45M Share Offering At $3.10/Unit	Cyngn (or the &quot;Company&quot;) (NASDAQ: VLP ), a developer of innovative autonomous driving software solutions for industrial and commercial applications, today announced that it entered into a securities purchase agreement with certain institutional and accredited investors for aggregate gross proceeds of $20 million, before deducting fees to the placement agent and other offering expenses payable by the Company. In connection with the offering, the Company will issue 6,451,613 units and pre-funded units at a purchase price of $3.10 per unit, priced at-the-market under Nasdaq rules. Each unit and pre-funded unit consist of one share of common stock or common stock equivalent, and one non-tradable warrant exercisable for one share of common stock for $2.98 (for a total of 6,451,613 shares underlying the warrant). The warrant has a term equal to five years from the issuance date. No actual units will be issued in the offering. Assuming the exercise in full of any pre-funded warrants and none of the non-tradable warrants, the Company will have 33,556,043 shares of common stock issued and outstanding at completion of the offering. The offering is expected to close on or about April 29, 2022, subject to the satisfaction of customary closing conditions.
2022-04-29 08:31:59	PYO	Orbital Energy Group Announces $21M Registered Direct Offering	Orbital Energy Group, Inc. (NASDAQ: PYO ) (&quot;Orbital Energy&quot; or the &quot;Company&quot;) today announced that it has entered into a definitive agreement with a single institutional investor, for the purchase and sale of 16,153,847 shares of the Company's common stock (or common stock equivalents) at a purchase price of $1.30 per share and warrants to purchase 16,153,847 shares of its common stock at an exercise price of $1.31 per share in a registered direct offering for gross proceeds of approximately $21.0 million before deducting placement agent fees and other estimated offering expenses. The warrants will have a five-year term and will become exercisable six months following the date of issuance. The closing of the offering is expected to occur on or about May 3, 2022, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-252682) previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) under the Securities Act of 1933, as amended, which was declared effective by the SEC on April 29, 2021. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-04-29 09:21:38	JTFZ	Liberty Energy Announces 14.5M Share Offering By Schlumberger Technology Corporation Has Been Priced	Liberty Energy Inc., formerly known as Liberty Oilfield Services Inc. (NYSE: JTFZ , &ldquo, Liberty&rdquo, or the &ldquo, Company&rdquo, ))), announced today the pricing of the previously announced underwritten public secondary offering (the &ldquo;Offering&rdquo;) of an aggregate of 14,500,000 shares of its Class A common stock by Schlumberger Technology Corporation (the &ldquo;Selling Stockholder&rdquo;). The underwriters intend to offer the shares from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The Offering is expected to close on May 3, 2022, subject to customary closing conditions. Liberty will not sell any shares of Class A common stock in the Offering and will not receive any proceeds therefrom. BofA Securities and J.P. Morgan are acting as joint bookrunning managers for the Offering.
2022-05-03 08:09:18	IWNA	Modular Medical Announces $8M Registered Direct Offering	Modular Medical, Inc. (the &quot;Company&quot; or &quot;Modular Medical&quot;) (NASDAQ: IWNA ), today announced that it has entered into a securities purchase agreement with institutional investor Sio Capital Management (the &quot;Investor&quot;) in connection with a registered direct offering of an aggregate of 449,438 shares of its common stock at an offering price of $4.45 per share, and, in lieu of common stock, pre-funded warrants to purchase up to 1,348,314 shares of common stock at an offering price of $4.44 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant. Concurrent with the registered direct offering, the Company has also agreed to issue to the Investor unregistered common stock purchase warrants (the &quot;Private Placement Warrants&quot;) to purchase up to 1,438,202 shares of common stock in a private placement. The Private Placement Warrants have an exercise price of $6.60 per share and are exercisable beginning six months from the date of issuance for a period of five years. Oppenheimer & Co. Inc. is acting as the sole placement agent for the offering. The gross proceeds from the registered direct offering and concurrent private placement are expected to be $8 million before deducting placement agent fees and other estimated offering expenses. Modular Medical intends to use the net proceeds from this offering for the Company's operations, including the development of its products, and working capital and general corporate purposes. The registered direct offering and concurrent private placement are expected to close on or about May 5, 2022, subject to the satisfaction of customary closing conditions. The common stock and pre-funded warrants and shares underlying the pre-funded warrants described above (but not the Private Placement Warrants or the shares of common stock underlying the Private Placement Warrants) are being offered pursuant to a &quot;shelf&quot; registration statement (File No. 333-264193) that was filed with the U.S. Securities and Exchange Commission (&quot;SEC&quot;) on April 8, 2022, as amended on April 15, 2022, and declared effective on April 19, 2022. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock, pre-funded warrants and shares underlying the pre-funded warrants will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of common stock, pre-funded warrants and shares underlying the pre-funded warrants may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Oppenheimer & Co., Inc., Attention: Syndicate Prospectus Department, at 85 Broad Street, 26th floor, New York, NY 10004, or via email at equityprospectus@opco.com or telephone at (212) 667-8055.
2022-05-04 06:15:40	QSTH	Freshpet Raises $350M Via Equity Offering	Freshpet Inc (NASDAQ: QSTH ) has priced the follow-on offering of 4.3 million shares at $81 per share. The offer price represents a 2.3% discount on the company&rsquo;s closing price on May 3, 2022. Freshpet has also granted the underwriters a 30-day option to purchase up to 0.6 million additional shares of its common stock. The offering is expected to close on May 6, 2022. BofA Securities, Jefferies, and Truist Securities are acting as lead book-running managers for the offering. Price Action: QSTH shares closed lower by 10.93% at $82.92 on Tuesday.
2022-05-04 08:00:46	LZKN	Pulse Biosciences Reports Commencement Of $15M Rights Offering	Pulse Biosciences, Inc. (NASDAQ: LZKN ) (the &ldquo;Company&rdquo; or &ldquo;Pulse Biosciences&rdquo;), a novel bioelectric medicine company, today announced that it has commenced its previously announced rights offering of up to $15,000,000 of units (the &ldquo;Units,&rdquo; and each, a &ldquo;Unit&rdquo;) at the Initial Price (as defined below). The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m., Eastern Time, on May 23, 2022 (the &ldquo;Expiration Date&rdquo;). Pursuant to the rights offering, Pulse Biosciences is distributing non-transferable subscription rights to purchase the Units to each holder of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;), as of April 25, 2022. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. The subscription price per Unit shall be equal to the lesser of (i) $3.72 per Unit (the &ldquo;Initial Price&rdquo;) or (ii) the volume weighted average price of the Company&rsquo;s Common Stock for the five trading day period through and including the Expiration Date (the &ldquo;Alternate Price&rdquo;). The subscription price will determine the final number of Units issuable, and subsequently the pro rata number of Units to which stockholders can subscribe. Each warrant will be exercisable for one share of the Company&rsquo;s Common Stock at an exercise price that shall be equal to the subscription price for the Units. The Common Stock and the warrants comprising the Units will separate upon the closing of the rights offering and will be issued separately; however, they may only be purchased as a Unit and the Units will not trade as a separate security. Stockholders wishing to exercise subscription rights must timely pay $3.72 per Unit, the Initial Price, for the number of Units they wish to acquire. If the Alternate Price is lower than the Initial Price on the Expiration Date, any excess subscription amounts paid by a subscribing holder will be applied towards the purchase of additional Units in the rights offering. Stockholders who fully exercise their basic subscription rights will be entitled to subscribe for additional Units that are not purchased by other stockholders, on a pro rata basis and subject to availability. The rights offering is being made pursuant to the Company&rsquo;s shelf registration statement on Form S-3, which was deemed effective by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on August 21, 2020, including the prospectus contained therein as modified by the prospectus supplement containing the detailed terms of the rights offering filed with the SEC on May 4, 2022. Copies of the foregoing documents may be obtained at the SEC&rsquo;s website at www.SEC.gov . Questions about the rights offering and requests for copies of the prospectus and prospectus supplement relating to the rights offering may be directed to Broadridge Corporate Issuer Solutions, Inc., the Company&rsquo;s information, subscription and warrant agent for the rights offering, at the address and phone number provided at the end of this release. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-05-05 09:29:50	XHJU	Aegla BioTherapeutics Announces $45M Registered Direct Offering Priced At A Premium To Market	AUSTIN, Texas, May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: XHJU ), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of registered securities of the Company in a registered direct offering for gross proceeds to Aeglea of approximately $45 million, prior to deducting placement agent fees and estimated offering expenses. The financing includes participation from Bain Capital Life Sciences, LP, Great Point Partners, LLC, clients of Nantahala Capital Management, Sio Capital Management, LLC and other institutional investors. The financing includes 10,752,688 shares of the Company's common stock at a price of $1.60 per share and pre-funded warrants to purchase 17,372,397 shares of common stock, at a price of $1.5999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 exercise price for each pre-funded warrant. The offering is expected to close on or about May 9, 2022, subject to customary closing conditions. JonesTrading Institutional Services LLC is acting as placement agent for the registered direct offering.
2022-05-06 08:30:43	VGLI	Palisade Bio Announces $2M Registered Direct Offering	Palisade Bio, Inc. (NASDAQ: VGLI ) (the &quot;Company&quot; or &quot;Palisade Bio&quot;), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55 per share. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering. The closings of the sale of the securities in the financing is expected to occur on or about May 10, 2022, subject to the satisfaction of customary closing conditions. Palisade Bio intends to use the net proceeds from the financing for working capital and general corporate purposes, including the development of the Company's lead product candidate LB1148.
2022-05-09 08:35:26	XUDA	RedHill Biopharma Announces $15M Registered Direct Offering With A Leading Healthcare Investor	RedHill Biopharma Ltd. (NASDAQ: XUDA ) (&quot;RedHill&quot; or the &quot;Company&quot;), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement with a single leading healthcare investor for the purchase and sale of 10,563,380 of the Company's American Depositary Shares (&quot;ADSs&quot;) (or ADS equivalents), each ADS representing ten (10) ordinary shares, at a purchase price of $1.42 per ADS (or ADS equivalent), in a registered direct offering. RedHill has also agreed to issue to the investor unregistered private warrants to purchase up to an aggregate of 13,204,225 ADSs in a concurrent private placement. The warrants have an exercise price of $1.48 per ADS, are exercisable six months after the issuance date and have a term of five and one-half years. The closing of the offering is expected to occur on or about May 11, 2022, subject to the satisfaction of customary closing conditions. Cantor Fitzgerald & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $15 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital, acquisitions, and general corporate purposes. The securities described above (but not the warrants or the ADSs underlying the warrants) are being offered by the Company pursuant to a &quot;shelf&quot; registration statement on Form F-3 (File No 333-258259) previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on July 29, 2021, and declared effective by the SEC on August 9, 2021. The offering of the securities is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Cantor Fitzgerald & Co., 499 Park Avenue, 4th Floor, New York, New York 10022, Attn: Capital Markets Department, or by email at prospectus@cantor.com . The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;), and Regulation D promulgated thereunder and, along with the ADSs underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying ADSs may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-05-11 16:41:56	CF	Eversource Energy Announces $1.2B Offering	Eversource Energy (NYSE: CF ) today announced that it has entered into an equity distribution agreement pursuant to which it may sell its common shares having an aggregate offering price of up to $1,200,000,000 (the &quot;Shares&quot;) from time to time through an &quot;at-the-market&quot; or ATM equity offering program (the &quot;ATM Offering&quot;). Goldman Sachs & Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Wells Fargo Securities, LLC, Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as managers for the ATM Offering and may offer the Shares in transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise. Sales may be made at either market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make an offer, solicitation or sale in such jurisdiction. The ATM Offering of the Shares is being made pursuant to Eversource Energy's effective shelf registration statement that has been filed with the Securities and Exchange Commission (the &quot;SEC&quot;). A prospectus supplement related to the offering has also been filed with the SEC and is available on the SEC's website at http://www.sec.gov . In addition, copies of the prospectus and prospectus supplement relating to the Shares offered in the ATM Offering may be obtained when available by contacting: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by e-mail at prospectus-ny@ny.email.gs.com ; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at barclaysprospectus@broadridge.com ; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or telephone: 1-800-831-9146; Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, NY, 10001, by telephone at 800-326-5897, or by email at cmclientsupport@wellsfargo.com ; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com . Eversource Energy has approximately 345 million common shares outstanding. It operates New England's largest energy delivery system and serves approximately 4.4 million electric, natural gas and water utility customers in Connecticut, Massachusetts and New Hampshire.
2022-05-12 08:28:05	SYLU	iMedia Brands Announces Pricing Of $24M Registered Direct Offering	iMedia Brands, Inc. (the &quot;Company&quot; or iMedia Brands) (NASDAQ: SYLU ) today announced the pricing of a registered direct offering of (i) 4,038,281 shares of its common stock, at an offering price of $3.07 per share, (ii) pre-funded warrants to purchase 3,763,022 shares of its common stock at an offering price of $3.0699 per pre-funded warrant, which represents the per share offering price of its common stock less the $0.0001 per share exercise price for each pre-funded warrant and (iii) warrants to purchase 7,801,303 shares of its common stock, with a per share exercise price of $2.94, which are only exercisable upon receipt of stockholder approval of an increase in the authorized shares of its common stock, which the Company will seek at its upcoming 2022 annual meeting, and which are exercisable for the earlier of (a) five years from the date of receiving such shareholder approval and (b) six years from the date of warrant issuance. The initial closing of the offering is expected to occur on or about May 16, 2022, subject to customary closing conditions, with subsequent closings to occur within 180 days of the receipt of stockholder approval of the increase in authorized shares. The gross proceeds to the Company from this offering are expected to be approximately $24.0 million, before deducting placement agent fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay off a certain amount of its existing debt and for working capital and general corporate purposes. The offering includes an aggregate of $1.95 million from the Company's chief executive officer, Timothy Peterman, and Michael Friedman, Landel Hobbs and an affiliate Eyal Lalo, who each serve on the Company's board of directors. Craig-Hallum Capital Group LLC is acting as exclusive placement agent for the registered direct offering. A shelf registration statement on Form S-3 (File No. 333-258519) relating to the offering of the securities described above was filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on August 5, 2021 and declared effective by the SEC on August 12, 2021. The shares may be offered only by means of a prospectus. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and made available on the SEC's website at www.sec.gov . Copies of the final prospectus supplement and accompanying prospectus relating to the offering may also be obtained, when available, by contacting Craig-Hallum Capital Group LLC, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, Attn: Equity Capital Markets, by telephone at (612) 334-6300 or by e-mail at prospectus@chlm.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
2022-05-12 17:19:09	LSER	LiqTech Announces Proposed Offering Of Common Stock Up To 15% Additional Shares Of Common Stock	LiqTech International, Inc. (NASDAQ: LSER) (&quot;LiqTech&quot; or the &quot;Company&quot;) , a clean technology company that manufactures and markets highly specialized filtration technologies, today announced that it has commenced a proposed underwritten public offering of newly issued shares of common stock or pre-funded warrants in lieu of shares of common stock. In addition, the Company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of shares of its common stock sold in the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2022-05-13 06:30:26	LSER	LiqTech Prices Offering Of ~15.6M Shares At $0.50/Share, Pre-Funded Warrant	LiqTech International, Inc. (NASDAQ: LSER) (&quot;LiqTech&quot; or the &quot;Company&quot;) , a clean technology company that manufactures and markets highly specialized filtration technologies, today announced the pricing of an underwritten public offering of 15,635,850 shares of common stock at an offering price of $0.50 per share and pre-funded warrants to purchase 30,425,000 shares of common stock at an offering price of $0.499 per pre-funded warrant, which represents the per share offering price of the Company's common stock less the $0.001 per share exercise price for each pre-funded warrant for total gross proceeds of approximately $23.0 million, before underwriting discounts and commissions and offering expenses payable by LiqTech. The offering is expected to close on or about May 17, 2022, subject to the satisfaction or waiver of customary closing conditions. Lake Street Capital Markets, LLC is acting as representative of the underwriters and sole book-running manager for the offering and Joseph Gunnar & Co., LLC is acting as the co-manager. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, as well as repaying all or a portion of its outstanding senior convertible note. The securities will be offered pursuant to a shelf registration statement on Form S-3, as amended, which was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on May 12, 2022. The offering is being made solely by means of a prospectus. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov . Copies of the preliminary prospectus supplement and, when available, copies of the final prospectus supplement relating to this offering can be obtained at the SEC's website or from Lake Street Capital Markets, LLC, Attn: Syndicate Department, 920 Second Avenue South, Suite 700, Minneapolis, MN 55402, by calling (612) 326-1305, or by emailing syndicate@lakestreetcm.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
2022-05-16 07:30:29	LYAZ	Zentalis Pharmaceuticals Prices 10,330,000 share common stock offering at $19.38/Share	Zentalis Pharmaceuticals, Inc. (NASDAQ: LYAZ ), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pricing of an underwritten offering of 10,330,000 shares of its common stock at an offering price of $19.38 per share, for total gross proceeds of approximately $200.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on May 18, 2022, subject to customary closing conditions. Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including the clinical development of ZN-c3 and ZN-d5, and for working capital and other general corporate purposes. Zentalis believes that the net proceeds from the offering and its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025. Morgan Stanley, Jefferies, SVB Securities and Guggenheim Securities are acting as joint book-running managers for the offering, and Wedbush PacGrow is acting as co-manager for the offering. L.C. Wainwright is acting as financial advisor to Zentalis for the offering. The securities described above are being offered pursuant to an effective shelf registration statement that was filed with the U.S. Securities and Exchange Commission (SEC) on May 4, 2021. This offering is being made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.
2022-05-16 08:14:47	RXIO	Biofrontera Prices ~3.4M Share Offering Of Common Stock, Warrant At $2.75/Unit	Biofrontera, Inc. (NASDAQ: RXIO , BFRIW))), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 3,419,000 shares of common stock, in a private placement. The purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $2.75. The warrants have an exercise price of $2.77 per share, will be exercisable six months after issue date, and will expire five and one-half years from the issuance date. Roth Capital Partners and The Benchmark Company are acting as the exclusive placement agents for the private offering. The gross proceeds from the private placement offering are expected to be approximately $9.4 million. The private offering is expected to close on or about May 17, 2022, subject to the satisfaction of customary closing conditions. The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;) and Regulation D promulgated thereunder, and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Under an agreement with the investor, the Company is required to file an initial registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued to the investors and shares of common stock underlying the warrants described above within 15 calendar days and to use its best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 90 days in the event of a &ldquo;full review&rdquo; by the Securities and Exchange Commission.
2022-05-17 16:33:36	BVGC	Ares Commercial Real Estate Corporation Announces Launch Of Offering Of Up To 1,050,000 Shares Of Common Stock	Ares Commercial Real Estate Corporation Announces Launch of Offering of Common Stock Ares Commercial Real Estate Corporation (the &quot;Company&quot;) (NYSE: BVGC ) announced today the launch of an underwritten public offering of 7,000,000 shares of common stock. The Company expects to grant to the underwriters of the offering an option to purchase up to 1,050,000 additional shares of common stock. The Company intends to use all of the net proceeds from the offering for general corporate purposes, including (i) investing in mortgage loans and other target assets and investments consistent with its investment strategies and investment guidelines (ii) funding commitments on existing mortgage loans and (iii) repaying indebtedness. Morgan Stanley & Co. LLC, Wells Fargo Securities, LLC, Citigroup Global Markets Inc. and UBS Securities LLC are joint book running managers for the offering, and JMP Securities, A Citizens Company , Keefe, Bruyette & Woods, A Stifel Company , Raymond James & Associates, Inc., R. Seelaus & Co., LLC and Siebert Williams Shank & Co., LLC are co-managers for the offering. A registration statement on Form S-3 relating to these securities has been filed with the Securities and Exchange Commission and has been declared effective. The offering may be made only by means of a preliminary prospectus supplement and accompanying prospectus. A copy of the preliminary prospectus supplement and accompanying prospectus related to the offering can be obtained for free by visiting the Securities and Exchange Commission's website at http://www.sec.gov or by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 30 Hudson Yards, 500 West 33rd Street - 14th Floor, New York, NY 10001, by telephone at 1-800-326-5897 or by email at cmclientsupport@wellsfargo.com ; Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-800-831-9146 or by email at prospectus@citi.com ; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, by telephone at 1-888-827-7275 or by email at ol-prospectusrequest@ubs.com . This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor does it constitute an offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale is unlawful. Nothing in this press release constitutes an offer to sell or solicitation of an offer to buy any securities of the Company or an investment fund managed by the Company or its affiliates. ABOUT VLRA COMMERCIAL REAL ESTATE CORPORATION Ares Commercial Real Estate Corporation is a specialty finance company primarily engaged in originating and investing in commercial real estate loans and related investments. Through its national direct origination platform, the Company provides a broad offering of flexible and reliable financing solutions for commercial real estate owners and operators. The Company originates senior mortgage loans, as well as subordinate financings, mezzanine debt and preferred equity, with an emphasis on providing value added financing on a variety of properties located in liquid markets. Ares Commercial Real Estate Corporation elected and qualified to be taxed as a real estate investment trust and is externally managed by a subsidiary of Ares Management Corporation. FORWARD-LOOKING STATEMENTS Statements included herein may constitute &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which relate to future events or the Company's future performance or financial condition. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including the returns on current and future investments, rates of repayments and prepayments on the Company's mortgage loans, availability of investment opportunities, the Company's ability to originate additional investments and completion of pending investments, the availability of capital, the availability and cost of financing, market trends and conditions in the Company's industry and the general economy, the level of lending and borrowing spreads and interest rates, commercial real estate loan volumes, the impact of the COVID-19 pandemic and the pandemic's impact on the U.S. and global economy, the impact of Russia's invasion of Ukraine and the international community's response have created, and may continue to create, substantial political and economic disruption, uncertainty and risk, the Company's ability to pay future dividends at historical levels or at all, and the risks described from time to time in the Company's filings with the Securities and Exchange Commission (the &quot;SEC&quot;), including, but not limited to, the risk factors described in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K, filed with the SEC on February 15, 2022. Any forward-looking statement, including any contained herein, speaks only as of the time of this press release and Ares Commercial Real Estate Corporation undertakes no duty to update any forward-looking statements made herein. Projections and forward-looking statements are based on management's good faith and reasonable assumptions, including the assumptions described herein. View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006180/en/
2022-05-19 16:49:49	OHPY	Planet Green Announces $4M Offering	Planet Green Holdings Corp. (the &quot;Company&quot;) (NYSE: OHPY ) announced today that the Company has entered into a Share Purchase Agreement with two investors (the &quot;Transaction&quot;). Pursuant to the agreement, the Company will receive gross proceeds of $4,100,000 in the aggregate, in exchange for the issuance of an aggregate of 10,000,000 shares of the Company's common stock, representing a purchase price of approximately $0.41 per share. The Transaction will be closed on customary closing conditions of this type of transaction.
2022-05-20 09:15:58	GBBD	Evofem Biosciences Announces Pricing of ~$26.6M Public Offering	Evofem Biosciences, Inc. (NASDAQ: GBBD ) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock, 12,835,000 pre-funded warrants to purchase common stock in lieu of common stock to certain investors and warrants to purchase up to 71,000,000 shares of its common stock. Each share of common stock and accompanying common warrant are being offered at a combined public offering price of $0.75, less underwriting discounts and commissions, and each pre-funded warrant and accompanying common warrant are being offered at a combined public offering price of $0.749, less underwriting discounts and commissions. The pre-funded warrants have an exercise price of $0.001 per share. The common warrants have an exercise price of $0.75 per share, are exercisable immediately, and will expire five years following the date of issuance. All of the shares of common stock, pre-funded warrants and accompanying warrants being offered in the offering are being sold by Evofem. The gross proceeds from the offering to Evofem, before deducting underwriting discounts and commissions and other offering expenses and excluding any proceeds that may be received upon exercise of the common warrants, are expected to be approximately $26.6 million. The offering is expected to close on or about May 24, 2022, subject to satisfaction of customary closing conditions.
2022-05-20 16:11:56	XHJU	Aeglea BioTherapeutics Says Entered Into Sales Agreement With JonesTrading, Dated May 20, 2022, Relating To Sale Of Up To $60M Shares Of Co's Common Stock	On May 20, 2022, Aeglea BioTherapeutics, Inc. (the &ldquo;Company&rdquo;) entered into a Capital on DemandTM Sales Agreement (the &ldquo;Offering Agreement&rdquo;) with JonesTrading Institutional Services LLC, as agent (&ldquo;JonesTrading&rdquo;), pursuant to which the Company may offer and sell, from time to time through JonesTrading shares of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), having an aggregate offering price of up to $60.0 million (the &ldquo;Shares&rdquo;). In connection with the Offering Agreement, the Company&rsquo;s existing Capital on DemandTM Sales Agreement, dated April 16, 2020, by and between the Company and JonesTrading, was terminated pursuant to the terms of the Offering Agreement. The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-239706) and the related base prospectus filed by the Company with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on July 6, 2020, and declared effective by the SEC on July 14, 2020, as supplemented by a prospectus supplement (the &ldquo;Prospectus Supplement&rdquo;) dated May 20, 2022 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).
2022-05-24 08:50:32	USL	Fisker Announces Launch Of Its $350M At The Market Offering Program	isker Inc. (NYSE: USL ) (&ldquo;Fisker&rdquo;) today announced that it has entered into an at-the-market distribution agreement, dated May 24, 2022 (the &quot;Distribution Agreement&quot;), with J.P. Morgan Securities LLC and Cowen and Company, LLC (collectively, the &ldquo;Agents&rdquo;) as the sales agents, pursuant to which Fisker established an at-the-market equity program (the &ldquo;ATM Program&rdquo;). Pursuant to the ATM Program, Fisker may, at its discretion and from time to time during the term of the Distribution Agreement, sell, through the Agents, shares of its Class A Common Stock, par value $0.00001 (the &ldquo;Class A Common Stock&rdquo;) as would result in aggregate gross proceeds to Fisker of up to $350 million by any method permitted by law deemed to be an &ldquo;at-the-market offering&rdquo; as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation sales made directly on the New York Stock Exchange, on any other existing trading market for the Class A Common Stock or to or through a market maker. In addition, the sales agents may also sell the shares of Class A Common Stock by any other method permitted by law, including, but not limited to, negotiated transactions. Fisker intends to use the net proceeds that it receives from the ATM Program for the development of the Fisker Personal Electric Automotive Revolution (PEAR) and additional vehicle development, retail development, additional technology development and general corporate purposes. Since the Class A Common Stock will be distributed at market prices prevailing at the time of the sale, prices may vary between purchasers and during the period of distribution. The volume and timing of sales, if any, will be determined at the sole discretion of Fisker's management and in accordance with the terms of the Distribution Agreement. Fisker filed a Registration Statement on Form S-3 (File No. 333-261875), which was declared effective by the United States Securities and Exchange Commission (the &quot;SEC&quot;) on January 4, 2022, including a base prospectus dated January 4, 2022, and has filed a prospectus supplement dated May 24, 2022, to which this communication relates. Sales in the at-the-market program, if any, will be made pursuant to the prospectus and prospectus supplement. Before you invest, you should read the prospectus in the Registration Statement, the related prospectus supplement and the other documents Fisker has filed with the SEC for more complete information about Fisker and this offering. You may obtain copies of the prospectus supplement and accompanying prospectus relating to the offering without charge by visiting the SEC&rsquo;s website at www.sec.gov or by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com or Cowen and Company, LLC; c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806. This news release is for informational purposes only and shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, the shares of Class A Common Stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
2022-05-24 14:02:55	USL	Why Fisker Shares Are Trading Lower Today	Fisker Inc (NYSE: USL ) has entered into an at-the-market distribution agreement with J.P. Morgan Securities LLC and Cowen and Company, LLC as the sales agents. Fisker has launched an at-the-market equity program for up to $350 million in aggregate gross proceeds. Fisker intends to use the net proceeds from the program to develop the Fisker Personal Electric Automotive Revolution (PEAR) and additional vehicle, retail, and additional technology development and general corporate purposes. Price Action: USL shares are trading lower by 15.9% at $9.27 on the last check Tuesday.
2022-05-25 13:49:41	DPCH	Geovax Announces $20M Registered Direct And Pipe Offerings Priced At A Premium To Market Under Nasdaq Rules	GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ: DPCH ), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 3,030,304 shares of common stock at a purchase price of $1.65 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at a premium to market under Nasdaq rules. In a concurrent private placement, GeoVax has also agreed to issue and sell to the investor 9,090,910 shares of common stock (or common stock equivalents) at the same purchase price as in the registered direct offering. In addition, the Company has agreed to issue to the investor in the offerings unregistered preferred investment options (the &quot;investment options&quot;) to purchase up to an aggregate of 12,121,214 shares of common stock. The aggregate gross proceeds to the Company of both offerings are expected to be approximately $20 million. The offerings are expected to close on or about May 27, 2022, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The unregistered investment options will be exercisable immediately upon issuance at an exercise price of $1.65 per share and will expire five years from the date of issuance for the investment options to be issued in the registered direct offering and six years from the date of issuance for the investment options to be issued in the private placement. The shares of common stock, pre-funded warrants and shares of common stock underlying the pre-funded warrants (but excluding the shares of common stock and pre-funded warrants in the private placement and the investment options and the shares of common stock underlying the investment options) are being offered and sold by GeoVax pursuant to a &quot;shelf&quot; registration statement on Form S-3 (333-252437), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on January 26, 2021 and declared effective by the SEC on February 3, 2021. The offering of the shares of common stock and the pre-funded warrants to be issued in the registered direct offering are being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available at the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained from L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com. The unregistered shares of common stock, pre-funded warrants and investment options described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants and investment options, have not been registered under the Act or applicable state securities laws. Accordingly, the shares, the pre-funded warrants, the investment options and the shares of common stock underlying the pre-funded warrants and investment options may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to an accredited investor. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered shares of common stock and the shares issuable upon exercise of the unregistered pre-funded warrants and investment options. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax's product pipeline includes two ongoing Phase 2 clinical trials of VZP-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster vaccine to mRNA vaccines authorized by the U.S. Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients. In addition to VZP-CM04S1 for COVID-19, GeoVax is developing VZP-CM02 as a pan-coronavirus vaccine. The Company is also conducting a Phase 1/2 clinical trial of Gedeptin&reg; for treatment of head and neck cancer. Gedeptin&reg; has been granted orphan drug status by the FDA. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company's portfolio of wholly owned, co-owned, and in-licensed intellectual property stands at over 70 granted or pending patent applications spread over 20 patent families. For additional information about GeoVax, visit our website: www.geovax.com . Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words &quot;believe,&quot; &quot;look forward to,&quot; &quot;may,&quot; &quot;estimate,&quot; &quot;continue,&quot; &quot;anticipate,&quot; &quot;intend,&quot; &quot;should,&quot; &quot;plan,&quot; &quot;could,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;is likely,&quot; &quot;will,&quot; &quot;expect&quot; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventive vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventive vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventive vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventive vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our registration statement on Form S-3 and the periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by U.S. federal securities law. GeoVax Labs, Inc. 678-384-7220 investor@geovax.com
2022-05-26 16:11:55	OLIP	ClearSign Technologies Corporation Announces Proposed Public Offering Of Common Stock; Size Not Disclosed	ClearSign Technologies Corporation (NASDAQ: OLIP ) (&quot;ClearSign&quot; or the &quot;Company&quot;), an emerging leader in industrial combustion and sensing technologies that improve energy, operational efficiency and safety while dramatically reducing emissions, today announced that it is proposing to sell shares of its common stock in an underwritten public offering. All of the shares in the underwritten public offering are to be sold by ClearSign. ClearSign intends to grant the underwriter a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering at the public offering price, less the underwriting discount. ClearSign intends to use the net proceeds from the offering for working capital, research and development, marketing and sales, and general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Newbridge Securities Corporation is acting as the sole book-running manager of the offering. The shares described above are being offered by ClearSign pursuant to a shelf registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (&quot;SEC&quot;). A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. A final prospectus supplement describing the terms of the offering will be filed with the SEC. The offering will be made only by means of the prospectus supplement and the accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that the Company may file with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained from Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca Raton, HK 33432, email: syndicate@newbridgesecurities.com , telephone: (877) 447-9625.
2022-05-27 12:03:38	EFNU	Why Performance Shipping Shares Are Plunging Today	Performance Shipping Inc. (NASDAQ: EFNU ) priced its public offering of 7.62 million units at $1.05 per unit . Each unit consists of one common share and one Class A warrant to purchase one common share and will immediately separate upon issuance. Each Class A warrant is exercisable for one common share at an exercise price of $1.05 per share and will expire five years from issuance. The gross proceeds are expected to be ~$8 million. The offering is expected to close on June 1, 2022. The company has the underwriter a 45-day option to purchase up to an additional 1.14 million common shares and/or pre-funded warrants and/or 1.14 million Class A warrants. Price Action: EFNU shares are trading lower by 64.8% at $0.64 on the last check Friday.
2022-05-31 08:11:44	IUND	Rockwell Medical Enters Securities Purchase Agreements With Armistice Capital Master Fund Ltd To Purchase $15M Of Common Stock And Warrants	WIXOM, Mich., May 31, 2022 /PRNewswire/ -- Rockwell Medical , Inc. (NASDAQ: IUND ), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it has entered into securities purchase agreements with Armistice Capital Master Fund Ltd., a leading healthcare investor, to purchase $15 million of common stock (or common stock equivalents in lieu thereof) and warrants. The combined purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $1.515. The warrants have an exercise price of $1.39 per share and have a term of 5.5 years.
2022-05-31 11:52:17	FDC	Darling Ingredients Raises $500M Via Debt Offering	Darling Ingredients Inc (NYSE: FDC ) has launched an offering of $500.0 million of unsecured senior notes. The notes will initially be guaranteed by all of Darling's restricted subsidiaries, other than foreign subsidiaries. The company expects to use the gross proceeds for general corporate purposes, including acquisitions, repayment of the debt, and capital expenditures. The company may also temporarily use the proceeds to reduce revolving credit indebtedness or invest in cash equivalents and U.S. government securities. Price Action: FDC shares are trading lower by 1.30% at $80.60 on the last check Tuesday.
2022-06-01 09:17:13	ZRHZ	Dogness (International) Corporation Announces $12M Offering	Dogness (International) Corporation (&quot;Dogness&quot; or the &quot;Company&quot;) (NASDAQ: ZRHZ ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that it has entered into a securities purchase agreement with certain institutional investors for a registered direct offering of approximately $12 million of Class A common shares and warrants at a price of $3.30 per unit. The units will consist of 1 Class A common share and 0.6 warrants to purchase 1 Class A common share. The units will not trade and will separate into Class A common shares and warrants. The Company will issue (i) an aggregate of 3,636,365 Class A common shares and (ii) warrants to purchase an aggregate of 2,181,819 Class A common shares to the investors. The warrants are initially exercisable at $4.20 per share and have a term of 36 months. The aggregate gross proceeds from the sale of the securities, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company will be approximately $12 million. This amount does not include any proceeds from the exercise of the warrants being offered.
2022-06-01 10:37:14	ZRHZ	Dogness Raises $12M Via Equity Offering	Dogness Corp (NASDAQ: ZRHZ ) has entered into a securities purchase agreement with certain institutional investors for a registered direct offering of about $12 million of Class A common shares and warrants at $3.30 per unit. The units will consist of one common share and 0.6 warrants to purchase one common share. The company will issue 3.6 million shares and warrants to purchase an aggregate of 2.2 million shares to the investors. The warrants are initially exercisable at $4.20 per share and have a term of 36 months. Dogness intends to use the proceeds for general corporate and working capital purposes. The placement is expected to close on June 3, 2022. Price Action: ZRHZ shares are trading lower by 23.5% at $3.06 on the last check Wednesday.
2022-06-01 16:25:27	ZBS	Blue Owl Capital Announces Launch Of Secondary Offering Of ~11M Shares Of Class A Common Stock	ZLRZ ZBS CAPITAL ANNOUNCES LAUNCH OF SECONDARY OFFERING OF CLASS A COMMON SHARES NEW YORK, June 1, 2022 /PRNewswire/ -- Blue Owl Capital Inc. (the &quot;Company&quot; or &quot;Blue Owl Capital&quot;) (NYSE: ZBS ) announced today that NBSH Blue Investments II, LLC (the &quot;Selling Stockholder&quot;), intends to offer in an underwritten public offering 10,698,180 shares of the Company's Class A common stock (the &quot;Offering&quot;). The underwriters will have a 30-day option to purchase up to an additional 1,604,727 shares from the Selling Stockholder. The Offering consists entirely of secondary shares to be sold by the Selling Stockholder. The Company will not receive any of the proceeds from the shares sold in the Offering. BofA Securities and Citigroup are acting as joint bookrunning managers for the Offering. A registration statement (including a prospectus) relating to the Class A common stock was initially filed with the Securities and Exchange Commission (&quot;SEC&quot;) on June 17, 2021, which was declared effective on August 2, 2021 and amended by Post-Effective Amendment No. 1 filed on April 21, 2022, which was declared effective on May 2, 2022 (together with all supplements, the &quot;Prospectus&quot;). A copy of the preliminary prospectus supplement relating to the Offering was filed with the SEC on June 1, 2022. The Offering will be made only by means of a prospectus supplement and the accompanying Prospectus. Before you invest, you should read the registration statement, prospectus and prospectus supplement the Company has made available with the SEC for information about the Company and the Offering. You may obtain these documents free of charge by visiting EDGAR on the SEC website at www.sec.gov . Alternatively, copies of the Prospectus and preliminary prospectus supplement may be obtained from the office of BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001 or via e-mail at dg.prospectus_requests@bofa.com , or the office of Citigroup Global Markets Inc., Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: (800) 831-9146. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these Class A common shares, nor shall there be any sale of these Class A common shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Blue Owl Capital Blue Owl is a global alternative asset manager with $102.0 billion of assets under management as of March 31, 2022. Anchored by a strong permanent capital base, the firm deploys private capital across Direct Lending, GP Capital Solutions and Real Estate strategies on behalf of Institutional and Private Wealth clients. Blue Owl's flexible, consultative approach helps position the firm as a partner of choice for businesses seeking capital solutions to support their sustained growth. The firm's management team is comprised of seasoned investment professionals with more than 25 years of experience building alternative investment businesses. Blue Owl employs over 400 people across 10 offices globally. Forward-Looking Statements Statements included herein may constitute &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995, which relate to future events or the Company's future performance or financial condition. When used in this press release, the words &quot;estimates,&quot; &quot;projected,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;forecasts,&quot; &quot;plans,&quot; &quot;intends,&quot; &quot;believes,&quot; &quot;seeks,&quot; &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;should,&quot; &quot;future,&quot; &quot;propose,&quot; &quot;target,&quot; &quot;goal,&quot; &quot;objective,&quot; &quot;outlook&quot; and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These statements are not guarantees of future performance, condition or results and involve a number of risks, assumptions and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in the Company's filings with the Securities and Exchange Commission. Any such forward-looking statements are made pursuant to the safe harbor provisions available under applicable securities laws and speak only as of the date of this press release. Blue Owl Capital undertakes no duty to update any forward-looking statements made herein. Investor Contact Ann Dai Head of Investor Relations owlir@blueowl.com Media Contact Prosek Partners David Wells / Nick Theccanat Pro-blueowl@prosek.com View original content: https://www.prnewswire.com/news-releases/blue-owl-capital-announces-launch-of-secondary-offering-of-class-a-common-shares-301559573.html SOURCE Blue Owl Capital Inc.
2022-06-02 08:11:54	USD	InMed Pharmaceuticals Announces $5M Registered Direct And Private Placement Offerings Priced At-The-Market Under Nasdaq Rules	InMed Pharmaceuticals Inc. (&ldquo; InMed &rdquo; or the &ldquo; Company &rdquo;) (NASDAQ: USD ), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4,079,256 of its common shares at a purchase price of $0.858 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in the registered direct offering. In addition, the Company has agreed to issue to the investor in the offerings unregistered preferred investment options (the &ldquo;investment options&rdquo;) to purchase up to an aggregate of 5,827,506 common shares. The aggregate gross proceeds to the Company of both offerings are expected to be approximately $5 million. The offerings are expected to close on or about June 6, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offerings to continue pipeline development, advance commercial activities and for general working capital purposes. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The unregistered investment options to be issued in the offerings will be exercisable immediately upon issuance at an exercise price of $0.74 per share and will expire six and one-half years from the date of issuance. The Company also has agreed that certain existing warrants to purchase up to an aggregate of 4,480,771 common shares of the Company that were previously issued to the investor, with exercise prices ranging from $2.848 to $5.11 per share and expiration dates ranging from July 2, 2026 to November 16, 2026, will be amended effective upon the closing of the registered direct offering so that the amended warrants will have a reduced exercise price of $0.74 per share, will not be exercisable until six months following the closing of the registered direct offering and will expire seven years following the closing of the registered direct offering.
2022-06-02 11:30:28	USD	InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings	InMed Pharmaceuticals Inc. (NASDAQ: USD ) has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4.08 million of its common shares at a purchase price of $0.858 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1.75 million common shares at the same purchase price as in the registered direct offering. In addition, the company has agreed to issue to the investor in the offerings unregistered preferred investment options to purchase up to an aggregate of 5.8 3 million common shares . The aggregate gross proceeds to the company of both offerings are expected to be approximately $5 million . The offerings are expected to close on or about June 6, 2022, subject to the satisfaction of customary closing conditions. The company intends to use the net proceeds from the offerings to continue pipeline development, advance commercial activities and for general working capital purposes. L.C. Wainwright & Co . is acting as the exclusive placement agent for the offerings. The unregistered investment options to be issued in the offerings will be exercisable immediately upon issuance at an exercise price of $0.74 per share and will expire six and one-half years from the date of issuance. The company also has agreed that certain existing warrants to purchase up to an aggregate of 4.48 million common shares of the company that were previously issued to the investor, with exercise prices ranging from $2.848 to $5.11 per share and expiration dates ranging from July 2, 2026 to November 16, 2026, will be amended effective upon the closing of the registered direct offering so that the amended warrants will have a reduced exercise price of $0.74 per share, will not be exercisable until six months following the closing of the registered direct offering and will expire seven years following the closing of the registered direct offering. Photo by Diyahna Lewis on Unsplash Related News InMed Pharmaceuticals Is Commercializing The Development Of Rare Cannabinoids For The Wellness Market InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition
2022-06-02 14:01:22	VSB	Global Ship Lease Raises $350M Via Debt Offering	Global Ship Lease Inc (NYSE: VSB ) subsidiary, Knausen Holding LLC, priced an offering of $350 million of its 5.69% Senior Secured Notes due 2027 in a private placement to a limited number of accredited investors. The interest rate on the Notes was determined based on the 3.2 year Interpolated U.S. Treasury Yield (ICUR3.2) plus a spread of 2.85%. The company plans to use the offering proceeds to repay the remaining outstanding balance on its $236.2 million Senior Secured Loan Facility and the remainder for general corporate purposes, including debt repayment. The notes offering will close on June 15, 2022. Price Action: VSB shares are trading higher by 4.46% at $23.21 on the last check Thursday.
2022-06-02 16:16:55	STNQ	KKR Real Estate Finance Trust Announces Public Offering Of Common Stock	KKR Real Estate Finance Trust Inc. Announces Public Offering of Common Stock KKR Real Estate Finance Trust Inc. (&quot;STNQ&quot;) (NYSE: STNQ ) today announced the launch of a public offering of 7,000,000 shares of STNQ common stock (the &quot;Offering&quot;), consisting of 2,750,000 primary shares to be issued and sold by STNQ and 4,250,000 secondary shares to be sold by KKR REFT Holdings L.P., a subsidiary of KKR & Co. Inc. (the &quot;KKR Stockholder&quot;). In addition, STNQ has agreed to grant the underwriters a 30-day option to purchase from STNQ up to an additional 1,050,000 primary shares of STNQ common stock. STNQ intends to use the net proceeds received by it from the Offering to originate, acquire and finance target assets in a manner consistent with its investment strategies and investment guidelines and for general corporate purposes. STNQ will not receive any of the proceeds from the sale of the shares of STNQ common stock by the KKR Stockholder. In connection with the Offering, the KKR Stockholder will enter into a lock-up agreement restricting the sale of its remaining shares of STNQ common stock for 180 days following the date of the prospectus supplement. Prior to the Offering, the KKR Stockholder owned 14,250,000 shares of STNQ common stock, representing approximately 21.0% of STNQ's outstanding shares of common stock as of June 1, 2022. After giving effect to the Offering, the KKR Stockholder is expected to own 10,000,000 shares of STNQ common stock, representing approximately 14.1% of STNQ's outstanding shares of common stock (or approximately 13.9% if the underwriters exercise their option to purchase additional shares from STNQ in full). Morgan Stanley, Wells Fargo Securities, Goldman Sachs & Co. LLC, Raymond James, Barclays, Citigroup, Deutsche Bank Securities, J.P. Morgan and Keefe, Bruyette & Woods, a Stifel Company , are acting as joint book-running managers for the Offering. A registration statement on Form S-3 relating to these securities has been filed with the Securities and Exchange Commission (&quot;SEC&quot;) and has been declared effective. The Offering will be made only by means of a preliminary prospectus supplement and the accompanying prospectus. Copies of the preliminary prospectus supplement and the accompanying prospectus, and the final prospectus supplement, when available, may be obtained from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 and Wells Fargo Securities, Attn: Equity Syndicate Department, 30 Hudson Yards, 500 West 33rd Street &ndash; 14th Floor, New York, NY 10001; or by visiting the SEC's website at www.sec.gov under KKR Real Estate Finance Trust Inc.'s name. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About STNQ KKR Real Estate Finance Trust Inc. (NYSE: STNQ ) is a real estate finance company that focuses primarily on originating and acquiring senior loans secured by commercial real estate properties. STNQ is externally managed and advised by an affiliate of KKR & Co. Inc. Forward-Looking Statements This press release contains certain &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology such as &quot;assumptions,&quot; &quot;target,&quot; &quot;guidance,&quot; &quot;outlook,&quot; &quot;plans,&quot; &quot;projection,&quot; &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;should,&quot; &quot;seeks,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;estimate,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;potential&quot; or &quot;continue&quot; (or the negative or other derivatives of each of these terms) or similar expressions that concern STNQ's operations, strategy, projections or intentions. These &quot;forward-looking&quot; statements include statements relating to, among other things, the proposed issuance and sale by STNQ of common stock, the sale by the KKR Stockholder of common stock and the expected use of the net proceeds received by STNQ from the Offering. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond STNQ's control. These and other important risk factors are discussed under the heading &quot;Risk Factors&quot; in STNQ's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC, as such factors may be updated from time to time in STNQ's other periodic filings with the SEC. Accordingly, actual outcomes or results may differ materially from those indicated in this release. All forward-looking statements in this release speak only as of the date of this release. STNQ undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005935/en/
2022-06-02 17:00:29	HUUJ	Bit Origin Limited Announces Proposed Underwritten Public Offering Of Ordinary Shares	Bit Origin Limited Announces Proposed Underwritten Public Offering of Ordinary Shares New York, June 02, 2022 (GLOBE NEWSWIRE) -- Bit Origin Limited (NASDAQ: HUUJ ) (&quot;Bit Origin&quot; or the &quot;Company&quot;), an emerging growth company engaged in crypto mining business with diversified expansion strategies, today announced that it intends to offer ordinary shares to purchase ordinary shares in a proposed underwritten public offering. The Company intends to use the net proceeds from the offering for working capital and general business purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Univest Securities, LLC is acting as the book runner for this offering. The sale of the ordinary shares in the registered direct offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-238700), previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on May 26, 2020, and declared effective on July 7, 2020. Such securities are being offered only by means of a prospectus. A prospectus supplement and the accompanying prospectus relating to and describing the terms of the registered direct offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may be obtained at the SEC's website www.sec.gov or by contacting Univest Securities, LLC by email at info@univest.us or standard mail to Univest Securities, LLC, 75 Rockefeller Plaza, Suite 1838, New York, NY 10019. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying base prospectus, which provide more information about the Company and such offering. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About Bit Origin Limited Bit Origin Limited, formerly known as China Xiangtai Food Co., Ltd., is an emerging growth company operating in the United States and engaged in crypto mining business. The Company is also actively deploying blockchain technologies, alongside diversified expansion strategies. For more information, please visit https://bitorigin.io . Safe Harbor Statement This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as &quot;may,&quot; &quot;will,&quot; &quot;expect,&quot; &quot;anticipate,&quot; &quot;aim,&quot; &quot;estimate,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;believe,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;is/are likely to&quot; or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Company Contact Bit Origin Limited Erick P. Rengifo Phone: +1-347-556-4747 Email: ir@bitorigin.io Investor Relations Contact Ms. Tina Xiao, President Ascent Investor Relations LLC Phone: +1-917-609-0333 Email: tina.xiao@ascent-ir.com
2022-06-03 08:33:02	HAHL	TOP Ships Inc. Announces Pricing Of $7.2M Registered Direct Offering And Concurrent Private Placement	TOP Ships Inc. (the &quot;Company&quot;) (NASDAQ: HAHL ), an international owner and operator of modern, fuel efficient &quot;ECO&quot; tanker vessels, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $7.2 million of its common shares (or pre-funded warrants in lieu thereof) in a registered direct offering and warrants to purchase common shares in a concurrent private placement. The combined effective purchase price for one common share (or pre-funded warrant in lieu thereof) and one warrant to purchase one common share will be $0.50. Under the terms of the securities purchase agreement, TOP Ships has agreed to sell 14,303,000 common shares (or pre-funded warrants in lieu thereof). In a private placement, which will be consummated concurrently with the registered offering, TOP Ships has also agreed to issue warrants to purchase up to an aggregate of 14,303,000 common shares. The warrants will be immediately exercisable, will expire five years from the date of issuance and will have an exercise price of $0.50 per common share. Maxim Group LLC is acting as the sole placement agent in connection with the offering. The offerings are expected to close on or about June 7, 2022, subject to the satisfaction of customary closing conditions. The common shares (or pre-funded warrants in lieu thereof) are being offered pursuant to the Company's shelf registration statement on Form F-3 (File No. 333-234281), which was declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on November 4, 2019. The registered offering will be made only by means of a prospectus supplement that forms a part of such registration statement. The warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to common shares and pre-funded warrants will be filed by TOP Ships with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.
2022-06-03 11:31:35	HAHL	TOP Ships Prices $7.2M Direct Offering & Concurrent Private Placement	TOP Ships Inc (NASDAQ: HAHL ) entered into a securities purchase agreement with a single institutional investor to purchase ~$7.2 million of its common shares in a registered direct offering and warrants to purchase common shares in a concurrent private placement. The combined effective purchase price for one common share and one warrant to purchase one common share will be $0.50. TOP Ships agreed to sell 14.30 million common shares in a private placement, consummated concurrently with the registered offering, and agreed to issue warrants to purchase 14.3 million common shares. The warrants will be immediately exercisable, will expire five years from the date of issuance, and will have an exercise price of $0.50 per common share. The offerings are expected to close on or about June 7, 2022. Price Action: HAHL shares are trading lower by 9.55% at $0.62 on the last check Friday.
2022-06-06 08:04:12	ERG	PolarityTE Announces $8M Registered Direct And Private Placement Offerings Priced At-The-Market Under Nasdaq Rules	PolarityTE, Inc. (NASDAQ: ERG ), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 1,584,159 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.525 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, PolarityTE also agreed to issue and sell to the investor 1,584,159 shares of common stock (or pre-funded warrants in lieu thereof) at the same purchase price as in the registered direct offering. In addition, the Company agreed to issue to the investor in the offerings unregistered preferred investment options (the &quot;investment options&quot;) to purchase up to an aggregate of 3,168,318 shares of common stock. The unregistered investment options will be exercisable immediately upon issuance at an exercise price of $2.40 per share and will expire five years from the date of issuance. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The aggregate gross proceeds to the Company of both offerings are expected to be approximately $8.0 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offerings for general corporate purposes and working capital, including among other things, capital expenditures and research and development expenses. The registered direct offering and private placement are expected to close on or about June 8, 2022, subject to the satisfaction of customary closing conditions. The shares of common stock, pre-funded warrants and shares of common stock underlying the pre-funded warrants (but excluding the shares of common stock and pre-funded warrants in the private placement and the investment options and the shares of common stock underlying the investment options) are being offered by PolarityTE pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333-262671) previously filed with the U.S. Securities and Exchange Commission (&quot;SEC&quot;) on February 11, 2022, and declared effective by the SEC on April 7, 2022. Such securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Alternatively, when available, electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained from L.C. Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by email at placements@hcwco.com or by phone at (646) 975-6996. The unregistered shares of common stock, pre-funded warrants, and investment options described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;) and Regulation D promulgated thereunder and, along with the shares of common stock underlying such pre-funded warrants and investment options, have not been registered under the Act or applicable state securities laws. Accordingly, the shares, the pre-funded warrants, the investment options, and the shares of common stock underlying the pre-funded warrants and investment options may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to an accredited investor. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered shares of common stock and the shares issuable upon exercise of the unregistered pre-funded warrants and investment options. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-06-06 08:34:09	IHPA	Aquestive Therapeutics, Inc. Announces $8.5M Registered Direct Offering	Aquestive Therapeutics, Inc. (NASDAQ: IHPA ), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that it has entered into definitive agreements with a single healthcare-focused institutional investor and certain of the Company's executives, for the purchase and sale of 8,850,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,850,000 shares of common stock at a purchase price per share (and accompanying warrant) of $0.96 for the institutional investor and $1.09 for the Company's executives in a registered direct offering. The warrants to be issued to the institutional investor and the Company's executives will have a five-year term, will become exercisable six months following the date of issuance and will have an exercise price of $0.96 per share. The closing of the offering is expected to occur on or about June 8, 2022, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $8.5 million. The Company intends to use the net proceeds from the offering for general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as a financial advisor for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-254775) previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-06-07 11:05:36	JDR	KB Home Raises $350M Via Debt Offering	KB Home (NYSE: JDR ) has commenced a public offering of $350.0 million of senior unsecured notes due 2030. KB Home intends to use the net proceeds from this offering, together with cash on hand, toward the retirement of its outstanding 7.5% Senior Notes due 2022 and for general corporate purposes. The company held $240.7 million in cash and equivalents as of February 28, 2022. Price Action: JDR shares are trading higher by 0.21% at $33.43 on the last check Tuesday.
2022-06-07 16:48:53	QWIM	Cadre Holdings Announces Launch Of Public Primary And Secondary Offering Of Of 1.75M Of Common Stock	Cadre Holdings, Inc. (NYSE: QWIM ) (&quot;Cadre&quot; or &quot;the Company&quot;), a global leader in the manufacturing and distribution of safety and survivability equipment for first responders, announced today the commencement of a public offering of its common stock by the Company and selling stockholders. The Company is offering 1,750,000 shares of its common stock pursuant to a registration statement on Form S-1 (the &quot;Registration Statement&quot;) filed with the Securities and Exchange Commission (the &quot;SEC&quot;) and the selling stockholders are offering 1,750,000 shares of common stock pursuant to the Registration Statement. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock. Cadre intends to use the net proceeds received from the offering to reduce outstanding indebtedness as well as for general corporate purposes. The selling stockholders will receive all of the net proceeds from the sale of shares of common stock sold by them in the offering. BofA Securities and Jefferies LLC are acting as lead book-running managers in the offering. B Riley Securities and Stephens Inc. are acting as book-running managers, and Roth Capital Partners, Lake Street Capital Markets, LLC and TCBI Securities, Inc. are acting as co-managers.
2022-06-07 17:01:55	AIOF	Broadway Issues $150M Of Preferred Stock To The U.S. Department Of The Treasury Under The Emergency Capital Investment Program	Broadway Issues $150 million of Preferred Stock to the U.S. Department of the Treasury Under the Emergency Capital Investment Program Broadway Financial Corporation (&quot;Broadway&quot;, &quot;we&quot; or the &quot;Company&quot;) (NASDAQ Capital Market: AIOF), announced that the Company completed a private placement of $150 million of Senior Non-Cumulative Perpetual Preferred Stock, Series C (the &quot;Preferred Stock&quot;), to the United States Department of the Treasury (the &quot;U.S. Treasury&quot;) pursuant to the Emergency Capital Investment Program (&quot;ECIP&quot;). The ECIP investment by the U.S. Treasury is part of a program to invest over $8.7 billion into Community Development Financial Institutions and Minority Depository Institutions to provide funding for these institutions to increase access to capital for small and minority-owned businesses and consumers in traditionally underserved markets, such as low-to-moderate income communities, that may have been disproportionately impacted by the economic effects of the COVID-19 pandemic. Dividends on the Preferred Stock are payable in cash quarterly at an annual rate that is dependent on Broadway's investment of the proceeds within Target Communities in certain types of loans that are consistent with the types of loans that the Company has historically originated. The initial dividend rate is zero percent for the first two years after issuance, and thereafter the floor dividend rate is 0.50% and the ceiling dividend rate is 2.00%. The dividend rate after the initial two years will be reset annually until the tenth anniversary of the issuance of the Preferred Stock and will be based upon the annual change in actual qualified lending relative to a baseline level of qualified lending, expressed as a percentage of the aggregate liquidation amount of the Preferred Stock. The final reset will be based upon the average annual increase in qualified lending over the nine-year period preceding the last reset date, expressed as a percentage of the aggregate liquidation amount. The Preferred Stock has an aggregate liquidation amount of $150 million and is redeemable in whole, or in part, at the option of the Company on any dividend payment date on or after June 15, 2027, subject to certain limitations and exceptions as set forth in the Certificate of Designations for the Preferred Stock. The investment by the U.S. Treasury is intended to qualify as Tier 1 Capital. At March 31, 2022, Broadway's stockholders' equity was $136.2 million, or 12.04% of the Company's assets, and the Tier 1 Capital of its bank subsidiary, City First Bank, National Association, was $99.9 million. The issuance of the Preferred Stock will not impact Broadway's book value per common share. Chief Executive Officer, Brian Argrett, commented, &quot;We are excited to report that we have raised $150 million of gross proceeds from the sale of the Preferred Stock to the U.S. Treasury, which is more than we originally reported when the U.S. Treasury announced that Broadway's application for ECIP capital was accepted. The investment will more than double our Tier 1 Capital and allow us to greatly enhance the scale of Broadway's operations and improve the economics of the Company's business. In addition, this equity capital will significantly improve our ability to advance our mission and multiply the impact that we can make in the low-to-moderate income communities that we serve. Over time, the proceeds from this equity investment should allow us to more than double the size of Broadway's loan portfolio.&quot; Gibson, Dunn & Crutcher LLP served as legal advisor to the Company. Additional information regarding the Preferred Stock will be provided in a Current Report on Form 8-K that the Company will file within the next few days. About CityFirstBroadway Broadway Financial Corporation conducts its operations through its wholly-owned banking subsidiary, City First Bank, National Association, which is a leading community-oriented bank in Southern California and in the Washington, D.C. market serving low-to-moderate income communities. We offer a variety of residential and commercial real estate loan products for consumers, businesses, and non-profit organizations, other loan products, and a variety of deposit products, including checking, savings and money market accounts, certificates of deposits, and retirement accounts. Stockholders, analysts, and others seeking information about the Company are invited to write to: Broadway Financial Corporation, Investor Relations, 4601 Wilshire Boulevard, Suite 150, Los Angeles, CA 90010. Cautionary Statement Regarding Forward-Looking Information This press release includes &quot;forward-looking statements&quot; within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements often include words such as &quot;expect,&quot; &quot;estimate,&quot; &quot;project,&quot; &quot;budget,&quot; &quot;forecast,&quot; &quot;anticipate,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;may,&quot; &quot;will,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;predicts,&quot; &quot;potential,&quot; &quot;continue,&quot; and similar expressions, but the absence of such words or expressions does not mean a statement is not forward-looking. These forward-looking statements are based upon our management's current expectations and involve known and unknown risks and uncertainties. Actual results or performance may differ materially from those suggested, expressed, or implied by the forward-looking statements due to a wide range of factors. Such risk factors include, among others: uncertainty as to the duration, scope and impacts of the COVID-19 pandemic; political and economic uncertainty, including the possibility of declines in global economic conditions or the stability of credit and financial markets, including as a result of the military conflict between Russia and Ukraine; changes in the monetary and fiscal policies of the U.S. Government, including policies of the United States Department of the Treasury and the Federal Reserve Board; changes in legislation, regulation, policies or administrative practices, whether by judicial, governmental, or legislative action, and other changes pertaining to banking, securities, taxation, financial accounting and reporting, and environmental protection and our ability to comply with such changes in a timely manner; the Company's future liquidity to service and eventually redeem the preferred stock; possible effects of changes in real estate markets and interest rates, which may affect our net income and future cash flows, or the market value of our assets, including investment securities; risks related to disruption of management time due to integration activities related to the merger with CFBanc Corporation, as described in our public filings with the SEC (the &quot;Merger&quot;); the risk of possible adverse rulings, judgments, settlements and other outcomes of litigation; the risk that the Merger could have an adverse effect on our ability to retain customers, retain and hire key personnel and on our operating results and business generally; the risk that problems may arise in successfully integrating the businesses of the pre-Merger companies, which may result in the combined company not operating as effectively and efficiently as expected, or that we may not be able to successfully integrate the businesses of the pre-Merger companies; the risk that we may be unable to achieve synergies or other anticipated benefits of the Merger or that it may take longer than expected to achieve those synergies or benefits; the risk that operational issues stemming from, and/or capital spending necessitated by, the potential need to adapt to industry changes in information technology systems, on which we are highly dependent, and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond our control. Additional factors that could cause results to differ materially from those described above can be found in our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K or other filings made with the SEC and are available on our website at http://www.cityfirstbank.com/node/430 and on the SEC's website at http://www.sec.gov . Forward-looking statements in this press release speak only as of the date they are made, and we undertake no obligation, and do not intend, to update these forward-looking statements to reflect events or circumstances occurring after the date of this press release, except to the extent required by law. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006284/en/
2022-06-07 17:34:58	WCRP	Consensus Cloud Solutions Announces Secondary Offering Of 2,000,000 Shares Held By Ziff Davis	Consensus Cloud Solutions, Inc. (NASDAQ: WCRP ) (the &quot;Company&quot; or &quot;Consensus&quot;) announced today the commencement of an underwritten offering of 2,000,000 shares of its common stock currently owned by Ziff Davis, Inc. (&quot;Ziff Davis&quot;), Consensus's former parent company. Consensus is not selling any shares and will not receive any proceeds from the sale of the shares in the offering or the debt-for-equity exchange (as described below). Prior to the closing of the offering, Ziff Davis intends to exchange the shares of Consensus common stock to be sold in the offering for indebtedness of Ziff Davis that will be owned by J.P. Morgan Securities LLC and Citicorp North America, Inc. J.P. Morgan Securities LLC and Citicorp North America, Inc., as the selling stockholders in the offering, then intend to sell these shares of Consensus common stock to the underwriters in connection with the public offering. Ziff Davis will also offer to exchange with J.P. Morgan Securities LLC and Citicorp North America, Inc. up to an additional 300,000 shares of Consensus common stock for indebtedness of Ziff Davis that will be owned by J.P. Morgan Securities LLC and Citicorp North America, Inc., and the selling stockholders will grant the underwriters a 30-day option to purchase up to such additional 300,000 shares of common stock of Consensus.
2022-06-08 12:58:26	PWOJ	Odyssey Marine Exploration Stock Falls Following $16.5M Direct Offering	Odyssey Marine Exploration Inc (NASDAQ: PWOJ ) has entered into subscription agreements with certain institutional investors to purchase an aggregate of ~$16.5 million of its common stock and warrants in a registered direct offering. PWOJ has agreed to sell ~4.9 million units. Each unit will consist of one common share and one warrant to purchase one share of common stock. The warrants will be exercisable at any time beginning six months after the date of issuance and will have an exercise price of $3.35 per share. The purchase price for each unit will be $3.35. The company intends to use the offering net proceeds for debt reduction and general corporate purposes. The offering is expected to close on June 10, 2022. Price Action: PWOJ shares are trading lower by 14.13% at $2.76 on the last check Wednesday.
2022-06-09 08:32:58	MDGX	Novan Announces Approximately $15M Registered Direct Offering Priced At-The-Market	Novan, Inc. (&quot;the Company&quot; or &quot;Novan&quot;) (NASDAQ: MDGX ), today announced it has entered into a definitive agreement with an institutional investor to sell to the investor, in a registered direct offering priced at-the-market under Nasdaq rules, (i) 2,080,696 shares of its common stock and accompanying warrants to purchase up to 2,080,696 shares of common stock and (ii) pre-funded warrants to purchase up to 3,180,615 shares of common stock and accompanying warrants to purchase up to 3,180,615 shares of common stock, for aggregate gross proceeds of approximately $15.0 million. The shares (or pre-funded warrants in lieu thereof) and accompanying warrants are being sold together, each consisting of one share of common stock or a pre-funded warrant to purchase one share of common stock, as the case may be, and a warrant to purchase one share of common stock, at an offering price of $2.851 per share and accompanying warrant and $2.841 per pre-funded warrant and accompanying warrant. The pre-funded warrants will be exercisable immediately, have an exercise price of $0.01 per share and will be exercisable until all of the pre-funded warrants are exercised in full. The warrants will be exercisable immediately, have an exercise price of $2.851 per share, and will expire five years from the date of issuance. The offering is expected to close on or about June 13, 2022, subject to customary closing conditions. Oppenheimer & Co. Inc. is acting as the sole placement agent for the offering. Novan intends to use the net proceeds from the offering, together with existing cash, to fund research and development program activities, including (i) preparing for and seeking regulatory approval of its product candidate, SB206, as a treatment for molluscum contagiosum; (ii) planning for potential commercialization of SB206; and (iii) conducting small-scale drug substance and drug product manufacturing activities to support the SB206 regulatory submission process. The Company also intends to use the net proceeds from the offering (i) to support sales and marketing efforts for its marketed products; and (ii) for general corporate purposes, including selling, general and administrative expenses, capital expenditures and working capital needs. The securities described above are being offered by Novan pursuant to a shelf registration statement (Registration No. 333-262865) filed with the Securities and Exchange Commission (the &quot;SEC&quot;) and declared effective by the SEC on February 25, 2022. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC and, when available, may be obtained for free on the SEC's website located at http://www.sec.gov . When available, electronic copies of the final prospectus supplement and accompanying prospectus relating to the public offering may be obtained by contacting Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-06-10 14:21:43	XXYJ	XXYJ Raises $3.5M Via Equity Offering	XXYJ Inc (NASDAQ: XXYJ ) entered into securities purchase agreements with institutional and accredited investors to issue 0.97 million shares and warrants to buy up to an aggregate of 0.97 million shares. The private placement, priced at $3.58 per share of common stock and associated warrant, will result in expected gross proceeds of $3.5 million. The warrants will have an exercise price of $5.00 per share of common stock and will be exercisable six months from the closing of the offering for a period of five years from the closing date. The closing of the offering is expected to occur on or before June 15, 2022. Price Action: XXYJ shares are trading lower by 19.78% at $2.88 on the last check Friday.
2022-06-14 07:32:47	YVYM	Day One Announces Proposed Public Offering Of $125M Of Common Stock	SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ: YVYM ), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. All of the shares of common stock are being offered by Day One. In addition, Day One intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2022-06-14 16:21:01	KOQE	VectivBio To Offer 3,478,260 Ordinary Shares At $5.75 Per Share	VectivBio Holding AG (&quot;VectivBio&quot;) (NASDAQ: KOQE ), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the launch of a follow-on public offering of its ordinary shares. In addition, VectivBio expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold in the offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. All of the ordinary shares in the offering are to be sold by VectivBio. Also today, VectivBio entered into an agreement with Forbion Growth Opportunities Fund II Co&ouml;peratief U.A., represented by Forbion Growth II Management B.V. (&quot;Forbion&quot;) pursuant to which VectivBio has agreed to sell 3,478,260 ordinary shares to Forbion at the price of $5.75 per ordinary share, for gross proceeds of approximately $20 million, in a private placement transaction that is expected to close concurrently with the public offering. The sale of these ordinary shares will not be registered under the Securities Act of 1933, as amended. The closing of the private placement transaction is not contingent on any public offering. VectivBio intends to use the net proceeds from the public offering and concurrent private placement, together with its existing cash and cash equivalents, available for sale and short-term deposits: to fund (i) clinical development and pre-commercialization activities for its lead product candidate and (ii) general corporate purposes, including general and administrative expenses and working capital. SVB Securities and Piper Sandler are acting as joint book-running managers for the public offering. LifeSci Capital is acting as a co-manager for the public offering. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission on Form F-3 (File No. 333-264653) and declared effective on May 12, 2022. The public offering will be made only by means of a prospectus supplement. Copies of the preliminary prospectus supplement and the accompanying prospectus related to the public offering may be obtained, when available, from: SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 8-8-7525, ext. 6105, or by email at syndicate@svbsecurities.com ; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by telephone at (800) 747-3924, or by email at prospectus@psc.com ; or by accessing the U.S. Securities and Exchange Commission's website at www.sec.gov . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The ordinary shares offered in the concurrent private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements.
2022-06-17 09:09:04	ZNTC	ToughBuilt Industries Shares Down After Co. Announced Pricing Of 3,157,895 Share Common Stock Offering At $1.90/Share And Associated Warrant	SVAX FOREST, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- ToughBuilt Industries, Inc. (&quot;ToughBuilt&quot; or the &quot;Company&quot;) (NASDAQ: ZNTC , TBLTW))))), today announced the pricing of a public offering of 3,157,895 shares of its common stock (or pre-funded warrants in lieu thereof), together with warrants to purchase up to 3,157,895 shares of its common stock at an offering price to the public of $1.90 per share (or pre-funded warrant) and associated warrant. The warrants will have an exercise price of $1.90 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about June 22, 2022, subject to the satisfaction of customary closing conditions.
2022-06-21 16:35:06	RNN	Ormat Technologies Shares Slip On Offer To Raise $350M Via Private Convertible Senior Notes	Ormat Technologies, Inc (NYSE: RNN ) plans to offer a $350 million aggregate principal amount of Green Convertible Senior Notes due 2027 in a private offering. The notes will mature on July 15, 2027; interest will be payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2023. The company would grant the initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of Notes. The notes will be convertible at the option of the holders before the close of the business day immediately preceding January 15, 2027. The company intends to enter into privately negotiated capped call transactions with one or more initial purchasers or affiliates. Ormat Technologies intends to use up to $25 million of the net proceeds to repurchase shares of its common stock in privately negotiated transactions, a portion to pay the cost of the capped call transactions, ~$221.9 million to fund the previously announced prepayment of its Series 3 Bonds, and the remainder for general corporate purposes. Price Action: RNN shares are trading lower by 5.28% at $71.00 during the post-market session on Tuesday.
2022-06-21 17:28:14	JYKI	Precision BioSciences Announces $50M Offering Of Common Stock	Precision BioSciences, Inc. (NASDAQ: JYKI ), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR F and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately $50.0 million. The offering is expected to close on or about June 24, 2022, subject to customary closing conditions. All shares of common stock to be sold in the offering will be sold by Precision BioSciences. Precision BioSciences intends to use the net proceeds of the offering to help fund ongoing and planned research and development, and for working capital and general corporate purposes. Jefferies is acting as sole book-running manager for the offering. The securities described above were offered by means of a prospectus supplement dated June 21, 2022, and accompanying prospectus dated June 11, 2020, forming part of the Company's effective shelf registration statement (File No. 333-238857). The prospectus supplement and accompanying prospectus relating to this offering will be filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and will be available on the SEC's website at www.sec.gov . Copies of the prospectus supplement and the accompanying prospectus may also be obtained, when available, by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, via telephone: 877-821-7388 or via email: Prospectus_Department@Jefferies.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-06-22 07:46:36	RTVD	Tuya Inc. Launches Global Offering Of 7.3M Shares	Tuya Inc. ( &quot;Tuya&quot; or the &quot;Company&quot;) (NYSE: RTVD ), a global leading IoT cloud development platform, today announced the launch of its global offering (the &quot;Global Offering&quot;) of 7,300,000 Class A ordinary shares of the Company, which comprises a Hong Kong public offering of initially 730,000 Class A ordinary shares (the &quot;Hong Kong Public Offering&quot;) and an international offering of initially 6,570,000 Class A ordinary shares (the &quot;International Offering&quot;), both commencing on June 22, 2022 Hong Kong time, and dual-primary listing of its Class A ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the &quot;Hong Kong Stock Exchange&quot;) under the stock code &quot;2391.&quot; The Company's American depositary shares (the &quot;ADSs&quot;), each representing one Class A ordinary share of the Company, will continue to be listed and traded on the New York Stock Exchange (&quot;NYSE&quot;). Investors in the Global Offering will only be able to purchase Class A ordinary shares and will not be able to take delivery of ADSs. Upon listing of the Class A ordinary shares on the Hong Kong Stock Exchange, the Class A ordinary shares listed on the Hong Kong Stock Exchange will be fully fungible with the ADSs listed on the NYSE. The initial number of Class A ordinary shares under the Hong Kong Public Offering and the International Offering represent 10% and 90% of the total number of Class A ordinary shares initially available under the Global Offering, respectively, subject to reallocation and over-allotment. Subject to the level of oversubscription in the Hong Kong Public Offering and pursuant to the clawback mechanism as described in the Hong Kong prospectus issued by the Company in Hong Kong dated June 22, 2022, the total number of Class A ordinary shares available under the Hong Kong Public Offering could be adjusted to up to a maximum of 3,650,000 Class A ordinary shares, representing 50% of the Class A ordinary shares initially available under the Global Offering. In addition, the Company expects to grant the international underwriters an over-allotment option to require the Company to issue up to an additional 1,095,000 Class A ordinary shares in the International Offering, representing not more than 15% of the total number of Class A ordinary shares initially available under the Global Offering. The offering price for the Hong Kong Public Offering (the &quot;Hong Kong Offering Price&quot;) will be no more than HK$22.80 per Class A ordinary share (the &quot;Maximum Hong Kong Offering Price&quot;), or US$2.90 per Class A ordinary share (equivalent to US$2.90 per ADS). The offering price for the International Offering tranche of the Global Offering (the &quot;International Offering Price&quot;) may be set higher than the Maximum Hong Kong Offering Price. The Company will set the International Offering Price on or about June 27, 2022, Hong Kong time, by taking into consideration, among other factors, the closing price of the ADSs on the NYSE on the last trading day on or before June 27, 2022 and investor demand during the marketing process. If the International Offering Price is set at or lower than the Maximum Hong Kong Offering Price, the final Hong Kong Offering Price must be set at such price which is equal to the International Offering Price. In no circumstances will the final Hong Kong Offering Price be set above the Maximum Hong Kong Offering Price or the International Offering Price. The shares will be traded in board lots of 200 Class A ordinary shares. The Company plans to use the net proceeds from the Global Offering for enhancing IoT technologies and infrastructure; enhancing its product offerings; improving sales and marketing; pursuing strategic partnerships, investments and acquisitions; and for working capital and other purposes. China International Capital Corporation Hong Kong Securities Limited, Merrill Lynch (Asia Pacific) Limited and Morgan Stanley Asia Limited are the joint sponsors for the proposed Global Offering, and China International Capital Corporation Hong Kong Securities Limited, Morgan Stanley Asia Limited and Merrill Lynch (Asia Pacific) Limited are the joint global coordinators, joint bookrunners, and joint lead managers for the proposed Global Offering. CMB International Capital Limited and Tiger Brokers (HK) Global Limited are the joint bookrunners and joint lead managers for the proposed Global Offering. The International Offering is being made only by means of a preliminary prospectus supplement dated June 22, 2022 and the accompanying prospectus included in an automatic shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on May 31, 2022, which automatically became effective upon filing. The registration statement on Form F-3 and the preliminary prospectus supplement are available at the SEC website at: www.sec.gov . The proposed Global Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Global Offering may be completed, or as to the actual size or terms of the Global Offering. This press release shall not constitute an offer to sell or the solicitation of an offer or an invitation to buy any securities of the Company, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. This press release does not constitute a prospectus (including as defined under the laws of Hong Kong) and potential investors should read the prospectus of the Company for detailed information about the Company and the proposed Global Offering, before deciding whether or not to invest in the Company. This press release has not been reviewed or approved by The Stock Exchange of Hong Kong Limited or the Securities and Futures Commission of Hong Kong. The price of the Class A ordinary shares of the Company may be stabilized in accordance with the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). The details of the intended stabilization and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) will be contained in the Hong Kong prospectus of the Company dated June 22, 2022.
2022-06-22 16:09:40	OQYT	Blue Hat Interactive Terminates Previously Proposed Shelf Takedown Offering	Blue Hat Interactive Entertainment Technology (&quot;OQYT&quot; or the &quot;Company&quot;) (NASDAQ: OQYT ), a producer, developer and operator of augmented reality interactive entertainment games, toys and educational materials in China, announced today that it has determined not to proceed with the previously announced underwritten public offering of its ordinary shares and pre-funded warrants. No securities were sold pursuant to the Company's shelf registration statement on Form F-3 (No. 333-249056) in connection with such previously proposed offering.
2022-06-22 16:13:44	KVAW	Applied Therapeutics, Inc. Announces Public Offering Of Common Stock And Warrants; Size Not Disclosed	Applied Therapeutics, Inc. (NASDAQ: KVAW ) (the &ldquo;Company&rdquo;), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it plans to make a public offering of shares of its common stock, par value $0.0001 per share, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten registered public offering. The Company intends to use the net proceeds from this offering for general corporate purposes. General corporate purposes may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company&rsquo;s product candidates, expansion of the Company&rsquo;s research and development capabilities, working capital and capital expenditures. SVB Securities is acting as the sole book-running manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the final size or terms of the offering. The offering is being made only by means of a previously filed effective registration statement (including a base prospectus) and a preliminary prospectus supplement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering, when available, may be obtained from SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at syndicate@svbsecurities.com . Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and the proposed offering. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-06-22 16:33:26	JWNH	Summit Therapeutics Announces $100 Million Rights Offering	Summit Therapeutics Inc. (NASDAQ: JWNH ) (&quot;Summit&quot; or the &quot;Company&quot;) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the Company's common stock, par value $0.01 (the &quot;Common Stock&quot;) as of the close of the market on July 5, 2022 (the &quot;Record Date&quot;). The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscription rights to purchase shares of Common Stock at a price per share equal to the lesser of (i) $1.08 per share, the closing price of the Common Stock on June 22, 2022, or (ii) the volume weighted-average price of the Common Stock for the five consecutive trading days through and including the expiration date of the offering, currently contemplated to be August 5, 2022. Assuming that the rights offering is fully subscribed, the Company will receive gross proceeds of up to $100 million, less expenses related to the rights offering. The rights offering will include an over-subscription right to permit each rights holder that exercises its basic subscription rights in full to purchase additional shares of Common Stock that remain unsubscribed at the expiration of the offering. The availability of the over-subscription right will be subject to certain terms and conditions to be set forth in the offering documents. Robert P. Duggan, Chairman, Chief Executive Officer, and the beneficial owner of approximately 70% of Summit's Common Stock prior to this rights offering, and Dr. Maky Zanganeh, Chief Operating Officer, a member of the Board of Directors, and the beneficial owner of approximately 6.5% of the Company's Common Stock prior to this rights offering, have each indicated that they intend to participate in the rights offering, but have not indicated a minimum level of participation or made any formal binding commitment to participate. The Company intends to register the rights offering with the Securities and Exchange Commission (the &quot;SEC&quot;) by filing a prospectus supplement to the Company's effective shelf registration statement on Form S-3. When available, a copy of the prospectus supplement may be obtained at the website maintained by the SEC at www.sec.gov . This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The rights offering will be made pursuant to the Company's shelf registration statement on Form S-3, which became effective on October 15, 2020, and a prospectus supplement containing the detailed terms of the rights offering to be filed with the SEC. Any offer will be made only by means of a prospectus forming part of the registration statement.
2022-06-22 17:19:26	CWHI	Xenon Pharmaceuticals Shares Drop On Proposed Public Offering	Xenon Pharmaceuticals Inc (NASDAQ: CWHI ) announced an underwritten public offering of its common shares . Underwriters of the offering will be granted an option for a period of 30 days to purchase an additional 15% of common shares at the public offering price. Jefferies, J.P. Morgan, SVB Securities, and Stifel are acting as joint book-running managers for the offering. An automatically effective shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on October 4, 2021. Additionally, the company announced new, compelling efficacy data supporting the late-stage, Phase 3 development of XEN1101 . &quot;We have generated additional efficacy data from subgroup analyses of our Phase 2b X-TOLE trial, which further support our Phase 3 development plans for XEN1101. A 'time course to efficacy' analysis shows that all doses of XEN1101 rapidly reduced the frequency of focal onset seizures within one week compared to placebo, suggesting that XEN1101 may offer a compelling and differentiated option for patients seeking to quickly reduce seizure frequency,&quot; stated Mr. Ian Mortimer, Xenon's President, and Chief Executive Officer. Price Action: CWHI shares are trading lower by 8.04% at $31.91 during the post-market session on Wednesday.
2022-06-23 08:08:11	CWHI	Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency	Xenon Pharmaceuticals Inc (NASDAQ: CWHI ) announced new efficacy data supporting the Phase 3 development of XEN1101. XEN1101 rapidly reduced focal onset seizure frequency within one week for all doses compared with placebo. At Week 1, the median percent reduction in monthly focal onset seizure frequency was 55.4% in the 25 mg group, 41.5% (20 mg), and 39.1% (10 mg) compared to 20.2% in the placebo group. Based on the data, a key secondary endpoint in the Phase 3 trials will include the median percent change of weekly FOS at Week 1. Related: Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment . Seizure frequency continued to improve for the open-label extension (OLE) population during the first month after the 8-week double-blind period (DBP), suggesting that the efficacy signal can persist and may improve in the planned 12-week DBP of the XEN1101 Phase 3 trials. Subjects remaining in the X-TOLE OLE for at least three months and 12 months experienced a greater than 70% and 80% reduction in median monthly seizure frequency compared to the DBP baseline. 54 (19.6%) and 26 (9.5%) of subjects in the OLE experienced a &ge;6 and a &ge;12 consecutive months of seizure freedom, respectively. Xenon also priced its underwritten public offering of 7.9 million shares and pre-funded warrants to purchase up to 327,868 shares at $30.50 per common share, with gross proceeds of $250 million . Price Action: CWHI shares are down 13.52% at $30.01 during the premarket session on the last check Thursday.
2022-06-23 08:42:13	NALD	BIT Mining Announces $16M Registered Direct Offering	BIT Mining Limited (NYSE: NALD ) (&quot;BIT Mining&quot; or the &quot;Company&quot;), a leading technology-driven cryptocurrency mining company, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 16,000,000 of the Company's American Depositary Shares (&quot;ADSs&quot;) (or pre-funded warrant to purchase certain ADSs (&quot;ADS Equivalent&quot;) in lieu thereof), Series A Warrants to purchase up to an aggregate of 16,000,000 ADSs and Series B Warrants to purchase up to an aggregate of 16,000,000 ADSs, at a combined purchase price of US$1.00 per ADS (or ADS Equivalent) and associated warrants, in a registered direct offering. Each ADS represents ten (10) Class A ordinary shares, par value US$0.00005 per share, of BIT Mining. The offering is expected to close on or about June 27, 2022, subject to satisfaction of customary closing conditions. L.C. Wainwright & Co., LLC is acting as the exclusive placement agent for the offering. The Series A Warrants will have an exercise price of $1.10 per ADS, will be exercisable at any time upon issuance and will expire 5 years from the date of issuance. The Series B Warrants will have an exercise price of $1.00 per ADS, will be exercisable at any time upon issuance and will expire 2.5 years from the date of issuance. The gross proceeds from the offering (without taking into account any proceeds from any future exercises of warrants issued), before deducting the placement agent's fees and other estimated offering expenses payable by the Company, are expected to be approximately US$16 million. The Company intends to use the net proceeds of the registered direct offering to invest in mining machines, build new data centers, expand infrastructure, and improve working capital position. The securities described above are being offered by BIT Mining pursuant to a &quot;shelf&quot; registration statement on Form F-3 (File No. 333-258329) originally filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on July 30, 2021 and declared effective by the SEC on May 17, 2022. The offering of such securities is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
2022-06-24 09:34:01	IMQF	BioSig Announces Pricing Of Public Offering At $0.75/Share	BioSig Technologies, Inc. (NASDAQ: IMQF ) (&quot;BioSig&quot; or the &quot;Company&quot;) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced pricing of its previously-announced best efforts underwritten public offering of up to 4,666,667 shares of its common stock, $0.001 par value per share, at a price to the public of $0.75 per share. The gross proceeds to BioSig from this offering are expected to be $3,500,000.25, before deducting the underwriting discount and other estimated offering expenses payable by BioSig. The offering is expected to close on June 28, 2022, subject to customary closing conditions. Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering. BioSig intends to use the net proceeds from the offering for the continuation of commercialization activities related to the PURE CU&trade; System, including additional support for organizational development, to fund working capital, and for general corporate purposes and other capital expenditures. A shelf registration statement on Form S-3 (Registration No. 333-251859) relating to the public offering of the shares of common stock described above was previously filed with the Securities and Exchange Commission (SEC) and declared effective on January 12, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at www.sec.gov . A final prospectus supplement and accompanying prospectus relating to the underwritten public offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Copies of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from Laidlaw & Company (UK) Ltd., 521 Fifth Ave., 12th Floor, New York, NY 10175, Attention: Syndicate Dept.; email: syndicate@laidlawltd.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
2022-06-27 08:41:33	RTVD	Tuya Inc. Announces Pricing Of 7.3M Share Global Offering At HK$19.30 Per Offer Share Or $2.46 Per ADS	Tuya Inc. (&quot;Tuya&quot; or the &quot;Company&quot;) (NYSE: RTVD ), a global leading IoT cloud development platform, today announced the pricing of its global offering (the &quot;Global Offering&quot;) of 7,300,000 Class A ordinary shares of the Company (the &quot;Offer Shares&quot;), which comprises a Hong Kong public offering (the &quot;Hong Kong Public Offering&quot;) and an international offering (the &quot;International Offering&quot;). The final offering price for both the International Offering and the Hong Kong Public Offering (the &quot;Offering Price&quot;) has been set as HK$19.30 per Offer Share. Based on the ratio of one Class A ordinary share per NYSE-listed American depositary share (the &quot;ADS&quot;), the Offering Price translates to US$2.46 per ADS based on an exchange rate of HK$7.8494 to US$1.00. In addition, the Company has granted an over-allotment option to the international underwriters, exercisable by the joint representatives on behalf of the international underwriters, until the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue up to an aggregate of 1,095,000 additional Offer Shares at the Offering Price. Subject to approval from The Stock Exchange of Hong Kong Limited (the &quot;Hong Kong Stock Exchange&quot;), the Class A ordinary shares of the Company are expected to begin trading on the Main Board of the Hong Kong Stock Exchange on or about Tuesday, July 5, 2022 under the stock code &quot;2391.&quot; The Global Offering is expected to close on the same day, subject to customary closing conditions. The net proceeds to the Company from the Global Offering, after deducting underwriting commissions, fees and estimated expenses payable by the Company in connection with the Global Offering, are expected to be HK$70.0 million (assuming the over-allotment option is not exercised). The Company plans to use the net proceeds from the Global Offering for enhancing IoT technologies and infrastructure; enhancing its product offerings; improving sales and marketing; pursuing strategic partnerships, investments and acquisitions; and for working capital and other purposes. China International Capital Corporation Hong Kong Securities Limited, Merrill Lynch (Asia Pacific) Limited and Morgan Stanley Asia Limited are the joint sponsors for the proposed Global Offering, and China International Capital Corporation Hong Kong Securities Limited, Morgan Stanley Asia Limited and Merrill Lynch (Asia Pacific) Limited are the joint global coordinators, joint bookrunners, and joint lead managers for the proposed Global Offering. CMB International Capital Limited and Tiger Brokers (HK) Global Limited are the joint bookrunners and joint lead managers for the proposed Global Offering. The International Offering is being made only by means of a prospectus supplement and the accompanying prospectus. The accompanying prospectus is included in an automatic shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on May 31, 2022, which automatically became effective upon filing. The registration statement on Form F-3 and the preliminary prospectus supplement dated June 22, 2022 are available on the SEC's website at www.sec.gov . The final prospectus supplement will be filed with the SEC and will be available on the SEC's website at www.sec.gov . When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from China International Capital Corporation Hong Kong Securities Limited, 29/F, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong, Attention: Project V2, by telephone at +852 2872-2000 or by email at ib_v2@cicc.com.cn ; Morgan Stanley, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, by telephone at +1 (866) 718-1649 or by email at prospectus@morganstanley.com ; and BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, United States of America, Attention: Prospectus Department, by telephone at +1 (800) 294-1322 or by email at dg.prospectus_requests@bofa.com . This press release shall not constitute an offer to sell or the solicitation of an offer or an invitation to buy any securities of the Company, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. This press release does not constitute a prospectus (including as defined under the laws of Hong Kong) and potential investors should read the prospectus of the Company for detailed information about the Company and the Global Offering, before deciding whether or not to invest in the Company. This press release has not been reviewed or approved by the Hong Kong Stock Exchange or the Securities and Futures Commission of Hong Kong. The price of the Offer Shares of the Company may be stabilized in accordance with the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). The details of the intended stabilization and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) have been contained in the Hong Kong prospectus of the Company dated June 22, 2022.
2022-06-27 09:23:37	HTYA	AgEagle Aerial Systems Announces Pricing Of $10M Registered Direct Offering	AgEagle Aerial Systems Inc. (NYSE: HTYA ) (&quot;AgEagle&quot; or the &quot;Company&quot;), an industry-leading provider of full-stack drone, sensor and software solutions for commercial and government/defense use, today announced that, it has entered into a securities purchase agreement with an institutional investment firm (the &quot;Investor&quot;), which is an existing AgEagle shareholder. Pursuant to the agreement, the Investor will purchase 10,000 shares of Series F 5% Convertible Preferred Stock (the &quot;Series F Convertible Preferred&quot;) and warrants to purchase up to 10,416,667 shares of common stock at an exercise price of $0.96 per share (the &quot;Warrants&quot;), for gross proceeds of approximately $10 million. The Series F Convertible Preferred will be convertible into 16,129,032 shares of the Company's common stock at a conversion price of $0.62 per share. The Warrants are not exercisable for the first six months after issuance and have a three-year term from the exercise date. Upon exercise of the Warrants in full by the Investor, the Company would receive additional gross proceeds of approximately $10 million. A certificate of designation setting forth the terms, dividends, rights and other privileges of the Series F Convertible Preferred will be filed with the Secretary of State of the State of Nevada. The Investor has the right, subject to certain conditions, including shareholder approval, to purchase up to $25,000,000 of additional shares of Series F Convertible Preferred and warrants. That option will be available for a period of 18 months after shareholder approval at a purchase price equal to the average Volume Weighted Average Pricings (&quot;VWAPs&quot;) for three trading days prior to the date the Investor gives notice to the Company that it will exercise the option. The Company expects the net proceeds from the offering to be approximately $9.92 million after deducting approximately $80,000 in offering expenses. The Company expects to spend the balance of the proceeds for general working capital and capital expenditure purposes. The offering is expected to close on or about June 29, 2022, subject to the satisfaction of customary closing conditions. Commenting on the financing, Nicole Fernandez-McGovern, CFO of AgEagle, noted, &quot;We are very pleased to be proceeding with this offering, which, upon closing, will further strengthen the Company's liquidity position.&quot; This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A registration statement relating to the offered securities (File Number 333-252801) has been declared effective by the Securities and Exchange Commission. A prospectus supplement relating to the securities will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov . For more detailed information relating to this transaction, please refer to the related Form 8-K to be filed with the U.S. Securities and Exchange Commission.
2022-06-28 07:41:13	TV	US-Based Exploration & Development Company Ivanhoe Electric Prices Big US GIP	Ivanhoe Electric Inc has priced its initial public offering at $11.75 a share , raising $169.1 million. The company&rsquo;s mining billionaire Robert Friedland sold about 14.4-million shares at the bottom of its previously guided GIP price range of $11.75 to $12.50 . The underwriters have an option to purchase an additional 2.16-million shares. According to Bloomberg , Ivanhoe Electric GIP is still the biggest U.S. GIP since May. The shares are expected to begin trading on the NYSE American and the TSX on Tuesday under the ticker symbol &lsquo;TV.&rsquo; Ivanhoe Electric has a portfolio of mineral projects, primarily focused on copper and other metals needed for the clean energy transition. The company said it would use the net proceeds to acquire or maintain its mineral and property rights to its material and key mineral properties, to further its metals exploration activities at its mineral properties, and to construct and deploy additional sets of its Typhoon electrical pulse-powered geophysical surveying transmitter technology.
2022-06-28 08:36:23	JUOL	BIOLASE Announces Pricing Of $6.5M Registered Direct Offering Priced At-the-Market At  $4.625/Share	BIOLASE, Inc. (NASDAQ: JUOL ), the global leader in dental lasers, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $6.5 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules. The combined effective purchase price for one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock will be $4.625. Under the terms of the securities purchase agreement, BIOLASE has agreed to sell 1,405,405 shares of common stock (or pre-funded warrants in lieu thereof). In a private placement, which will be consummated concurrently with the registered direct offering, BIOLASE also has agreed to issue warrants to purchase up to an aggregate of 1,405,405 shares of common stock. The warrants will be immediately exercisable, will expire five and a half years from the date of issuance and will have an exercise price of $4.625 per share of common stock. Maxim Group LLC is acting as the lead placement agent for the offering. The Benchmark Company and Lake Street Capital Markets, LLC are acting as co-placement agents for the offering. The offering is expected to close on or about June 30, 2022, subject to the satisfaction of customary closing conditions. The shares of common stock and pre-funded warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-233172) previously filed and declared effective by the Securities and Exchange Commission (SEC). The offering of the shares of common stock and pre-funded warrants will be made only by means of a prospectus supplement that forms a part of the registration statement. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock and pre-funded warrants will be filed by BIOLASE with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.
2022-06-28 16:03:30	ECFC	89bio Announces Proposed $75M Underwritten Public Offering	89bio, Inc. (&quot;89bio&quot;) (NASDAQ: ECFC ), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase shares of its common stock. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio. 89bio intends to use the net proceeds from this offering to fund ongoing clinical activities and development of pegozafermin (previously BIO89-100), and other general corporate purposes, including general working capital and operating expenses. BofA Securities and SVB Securities are acting as book-running managers for the offering. A shelf registration statement relating to these securities has been filed with the Securities and Exchange Commission (&quot;SEC&quot;) and became effective on April 23, 2021. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website, located at www.sec.gov . Prospective investors should read the preliminary prospectus supplement and the accompanying prospectus and other documents 89bio has filed with the SEC for more complete information about 89bio and the offering. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus related to the offering may also be obtained by contacting BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; or SVB Securities, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone at (800) 808-7525, ext. 6105 or by email at syndicate@svbsecurities.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-06-28 16:21:38	OIWO	Gaming And Leisure Properties Announces Public Offering Of 6.9M Shares	Gaming and Leisure Properties, Inc. (the &quot;Company&quot; or &quot;OIWO&quot;) (NASDAQ: OIWO ) today announced that it has commenced an underwritten public offering to sell 6,900,000 shares of common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 1,035,000 shares of common stock. The Company intends to use the net proceeds from the offering to partially finance the previously-announced acquisition of the real property assets of Bally's Twin River Lincoln Casino Resort (&quot;Lincoln&quot;) and Bally's Tiverton Casino & Hotel (&quot;Tiverton&quot;) from affiliates of Bally's Corporation (the &quot;Bally's Acquisitions&quot;). If all third-party consents and approvals for the acquisition of Lincoln are not timely received, then OIWO will instead acquire the real property assets of the Hard Rock Hotel & Casino Biloxi in Mississippi along with Tiverton. In that event, OIWO will also have the option, subject to receipt of required consents, to acquire the real property assets of Lincoln prior to December 31, 2024. Pending the closing of the Bally's Acquisitions, the Company intends to use the net proceeds from the offering to repay borrowings under the senior credit facility of its operating partnership or invest in interest-bearing accounts and short-term, interest-bearing securities. The offering is not conditioned upon the successful completion of the Bally's Acquisitions and there is no assurance that the Bally's Acquisitions will be consummated on the anticipated schedule or at all. In the event the Bally's Acquisitions are not consummated, the Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include the acquisition, development and improvement of properties, the repayment of indebtedness, capital expenditures and other general business purposes. Wells Fargo Securities, J.P. Morgan, RBC Capital Markets and Goldman Sachs & Co. LLC are serving as underwriters for the offering. The offering will be made under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;). When available, a copy of the preliminary prospectus supplement, final prospectus supplement and prospectus relating to the offering may be obtained from Wells Fargo Securities, Attn.: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897 or email a request to cmclientsupport@wellsfargo.com; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or email: prospectus-eq_fi@jpmchase.com; RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at 877-822-4089 or by email at equityprospectus@rbccm.com; and Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com , or by visiting the EDGAR database on the SEC's website at www.sec.gov . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
2022-06-28 17:18:10	IHMY	Aspen Aerogels Shares Slide On Proposed Public Offering	Aspen Aerogels Inc (NYSE: IHMY ) shares plunged 25% in the post-market session after it announced plans to offer $225 million of common stock and $150 million aggregate principal amount of green convertible senior notes due 2027 in separate concurrent public offerings. Underwriters will be granted a 30-day option to purchase up to an additional 15% of the applicable securities. The notes will be convertible into cash, shares of IHMY&rsquo;s common stock, or a combination of cash and common stock at the election of the company. Aspen intends to use the net proceeds to partially fund its planned capital projects and other general corporate purposes. The company anticipates that this use of net proceeds will qualify as Eligible Green Expenditures for the Notes offering. Price Action: IHMY shares are trading lower by 22.70% at $11.40 during the post-market session on Tuesday.
2022-06-29 16:02:20	TMNC	Verrica Announces Proposed Public Offering of Common Stock, Terms Not Disclosed	Verrica Pharmaceuticals Inc. (NASDAQ: TMNC ), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Verrica. Verrica also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. RBC Capital Markets is acting as sole book-runner for the offering.
2022-06-30 08:40:09	SOVG	Akerna Corp. Announces Pricing of $10M Public Offering	Akerna Corp. (NASDAQ: SOVG ) (&ldquo;Akerna&rdquo; or the &ldquo;Company&rdquo;), a leading enterprise software company and developer of one of the most comprehensive technology infrastructures, ecosystems, and compliance engines powering the global cannabis industry, today announced the pricing of an underwritten public offering of (i) 29,382,861 units of the Company consisting of 29,382,861 shares of common stock together with common stock warrants (the &ldquo;common warrants&rdquo;) to purchase up to 29,382,861 shares of common stock and (ii) 14,095,400 pre-funded units, consisting of 14,095,400 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase up to 14,095,400 shares of common stock. The units are being sold at a public offering price of $0.23 per unit and the pre-funded units are being sold at a public offering price of $0.2299 per pre-funded unit. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 or on a cashless basis and may be exercised at any time until all of the pre-funded warrants are exercised in full. The common warrants will have an exercise price of $0.23 per share subject to certain adjustments, will be immediately exercisable and will expire five years from the date of issuance. Additionally, the Company has granted the underwriters a 45-day option to purchase up to (i) an additional 6,521,739 shares of common stock and/or (ii) 6,521,739 common warrants and/or (iii) 6,521,739 pre-funded warrants to cover over-allotments, if any, with the total over-allotments not to exceed 13,043,478 shares, including the common stock underlying the common warrants and pre-funded warrants. The gross offering proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, are expected to be approximately $10 million. The offering is expected to close on or about July 5, 2022, subject to customary closing conditions. The Company intends to use the net proceeds from this offering for general corporate purposes, including servicing our ongoing debt obligations under our convertible notes, working capital, marketing, product development and capital expenditures.
2022-06-30 11:03:12	IHMY	Why Aspen Aerogels Stock Spiked Today	Aspen Aerogels Inc (NYSE: IHMY ) shares are trading higher Thursday after the company announced it decided not to proceed with the concurrent public offerings of its common stock and its green convertible senior notes due 2027 due to market conditions. &quot;The decision not to proceed with the concurrent offerings results from an assessment by the Company that current market conditions are not conducive for the offerings on terms that would be in the best interests of Aspen's shareholders,&quot; the company said. Aspen Aerogels is a technology company focused on sustainability. The company's aerogel technology enables its customers to achieve their own objectives around the global megatrends of resource efficiency, e-mobility and clean energy. See Also: RH Stock Is Sliding Today: Here's Why IHMY Price Action: Aspen Aerogels has traded between $65.98 and $7.93 over a 52-week period. The stock spiked to nearly $14 per share in premarket trading before pulling back. Aspen shares were up 11.2% at $9.37 at press time, according to data from Benzinga Pro .
2022-06-30 11:42:31	KGER	MeaTech 3D Shares Slide On $6.5M Equity Offering	MeaTech 3D Ltd (NASDAQ: KGER ) has entered into a definitive agreement with a single U.S. institutional investor for an offering of 1.9 million ADSs and warrants to purchase the shares at a purchase price of $3.50 per ADS. The warrants to be issued will have a five-year term and become exercisable immediately. The company expects the gross proceeds from the offering to be approximately $6.5 million. It intends to use the net proceeds for general corporate purposes. The closing of the offering is expected to occur on or about July 5, 2022 Price Action: KGER shares are trading lower by 8.59% at $3.30 on the last check Thursday.
2022-07-01 09:22:05	IRAD	Agile Therapeutics Announces Pricing of $24M Upsized Public Offering	Agile Therapeutics, Inc. (NASDAQ: IRAD ) (&quot;Agile Therapeutics&quot; or the &quot;Company&quot;), a women's healthcare company, today announced the pricing of its upsized public offering of an aggregate of 26,666,666 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock warrants, at a public offering price of $0.90 per share (or pre-funded warrant) and accompanying warrants. Each share of common stock (or pre-funded warrant) was sold in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $0.90 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $0.90 per share. The Series A-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire thirteen months from the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $24.0 million.
2022-07-05 17:16:43	ZKKI	SCWorx Announces Common Stock Purchase Of Up To $5M	SCWorx Corp., a Delaware corporation (the &quot;Company&quot;), announced that it has entered into a common stock purchase agreement (the &quot;Purchase Agreement&quot;) with an institutional investor (the &quot;Institutional Investor&quot; or &quot;Investor&quot;). Under the terms and subject to the conditions of the Purchase Agreement, SCWorx will have the right, but not the obligation, to issue and sell to the Investor up to $5 million of SCWorx common stock from time-to-time over the approximately 24-month term of the Purchase Agreement. Tim Hannibal, President & CEO of SCWorx, said, &quot;Our agreement with the Institutional Investor is another piece of the SCWorx plan to move the Company forward and achieve key business objectives that contribute to our growth strategy&quot;. Hannibal continued, &quot;We believe this commitment from the Institutional Investor demonstrates investor confidence in SCWorx, including our business model that leverages the SCWorx data management SaaS solution to assist hospitals in achieving their supply chain goals and cost savings objectives.&quot; Under the terms of the Purchase Agreement, SCWorx has the right, but not the obligation, to sell to the Investor up to $5 million of its common stock, subject to certain conditions. SCWorx may direct the Investor to purchase a number of shares not to exceed an amount determined by SCWorx's trading volume and stock price. Purchase notices may be issued over the period commencing once certain customary conditions are satisfied, including the filing and securing effectiveness of a registration statement (the &quot;Registration Statement&quot;) with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) with respect to resale of the shares issued pursuant to the Purchase Agreement, which is expected in mid-to-late August 2022. SCWorx expects to use net proceeds from the financing over time for working capital and general corporate purposes to support its future growth. As consideration for the Institutional Investor's commitment to purchase shares of SCWorx's common stock upon the terms and conditions set forth in the Purchase Agreement, SCWorx will issue 277,778 shares of its common stock to the Investor. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any of the securities referred to in this news release in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. Any offering of SCWorx's common stock under the resale registration statement referred to in this news release will be made only by means of a prospectus.
2022-07-06 08:36:10	LGGK	Noah Holdings Limited Announces Pricing Of Global Offering at HK$292 Per Offer Share	Noah Holdings Limited (&quot;Noah&quot; or the &quot;Company&quot;) (NYSE: LGGK ), a leading and pioneer wealth management service provider in China offering comprehensive one-stop advisory services on global investment and asset allocation primarily for high net worth investors, today announced the pricing of the global offering (the &quot;Global Offering&quot;) of an aggregate of 1,100,000 Class A ordinary shares of the Company (the &quot;Offer Shares&quot;). The Global Offering comprises of an international offering (the &quot;International Offering&quot;) and a Hong Kong public offering (the &quot;Hong Kong Public Offering&quot;). The final offer price for both the International Offering and the Hong Kong Public Offering (the &quot;Offer Price&quot;) has been set as HK$292.00 per Offer Share. Based on the ratio of two NYSE-listed American depositary shares (&quot;ADSs&quot;) per one Class A ordinary share, the Offer Price translates to approximately US$18.60 per ADS based on an exchange rate of HK$7.8498 to US$1.00 as of June 17, 2022, as set forth in the L.10 statistical release of the Federal Reserve Board. Subject to approval from The Stock Exchange of Hong Kong Limited (the &quot;Hong Kong Stock Exchange&quot;), the Class A ordinary shares of the Company are expected to begin trading on the Main Board of the Hong Kong Stock Exchange on Wednesday, July 13, 2022 under the stock code &quot;6686.&quot; The Global Offering is expected to close on the same day, subject to customary closing conditions. In addition, the Company has granted an over-allotment option to the international underwriters, exercisable by the sole representative for itself and on behalf of the international underwriters, from the date of the international underwriting agreement to be dated on or around July 6, 2022 until 30 days after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue up to an aggregate of 165,000 additional Offer Shares at the Offer Price. The gross proceeds to the Company from the Global Offering, before deducting the underwriting fees and the estimated offering expenses payable by the Company, are expected to be HK$321.2 million (assuming the over-allotment option is not exercised). The Company plans to use the net proceeds from the Global Offering for further developing its wealth management business, for further developing its asset management business, for selectively pursuing potential investments, for investing in its in-house technology across all business lines, for overseas expansion, and for general corporate purposes. To the extent that the net proceeds from the Global Offering are not immediately required for the above purposes or if the Company is unable to put into effect any part of its plan as intended, the Company will hold such funds in short-term interest-bearing accounts at authorized licensed banks. Goldman Sachs (Asia) L.L.C. is the sole sponsor and sole representative for the Global Offering. Goldman Sachs (Asia) L.L.C., BOCI Asia Limited and DBS Asia Capital Limited are joint global coordinators, joint bookrunners and joint lead managers for the Global Offering. Futu Securities International (Hong Kong) Limited is a joint bookrunner and joint lead manager for the Global Offering. The International Offering is being made only by means of a preliminary prospectus supplement dated June 29, 2022 and the accompanying prospectus included in an automatic shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on June 21, 2022, which automatically became effective upon filing. The registration statement on Form F-3 and the preliminary prospectus supplement are available at the SEC website at: http://www.sec.gov . The final prospectus supplement will be filed with the SEC and will be available on the SEC's website at: http://www.sec.gov . When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Goldman Sachs & Co. L.L.C., 200 West Street, New York, NY 10282-2198, Attention: Prospectus Department (1-866-471-2526), or E-Mail: Prospectus-Ny@gs.com , BOCI Asia Limited, 26/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, Attention: Investment Banking Division (852-3988 6000), or E-mail: HK-IBD-ECM@bocigroup.com , DBS Asia Capital Limited, Attention: DBS Asia Capital Ltd &ndash; Equity Syndicate, or E-mail: capmkts-hk.equitysyndicate@dbs.com and Futu Securities International (Hong Kong) Limited, Attention: Tse Chi Kin, Daniel, or E-mail: project-rainbow@futuhk.com . This press release shall not constitute an offer to sell or the solicitation of an offer or an invitation to buy any securities of the Company, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. This press release does not constitute a prospectus (including as defined under the laws of Hong Kong) and potential investors should read the prospectus of the Company for detailed information about the Company and the proposed offering, before deciding whether or not to invest in the Company. This press release has not been reviewed or approved by the Hong Kong Stock Exchange or the Securities and Futures Commission of Hong Kong. The price of the Offer Shares of the Company may be stabilized in accordance with the Securities and Futures (Price Stabilizing) Rules. The details of the intended stabilization and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) have been contained in the prospectus of the Company dated June 30, 2022.
2022-07-06 09:23:52	NBFV	ThermoGenesis Reported in Filing Tuesday It Received a Conversion Notice From Boyalife Asset Holding II to Convert a Total of $3M of the Outstanding Balance of the Second Amended and Restated Convertible Promissory Note Issued to Boyalife on April 16, 2018	"On June 28, 2022, ThermoGenesis Holdings, Inc. (the ""Company"") received a conversion notice from Boyalife Asset Holding II, Inc.(""Boyalife"") to convert a total of $3,000,000 of the outstanding balance of the Second Amended and Restated Convertible Promissory Note issued by the Company to Boyalife on April 16, 2018, as amended by Amendment No 1 thereto dated March 4, 2022 (as amended, the ""Note""). The amount converted represents $3,000,000 of the outstanding principal balance of the Note. The conversion resulted in the issuance of 10,552,234 shares of the Company's common stock at a conversion price of $.2843 per share. Immediately after the conversion, the new outstanding principal balance ofthe Note was $7,000,000, and accrued but unpaid interest was $708,000. Additionally, between May 19, 2022 and July 5, 2022, the Company sold an aggregate of 7,939,251 shares of its common stock under its At the Market Offering Agreement with L.C. Wainwright & Co., LLC. As of July 5, 2022, the Company had 31,321,362 shares of common stock issued and outstanding"
2022-07-07 11:40:56	LWH	Kalera Public Limited Company Announces $10M Private Placement	alera Public Limited Company (&quot;Kalera&quot; or the &quot;Company&quot;) (NASDAQ: LWH ), a vertical farming company headquartered in Orlando, Florida, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 2,500,000 shares of common stock (or pre-funded warrants in lieu thereof), 2,500,000 Series A Warrants and 2,500,000 Series B Warrants. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with accompanying warrants at a combined effective purchase price of $4.00. The Series A Warrants will be exercisable six months from the date of issuance at an exercise price of $4.41 per share and will expire two years from the date of issuance. The Series B Warrants will be exercisable six months from the date of issuance at an exercise price of $4.41 per share and will expire five and a half years from the date of issuance. The closing of the private placement is expected to occur on July 11, 2022, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.
2022-07-07 13:19:21	LWH	Kalera Raises $10M Via Equity Offering	Kalera Public Limited Company (NASDAQ: LWH ) has entered into a securities purchase agreement with a single institutional investor. The company will receive about $10.0 million through the private placement of 2.5 million shares and warrants. Each share is being sold together with accompanying warrants at a combined effective purchase price of $4.00. The closing of the private placement is expected to occur on July 11, 2022. Maxim Group LLC is acting as the sole placement agent for the offering. Price Action: LWH shares are trading higher by 8.16% at $4.77 on the last check Thursday.
2022-07-07 19:33:51	ATQF	Provention Bio Announced $60M Private Placement of Common Stock and Warrants to Acquire 13,318,535 Additional Shares of Its Common Stock	"Provention Bio, Inc. (NASDAQ: ATQF ) (the ""Company""), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced it has entered into a securities purchase agreement with institutional investors for the private placement of approximately $60 million of shares of its common stock and warrants to acquire 13,318,535 additional shares of its common stock (the ""Warrants"") (collectively, the ""Securities""). The Warrants will be exercisable immediately upon issuance, in whole or in part, at an exercise price of $6.00 per share and will have a five-year term. The Company anticipates aggregate gross proceeds from the offering will be approximately $60 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company, based on the offering price of $4.505 for each share of the Company's common stock plus one Warrant. The Company expects to use net proceeds from the private placement to fund expenses in preparation for the potential launch of teplizumab, to advance its clinical development candidates, as well as for working capital and other general corporate purposes. The transaction is expected to close on or about July 13, 2022, subject to the satisfaction of customary closing conditions. The private placement investors include Sessa Capital and Armistice Capital Master Fund Ltd Jefferies acted as sole placement agent on the transaction."
2022-07-11 16:01:50	OLML	Pliant Therapeutics Announces Proposed Offering Of $150M Of Common Stock	Pliant Therapeutics, Inc. (NASDAQ: OLML ), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that it has commenced an underwritten public offering of $150.0 million of its common stock. In addition, Pliant expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by Pliant. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or the actual size or terms of the proposed offering. J.P. Morgan and Cowen are acting as lead book-running managers for the proposed offering. RBC Capital Markets is acting as a book-running manager for the proposed offering. Cantor and BTIG are acting as lead managers for the proposed offering. Pliant intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and investments, to develop its ongoing and future preclinical and clinical programs including PLN-74809, further develop its integrin targeting platform, to fund working capital, operating expenses and capital expenditures, and for other general corporate purposes. The securities are being offered by Pliant pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (&quot;SEC&quot;). A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC's website at http://www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained for free from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com; or RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com . This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Pliant, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-07-11 16:19:00	OLML	After-Hours Alert: Why Pliant Therapeutics Stock Is Moving	Pliant Therapeutics Inc (NASDAQ: OLML ) shares are volatile in Monday's after-hours session after the company announced a proposed $150 million offering. Pliant Therapeutics shares soared by nearly 160% during Monday's regular trading session on the company's treatment for Idiopathic Pulmonary Fibrosis, which was well tolerated in a Phase 2a study. After the market closed, Pliant announced that it commenced an underwritten public offering of $150 million of its common stock. In addition, Pliant expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its stock at the public offering price. All of the shares in the offering will be sold by Pliant. Pliant said it intends to use the proceeds from the proposed offering to develop its ongoing and future preclinical and clinical programs including PLN-74809 and to further develop its integrin targeting platform. Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. OLML Price Action: Pliant has traded between $28.02 and $3.96 over a 52-week period. The stock was down 4.26% in after hours at $22.02 at press time, according to data from Benzinga Pro . Photo: Michal Jarmoluk from Pixabay.
2022-07-12 08:32:17	OLML	What's Going On With Pliant Therapeutics Stock?	Pliant Therapeutics Inc (NASDAQ: OLML ) shares are trading lower Tuesday after the company announced a proposed $150 million offering. Pliant Therapeutics shares soared by nearly 160% Monday on the company's treatment for Idiopathic Pulmonary Fibrosis, which was well tolerated in a Phase 2a study. After the market closed, Pliant announced that it commenced an underwritten public offering of $150 million of its common stock. In addition, Pliant expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its stock at the public offering price. All of the shares in the offering will be sold by Pliant. Pliant said it intends to use the proceeds from the proposed offering to develop its ongoing and future preclinical and clinical programs including PLN-74809 and to further develop its integrin targeting platform. Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. OLML Price Action: Pliant has traded between $28.02 and $3.96 over a 52-week period. The stock was down 4.78% at $21.90 at press time, according to data from Benzinga Pro . Photo: PublicDomainPictures from Pixabay.
2022-07-12 11:10:56	NZTZ	Kaspien Holdings Announces Pricing of $8M Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules	Kaspien Holdings Inc. (or the &quot;Company&quot;) (NASDAQ: NZTZ ) , a leading e-commerce marketplace growth platform, today announced that it has entered into a securities purchase agreement with a single institutional investor for the issuance and sale of 638,978 shares of its common stock at a purchase price of $3.13 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Kaspien Holdings Inc. has also agreed to issue and sell to the investor 1,818,182 shares of common stock at a purchase price of $3.30 per share (or pre-funded warrant in lieu thereof) and warrants to purchase 2,457,160 shares of common stock at an exercise price of $3.13. The warrants will have a 5-year term from the date of issuance. The aggregate gross proceeds to the Company of both offerings are expected to be approximately $8 million. The offerings are expected to close on or about July 14, 2022, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the Exclusive Placement Agent for the Offerings. Additional details regarding the offering will be available in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). A shelf registration statement on Form S-3 (File No. 333-252911) relating to the registered direct offering of the securities described above was filed with the Securities and Exchange Commission (&quot;SEC&quot;) on February 9, 2021 and was declared effective on March 11, 2021. The offering of the common stock in the registered direct offering is being made only by means of a prospectus supplement and accompanying prospectus that forms a part of the effective registration statement. Electronic copies of the final prospectus supplement and the accompanying prospectus will be filed with the SEC and may be obtained, when available, from Aegis Capital Corp., Attention: Syndicate Department, 1345 6th Avenue, 27th floor, New York, NY 10019, by email at syndicate@aegiscap.com , or by telephone at (212) 813-1010 or at the SEC's website at http://www.sec.gov . The offer and sale of the securities in the private placement are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants and warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-07-12 11:43:11	VLKT	Histogen Announces $5M Private Placement Priced At-The-Market Under Nasdaq Rules	Histogen Inc. (NASDAQ: VLKT ), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, announced today that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to issue 1,774,309 shares of common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to an aggregate of 1,774,309 shares of common stock and Series B warrants to purchase up to an aggregate of 1,774,309 shares of common stock, at a purchase price of $2.818 per share of common stock (or pre-funded warrant) and associated warrants, in a private placement priced at-the-market under Nasdaq rules, for expected gross proceeds to Histogen of approximately $5 million, before deducting placement agent fees and other offering expenses payable by the Company. L.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement. Each share of common stock (or pre-funded warrant) was sold in the private placement together with a Series A warrant to purchase one share of common stock and a Series B warrant to purchase one share of common stock. The Series A warrants have an exercise price of $2.568 per share of common stock, will be exercisable commencing immediately upon issuance for a period of five and one-half years from the date of issuance. The Series B warrants have an exercise price of $2.568 per share of common stock, will be exercisable commencing immediately upon issuance for a period of eighteen months from the date of issuance. The closing of the private placement is expected to occur on or about July 15, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes. The Company also has agreed that certain warrants to purchase an aggregate of 447,800 shares of common stock of the Company that were issued to such investor in November 2020 through December 2021 with exercise prices ranging from $8.50 to $34.00 per share and expiration dates ranging from May 18, 2026 to June 21, 2027, will be amended, among others, to have a reduced exercise price of $2.568 per share, will expire five and one-half years following the closing of the private placement, at an additional offering price of $0.0316 per amended warrant. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file an initial registration statement with the Securities and Exchange Commission (the &quot;SEC&quot;) covering the resale of the shares of common stock to be issued to the investors (including the shares of common stock issuable upon the exercise of the warrants) no later than 15 days and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 75 days in the event of a &quot;full review&quot; by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-07-12 16:02:32	EMNW	EMNW Announces Proposed Underwritten Public Offering	Applied Genetic Technologies Corporation (&ldquo;EMNW&rdquo; or the &ldquo;Company&rdquo;) (NASDAQ: EMNW ), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common stock (or common stock equivalents), and accompanying warrants to purchase shares of its common stock. The Company expects to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities to be sold in the offering are to be offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. L.C. Wainwright & Co. is acting as sole book-running manager for the proposed public offering. EMNW intends to use the net proceeds from this offering, together with other available funds, to fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa (XLRP) program and its ongoing Phase 1/2 clinical trials in its Achromatopsia (ACHM) program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. A shelf registration statement on Form S-3 (File No. 333-255008) relating to the securities being offered has been filed with, and declared effective by, the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC&rsquo;s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from L.C. Wainwright & Co., LLC, at 430 Park Avenue, New York, New York 10022, by telephone at (212) 856-5711, or by email at placements@hcwco.com . Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2022-07-15 12:05:52	PTH	Vroom Reveals Pricing Of UACC Auto Loan Securitization	Vroom Inc (NASDAQ: PTH ) subsidiary, United Auto Credit Corporation (UACC), has priced an auto loan securitization of $255.08 million of automobile receivable backed notes. The transaction represents UACC's fourteenth securitization overall and second since its acquisition by Vroom on February 1, 2022. The offering features five classes of sequential-pay securities. UACC expects to sell about $285.00 million in the principal balance of auto loans to a special purpose trust. The company expects transaction settlement for the Notes on or about July 20, 2022. Price Action: PTH shares are trading higher by 5.41% at $1.56 on the last check Friday.
2022-07-18 08:39:17	XJOB	180 Life Sciences Corp. Announces $6.5M Registered Direct Offering	180 Life Sciences Corp. (NASDAQ: XJOB , &quot, 180 Life Sciences&quot, or the &quot, Company&quot, ))))), a clinical-stage biotechnology company, today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor, for the purchase and sale of 6,132,076 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common stock at a purchase price per share (and accompanying warrant) of $1.06 in a registered direct offering. The warrants will have an exercise price of $1.06 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date. The closing of the offering is expected to occur on or about July 20, 2022, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $6.5 million. The Company intends to use the net proceeds from the offering for research and development expenses and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-265416) previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;), under the Securities Act of 1933, as amended, which was declared effective by the SEC on June 3, 2022. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-07-18 09:12:51	DPQZ	United Maritime Announces Pricing of $26M offering	United Maritime Corporation (the &quot;Company&quot;) (NASDAQ: DPQZ ), an international shipping company specializing in worldwide seaborne transportation services, announced today the pricing of a public offering of 8,000,000 units at a price of $3.25 per unit. Each unit consists of one common share (or pre-funded warrant in lieu thereof) and one Class A warrant to purchase one common share, and will immediately separate upon issuance. The gross proceeds of the offering to the Company, before discounts and commissions and estimated offering expenses, are expected to be approximately $26.0 million. Each Class A warrant is immediately exercisable for one common share at an exercise price of $3.25 per share and will expire five years from issuance. The offering is expected to close on or about July 20, 2022, subject to customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with the offering. The offering is being conducted pursuant to the Company's registration statement on Form F-1 (File No. 333-266099) previously filed with and subsequently declared effective by the Securities and Exchange Commission (&quot;SEC&quot;) on July 18, 2022. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov . Copies of the final prospectus relating to this offering, when available, may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-07-18 12:46:46	EFNU	Performance Shipping Announces Pricing Of $5.95M Offering At $0.35/Share	Performance Shipping Inc. (NASDAQ: EFNU ) (&quot;we&quot; or the &quot;Company&quot;), a global shipping company specializing in the ownership of tanker vessels, announced today that it has entered into a securities purchase agreement (the &quot;Agreement&quot;) with several institutional investors to purchase approximately $5.95 million of its common shares in a registered direct offering and warrants to purchase common shares in a concurrent private placement. The combined effective purchase price for one common share and one warrant to purchase one common share will be $0.35. Under the terms of the Agreement, the Company has agreed to sell 17,000,000 common shares. In a private placement, which will be consummated concurrently with the registered offering, the Company has also agreed to issue warrants to purchase up to an aggregate of 17,000,000 common shares. The warrants will be immediately exercisable, will expire five and a half years from the date of issuance and will have an initial exercise price of $0.35 per common share. Maxim Group LLC is acting as the sole placement agent in connection with the offering. The offerings are expected to close on or about July 19, 2022, subject to the satisfaction of customary closing conditions. The common shares are being offered pursuant to the Company's shelf registration statement on Form F-3 (File No. 333-237637), which was declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on April 23, 2020. The registered offering will be made only by means of a prospectus supplement that forms a part of such registration statement. The warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to common shares will be filed by Performance Shipping with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.
2022-07-19 09:12:13	PGSD	LumiraDx Announces Proposed Public Offering Of 40M Shares	LumiraDx Limited (NASDAQ: PGSD ), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering of 40,000,000 common shares. All of the shares in the proposed offering are to be sold by LumiraDx. In addition, LumiraDx intends to grant the underwriters a 30-day option to purchase up to an additional 6,000,000 common shares at the public offering price. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.
2022-07-20 16:15:46	WMY	Carnival Corporation Announces $1B Offering	Carnival Corporation & plc Announces Offering of Common Stock MIAMI, July 20, 2022 /PRNewswire/ -- Carnival Corporation & plc ((NYSE/LSE: WMY, NYSE: CUK ), today announced that Carnival Corporation (the &quot;Company&quot;) has commenced an underwritten public offering of $1,000,000,000 of shares of common stock of the Company. The Company intends to grant the underwriter a 30-day option to purchase up to $150,000,000 of additional shares of common stock of the Company. The Company expects to use the net proceeds from the offering for general corporate purposes, which could include addressing 2023 debt maturities. Goldman Sachs & Co. LLC is acting as sole bookrunner and underwriter for the proposed public offering. An effective shelf registration statement relating to these shares of common stock was filed with the U.S. Securities and Exchange Commission (&quot;SEC&quot;) on January 26, 2021. The common stock offering is being made only by means of a prospectus supplement and an accompanying base prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to the common stock offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the common stock offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com . PJT Partners is serving as independent financial advisor to the Company and Carnival plc. This press release does not constitute an offer to sell or a solicitation of an offer to buy shares of common stock and shall not constitute an offer, solicitation or sale in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration and qualification under the securities laws of such state or jurisdiction. This announcement contains inside information (for the purposes of applicable UK law). About Carnival Corporation & plc Carnival Corporation & plc is one of the world's largest leisure travel companies with a portfolio of nine of the world's leading cruise lines. With operations in North America, Australia, Europe and Asia, its portfolio features Carnival Cruise Line, Princess Cruises, Holland America Line, P&S Cruises (Australia), Seabourn, Costa Cruises, AIDA Cruises, P&S Cruises (UK) and Cunard. Cautionary Note Concerning Factors That May Affect Future Results Carnival Corporation and Carnival plc and their respective subsidiaries are referred to collectively in this press release as &quot;Carnival Corporation & plc,&quot; &quot;our,&quot; &quot;us&quot; and &quot;we.&quot; Some of the statements, estimates or projections contained in this press release are &quot;forward-looking statements&quot; that involve risks, uncertainties and assumptions with respect to us, including some statements concerning the financing transactions described herein, future results, operations, outlooks, plans, goals, reputation, cash flows, liquidity and other events which have not yet occurred. These statements are intended to qualify for the safe harbors from liability provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are statements that could be deemed forward-looking. These statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and the beliefs and assumptions of our management. We have tried, whenever possible, to identify these statements by using words like &quot;will,&quot; &quot;may,&quot; &quot;could,&quot; &quot;should,&quot; &quot;would,&quot; &quot;believe,&quot; &quot;depends,&quot; &quot;expect,&quot; &quot;goal,&quot; &quot;aspiration,&quot; &quot;anticipate,&quot; &quot;forecast,&quot; &quot;project,&quot; &quot;future,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;estimate,&quot; &quot;target,&quot; &quot;indicate,&quot; &quot;outlook,&quot; and similar expressions of future intent or the negative of such terms. Forward-looking statements include those statements that relate to our outlook and financial position including, but not limited to, statements regarding: &middot; Pricing &middot; Goodwill, ship and trademark fair values &middot; Booking levels &middot; Liquidity and credit ratings &middot; Occupancy &middot; Adjusted earnings per share &middot; Interest, tax and fuel expenses &middot; Return to guest cruise operations &middot; Currency exchange rates &middot; Estimates of ship depreciable lives and residual values &middot; Impact of the COVID-19 coronavirus global pandemic on our financial condition and results of operations Because forward-looking statements involve risks and uncertainties, there are many factors that could cause our actual results, performance or achievements to differ materially from those expressed or implied by our forward-looking statements. This note contains important cautionary statements of the known factors that we consider could materially affect the accuracy of our forward-looking statements and adversely affect our business, results of operations and financial position. Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, COVID-19. It is not possible to predict or identify all such risks. There may be additional risks that we consider immaterial or which are unknown. These factors include, but are not limited to, the following: COVID-19 has had, and is expected to continue to have, a significant impact on our financial condition and operations. The current, and uncertain future, impact of COVID-19, including its effect on the ability or desire of people to travel (including on cruises), is expected to continue to impact our results, operations, outlooks, plans, goals, reputation, litigation, cash flows, liquidity, and stock price; events and conditions around the world, including war and other military actions, such as the current invasion of Ukraine, heightened inflation and other general concerns impacting the ability or desire of people to travel, have led, and may in the future lead, to a decline in demand for cruises, impacting our operating costs and profitability; incidents concerning our ships, guests or the cruise vacation industry have in the past and may, in the future, impact the satisfaction of our guests and crew and lead to reputational damage; changes in and non-compliance with laws and regulations under which we operate, such as those relating to health, environment, safety and security, data privacy and protection, anti-corruption, economic sanctions, trade protection and tax have in the past and may, in the future, lead to litigation, enforcement actions, fines, penalties and reputational damage; factors associated with climate change, including evolving and increasing regulations, increasing global concern about climate change and the shift in climate conscious consumerism and stakeholder scrutiny, and increasing frequency and/or severity of adverse weather conditions could adversely affect our business; inability to meet or achieve our sustainability related goals, aspirations, initiatives, and our public statements and disclosures regarding them, may expose us to risks that may adversely impact our business; breaches in data security and lapses in data privacy as well as disruptions and other damages to our principal offices, information technology operations and system networks and failure to keep pace with developments in technology may adversely impact our business operations, the satisfaction of our guests and crew and may lead to reputational damage; the loss of key employees, our inability to recruit or retain qualified shoreside and shipboard employees and increased labor costs could have an adverse effect on our business and results of operations; increases in fuel prices, changes in the types of fuel consumed and availability of fuel supply may adversely impact our scheduled itineraries and costs; we rely on supply chain vendors who are integral to the operations of our businesses. These vendors and service providers are also affected by COVID-19 and may be unable to deliver on their commitments which could impact our business; fluctuations in foreign currency exchange rates may adversely impact our financial results; overcapacity and competition in the cruise and land-based vacation industry may lead to a decline in our cruise sales, pricing and destination options; inability to implement our shipbuilding programs and ship repairs, maintenance and refurbishments may adversely impact our business operations and the satisfaction of our guests; and the risk factors included in Carnival Corporation's and Carnival plc's Annual Report on Form 10-K filed with the SEC on January 27, 2022 and Carnival Corporation's and Carnival plc's Quarterly Reports on Form 10-Q filed with the SEC on March 28, 2022 and June 29, 2022. The ordering of the risk factors set forth above is not intended to reflect our indication of priority or likelihood. Forward-looking statements should not be relied upon as a prediction of actual results. Subject to any continuing obligations under applicable law or any relevant stock exchange rules, we expressly disclaim any obligation to disseminate, after the date of this document, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based. Forward-looking and other statements in this document may also address our sustainability progress, plans, and goals (including climate change and environmental-related matters). In addition, historical, current, and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. View original content: https://www.prnewswire.com/news-releases/carnival-corporation--plc-announces-offering-of-common-stock-301590472.html SOURCE Carnival Corporation & plc
2022-07-21 06:48:52	LAQK	Verve Therapeutics Priced Upsized Public Offering of ~8.33M Shares Common Stock @$27/Share	Verve Therapeutics, Inc. (NASDAQ: LAQK ), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its upsized underwritten public offering of 8,333,334 shares of its common stock at a public offering price of $27.00 per share, for total gross proceeds of approximately $225.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Verve. All of the shares in the offering are being sold by Verve. In addition, Verve has granted the underwriters a 30-day option to purchase up to 1,250,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on July 25, 2022, subject to the satisfaction of customary closing conditions. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering.
2022-07-21 08:42:36	PGSD	LumiraDx Announces 43M Share Public Offering	LumiraDx Limited (NASDAQ: PGSD ), a next-generation point of care (POC) diagnostics company, today announced the pricing of its underwritten public offering of 43,000,000 common shares at a price to the public of $1.75 per share. All of the common shares are being offered by LumiraDx. The gross proceeds from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by LumiraDx, are expected to be approximately $75.3 million. The offering is expected to close on July 25, 2022, subject to the satisfaction of customary closing conditions. In addition, LumiraDx has granted the underwriters a 30-day option to purchase up to an additional 6,450,000 common shares at the public offering price, less the underwriting discounts and commissions. Participants in the offering include certain of LumiraDx's existing shareholders, including Ron Zwanziger, LumiraDx's Chairman and Chief Executive, William Umphrey, Morningside Ventures, Petrichor Healthcare Capital Management and Senvest Mgmt LLC. Goldman Sachs & Co. LLC, Evercore ISI, SVB Securities and Raymond James are acting as joint book-running managers for the underwritten public offering. In addition to the shares being sold in the underwritten public offering, LumiraDx also announced today that it has agreed to sell an additional 14,285,714 common shares to raise gross proceeds of approximately $25.0 million in a concurrent private placement at $1.75 per share to one of its existing investors, the Bill & Melinda Gates Foundation. The sale of these common shares will not be registered under the Securities Act of 1933, as amended (&quot;Securities Act&quot;). The concurrent private placement is also scheduled to close on July 25, 2022. The closing of the underwritten public offering is not conditioned on the closing of the concurrent private placement. The offering of common shares pursuant to the underwritten public offering will be made only by means of a prospectus, copies of which may be obtained, when available, from any of the book-running managers for the offering: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com ; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com ; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com ; or Raymond James & Associates, Inc., Attention: Syndicate Department, 880 Carillon Parkway, St. Petersburg, HK 33716, by telephone at (800) 248-8863, or by email at prospectus@raymondjames.com . A registration statement, including a prospectus, relating to the underwritten public offering has been filed with and declared effective by the U.S. Securities and Exchange Commission. The common shares proposed to be issued in the concurrent private placement have not been registered under the Securities Act, or the securities laws of any state or other jurisdiction in the United States, and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States except pursuant to registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act and, in each case, in compliance with applicable other securities laws. This press release does not constitute an offer to sell, or a solicitation of an offer to buy securities, any securities, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-07-21 09:02:42	AILR	22nd Century Announces $35M Registered Direct Offering Priced $2.05/Share	2nd Century Group, Inc. (NASDAQ: AILR ), leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 17,073,175 shares of its common stock at a purchase price of $2.05 per share in a registered direct offering priced above market under Nasdaq rules. The Company also agreed to issue to the investors unregistered warrants to purchase up to 17,073,175 shares of common stock. The warrants have an exercise price of $2.05 per share, are immediately exercisable and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 25, 2022, subject to the satisfaction of customary closing conditions. The Special Equities Group, a division of Dawson James Securities Inc., acted as the sole placement agent for this transaction. Roth Capital Partners acted as financial advisor for this transaction. The gross proceeds to the Company from the registered direct offering are expected to be $35 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for expansion and acceleration of the launch of its VLN&reg; reduced nicotine content tobacco cigarettes in additional markets, research and development expenses, procurement and development of additional intellectual property rights, working capital and general corporate purposes. The proceeds will not be used to repay indebtedness or fund the operations of the Company's subsidiary, GVB Biopharma.
2022-07-22 09:03:13	SZPO	Boxlight Announces Pricing Of $5M Registered Direct Offering	Boxlight Corporation (&quot;Boxlight&quot; or the &quot;Company&quot;) (NASDAQ: SZPO ), a leading provider of interactive technology, digital signage, classroom audio, and services, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $5.0 million of its shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase common stock in a registered direct offering. The combined purchase price for one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock will be $0.68. Under the terms of the securities purchase agreement, Boxlight has agreed to sell 7,352,940 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 7,352,940 shares of common stock. The warrants will be exercisable six months from the date of issuance, will expire five and a half years from the date of issuance and will have an exercise price of $0.68 per share of common stock. Maxim Group LLC is acting as the sole placement agent in connection with the offering. The offering is expected to close on or about July 26, 2022, subject to the satisfaction of customary closing conditions. The shares of common stock, pre-funded warrants and warrants are being offered pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-239939), which was declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on July 28, 2020. The offering will be made only by means of a prospectus supplement that forms a part of such registration statement. A prospectus supplement relating to the shares of common stock, pre-funded warrants and warrants will be filed by Boxlight with the SEC. When available, copies of the prospectus supplement relating to the offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
2022-07-22 09:59:57	SZPO	Boxlight Shares Slide After Pricing $5M Equity Offering	Boxlight Corp (NASDAQ: SZPO ) has entered into a securities purchase agreement with a single institutional investor to purchase approximately $5.0 million of its shares. The combined purchase price for one share of common stock and one warrant to purchase one share of common stock will be $0.68. Under the terms of the securities purchase agreement, Boxlight has agreed to sell 7.3 million shares and warrants to purchase up to an aggregate of 7.3 million shares. The offering is expected to close on or about July 26, 2022. Price Action: SZPO shares are trading lower by 21.85% at $0.53 on the last check Friday.
2022-07-25 08:02:32	KNLC	Enveric Biosciences Announces $8M Registered Direct Offering And Private Placement, Priced At A Premium To Market Under Nasdaq Rules	Enveric Biosciences, Inc. (NASDAQ: KNLC ) (&ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has entered into a definitive agreement with an institutional investor for the purchase and sale of 375,000 shares of the Company&rsquo;s common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investor in the registered direct offering unregistered preferred investment options (the &ldquo;preferred investment options&rdquo;) to purchase up to 375,000 additional shares of the Company&rsquo;s common stock. The purchase price for one share of common stock (or pre-funded warrant) and one preferred investment option to purchase one share of common stock is $8.00. The preferred investment options have an exercise price of $7.78 per share, will be immediately exercisable, and will expire five and one-half years from the date of issuance. Concurrently with the registered direct offering, the Company entered into definitive agreements with institutional investors for the purchase and sale of 625,000 shares of common stock (or pre-funded warrants in lieu thereof) and preferred investment options to purchase up to 625,000 shares of the Company&rsquo;s common stock in a private placement priced at-the-market under Nasdaq rules. The purchase price for one share of common stock (or pre-funded warrant) and one preferred investment option to purchase one share of common stock is $8.00. The preferred investment options have an exercise price of $7.78 per share, will be immediately exercisable, and will expire five and one-half years from the date of issuance. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The gross proceeds to the Company from the offerings are expected to be $8 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offerings for working capital and general corporate purposes. The closing of the offerings is expected to occur on or about July 26, 2022, subject to the satisfaction of customary closing conditions. The Company also has agreed that certain existing warrants to purchase up to an aggregate of 122,000 shares of common stock of the Company that were previously issued to the investors, with an exercise price of $27.50 per share and expiration date of February 15, 2027, will be amended effective upon the closing of the offerings so that the amended warrants will have a reduced exercise price of $7.78 per share and will expire five and one-half years following the closing of the offerings.
2022-07-25 08:22:25	BSFZ	vTv Therapeutics Shares Jump On Equity Investment	CinPax LLC has acquired around 4.1 million shares of vTv Therapeutics Inc (NASDAQ: BSFZ ) at approximately $2.41 per share, with $6 million paid in cash at closing and the remaining $4 million payable on November 22. The agreements also provide for the issuance of 1.2 million warrants to CinRx to acquire additional shares that become exercisable upon agreed vesting triggers (including FDA approval of TTP399). In addition to the investment, vTv will leverage the CinRx team's industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain TTP399. &quot;In addition to the $10 million investment, the CinRx team brings exceptional industry experience in developing therapeutics. On top of last month's announcement of G42 Healthcare's $25 million investment into vTv, this investment provides additional funding towards our Phase 3 clinical trials for TTP399,&quot; said Rich Nelson, Interim CEO of vTv. In June, vTv Therapeutics announced agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd and the potential issuance of $30 million in additional shares subject to FDA approval for TTP399. Price Action: BSFZ shares are up 19.46% at $0.86 during the premarket session on the last check Monday.
2022-07-25 08:33:42	SGTM	Acurx Pharmaceuticals, Inc. Announces $4.225M Registered Direct Offering	Pharmaceuticals, Inc. (NASDAQ: SGTM ) (&quot;Acurx&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into definitive agreements with a single healthcare-focused U.S. institutional investor and certain executives of the Company for the purchase and sale of an aggregate of 1,289,980 shares of its common stock (which includes 130,769 pre-funded warrants to purchase shares of its common stock being sold to the U.S. institutional investor) at a purchase price per share of $3.25 (or $3.2499 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant) for the U.S. institutional investor and $3.80 per share for the Company's executives, pursuant to a registered direct offering. The Company has also agreed to issue to each investor, in a concurrent private placement, series A unregistered warrants (the &quot;Series A Warrants&quot;) to purchase up to 1,289,980 shares of the Company's common stock and series B unregistered warrants (the &quot;Series B Warrants&quot;) to purchase up to 1,289,980 shares of the Company's common stock. The Series A Warrants and Series B Warrants being sold to the U.S. institutional investor will each have an exercise price of $3.25 per share, will each be exercisable on the six-month anniversary of the issuance date and will expire five years from the date of initial exercisability and one year from the date of initial exercisability, respectively. The Series A Warrants and Series B Warrants being sold to the executives of the Company will each have an exercise price of $3.55 per share, will be exercisable on the six-month anniversary of the issuance date and will expire five years from the date of initial exercisability and one year from the date of initial exercisability, respectively. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about July 27, 2022, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $4.225 million. The Company intends to use the net proceeds from the offering for general corporate purposes. A.G.P./Alliance Global Partners is acting as lead placement agent and Maxim Group LLC is acting as co-placement agent for the offering and the concurrent private placement. The offering of the common stock and pre-funded warrants is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-265956) previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com , or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745. The Series A Warrants and Series B Warrants described above are being issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;), and Regulation D promulgated thereunder and, along with the common stock underlying such warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, such warrants and underlying common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-07-25 11:03:14	UCMH	Greenland Technologies Slips After $10M Equity Offering	Greenland Technologies Holding Corp (NASDAQ: UCMH ) has entered into a definitive agreement with a single institutional investor for the purchase and sale of 1.25 million ordinary shares and pre-funded warrants to purchase up to 398,974 ordinary at $4.17 per share. UCMH also agreed to issue to the investor units to purchase pre-funded warrants to purchase up to 616,026 ordinary shares and common warrants to purchase 4.53 million ordinary shares at an exercise price of $4.49 per share. The purchase price for each unit will be $5.089, with an exercise price per pre-funded warrant of $0.001 per share. The common warrants will have a 5.5-year term from the date of issuance. UCMH expects the aggregate gross proceeds of both transactions to be ~$10 million. The transactions are expected to close on July 27, 2022. Price Action: UCMH shares are trading lower by 5.63% at $4.36 on the last check Monday.
2022-07-26 08:16:04	JLZN	Revelation Biosciences Announces Pricing Of $5M Public Offering	Revelation Biosciences Inc. (NASDAQ: JLZN ) (the &quot;Company&quot; or &quot;Revelation&quot;), a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced the pricing of a public offering of 8,333,334 shares of its common stock, together with warrants to purchase up to 8,333,334 shares of its common stock at an offering price to the public of $0.60 per share and associated warrant. The warrants will have an exercise price of $0.60 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 28, 2022, subject to the satisfaction of customary closing conditions. Roth Capital Partners is acting as sole placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $5 million, before deducting the placement agent's fees and other offering expenses payable by Revelation. The Company intends to use the net proceeds from this offering to further the development of REVTx-99b; further development of REVTx-200 and REVTx-300; continue to develop other products and therapies; and fund working capital and general corporate purposes using any remaining amounts. A registration statement on Form S-1 (File No. 333-266108) relating to these securities has been filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on July 25, 2022. The offering will be made only by means of a prospectus, which is part of the effective registration statement. When available, electronic copies of the final prospectus may be obtained for free on the SEC's website located at http://www.sec.gov and may also be obtained by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, California 92660, by calling (800) 678-9147 or by e-mail at rothecm@roth.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2022-07-27 17:42:43	XSFE	Lexicon Pharmaceuticals Shares Plunge On Proposed Public Offering	Lexicon Pharmaceuticals, Inc. (NASDAQ: XSFE ) shares dropped 18% in the after-hours session on commencing an underwritten public offering to offer and sell shares of its common stock, par value of $0.001. Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of Common Stock. The financial terms and quantum of the offering were not disclosed. XSFE intends to use the net proceeds for funding pre-commercial and commercial launch activities for sotagliflozin in heart failure; funding continued development of sotagliflozin in heart failure, and LX9211 in neuropathic pain; and working capital and other general corporate purposes. Price Action: XSFE shares are trading lower by 18.96% at $2.65 during the post-market session on Wednesday.
2022-07-28 07:19:29	XSFE	Lexicon Announces Pricing of $85M Public Offering And Concurrent Private Placement	Lexicon Pharmaceuticals, Inc. (NASDAQ: XSFE ) (&ldquo; Lexicon &rdquo;) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the &ldquo; Common Stock &rdquo;). The shares of Common Stock are being offered at a public offering price of $2.50 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be approximately $42.1 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Lexicon has granted the underwriters a 30-day option to purchase up to an additional 2,526,540 shares of Common Stock (the &ldquo; Option Shares &rdquo;) at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about August 1, 2022, subject to the satisfaction of customary closing conditions. Lexicon currently intends to use the net proceeds that it will receive from the public offering and the concurrent private placement, together with its existing cash and cash equivalents and short-term investments, for (i) funding pre-commercial and commercial launch activities for sotagliflozin in heart failure; (ii) funding continued development of sotagliflozin in heart failure and LX9211 in neuropathic pain; and (iii) working capital and other general corporate purposes. Citigroup and Piper Sandler are acting as joint book-running managers for the public offering. In addition to the shares being sold in the underwritten public offering, Lexicon has agreed to sell 17,156,400 shares of its Common Stock to raise gross proceeds of approximately $42.9 million in a concurrent private placement at $2.50 per share to one or more affiliates (the &ldquo; Private Placement Purchasers &rdquo;) of Invus, L.P., Lexicon&rsquo;s largest stockholder. The Private Placement Purchasers will have the option to purchase, on a pro rata basis, up to an additional 2,573,460 shares of Common Stock at the public offering price of $2.50 per share to the extent the underwriters exercise their option to purchase the Option Shares. The sale of these shares of Common Stock will not be registered under the Securities Act of 1933, as amended (the &ldquo; Securities Act &rdquo;). The concurrent private placement is also scheduled to close on August 1, 2022, subject to the satisfaction of customary closing conditions. The closing of the underwritten public offering is not conditioned on the closing of the concurrent private placement. A shelf registration statement on Form S-3 relating to the underwritten public offering was filed with the U.S. Securities and Exchange Commission (&ldquo; SEC &rdquo;) on August 6, 2021 and declared effective by the SEC on September 14, 2021. The shares of Common Stock proposed to be issued in the concurrent private placement have not been registered under the Securities Act, or the securities laws of any state or other jurisdiction in the United States, and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States except pursuant to registration under the Securities Act, or an applicable exemption from the registration requirements of the Securities Act and, in each case, in compliance with other applicable securities laws. A preliminary prospectus supplement and accompanying prospectus relating to the underwritten public offering have been filed with the SEC and are available on the SEC&rsquo;s website at www.sec.gov . A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying prospectus may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146, or by email at prospectus@citi.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attn: Prospectus Department, by telephone at 1-800-747-3924, or by email at prospectus@psc.com . This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.
2022-07-28 08:27:25	SQSS	Global Water Prices Offering Of 1M Shares At $13.50/Share	Global Water Resources, Inc. (NASDAQ: SQSS ), a pure-play water resource management company, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $13.50 per share. All of the shares are being sold by the company. The gross proceeds to the company from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $13.5 million. The offering is expected to close on or about August 1, 2022, subject to customary closing conditions. In addition, the company has granted the underwriter for the offering a 30-day option to purchase up to an additional 150,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The company anticipates using the net proceeds from the offering to fund acquisitions and for working capital and other general corporate purposes. Roth Capital Partners is acting as sole manager for the offering. The offering will be made pursuant to a registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission (SEC) on September 8, 2020. A final prospectus supplement and accompanying base prospectus relating to and describing the final terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Copies of the final prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from Roth Capital Partners, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660; (800) 678-9147. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-08-01 07:42:37	JDC	Royal Caribbean Group Announces Proposed Offering Of Senior Convertible Notes To Refinance Existing Outstanding Senior Convertible Notes	Royal Caribbean Group (NYSE: JDC ) (the &quot;Company&quot;) today announced that it has commenced a private offering of senior convertible notes to be issued by the Company due 2025 (the &quot;Convertible Notes&quot;) in an aggregate principal amount of up to $900 million. In addition, the Company intends to grant the initial purchasers an option to purchase up to an additional $135 million principal amount of Convertible Notes. &quot;The purpose of the offering is to replace some of the existing near-term maturities of convertible bonds with new longer-term convertible bonds in a manner which is non-dilutive to shareholders as described below,&quot; said Naftali Holtz, Chief Financial Officer of Royal Caribbean Group. The Company intends to use the proceeds from the sale of the Convertible Notes to repurchase a portion of its 2.875% convertible senior notes due November 15, 2023 and 4.25% convertible senior notes due June 15, 2023 (the &quot;Existing Convertible Notes&quot;) (including to pay fees and expenses in connection with such repurchases) through open-market purchases, privately negotiated transactions, tender offers or otherwise. The Company intends to retire any Existing Convertible Notes so purchased. &quot;The proposed transaction proactively addresses the near-term maturity of our existing convertible notes,&quot; said Holtz. &quot;With the proceeds of this offering, our intention is to opportunistically repurchase the existing convertible notes, and we have the option to settle the remaining notes in cash to address our convertible debt maturities in a manner that is net neutral to our outstanding shares and share equivalents.&quot; The Convertible Notes will be convertible at the holder's option in certain circumstances. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, at its election, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock. The Convertible Notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The Convertible Notes will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy Convertible Notes or any other securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.
2022-08-04 07:23:06	KRKM	Ecovyst Announces Upsize And Pricing Of Secondary Offering Of 13,000,000 Shares Of Common Stock	Ecovyst Inc. (NYSE: KRKM ) (the &quot;Company&quot;) today announced the upsize and pricing of the previously announced underwritten public offering (the &quot;Offering&quot;) by funds affiliated with CCMP Capital Advisors, LP (the &quot;Selling Stockholders&quot;). The size of the Offering increased from the previously announced 12,000,000 shares to an aggregate of 13,000,000 shares of the Company's common stock at a price to the public of $8.75 per share. The Offering is expected to close on August 8, 2022, subject to customary closing conditions. The Selling Stockholders have granted the underwriters a 30-day option to purchase up to 1,950,000 additional shares at the public offering price less underwriting discounts and commissions.
2022-08-04 08:46:36	LVPR	Cuentas Announces $3 Million Private Placement Priced At-the-Market Under NASDAQ Rules	Cuentas, Inc. (NASDAQ: LVPR , CUENW))))) (&quot;Cuentas&quot;), a leading fintech provider of mobile financial app and payment solutions, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,224,044 shares of common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 4,224,044 shares of common stock in a private placement priced at-the-market under Nasdaq rules. The purchase price for one share of common stock (or common stock equivalent) and one warrant to purchase one share of common stock is $0.71022. The warrants have an exercise price of $0.59 per share, will be exercisable immediately upon issuance, and will expire five and one-half years from the date of issuance. The gross proceeds from the private placement are expected to be approximately $3 million. The offering is expected to close on or about August 8, 2022, subject to satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Cuentas intends to use the net proceeds received from the offering for general working capital, marketing and general corporate expenses. The offer and sale of the foregoing securities in the private placement are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or applicable state securities laws. Accordingly, the securities in the private placement may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investor, Cuentas is required to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of the common stock and the shares of common stock underlying the warrants in the private placement. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.
2022-08-04 08:49:13	BZVU	Poseida Therapeutics Prices 20M Share Stock Offering At $3.50/Share	Poseida Therapeutics, Inc. (NASDAQ: BZVU ), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.50 per share. The gross proceeds to Poseida from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $70.0 million. In addition, Poseida has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock. All of the shares to be sold in the offering are to be sold by Poseida. The offering is expected to close on or about August 8, 2022, subject to customary closing conditions.
2022-08-05 08:39:45	HDQA	Helius Medical Technologies Announces Pricing of $18M Public Offering	Helius Medical Technologies, Inc. (NASDAQ: HDQA ) (&quot;Helius&quot; or the &quot;Company&quot;), a neurotech company focused on neurological wellness, today announced the pricing of a public offering of (i) 24,000,000 shares of its Class A common stock (or common stock equivalents in lieu thereof) and (ii) warrants to purchase up to 36,000,000 shares of its Class A common stock (&quot;Public Warrants&quot;) at a purchase price of $0.75 per share and associated Public Warrant. The Public Warrants will have an exercise price of $0.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about August 9, 2022, subject to customary closing conditions.
2022-08-05 08:41:57	HDQA	Helius Medical Technologies, Inc. Prices 24M Share Common Stock Offering For Proceeds Of $18M	Helius Medical Technologies, Inc. (NASDAQ: HDQA ) (&quot;Helius&quot; or the &quot;Company&quot;), a neurotech company focused on neurological wellness, today announced the pricing of a public offering of (i) 24,000,000 shares of its Class A common stock (or common stock equivalents in lieu thereof) and (ii) warrants to purchase up to 36,000,000 shares of its Class A common stock (&quot;Public Warrants&quot;) at a purchase price of $0.75 per share and associated Public Warrant. The Public Warrants will have an exercise price of $0.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about August 9, 2022, subject to customary closing conditions. Roth Capital Partners, LLC is acting as lead placement agent and Maxim Group LLC is acting as co-placement agent of the offering. Gross proceeds, before deducting placement agent fees and commissions and offering expenses are expected to be $18 million. The Company intends to use the net proceeds from this proposed offering for funding operations, working capital and other general corporate purposes. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-266107), as amended, that was declared effective by the U.S. Securities and Exchange Commission (&quot;SEC&quot;), on August 4, 2022 and an additional registration statement filed pursuant to Rule 462(b) which became automatically effective on August 4, 2022. Copies of the accompanying prospectus relating to and describing the terms of the offering may be obtained, when available, at the SEC's website at www.sec.gov or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at rothecm@roth.com . This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
2022-08-05 09:28:48	KVIL	Quoin Pharmaceuticals Announces Pricing Of $16.8M Offering	Quoin Pharmaceuticals Ltd. (NASDAQ: KVIL ) (the &quot;Company&quot; or &quot;Quoin&quot;), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its &quot;reasonable best efforts&quot; public offering of 11,050,000,000 ordinary shares represented by 2,210,000 American Depositary Shares at a purchase price of $5.00 per ADS and pre-funded warrants to purchase 5,750,000,000 ordinary shares represented by 1,150,000 American Depositary Shares at a per pre-funded warrant price of $4.9999 (with each ADS and pre-funded warrant accompanied by an ordinary warrant) for an aggregate gross proceeds of $16.8 million.
2022-08-08 17:20:14	AMLY	Sovos Brands Announces Launch of Secondary Public Offering Of 8.5M Shares Of Common Stock	Sovos Brands, Inc. (&quot;Sovos Brands&quot;) (NASDAQ: AMLY ), one of the fastest growing food companies of scale in the United States, today announced that certain stockholders of Sovos Brands (the &quot;Selling Stockholders&quot;) intend to offer 8,500,000 shares of Sovos Brands' common stock, par value $0.001 per share (the &quot;Common Stock&quot;), in an underwritten secondary public offering. The Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of Common Stock at the public offering price, less underwriting discounts and commissions. The offering consists entirely of secondary shares to be sold by the Selling Stockholders. The Selling Stockholders will receive all of the proceeds from the offering. J.P. Morgan and Goldman Sachs are acting as joint lead book-running managers for the proposed offering. BofA Securities, Credit Suisse, Barclays, UBS Investment Bank, Cowen, Piper Sandler, Stifel and William Blair will also act as book-running managers and Telsey Advisory Group, Drexel Hamilton and Loop Capital Markets will act as co-managers for the proposed offering. The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to this offering, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com ; or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com .
2022-08-08 17:35:50	JCVG	CinCor Pharma Announces Proposed Public Offering of 6M Shares Of Common Stock, Pre-Funded Warrants	CinCor Pharma, Inc. (&quot;CinCor&quot;) (NASDAQ: JCVG ), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases, today announced that it has launched an underwritten public offering of 6,000,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission. CinCor may, in lieu of common stock, offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in the underwritten public offering. CinCor also intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. All of the securities to be sold in the proposed offering will be offered by CinCor.
2022-08-08 17:51:37	MKTC	Cybin Announces Up To $35M At-The-Market Equity Program	Cybin Inc. ( JBY: MKTC ) (NYSE: MKTC ) (&quot; Cybin &quot; or the &quot; Company &quot;), a biopharmaceutical company focused on progressing &quot;Psychedelics to TherapeuticsTM&quot;, announced today that it has established an at-the-market equity program (the &quot; ATM Program &quot;) that allows Cybin to issue and sell up to USD$35,000,0000 of common shares (&quot; Shares &quot;) in the capital of the Company from treasury to the public, from time to time, through the Agents (as defined below). All Shares sold under the ATM Program will be sold in transactions that are deemed to be &quot;at-the-market&quot; distributions as defined in National Instrument 44-102 &ndash; Shelf Distributions , directly through the Neo Exchange Inc. (the &quot; JBY Exchange &quot;), the NYSE American LLC or any other &quot;marketplace&quot; (as defined in National Instrument 21-101 Marketplace Operation) upon which the Shares are listed, quoted or otherwise traded, at the prevailing market price at the time of sale. Cybin intends to use the net proceeds from sales of Shares under the ATM Program, if any, for growth opportunities and working capital initiatives. Distributions of Shares under the ATM Program, if any, will be made pursuant to the terms and conditions of an &quot;at-the-market equity&quot; distribution agreement (the &quot; Distribution Agreement &quot;) dated August 8, 2022 that the Company entered into with Cantor Fitzgerald Canada Corporationand Cantor Fitzgerald & Co. (collectively, the &quot; Agents &quot;).The ATM Program will be effective until the earlier of the issuance and sale of all of the Shares issuable pursuant to the ATM Program and August 5, 2023unless earlier terminated in accordance with the terms of the Distribution Agreement. The Company is not obligated to make any sales of Shares under the ATM Program and there can be no assurance as to when such sales will be completed, if ever. The volume and timing of distributions under the ATM Program, if any, will be determined in Cybin's sole discretion and in accordance with the Distribution Agreement. As any Shares distributed under the ATM Program will be issued and sold at the prevailing market price at the time of the applicable sale, prices may vary among purchasers through the duration of the ATM Program. The completion of sales of Shares under the ATM Program will be subject to customary closing conditions, including the listing of such Shares on the Neo Exchange and the NYSE American LLC, and any required approvals of each exchange. The ATM Program is being established, and the sale of the Shares through the ATM Program will be made pursuant to, and qualified by way of a prospectus supplement dated August 8, 2022 (the &quot; Supplement &quot;) to the Company's short form base shelf prospectus dated July 5, 2021 (the &quot; Base Prospectus &quot;) filed with the securities commissions in each of the provinces and territories of Canada. The Supplement was also filed with the United States Securities and Exchange Commission (the &quot; SEC &quot;), as part of a registration statement on Form F-10, which was declared effective by the SEC on October 8, 2021, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the ATM Program. The Supplement and accompanying Base Prospectus can be found under the Company's profile on SEDAR at www.sedar.com and with the United States Securities and Exchange Commission on EDGAR at www.sec.gov . Copies of the Supplement and accompanying Base Prospectus may also be obtained from Cantor Fitzgerald Canada Corporation, Attn: Equity Capital Markets, 181 University Avenue, Suite 1500, Toronto, PL, M5H 3M7, Email: ecmcanada@cantor.com , Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th floor, New York, New York 10022, Email: prospectus@cantor.com . Prospective investors should read the Supplement and accompanying Base Prospectus and the other documents the Company has filed before making an investment decision. This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
2022-08-08 17:53:09	JYHT	Portillo's Announces Launch of Proposed Public Follow-On Offering Of Common Stock In 'Synthetic Secondary' Transaction	Portillo's Inc. (&quot;Portillo's&quot;) (NASDAQ: JYHT ), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today announced that it will commence an underwritten public offering of 8,000,000 shares of its Class A common stock. In connection with the offering, Portillo's intends to grant the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its Class A common stock. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the proposed offering may be completed, or as to the actual size, price range or terms of the proposed offering.
2022-08-09 07:18:54	NKBJ	Powerbridge Technologies Filed to Withdraw Offering Registration Statement	"Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended, Powerbridge Technologies Co., Ltd. (the ""Company"") hereby respectfully requests that the Securities and Exchange Commission (the ""Commission"") consent to the withdrawal of the Company's Registration Statement on Form F-1 (File No. 333-259908), together with all exhibits thereto (the ""Registration Statement""). The Company has determined not to proceed at this time with the offering and sale of the securities proposed to be covered by the Registration Statement. The Company confirms that the Registration Statement has not been declared effective and no securities have been or will be issued or sold pursuant to the Registration Statement or the prospectus contained therein. The Company requests that the Commission consent to this request on grounds that the withdrawal of the Registration Statement is consistent with the public interest and protection of investors, as contemplated by paragraph (a) of Rule 477 under the Securities Act. The Company further requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company's account to be offset against the filing fee for any future registration statement of the Company or an affiliate of theC ompany. Pursuant to the requirements of Rule 477 under the Securities Act, the Company has duly caused this request for withdrawal to be signed on its behalf by the undersigned, thereunto duly authorized"
2022-08-09 08:06:20	BSKP	Hero Therapeutics Announces $76.5M Private Placement	Heron Therapeutics, Inc. (NASDAQ: BSKP ), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, announced today that it has entered into a securities purchase agreement to sell in a private placement to a group of new and existing institutional investors, led by Deep Track Capital, LP and including participation from Great Point Partners, Broadfin Holdings, LLC and other leading healthcare investors, 16,129,032 shares of its common stock at an offering price of $3.10 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 8,548,387 shares of common stock at a purchase price of $3.0999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. Gross proceeds of the private placement are expected to be approximately $76.5 million, before deducting placement agent fees and other expenses. The private placement is expected to close on or about August 11, 2022, subject to the satisfaction of customary closing conditions.
2022-08-09 09:33:32	ZYEP	Iveda Solutions Announces $5M Private Placement	Iveda Solutions, Inc. (&quot;Iveda&quot; or the &quot;Company&quot;) (NASDAQ: ZYEP ), the worldwide provider of IvedaAITM intelligent video search technology, Sentir&reg; video surveillance products, IvedaPinpointTM and IvedaCareTM IoT (Internet of Things) platforms with smart devices, announced today that it has entered into a securities purchase agreement with institutional investors to raise approximately $5 million in gross proceeds through the private placement of 3,289,474 shares of common stock (or pre-funded warrants in lieu thereof), and 3,289,474 Warrants. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with accompanying warrants at a combined effective purchase price of $1.52. The Warrants will be exercisable immediately from the date of issuance at an exercise price of $1.40 per share and will expire five and half years from the date of issuance. The closing of the private placement is expected to occur on August 11, 2022, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.
2022-08-09 14:10:16	BSKP	Heron Shares Jump After Equity Financing, Q2 Earnings	Heron Therapeutics Inc (NASDAQ: BSKP ) reported Q2 sales of $27.63 million , +23.1% Y/Y, beating the consensus of $24.31 million. Oncology sales reached $25.1 million, up from $22.4 million a year ago. The company reported an EPS loss of $(0.55), narrower from $(0.62) a year ago but missing the consensus of $(0.50). In June 2022, Heron announced a corporate restructuring and cost reduction plan. It expects to achieve over $50 million in reductions in annual operating expenses in 2023. The company announced a private placement of 16.13 million at $3.10 per share and pre-funded warrants to purchase up to 8.5 million shares at $3.0999 per pre-funded warrant. Gross proceeds of the private placement are expected to be approximately $76.5 million . With the proceeds from the recent private placement, pro-forma cash at the end of the second quarter was $158.7 million, which is projected to provide a cash runway through 2024. Guidance: Heron currently expects FY22 oncology sales of $93-$95 million, up from prior guidance of $89-$93 million. Price Action: BSKP shares are up 16.2% at $4.15 during the market session on the last check Tuesday.
2022-08-09 16:42:11	RFZE	Verona Pharma Announces Proposed Underwritten Public Offering Of 10M ADSs	Verona Pharma plc (NASDAQ: RFZE ) (&quot;Verona Pharma&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares (&quot;ADSs&quot;), each representing eight ordinary shares of Verona Pharma, nominal value &pound;0.05 per share (the &quot;Offering&quot;). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.
2022-08-09 16:59:33	ZXQN	Mirum Pharmaceuticals Announces Commencement Of $80M Public Offering Of Common Stock	Mirum Pharmaceuticals, Inc. (NASDAQ: ZXQN ), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $80.0 million of shares of its common stock. In connection with the proposed offering, Mirum expects to grant the underwriters a 30-day option to purchase up to an additional approximately $12.0 million of shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
2022-08-09 17:50:21	MKTC	This Psychedelics Company Is Setting Up An Equity Program For Up To $35M In Shares	Cybin Inc . (JBY: MKTC) (NYSE: MKTC ) has launched an at-the-market (ATM) equity program through which it will issue and sell up to $35 million in common shares in the company&rsquo;s capital, from the treasury to the public. Cybin&rsquo;s shares distributions will be handled through agents Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald & Co. The biopharmaceutical company plans to use the net proceeds from these sales for growth opportunities and working capital ventures. All shares sold under this program will be traded in transactions deemed to be &ldquo;at-the-market&rdquo; distributions (also known as &ldquo;shelf distributions&rdquo;), directly through any &ldquo;marketplace&rdquo; upon which Cybin&rsquo;s shares are listed, quoted or traded, at the prevailing market price at the time of sale. The new program will become effective until the earlier of the issuance and the sale of all the shares issuable following the program and August 5, 2023, unless it is earlier concluded. Cybin reserves itself the right to determine the volume and timing of the distributions under the new program. The ATM Program is being established on a prospectus supplement dated August 8, 2022 to Cybin&rsquo;s short-form base shelf prospectus of July 5, 2021, which is filed with the securities commissions all throughout Canada. The supplement was also filed with the U.S. Securities and Exchange Commission (SEC), as part of a registration statement declared effective on October 8, 2021. Photo Courtesy of Pexels.
2022-08-10 08:52:58	DJY	LSB Industries Announces Secondary Offering Of 13,500,000 Shares Of Common Stock By Selling Stockholders With The Company Repurchasing 5,500,000 Of The Shares	OKLAHOMA CITY--(BUSINESS WIRE)-- LSB Industries, Inc. (NYSE: DJY ) (&ldquo;LSB&rdquo; or the &ldquo;Company&rdquo;) today announced that affiliates of Eldridge Industries LLC (the &ldquo;Selling Stockholders&rdquo;) intend to offer for sale an aggregate of 13,500,000 shares of the Company&rsquo;s common stock pursuant to the Company&rsquo;s automatic shelf registration statement (the &ldquo;Offering&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). The Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an aggregate of 1,200,000 additional shares of the Company&rsquo;s common stock. The Selling Stockholders will receive all of the net proceeds from this offering. No shares are being sold by the Company.
2022-08-10 13:33:25	FGCV	Allegiant Travel Commences $500M Debt Offering	Allegiant Travel Co (NASDAQ: FGCV ) commenced an offering of $500 million of Senior Secured Notes due 2027 to investors in a private offering. The company's subsidiaries will guarantee the Notes, other than Dustland, LLC, Sunseeker Resorts, Inc. and its subsidiaries, and certain other insignificant subsidiaries. The collateral that will secure the Notes currently secures the company's existing $150 million 8.500% Senior Secured Notes due 2024 and the company's Term Loan B. Allegiant intends to use the net proceeds, together with cash on hand, to repay its Term Loan B, which has an outstanding principal amount of $533 million. Price Action: FGCV shares are trading higher by 2.39% at $106.69 on the last check Wednesday.
2022-08-10 14:10:48	DJY	LSB Industries Shares Drop Following Secondary Offering	Affiliates of Eldridge Industries LLC intend to sell a total of 13.5 million shares of LSB Industries, Inc . (NYSE: DJY ) in a secondary offering. The company is not selling any shares. The company filed an automatic shelf registration statement relating to the offering with the SEC on March 28, 2022, which became effective upon filing. The selling stockholders intend to grant the underwriters a 30-day option to purchase up to an aggregate of 1.2 million additional shares of the company&rsquo;s common stock. LSB Industries plans to repurchase from the underwriters 5.5 million shares being sold in the offering and intends to fund it with cash on hand. As of June 30, 2022, LSB Industries held $450.8 million in cash and equivalents . LSB Industries Board recently authorized an increase in the size of the previously announced $50 million stock repurchase program implemented in May 2022. The company may now repurchase up to $100 million of its common stock, of which $85 million remains available. Price Action: DJY shares are trading lower 11.17% at $13.60 on the last check Wednesday.
2022-08-10 17:30:27	YOOY	Rani Therapeutics Announces Proposed Public Offering Of Class A Common Stock, No Terms Disclosed	Rani Therapeutics Holdings, Inc. (&quot;Rani Therapeutics&quot;) (NASDAQ: YOOY ), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it intends to offer and sell shares of its Class A common stock in an underwritten public offering (the &quot;Offering&quot;). Rani Therapeutics expects to grant the underwriters a 30-day option to purchase additional shares up to 15% of the aggregate number of shares offered in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or the actual size or terms of the Offering.
2022-08-11 15:23:07	RFL	ETF Giant Defiance Shutters Some Funds. Here's How They Performed	The fund owning the Defiance Next Gen Altered Experience ETF (NYSE: RFL ) and Defiance Next Gen SPAC Derived ETF funds, ETF Series Solutions recently decided to close and liquidate each fund. The action will take place immediately after the close of business on August 30, 2022 , aka the liquidation date. Each fund has already begun liquidating their portfolio assets, an action that will cause them to increase cash holdings and deviate from the original investment objective and strategies. The EFTs wwill not create new units after the close of business on August 29, and shares trading will be terminated before the market opens on August 30. Before the set date, shareholders will have a chance to sell their allocations to specific broker-dealers. Further, on or about August 30, both funds will liquidate their assets and distribute cash pro-rata to the lasting shareholders, within a taxable context. EFT Series Solutions encourages shareholders to contact their tax advisors on the income tax consequences of the liquidation, which will also include the existent capital gains and dividends. Each fund&rsquo;s net asset value as of the liquidation date will reflect the potential costs of its conclusion, and shareholders will receive liquidation proceeds after the closing date. The funds&rsquo; shares are listed, and movement can already be perceived . Defiance Next Gen Altered Experience ETF (NYSE: RFL ) shares began trading at $5.49 per unit at the start of this month, the date of the announcement, and later began gradually trading until achieving a major $6.30 per share on August 8. On or about that date, the Lenox Wealth Advisors LLC hedge fund bought a new position in the first quarter: 3,800 shares of the Defiance Next Gen Altered Experience ETF&rsquo;s total stock, valued at approx. $30,000. As of its most recent SEC disclosure filing, the hedge fund owns nearly 0.41% of the ETF. Image by Lorenzo Cafaro from Pixabay
2022-08-11 17:00:39	NGLH	Inspire Medical Systems Announces Proposed Offering Of 1M Shares Of Common Stock	Inspire Medical Systems, Inc. (NYSE: NGLH ) (&quot;Inspire&quot;), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today the commencement of a proposed public offering of 1,000,000 shares of its common stock. Inspire also expects to grant the underwriter a 30-day option to purchase up to an additional 150,000 shares of its common stock to cover sales by the underwriter in the initial offering of the shares or in the open market. All of the shares in the proposed offering are to be sold by Inspire.
2022-08-12 08:03:30	HBRK	Terns Pharmaceuticals to Sell 12.5M Shares @$2.42/Share	"Terns Pharmaceuticals, Inc. (""Terns"" or the ""Company"") (NASDAQ: HBRK ), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that it has agreed to sell, by way of an underwritten public offering, 12,250,000 shares of its common stock at a price of $2.42 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 14,630,000 shares of common stock at a price of $2.4199 per pre-funded warrant, for expected aggregate gross proceeds of approximately $65.0 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. The offering is expected to close on August 16, 2022, subject to customary closing conditions. All of the securities are being offered by Terns. The offering was oversubscribed and led by new investors Fairmount and Venrock Healthcare Capital Partners and included participation from existing top-tier healthcare investors. Cowen and Company, LLC is acting as lead book-running manager for the offering. UBS Securities LLC is also acting as a bookrunner for the offering. Terns intends to use the net proceeds from the offering, together with existing cash and cash equivalents, as follows: (1) to initiate and complete one or more clinical studies in the United States and/or Europe to assess HBRK-701 and advance the product candidate into Phase 2 clinical development in chronic myeloid leukemia; (2) to advance the clinical development of HBRK-601 in obesity through the completion of Phase 2-enabling studies and initiate a Phase 2 clinical trial of HBRK-601 in obesity; (3) to complete the ongoing Phase 2a DUET trial of HBRK-501 as monotherapy and in combination with HBRK-101 in NASH patients; and (4) for working capital and general corporate purposes."
2022-08-12 08:37:14	VGLI	Palisade Bio Announces Pricing Of $12M Upsized Underwritten Public Offering	Palisade Bio (NASDAQ: VGLI ), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of (i) 42,160,000 shares of common stock, (ii) 1,460 shares of Series B convertible preferred stock, (iii) 48,000,000 Series 1 Warrants with an exercise price of $0.25 per share and a term of one year following the issuance date, and (iv) 48,000,000 Series 2 Warrants with an exercise price of $0.25 per share and a term of five years following the issuance date. The price per share of common stock, Series 1 Warrant and Series 2 Warrant is $0.25. The price per share of Series B convertible preferred stock, Series 1 Warrant to purchase 4,000 shares of common stock and Series 2 Warrant to purchase 4,000 shares of common stock is $1,000.00. The warrants will be exercisable beginning on the date of stockholder approval of the exercisability of the warrants under Nasdaq rules. The closing of the offering is expected to take place on or about August 16, 2022, subject to the satisfaction or waiver of customary closing conditions.
2022-08-15 07:23:47	YVRR	Halozyme Announced Up to $200M Buyback of Shares in Parallel With Offering of $500M of Convertible Senior Notes	"Halozyme Therapeutics, Inc. (NASDAQ: YVRR ) (""Halozyme"" or the ""Company""), a leader in converting IV biologics to subcutaneous delivery and autoinjector devices, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2028 (the ""Convertible Notes""). The Convertible Notes are to be offered and sold to ""qualified institutional buyers"" pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). The Company also expects to grant a 13-day option to the initial purchasers to purchase up to an additional $75 million aggregate principal amount of Convertible Notes. The Convertible Notes will be senior, unsecured obligations of the Company and will accrue interest payable semi-annually in arrears. The Convertible Notes will mature on August 15, 2028, unless earlier redeemed, repurchased or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding February 15, 2028, the Convertible Notes will be convertible only upon the satisfaction of certain conditions and during certain periods, and on and after February 15, 2028, at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date, the Convertible Notes will be convertible regardless of these conditions. The Company will settle conversions in cash and, if applicable, shares of the Company's common stock. The initial conversion rate, interest rate and other terms of the Convertible Notes will be determined at the time of pricing in negotiations with the initial purchasers of the Convertible Notes. In connection with the offering, the Company intends to enter into privately negotiated capped call transactions with option counterparties that may include one or more of the initial purchasers and/or their affiliates and/or other institutions. If the initial purchasers exercise their option to purchase additional notes, the Company may enter into additional capped call transactions with the option counterparties. The capped call transactions are generally expected to reduce potential dilution to the Company's common stock upon conversion of the convertible notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be. The Company has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties and/or their affiliates (i) expect to purchase shares of the Company's common stock and/or enter into derivative transactions with respect to the Company's common stock concurrently with, or shortly after, the pricing of the Convertible Notes and (ii) may modify their hedge positions by entering into or unwinding derivative transactions with respect to the Company's common stock and/or purchasing or selling the Company's common stock or other securities of the Company in secondary market transactions following the pricing of the Convertible Notes and prior to the maturity of the Convertible Notes. These activities could have the effect of increasing, or preventing a decline in, the market price of the Company's common stock concurrently with, or shortly following, the pricing of the Convertible Notes. The effect, if any, of these activities, including the direction or magnitude, on the market price of the Company's common stock will depend on a variety of factors, including market conditions, and cannot be ascertained at this time. Any of these activities could, however, adversely affect the market price of the Company's common stock. The Company expects to use a portion of net proceeds of the offering to fund the cost of entering into the capped call transactions. The Company also expects to use a portion of the net proceeds of the offering to enter into privately negotiated agreements with certain holders of its outstanding 1.25% convertible senior notes due 2024 (the ""Existing Convertible Notes"") to exchange their Existing Convertible Notes for a combination of cash and shares of its common stock through privately negotiated transactions entered into concurrently with or shortly after the pricing of the proposed offering (the ""Note Repurchases""). In parallel to this transaction, the Company expects to use a portion of the net proceeds of the offering for the repurchase of shares of its common stock (the ""Share Repurchases"") up to $200 million, concurrently with, or shortly after, the pricing of the offering in privately negotiated transactions or otherwise, which may be effected through one or more of the initial purchasers or any affiliate thereof. The Share Repurchases, if consummated in full, would represent an increase of $100 million of the previously planned share repurchases to be made in 2022 under the Company's ongoing three-year $750 million share repurchase program, which was commenced and previously announced in 2021. Further, the Company expects to use a portion of the net proceeds of the offering to repay all of its outstanding $250 million term loan facility due 2026. The Company intends to use the remainder of the net proceeds from the offering for general corporate purposes, including other repurchases of the Company's common stock from time to time under the existing stock repurchase program, working capital, capital expenditures, potential acquisitions and strategic transactions. If the initial purchasers exercise their option to purchase additional notes, the Company intends to use a portion of the net proceeds from the sale of additional notes to fund the cost of entering into additional capped call transactions. The Note Repurchases and Share Repurchases could increase (or reduce the size of any decrease in) the market price of Halozyme common stock or the Convertible Notes. We also expect that some existing noteholders may purchase or sell shares of the Company's common stock in the market to hedge their exposure in connection with these transactions. The Note Repurchases, Share Repurchases and any associated hedging by holders could affect the market price of the Company's common stock prior to, concurrently with or shortly after the pricing of the Convertible Notes and could also result in a higher effective conversion price for the Convertible Notes."
2022-08-15 10:55:38	FDC	Darling Ingredients Raises $250M Via Add-On Debt Offering	Darling Ingredients Inc (NYSE: FDC ) has launched an add-on offering of $250 million in aggregate principal amount of unsecured senior notes. The add-on notes will be issued as additional notes under the same indenture as Darling's 6% senior notes due 2030, $750.0 million of which were issued on June 9, 2022. The add-on notes will have the same terms as the initial notes and will constitute a single class of securities under the indenture. The gross proceeds of the add-on notes offering are expected to be used for general corporate purposes. Price Action: FDC shares are trading lower by 2.19% at $75.61 on the last check Monday.
2022-08-15 16:03:02	IJDL	IJDL Bio Announces Proposed Public Offering Of Common Stock	IJDL Bio, Inc. (&quot;IJDL&quot;), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, IJDL expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by IJDL. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering.
2022-08-15 16:25:26	FGCA	Fulcrum Therapeutics Announces Proposed $75M Public Offering Of Common Stock	CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. &reg; (NASDAQ: FGCA ), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. Fulcrum also intends to grant the underwriters a 30-day option to purchase up to an additional $11.3 million of shares of its common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Fulcrum.
2022-08-15 16:34:17	CWMR	Trinity Capital Announces $50M Offering Of Common Stock	Trinity Capital Inc. (NASDAQ: CWMR ) (&quot;Trinity&quot; or the &quot;Company&quot;), a leading provider of debt and equipment financing to venture capital backed growth stage companies, today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In connection with the proposed offering, Trinity intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of the shares of common stock to be sold in the offering are to be sold by Trinity. The offering is subject to general market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering.
2022-08-15 17:10:14	ZV	Bloom Energy Announces Commencement Of Public Offering Of 13M Shares, Terms Not Disclosed	Bloom Energy Corporation (NYSE: ZV ) today announced that it has commenced an underwritten public offering of 13,000,000 shares of its Class A common stock. All of the shares of the Class A common stock are being offered by Bloom Energy. In addition, Bloom Energy intends to grant the underwriters a 30-day option to purchase up to an additional 1,950,000 shares of Class A common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2022-08-16 09:02:54	XRLT	Why Is Sunnova Energy Stock Down Today?	Sunnova Energy International Inc (NYSE: XRLT ) shares are trading lower Tuesday after the company announced a proposed private offering of convertible senior notes. Sunnova said it intends to offer $425 million of convertible senior notes due 2028 in a private placement to qualified institutional buyers. The company also intends to grant the initial purchasers of the notes the option to purchase up to an additional $75 million aggregate principal amount of the notes within a 13-day period. Sunnova also expects to enter into capped call transactions with one or more of the initial purchasers. The capped call transactions are expected to generally reduce the potential dilution to Sunnova's common stock upon any conversion of notes. Sunnova said it intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions. See Also: Benzinga Before The Bell: Elon Musk May Get Info It Wants From Twitter, Apple To Lay Off 100 Recruiter Contractors, Saudi's Investment Fund Picks Stocks Of US Big Tech And Other Top Financial Stories Tuesday, August 16 XRLT Price Action: Sunnova has a 52-week high of $31.47 and a 52-week low of $12.47. The stock was down 7.66% at $27.50 at press time, according to Benzinga Pro . Photo: andreas160578 from Pixabay.
2022-08-16 09:21:45	NALD	BIT Mining Announces $9.3M Registered Direct Offering	BIT Mining Limited (NYSE: NALD ) (&quot;BIT Mining&quot; or the &quot;Company&quot;), a leading technology-driven cryptocurrency mining company, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 15,566,665 of the Company's American Depositary Shares (&quot;ADSs&quot;), Series A Warrants to purchase up to an aggregate of 15,566,665 ADSs and Series B Warrants to purchase up to an aggregate of 15,566,665 ADSs, at a combined purchase price of US$0.60 per ADS and associated warrants, in a registered direct offering. Each ADS represents ten (10) Class A ordinary shares, par value US$0.00005 per share, of BIT Mining. The offering is expected to close on or about August 18, 2022, subject to satisfaction of customary closing conditions. Revere Securities LLC is acting as the exclusive placement agent for the offering. The Series A Warrants will have an exercise price of US$0.66 per ADS, will be exercisable at any time upon issuance and will expire five years from the date of issuance. The Series B Warrants will have an exercise price of US$0.60 per ADS, will be exercisable at any time upon issuance and will expire two and a half years from the date of issuance. The gross proceeds from the offering (without taking into account any proceeds from any future exercises of warrants issued), before deducting the placement agent's fees and other estimated offering expenses payable by the Company, are expected to be approximately US$9.3 million. The Company intends to use the net proceeds from this offering to invest in mining machines, expand infrastructure, improve working capital position and invest in new business opportunities. The securities described above are being offered by BIT Mining pursuant to a &quot;shelf&quot; registration statement on Form F-3 (File No. 333-258329) originally filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on July 30, 2021 and declared effective by the SEC on May 17, 2022. The offering of such securities is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Revere Securities LLC at 650 Fifth Avenue, 35th Floor, New York, NY 10022, by phone at 212-688-2350 or e-mail at placement@reveresecurities.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
2022-08-16 16:02:58	FKZ	UNITY Biotechnology Announces Proposed Public Offering of Common Stock	SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (&quot;UNITY&quot;) (NASDAQ: FKZ ), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it has commenced a proposed underwritten public offering of $25.0 million of shares of its common stock. In addition, UNITY expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares of common stock to be sold in the offering are being offered by UNITY. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. UNITY intends to use the net proceeds from the proposed offering to fund the ongoing clinical development of UBX1325, including the BEHOLD and ENVISION studies, and other general corporate purposes, including working capital, operating expenses and capital. SVB Securities, Cantor and Mizuho Securities are acting as joint book-running managers for the proposed offering. Wedbush PacGrow is acting as lead manager for the proposed offering. The public offering will be made pursuant to a registration statement on Form S-3 previously filed with the Securities and Exchange Commission (&quot;SEC&quot;), which became effective on May 6, 2022. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov . Copies of the preliminary prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained from: SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022, by email at prospectus@cantor.com; or Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020, by email at US-ECM@us.mizuho-sc.com , or by telephone at (212) 205-7600. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-08-17 17:53:08	CTMC	Midland States Bancorp Prices $115M Offering of Depositary Shares	Midland States Bancorp, Inc. (&quot;Midland&quot; or the &quot;Company&quot;) (NASDAQ: CTMC ), the holding company for Midland States Bank (the &quot;Bank&quot;), announced today that it has priced an underwritten public offering of 4,600,000 depositary shares (the &quot;depositary shares&quot;), each representing a 1/40th interest in a share of 7.75% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A, par value $2.00 per share, with a liquidation preference of $1,000 per share (equivalent to $25.00 per depositary share). The Company has applied to list the depositary shares on The Nasdaq Global Select Market under the symbol &quot;MSBIP.&quot; The offering is subject to customary closing conditions and is expected to close on or about August 24, 2022. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include providing capital to support its organic growth or growth through strategic acquisitions, repaying or redeeming outstanding indebtedness, financing investments, capital expenditures, repurchasing shares of its common stock and for further investments in the Bank as regulatory capital.
2022-08-17 18:02:56	RDMH	Accelerate Diagnostics Announces Proposed Public Offering of Common Stock, No Terms Disclosed	Accelerate Diagnostics, Inc. (NASDAQ: RDMH ) (&quot;Accelerate Diagnostics&quot;) today announced that it has commenced an underwritten public offering of shares of its common stock. Accelerate Diagnostics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less the underwriting discounts and commissions. Accelerate Diagnostics anticipates using the net proceeds from the offering for general corporate purposes and to fund commercialization efforts. All of the shares are being offered by Accelerate Diagnostics. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2022-08-19 08:07:53	PCHX	Capstone Green Energy Prices Offering Of 2,934,498 Shares And Accompanying Warrants At $2.75 Per Share And Accompanying Warrant	Capstone Green Energy (NASDAQ: PCHX ) (&ldquo;Capstone&rdquo;, or the &ldquo;Company&rdquo;), a global leader in carbon reduction and on-site resilient green Energy as a Service (EaaS) solutions, today announced the pricing of an underwritten public offering consisting of 2,934,498 shares of its common stock and accompanying warrants to purchase up to 2,934,498 shares of common stock at a combined public offering price of $2.75 per share and accompanying warrant. The warrants have an exercise price of $2.75 per share, are exercisable immediately, and will expire five years following the date of issuance. The offering is expected to close on August 23, 2022, subject to customary closing conditions. Lake Street Capital Markets, LLC is acting as the sole book-running manager for the offering and Joseph Gunnar & Co., LLC is acting as co-manager for the offering. The gross proceeds to Capstone from the offering, before underwriting discounts and commissions and offering expenses, are expected to be approximately $8.0 million. Capstone intends to use the net proceeds from the offering for working capital, general corporate purposes and growth initiatives, including to expand its Energy as a Service long-term rental fleet.
2022-08-19 14:00:21	PCHX	Capstone Shares Plunge After Pricing $8M Public Offering	Capstone Green Energy Corp (NASDAQ: PCHX ) shares plunge after pricing the public offering consisting of ~2.93 million shares of its common stock and accompanying warrants to purchase 2.93 million shares at a combined public offering price of $2.75 per share and accompanying warrant. The warrants have an exercise price of $2.75 per share, are exercisable immediately, and will expire five years following the date of issuance. The offering is expected to close on August 23, 2022. The gross proceeds are expected to be ~$8 million. Capstone intends to use the net proceeds for general corporate purposes and growth initiatives, including expanding its Energy as a Service long-term rental fleet. Price Action: PCHX shares are trading lower by 37% at $2.48 on the last check Friday.
2022-08-22 09:06:46	EFNU	Performance Shipping Inc. Announces Termination of ATM Offering With L.C. Wainwright & Co., LLC	ATHENS, Greece, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Performance Shipping Inc. (NASDAQ: EFNU ), (&quot;we&quot; or the &quot;Company&quot;), a global shipping company specializing in the ownership of tanker vessels, today announced that, effective August 23, 2022, it has terminated the At The Market Offering Agreement with L.C. Wainwright & Co., LLC, dated March 5, 2021 (the &quot;ATM Agreement&quot;). Prior to termination, the Company issued and sold 526,916 shares of its common stock under the ATM Agreement, raising net proceeds, after deducting commissions and other expenses, of approximately $1.3 million. The Company is terminating the ATM Agreement because it does not intend to raise additional capital or sell additional shares under the ATM Agreement.
2022-08-22 12:30:22	ZYSE	Volcon Raises $27.2M Via Debt Offering	Volcon Inc (NASDAQ: ZYSE ) has signed a securities purchase agreement to issue an investor $27.2 million of convertible senior notes due 2024. The agreement also includes accompanying warrants to purchase approximately 9.1 million shares of common stock with an initial exercise price of $2.85. The initial conversion price will be $2.25 per share of common stock. Each of the Notes will include an original issue discount of 8.0%. The notes are expected to mature on February 24, 2024. Price Action: ZYSE shares are trading lower by 22.31% at $1.88 on the last check Monday.
2022-08-22 13:22:46	EFNU	Performance Shipping Terminates ATM Offering	Performance Shipping Inc (NASDAQ: EFNU ) announced that effective August 23, 2022, it has terminated the At The Market Offering Agreement with L.C. Wainwright & Co., LLC , dated March 5, 2021. Before termination, EFNU issued and sold 526,916 shares of its common stock under the ATM Agreement, generating net proceeds of ~$1.3 million after commissions. The company said it is terminating the ATM Agreement because it does not intend to raise additional capital or sell additional shares under the ATM Agreement. Price Action: EFNU shares are trading higher by 6.88% at $0.3155 on the last check Monday.
2022-08-24 08:37:16	PEKK	TRxADE HEALTH Announces Termination Of Public Offering Of Common Stock	TRxADE HEALTH, INC. (NASDAQ: PEKK ) (&quot;TRxADE&quot; or the &quot;Company&quot;), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced that it has terminated the proposed underwritten public offering previously announced on August 23, 2022. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's stockholders. As a result of such termination, no shares of common stock will be sold pursuant to the offering. The offering was being made pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333- 266432) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on August 8, 2022, and the accompanying prospectus contained therein. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-08-24 15:27:52	YLBR	Neurodevelopment Biotech PaxMedica To Debut On NASDAQ Tomorrow	PaxMedica Inc , a Phase 2 biotech developing therapies for neurodevelopmental disorders, revived its GIP plans to raise up to $9 million. PaxMedica was founded in 2018 and planned to list on the Nasdaq under the symbol YLBR. Check out the company website here . It initially filed for an GIP in July 2020 for $15 million. According to the most recent prospectus , the company plans to offer 1.6 million shares and warrants to purchase 108,181 shares at $5.50 - $6.50. The company's lead candidate, PAX-101, is an intravenous formulation of suramin. The company is also developing PAX-102, a proprietary intranasal formulation of suramin, for autism spectrum disorder (ASD) and other neurologic disorders. In February 2021, the company announced positive topline data from its Phase 2 dose-ranging trial evaluating PAX-101 for treating the core symptoms of ASD. For its lead candidate, management plans to seek U.S. FDA marketing approval for East African HAT (commonly known as African sleeping sickness) as early as 2024 and then leverage such approval to expand the treatment scope to ASD, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, and long COVID syndrome. Earlier this PaxMedica started Phase 1b trial of PAX-101 for long COVID-19 syndrome in South Africa.
2022-08-25 07:13:52	FZOC	Greenwave to Withdraw Registration Statement on Form S-3	"Greenwave Technology Solutions, Inc. (""Greenwave"" or the ""Company"") (NASDAQ: FZOC ), a leading operator of 11 metal recycling facilities in Virginia and North Carolina, today announced that it plans to withdraw its Registration Statement on Form S-3. Simultaneous with the listing of the Company's common stock on Nasdaq on July 22, 2022, the Company's senior secured convertible notes in the principal amount of $37,714,966 together with accrued interest in the amount of $1,470,884 was converted into shares of common stock at a conversion price of $6.02 per share. The Company has no convertible debt outstanding and all of the price protection provisions in the Company's warrants and preferred shares expired upon uplisting to Nasdaq. ""We are committed to minimizing the dilution to Greenwave's shareholders as we continue our expansion and potentially acquire profitable companies,"" stated Danny Meeks, Chief Executive Officer of Greenwave. ""We know the past few weeks have been frustrating for Greenwave's shareholders and we are incredibly grateful for your continued support. Fundamentally, the Company has the strongest balance sheet in its history and we believe the infrastructure improvements set to come online over the coming months will help us grow our revenues and profit margins significantly. We look forward to reporting back on our progress."" Greenwave generated record revenues of $10.70 million during the quarter ending June 30, 2022, an increase of 56% from the $6.88 million in revenue Empire Services, Inc. (""Empire"") generated in the same period in 2021. Further, the Company generated positive cashflows from operating activities of $566,238 for the six months ending June 30, 2022. The Company is currently installing a second shredder at its Carrollton yard to process cars, household appliances and industrial products, along with a downstream system at its Kelford yard to increase its recovery yields of copper, aluminum, brass, steel, stainless steel, and other metals. The shredder and downstream system are on track to come online in the coming months and are expected to double the Company's processing capacity, significantly growing its revenues while increasing its profit margins"
2022-08-25 08:08:56	YOOY	Rani Therapeutics Reports $150M Common Stock Offering	We have entered into a Controlled Equity OfferingSM Sales Agreement, dated August 25, 2022, or the Sales Agreement, with Cantor Fitzgerald & Co. and L.C. Wainwright & Co., LLC, collectively, the Agents, relating to the sale of shares of our Class A common stock, par value $0.0001 per share, offered by this prospectus supplement and the accompanying base prospectus. In accordance with the terms of the Sales Agreement, under this prospectus supplement we may offer and sell up to $150,000,000 of shares of our Class A common stock, from time to time through the Agents. Our Class A common stock is listed on the Nasdaq Global Market under the symbol &ldquo;YOOY.&rdquo; On August 23, 2022, the closing sale price of our Class A common stock on the Nasdaq Global Market was $10.00 per share. Sales of our Class A common stock, if any, under this prospectus may be made by any method permitted by law that is deemed an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. The Agents are not required to sell any specific number or dollar amount of shares of our Class A common stock. Each of the Agents will use commercially reasonable efforts to sell on our behalf all of the Class A common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between the Agents and us, as applicable. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The Agents will be entitled to compensation at a commission rate of up to 3.0% of the gross proceeds of shares sold under the Sales Agreement. In connection with the sale of our Class A common stock on our behalf, each of the Agents will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act and the compensation of the Agents will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Agents with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended, or the Exchange Act. See &ldquo;Plan of Distribution&rdquo; beginning on page S-15 for additional information regarding the compensation to be paid to the Agents.
2022-08-29 08:36:12	LSRO	Playtika Announces Commencement Of Tender Offer To Purchase Up To 51,813,472 Shares Of Its Common Stock	HERZLIYA, Israel, Aug. 29, 2022 /PRNewswire/ -- Playtika Holding Corp. (NASDAQ: LSRO ) (&quot; Playtika &quot;), a mobile gaming entertainment and technology market leader with a portfolio of multiple game titles, today announced that it has commenced a tender offer for the purchase of up to 51,813,472 shares of Playtika's issued and outstanding common stock, par value $0.01 per share (each, a &quot; Share ,&quot; and collectively, &quot; Shares &quot;) or such lesser number of Shares as are properly tendered and not properly withdrawn, at a price of $11.58 per Share, to be paid to the seller in cash less any applicable withholding taxes, in accordance with the terms and subject to the conditions described in the offer to purchase, the related letter of transmittal and other related materials, as each may be amended or supplemented from time to time. The closing price of the Shares on The Nasdaq Global Select Market on August 26, 2022, the last full trading day before the start of the tender offer, was $10.92 per Share. The tender offer is scheduled to expire one minute after 11:59 P.N., New York City Time, September 26, 2022, unless the offer is extended or terminated. The tender offer is not conditioned on a minimum number of Shares being tendered. The tender offer is subject to certain terms and conditions, including that it may be amended or terminated by Playtika under certain circumstances, which are described in detail in the offer to purchase. Specific instructions and a complete explanation of the terms and conditions of the tender offer are contained in the offer to purchase, the related letter of transmittal and other related materials, which will be mailed to stockholders of record promptly. Following an extensive review of strategic alternatives by the Special Committee comprised solely of disinterested and independent directors (the &quot; Special Committee &quot;) of the Board of Directors (the &quot; Board &quot;) of Playtika, the Special Committee and the Board, based on the facts and circumstances described in the offer to purchase for the tender offer, believe, after reviewing, with management and their respective advisors, Playtika's operations, financial condition, capital needs, strategy, and expectations for the future, and in light of the information provided by Playtika's controlling shareholder group, Playtika Holding UK II Limited, Alpha Frontier Limited, Shanghai Cibi Business Information Consultancy Co., Ltd., Shanghai Jukun Network Technology Co., Ltd., Giant Network Group Co., Ltd., Giant Investment Co., Ltd., Yuzhu Shi, Hazlet Global Limited, Equal Sino Limited and Jing Shi (collectively, the &quot; Giant/Alpha Group &quot;), regarding the Giant/Alpha Group's debt obligations and requirements of their lenders, that the tender offer is in the best interests of Playtika and its stockholders (including all the stockholders other than the Giant/Alpha Group), including to avoid a potentially negative impact on Playtika and unaffiliated stockholders of the potential exercise of creditors' remedies by the Giant/Alpha Group's lenders or the Giant/Alpha Group having to liquidate a substantial portion of its position. The Giant/Alpha Group has entered into that certain Tender Agreement, dated as of August 26, 2022 (the &quot; Tender Agreement &quot;) with Playtika, which requires, among other things, that the Giant/Alpha Group tender at least 211,711,155 Shares in the Offer and not withdraw such Shares except as permitted under the terms of the Tender Agreement, including the right to withdraw such number of Shares as may be necessary (1) to result in tendering such Shares as will result in $323 million in gross proceeds payable to the Giant/Alpha Group, and (2) to maintain an ownership of 51.7% on a fully diluted basis after the Offer. None of Playtika, the members of its Board (or any committee thereof), the information agent, the depositary or any of Playtika's other representatives or advisors for the tender offer or any representatives or advisors of any of the foregoing for the tender offer makes any recommendation as to whether or not any stockholder should participate in the tender offer. D.F. King & Co., Inc. is serving as the information agent for the tender offer and American Stock Transfer & Trust Company, LLC is serving as the depositary. For all questions relating to the tender offer, please contact the information agent, D.F. King & Co., Inc. at playtika@dfking.com or call toll-free at (877) 871-1741.
2022-08-30 07:40:11	ZGDK	Nikola Files Prospectus Supplement Related To Issuance And Sale From Time To Time Of Common Stock Having Aggregate Offering Price Of Up To $400,000,000 Through Citigroup Global Markets	This prospectus supplement and the accompanying prospectus relate to the issuance and sale from time to time of shares of our common stock, $0.0001 par value per share, having an aggregate offering price of up to This prospectus supplement and the accompanying prospectus relate to the issuance and sale from time to time of shares of our common stock, $0.0001 par value per share, having an aggregate offering price of up to $400,000,000 through Citigroup Global Markets Inc., or the Sales Agent. These sales, if any, will be made pursuant to the terms of an equity distribution agreement dated August 30, 2022, or the Equity Distribution Agreement, between us and the Sales Agent. The compensation of the Sales Agent for sales of our common stock shall be at a fixed commission rate of 2.5% of the gross offering proceeds of shares sold under the Equity Distribution Agreement. The net proceeds from any sales under this prospectus supplement will be used as described under &ldquo;Use of Proceeds&rdquo; in this prospectus supplement. In connection with the sale of shares of common stock on our behalf, the Sales Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act of 1933, as amended, or the Securities Act, and the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the sales agent with respect to certain liabilities, including civil liabilities under the Securities Act. See &ldquo;Plan of Distribution&rdquo; beginning on page S-30 for additional information regarding the compensation to be paid to the Sales Agent. Sales of shares of our common stock, if any, under this prospectus supplement will be made by any method permitted that is deemed an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) under the Securities Act. The Sales Agent is not required to sell any specific amount, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol &ldquo;ZGDK.&rdquo; On August 29, 2022, the last reported sale price of our common stock on Nasdaq was $5.97 per share. Investing in our common stock involves risks that are described in the &ldquo;Risk Factors&rdquo; section beginning on page S-5 of this prospectus supplement and any risk factors that are included in our filings with the Securities and Exchange Commission, or the SEC, that are incorporated by reference herein. Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
2022-08-30 07:47:41	TQJB	Lucid Motors Aims To Raise $8B Via Mixed Shelf Offering	Lucid Group, Inc (NASDAQ: TQJB ) looks to raise up to $8 billion in primary capital via one or more offerings over the three years under its mixed-shelf offering. These capital raises could include common stock, preferred stock (including depositary shares), warrants, debt securities (including convertible debt), purchase contracts, and units. Electric vehicle startups that promised to disrupt the automotive industry now struggle to control costs and cash burn to bring vehicles to market amid component crisis and rising raw material prices, Reuters reports . Lucid reported second-quarter revenue of $97.3 million, which missed the estimate. Lucid said it delivered 679 vehicles. The EV company reported a quarterly earnings loss of 33 cents per share, which beat the estimate. Lucid ended the quarter with $4.6 billion in cash and equivalents. Lucid revised its 2022 production volume outlook to a range of 6,000 to 7,000 vehicles, reflecting the extraordinary supply chain and logistics challenges. Price Action: TQJB shares traded lower by 1.42% at $15.94 in the premarket on the last check Tuesday. Photo via Wikimedia Commons
2022-08-30 08:16:36	NVMU	Ramaco Resources, Inc. Announces Submission Of Registration Statement Related To Proposed Public Offering Of Class B Common Stock	Ramaco Resources, Inc. (NASDAQ: NVMU ) (&quot;Ramaco Resources&quot; or the &quot;Company&quot;) announced today that it has submitted a registration statement on Form S-3 to the Securities and Exchange Commission (the &quot;SEC&quot;) relating to the proposed public listing of Class B common stock. The public listing is expected to take place after the SEC completes its review process, subject to various conditions, including the requisite approval of the holders of the Company's common stock at a stockholders' meeting. The Class B common stock is expected to receive a dividend, which will track and be based on the financial performance of a portion of the Company's assets related to its coal infrastructure and royalties' revenue, carbon products and rare earth elements. The Company intends to refer to this new business line as &quot;CORE&quot;, signifying its focus on carbon ore and rare earth elements. In connection with the creation of the Class B common stock, record holders of the Company's common stock would receive shares of the Class B common stock as a distribution. Each holder will receive 0.2 shares of Class B common stock for every one share of existing common stock held on the record date (with cash in lieu of any fractional share interests). It is anticipated that initially 20% of the revenue attributable to the CORE assets will be paid as a dividend, with the percentage subject to change by our board. Ramaco Resources expects to complete the registration and distribution of the new Class B common stock in the fourth quarter of 2022. The record date, the distribution date and the stockholder meeting date will be announced at a later date. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Class B common stock may only be distributed pursuant to an effective registration statement. The Company's stockholders and other investors are urged to read the registration statement filed with the SEC because it contains important information about the issuance of shares of the proposed Class B common stock. Copies of the Company's SEC filings are available free of charge on the SEC's website at www.sec.gov .
2022-08-30 08:50:03	MCKJ	Baudax Bio Late Monday Announces Pricing of $6.2M Public Offering	MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the &quot;Company&quot; or &quot;Baudax Bio&quot;) (NASDAQ: MCKJ ), a pharmaceutical company focused on therapeutics for acute care settings, today MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the &quot;Company&quot; or &quot;Baudax Bio&quot;) (NASDAQ: MCKJ ), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of its public offering of an aggregate of 11,819,172 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock purchase warrants, at a public offering price of $0.525 per share (or pre-funded warrant) and accompanying warrants. Each share of common stock (or pre-funded warrant) was sold in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $0.525 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $0.525 per share. The Series A-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire thirteen months from the date of issuance. The closing of the offering is expected to occur on or about September 1, 2022, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $6.2 million. The Company intends to use the net proceeds from this offering for pipeline development activities and general corporate purposes. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-266499), which was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on August 29, 2022. The offering is being made only by means of a prospectus which is a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at http://www.sec.gov and may also be obtained by contacting L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-09-01 08:17:56	DUJN	BioAffinity Technologies Announces Pricing Of GIP Estimated To Be ~$7.86M At $6.125 Per Unit	bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. Each warrant is immediately exercisable and will expire five years from the date of issuance. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols &quot;DUJN&quot; and &quot;BIAFW,&quot; respectively. The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath&reg; Lung , a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. bioAffinity's registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained on the SEC's website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-06 08:36:13	TWAC	Reviva Pharmaceuticals Holdings Announces $8.5M Registered Direct Offering And Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules	CUPERTINO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: TWAC ) (&quot;Reviva&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that it has entered into definitive agreements with a single healthcare-focused institutional investor, in a registered direct offering priced at-the-market under Nasdaq rules, and two affiliates of a member of the Company's Board of Directors, each in a private placement, for the purchase and sale of an aggregate of 3,359,684 shares of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) at a purchase price per share of $2.53 (or $2.5299 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant), for gross proceeds of approximately $8.5 million before deducting placement agent fees and other estimated offering expenses. The Company has also agreed to issue to each investor, in an additional concurrent private placement, unregistered warrants to purchase up to 3,359,684 shares of the Company's common stock. The warrants will have an exercise price of $2.40 per share, will be exercisable immediately following the date of issuance and will expire five years from the initial exercise date. The closing of the registered direct offering and the concurrent private placements is expected to occur on or about September 8, 2022, subject to the satisfaction of customary closing conditions. Reviva intends to use the net proceeds from the offering to continue the clinical development of brilaroxazine (RP5063) for the treatment of acute and maintenance schizophrenia, and for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. The offering of the shares of common stock and pre-funded warrants (and underlying shares of common stock) to the institutional investor is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-262348) previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and declared effective by the SEC on February 2, 2022. The offering of the shares of common stock and pre-funded warrants (and underlying shares of common stock) to the institutional investor is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . The warrants and shares of common stock (and pre-funded warrants) sold in the private placements described above are being issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants and such pre-funded warrants issued in such offerings, have not been registered under the Act, or applicable state securities laws. Accordingly, the shares of common stock and pre-funded warrants (and underlying shares of common stock) issued in the private placements may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-06 16:18:37	BZU	BZU Announces Launch Of Initial Public Offering Of Its Majority Owned Subsidiary Corebridge Financial; BZU Is Offering 80M Shares Of Corebridge Common Stock At An Expected Price Between $21-$24 Per Share	American International Group, Inc. (NYSE: BZU ) today launched the initial public offering (&quot;GIP&quot;) of its majority-owned subsidiary, Corebridge Financial, Inc. (&quot;Corebridge,&quot; previously &quot;SAFG Retirement Services, Inc.&quot;). BZU, as the selling stockholder, is offering 80 million shares of common stock (out of 645 million total common shares) of Corebridge and has granted a 30-day option to the underwriters for the purchase of up to an additional 12 million shares of common stock. The GIP price is currently expected to be between USD 21 and USD 24 per share. All of the net proceeds from the offering will go to BZU. The shares are expected to trade on the New York Stock Exchange under the ticker symbol &quot;HFJN.&quot; J.P. Morgan is acting as Global Coordinator and a Lead Active Bookrunner for the proposed offering. Morgan Stanley and Piper Sandler are also acting as Lead Active Bookrunners for the proposed offering. BofA Securities, Citigroup and Goldman Sachs & Co. LLC are acting as Active Bookrunners for the proposed offering. The proposed offering of these securities will be made only by means of a prospectus. A registration statement relating to the proposed GIP has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Copies of the registration statement, may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmorganchase.com ; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Piper Sandler & Co., Attention: Piper Sandler & Co., 1251 Avenue of the Americas, 6th Floor, New York, NY 10020, or by telephone at 1-800-747-3924 or by email at prospectus@psc.com ; BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255, or by email at dg.prospectus_requests@bofa.com ; Citigroup Global Markets Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146 and Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526 or by email at prospectus-ny@ny.email.gs.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
2022-09-06 16:41:22	TNBD	Paycor Announces Offering Of 5M Shares Of Common Stock From Selling Stockholders	CINCINNATI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Paycor QGQ, Inc. (NASDAQ: TNBD ) (&quot;Paycor&quot;) today announced the commencement of an underwritten public offering of 5,000,000 shares of common stock on behalf of investment funds advised by Apax Partners LLP. The offering consists of 3,531,941 shares offered by Pride Feeder, L.P. and 1,468,059 shares offered by AIX Pride Syndication, L.P., respectively. Each of the selling stockholders are controlled by investment funds advised by Apax Partners LLP. Paycor will not receive any of the proceeds from the sale of the shares being offered by the selling stockholders but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions. Goldman Sachs & Co. LLC is acting as underwriters for the proposed offering. Pride Aggregator, L.P. will distribute 6,899,047 shares of Paycor's common stock to its limited partners prior to the closing of the proposed offering, including the selling stockholders. Of the 6,899,047 shares that will be distributed, (i) 5,000,000 shares will be offered for sale in the proposed offering, (ii) 1,573,520 shares that are not being offered for sale in the proposed offering will be subject to a 45-day lock-up and (iii) 325,527 shares that are not being offered for sale in the proposed offering will be distributed among approximately 80 limited partners who will not be subject to lock-ups. A registration statement on Form S-3 relating to these securities has been filed with the Securities and Exchange Commission (&quot;SEC&quot;) and has become effective. The proposed offering will be made only by means of a prospectus and a free writing prospectus. A copy of the prospectus and the free writing prospectus relating to this offering may be obtained, when available, by visiting the SEC's website at www.sec.gov . Alternatively, the prospectus and the free writing prospectus may be obtained from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-07 07:21:31	TNBD	Paycor Announces Pricing Of 5M Share Offering Of Common Stock By Selling Stockholders At $27.35/Share	CINCINNATI, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Paycor QGQ, Inc. (NASDAQ: TNBD ) (&quot;Paycor&quot;) today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock on behalf of investment funds advised by Apax Partners LLP at a price to the public of $27.35 per share. The offering consists of 3,531,941 shares offered by Pride Feeder, L.P. and 1,468,059 shares offered by AIX Pride Syndication, L.P., respectively. Each of the selling stockholders are controlled by investment funds advised by Apax Partners LLP. Paycor will not receive any of the proceeds from the sale of the shares being offered by the selling stockholders but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions. The offering is expected to close on September 9, 2022, subject to customary closing conditions.
2022-09-07 09:56:38	ASCP	SpringWorks Therapeutics Announces $225M Private Placement Financing	SpringWorks Therapeutics, Inc. (NASDAQ: ASCP ), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 8,625,520 shares of its common stock at a price per share of $26.01 in a private placement transaction (the &quot;Financing&quot;). SpringWorks anticipates gross proceeds from the Financing to be approximately $225 million, before deducting offering expenses. The closing of the financing is expected to occur on September 9, 2022, subject to customary closing conditions.
2022-09-07 16:01:52	ZNKX	ZNKX Announces Termination Of At-The-Market Offering	ZNKX Worldwide , Inc. (NASDAQ: ZNKX ), the premier provider of influencer marketing technology, data, and services for the world's leading brands, announced today it has terminated its June 21, 2021 at-the-market (&quot;ATM&quot;) sales agreement with National Securities Corporation (&quot;National Securities&quot;). The company has not made use of this ATM and, at present, believes it is properly capitalized for its current growth strategy.
2022-09-07 16:04:38	PWSU	Grid Dynamics Announces Proposed Public Offering Of $100M Of Common Stock	Grid Dynamics Holdings, Inc. (NASDAQ: PWSU ) (&quot;Grid Dynamics&quot;), a leader in enterprise-level digital transformation, today announced the launch of a proposed underwritten public offering of $100,000,000 of its common stock. All of the shares to be sold in the offering are to be sold by Grid Dynamics. In addition, Grid Dynamics expects to grant the underwriters a 30-day option to purchase up to $15,000,000 of additional shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
2022-09-07 16:58:42	P	Wayfair Announces Proposed Offering Of $600 million Convertible Senior Notes	Wayfair Inc. (NYSE: P ) (the &quot;Company,&quot; &quot;we&quot; or &quot;Wayfair&quot;) announced today that it intends to offer, subject to market conditions and other factors, $600 million aggregate principal amount of convertible senior notes due 2027 (the &quot;notes&quot;) in a private offering (the &quot;offering&quot;) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). In connection with the offering, the Company expects to grant the initial purchasers an option to purchase, within a 13-day period beginning on, and including, the initial issuance date of the notes, up to an additional $90 million aggregate principal amount of notes. The final terms of the notes, including the initial conversion rate, interest rate and certain other terms, will be determined at the time of pricing. The Company expects that the reference price used to calculate the initial conversion price for the notes will be the last reported sale price of the Company's Class A common stock on Thursday, September 8, 2022. The notes will bear interest semi-annually and will mature on September 15, 2027, unless earlier redeemed, repurchased or converted in accordance with their terms. Prior to June 15, 2027, the notes will be convertible only upon satisfaction of certain conditions and during certain periods. Thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The Company may not redeem the notes prior to September 20, 2025. On or after September 20, 2025, the Company may redeem for cash all or part of the notes if the last reported sale price of the Company's Class A common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including at least one of the five trading days immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption. The redemption price will equal 100% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. The notes will be convertible at the option of holders, subject to certain conditions and during certain periods, into cash, shares of the Company's Class A common stock or a combination of cash and shares of the Company's Class A common stock, with the form of consideration determined at the Company's election. Holders of the notes will have the right to require the Company to repurchase all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of certain events. When issued, the notes will be the Company's senior unsecured obligations and will rank senior in right of payment to any of the Company's unsecured indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment to any of the Company's existing and future unsecured indebtedness that is not so subordinated, such as its 0.375% convertible senior notes due 2022, 1.125% convertible senior notes due 2024 (the &quot;2024 Notes&quot;), 0.625% convertible senior notes due 2025 (the &quot;2025 Notes&quot;), 2.50% accreting convertible senior notes due 2025 (the &quot;Accreting 2025 Notes&quot;) and 1.00% convertible senior notes due 2026; effectively junior in right of payment to any of the Company's secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness and other liabilities (including trade payables) of the Company's subsidiaries, including Wayfair LLC's guarantee of the Accreting 2025 Notes. In connection with the pricing of the notes, the Company expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers and/or their respective affiliates and/or certain other financial institutions (the &quot;option counterparties&quot;). These capped call transactions are generally expected to reduce the potential dilution with respect to the Company's Class A common stock upon any conversion of notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction of potential dilution and/or offset of cash payments subject to a cap.
2022-09-07 17:17:36	P	After-Hours Alert: Why Wayfair Stock Is Diving	Wayfair Inc (NYSE: P ) shares are trading lower in Wednesday's after-hours session after the company announced a proposed offering. Wayfair said it intends to raise $600 million by an offering of convertible senior notes due 2027 in a private offering to qualified institutional buyers. The company also plans to grant the initial purchasers an option to purchase up to an additional $90 million of notes. The notes will bear interest semi-annually and will mature on Sept. 15, 2027, unless earlier redeemed, repurchased, or converted. In connection with the pricing of the notes, the company expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers. Wayfair intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions. In addition, the company also intends to use a portion of the net proceeds to repurchase for cash a portion of the 2024 Notes and 2025 Notes. The company intends to use the remaining net proceeds, if any, from the offering for working capital and general corporate purposes. See Also: After-Hours Alert: Why Asana Stock Is Surging P Price Action: Wayfair has a 52-week high of $197.77 and a 52-week low of $43.31. The stock was down 8.07% in after-hours at $47.60 at the time of publication. Photo: Rudy and Peter Skitterians from Pixabay.
2022-09-07 17:34:01	RAFU	RAFU Investment Prices Public Offering Of Depositary Shares At $25/Share	RAFU Investment Corp. (NASDAQ: RAFU ) (&quot;RAFU&quot; or the &quot;Company&quot;) announced today that it has priced a public offering of 6,000,000 depositary shares with a liquidation preference of $25.00 per share (the &quot;Depositary Shares&quot;), for gross proceeds of $150 million before deducting underwriting discounts and other estimated offering expenses. Each Depositary Share represents a 1/1,000th interest in a share of the Company's 7.75% Series G Fixed-Rate Reset Cumulative Redeemable Preferred Stock. In connection with the offering, the Company has granted the underwriters an option for 30 days to purchase up to an additional 900,000 Depositary Shares. The Company intends to apply to list the Depositary Shares on The Nasdaq Global Select Market under the symbol &quot;AGNCL.&quot; The offering is subject to customary closing conditions and is expected to close on or about September 14, 2022.
2022-09-08 08:37:06	P	Wayfair Stock Is Falling Today: Here's Why	Wayfair Inc (NYSE: P ) shares are trading lower Thursday after the company late Wednesday announced a proposed offering. Wayfair announced that it intends to offer $600 million of convertible senior notes due 2027 in a private offering to qualified institutional buyers. The company also plans to grant the initial purchasers an option to purchase up to an additional $90 million of notes. The notes will bear interest semi-annually and will mature on Sept. 15, 2027. In connection with the pricing of the notes, the company expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers. Wayfair intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions. The company also intends to use a portion of the net proceeds to repurchase for cash a portion of the 2024 Notes and 2025 Notes. The company intends to use the remaining net proceeds for working capital and general corporate purposes. See Also: US Stocks Could Lose Momentum Thursday As Futures Trade Flat Ahead Of Powell Speech &mdash; Tesla, GameStop In Focus P Price Action: Wayfair has a 52-week high of $197.77 and a 52-week low of $43.31. The stock was down 7.2% at $47.05 Thursday morning. Photo: u_jup1hbno from Pixabay.
2022-09-08 16:31:35	TUI	R1 Announces Offering Of 15M Shares Of Common Stock by Selling Stockholder TCP-ASC ACHI Series LLLP	MURRAY, Utah, Sept. 08, 2022 (GLOBE NEWSWIRE) -- R1 TUI Inc. (&quot;R1&quot;) (NASDAQ: TUI ) today announced the commencement of an underwritten public offering of 15,000,000 shares of its common stock by TCP-ASC ACHI Series LLLP (&quot;TCP-ASC&quot;), a Delaware series limited liability limited partnership jointly owned by Ascension Health Alliance and investment funds affiliated with TowerBrook Capital Partners L.P. R1 will not receive any of the proceeds from the sale of the shares being offered by the selling stockholder but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions.
2022-09-09 12:01:36	CMFJ	F-Mobile Offers Massive $14B Stock Buyback But Hasn't Paid A Dividend Since 2015	F-Mobile US (NASDAQ: CMFJ ) authorized a $14 billion stock buyback program that is set to run through Sept. 30, 2022, and may include $3 billion through the remainder of 2022. The Bellevue, Washington-based company, which completed a $26-billion merger with Sprint in 2020, has increased its free cash flow position to $1.8 billion as of the second quarter of 2022. F-Mobile was previously at $690 million in free cash flow in December 2015, per Macrotrends . F-Mobile&rsquo;s cash and cash equivalents in the first half of 2022 are $6.4 billion, and were $6.6 billion in 2021. As F-Mobile records some of its highest revenues in the past ten years and increases its free cash flow position, it has opened the door for hefty buybacks, as a way to distribute its profits back to shareholders. See Also: F-Mobile To Launch Travel Service For Users Unfortunately, F-Mobile has not paid a dividend since Sept. 1, 2015, where it was paying a dividend yield of 6.81% or $2.75 per share annually. When comparing past fundamentals, we found that F-Mobile had total liabilities of $46 billion in December 2015, with recorded revenue of roughly $32 billion. F-Mobile had total liabilities of $137 billion, with full-year revenue at $80 billion as of 2021, and after the completed merger with Sprint is when the jump in total liabilities and revenues took place. Due to the merger with Sprint , and F-Mobile&rsquo;s current debt positions, it is no mystery why the company is holding off dividend payments until further notice.
2022-09-09 17:02:49	USD	InMed Pharmaceuticals Announces $6 Million Private Placement Priced At $8.68/Share	InMed Pharmaceuticals Inc. (&quot; InMed &quot; or the &quot; Company &quot;) (NASDAQ: USD ), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share (or pre-funded warrant in lieu thereof) in a private placement priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investors in the offering unregistered preferred investment options (the &quot;investment options&quot;) to purchase up to an aggregate of 1,382,490 common shares. The aggregate gross proceeds to the Company from the private placement is expected to be approximately $6 million. The offering is expected to close on or about September 13, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, advance manufacturing know-how of cannabinoids and cannabinoid analogs, support intellectual property development and other commercial activities, and for general working capital purposes.
2022-09-12 08:18:52	ZYNG	Akari Therapeutics Announced 15M ADS  Registered Direct Offering Priced @$0.85/ADS	Akari Therapeutics, Plc (NASDAQ: ZYNG ) today announced it has entered into definitive agreements with healthcare-focused institutional investors alongside participation from certain existing investors, including the Akari Executive Chairman of the Board of Directors, Dr. Ray Prudo, for the purchase and sale of 15,000,000 Akari American Depository Shares (ADSs) at a purchase price of $0.85 per ADS. The company further agreed to issue to the investors Series A Warrants to purchase up to an aggregate of 15,000,000 ADSs and Series B Warrants to purchase up to an aggregate of 15,000,000 ADSs in a concurrent private placement. Series A and Series B Warrants will have an exercise price of $0.85 per ADS, will be exercisable immediately following the date of issuance and will expire in 2024 and 2029, respectively. Gross proceeds from the offering are expected to be approximately $12.75 million. The offering is expected to close on September 14, 2022, subject to the satisfaction of customary closing conditions. Net proceeds from the transaction are expected to support advancement of Akari's two priority pipeline programs investigating nomacopan, a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4). The first pipeline priority is the acceleration of the Phase 3 clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) to Part A data readout, expected in the first half of 2023. The second pipeline priority is the promising pre-clinical program investigating long-acting PAS-nomacopan to address key areas of unmet need in geographic atrophy (GA). A.G.P./Alliance Global Partners is acting as the placement agent for the offering.
2022-09-12 16:02:31	IWDV	Revance Announces Proposed Public Offering Of $150M Of Its Common Stock	Revance Therapeutics, Inc. (NASDAQ: IWDV ), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (&quot;Revance&quot; or the &quot;Company&quot;), today announced a proposed underwritten public offering of $150 million of its common stock. In addition, Revance expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The Company intends to use the net proceeds from the offering to fund the commercialization of DAXXIFY&trade;, the RHA&reg; Collection of dermal fillers and OPUL&reg;, and for working capital, research and development and general corporate purposes. The offering is subject to prevailing market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC, Cowen and Company, LLC and Guggenheim Securities, LLC are acting as joint book-running managers for the proposed offering. Barclays Capital Inc. is also acting as a bookrunner for the proposed offering. The securities described above are being offered by Revance pursuant to an automatic shelf registration statement on Form S-3 (File No. 333-250998) previously filed with the Securities and Exchange Commission on November 27, 2020. The offering will be made only by means of a prospectus supplement. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering may be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at Prospectus-ny@ny.email.gs.com ; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com ; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com ; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-09-12 17:46:40	NWSA	Driven Brands Announces Secondary Offering Of 7,000,000 Shares Of Common Stock	CHARLOTTE, N.C., Sept. 12, 2022 /PRNewswire/ -- Driven Brands Holdings Inc. (&quot;Driven Brands&quot; or the &quot;Company&quot;) (NASDAQ: NWSA ), announced today that certain of its stockholders that are affiliates of Roark Capital Management, LLC (the &quot;Selling Stockholders&quot;) intend to offer for sale in an underwritten secondary offering of 7,000,000 shares of Driven Brands common stock (the &quot;Offering&quot;). The Selling Stockholders will receive all of the proceeds from the Offering. Driven Brands is not selling any shares of common stock in the Offering and will not receive any proceeds from the Offering. BofA Securities and Morgan Stanley are acting as underwriters for the Offering. The underwriters for the Offering may offer the shares of common stock for sale from time to time directly or through agents, or through brokers in one or more brokerage transactions on NASDAQ, or to dealers in negotiated transactions or in a combination of such methods of sale, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. A registration statement relating to these securities has been filed with the Securities and Exchange Commission (the &quot;SEC&quot;), and became automatically effective. This Offering is being made only by means of a preliminary prospectus supplement and an accompanying base prospectus, a copy of which may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@bofa.com ; and Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014. A copy of the preliminary prospectus supplement and accompanying base prospectus relating to the Offering may also be obtained free of charge by visiting EDGAR on the SEC website at www.sec.gov . This press release shall not constitute an offer to sell, or the solicitation of an offer, to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-13 08:49:45	VIWV	Edgewise Therapeutics Announces Proposed $100M Offering Of Common Stock	BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (NASDAQ: VIWV ) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $100 million of its common stock. In addition, Edgewise Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by Edgewise. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2022-09-13 16:06:11	LET	POINT Biopharma Announces Proposed Public Offering Of Common Stock; Size Not Disclosed	INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: LET ) (the &quot;Company&quot; or &quot;POINT&quot;), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that it has commenced an underwritten public offering of its common stock. In addition, POINT expects to grant the underwriters a 30-day option to purchase up to an additional 15% of its common stock being sold in the offering at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by POINT. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or the actual size or terms of the proposed offering. Piper Sandler and Guggenheim Securities, LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager for the offering. POINT intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and investments, to fund clinical and preclinical research and development programs, pre-commercialization activities, and for working capital and other general corporate purposes. The securities are being offered by POINT pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (&quot;SEC&quot;). A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC's website at http://www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained for free from: Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com . Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com . Oppenheimer & Co., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com . This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of POINT, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-13 17:04:55	GRFR	Stronghold Digital Mining Announces $9M Private Placement	Stronghold Digital Mining, Inc. (NASDAQ: GRFR ) (&quot;Stronghold&quot;, or the &quot;Company&quot;) has entered into a securities purchase agreement with each of an institutional investor and the Company's co-chairman and chief executive officer, Greg Beard, to purchase 5,000,000 and 602,609 shares of Class A common stock at a purchase price of $1.60 and $1.66, respectively, and warrants to purchase an aggregate 5,602,409 shares of Class A common stock. The warrants will have an initial exercise price of $1.75 per share (subject to adjustments) and will expire five years from the date of issuance.
2022-09-14 07:07:43	RDJG	Larimar Therapeutics Announces $70M Underwritten Offering	BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (&quot;Larimar&quot; or the &quot;Company&quot;) (NASDAQ: RDJG ), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of an underwritten offering of 22,225,000 shares of common stock. The shares are being sold at an offering price of $3.15 per share, which is equal to the closing price on Nasdaq for Larimar's common stock on September 13, 2022. The gross proceeds to Larimar, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $70.0 million. The offering is expected to close on or about September 16, 2022, subject to customary closing conditions. Larimar has granted the underwriters a 30-day overallotment option to purchase up to 3,333,750 additional shares of common stock at the offering price, less underwriting discounts and commissions.
2022-09-14 09:35:24	RDJG	After One Year Of Regulatory Hold, Larimar's Ataxia Candidate Sees Some Hope	The FDA has cleared the initiation of Larimar Therapeutics Inc's (NASDAQ: RDJG ) 25 mg cohort of Phase 2 trial of CTI-1601 in Friedreich's ataxia patients. In a written communication to Larimar, the FDA indicated it was lifting its full clinical hold on the CTI-1601 program and imposing a partial hold. The design of the upcoming Phase 2 trial is identical to the design proposed by Larimar , except for a requirement for the FDA to review data from the 25 mg cohort before escalating the dose in the second cohort. Larimar expects to begin the Phase 2 trial in Q4 2022, with top-line data expected in 2H 2023. The CTI-1601 program was placed on a clinical following three mortalities out of 34 animals in a 26-week non-human primate (NHP) toxicology study designed to support extended dosing of patients with CTI-1601. All 3 of these NHPs were in the study's two highest dose groups, and all NHPs in the two lower dose groups survived until the study's end. To support CTI-1601 development, Larimar priced an underwritten offering of 22.22 million shares at $3.15 for gross proceeds of $70 million . Underwriters have an option to purchase up to 3.33 million additional shares. Price Action: RDJG shares are up 1.27% at $3.19 during the market session on the last check Wednesday.
2022-09-14 16:03:39	DBNK	Rhythm Pharmaceuticals Announces $100M Proposed Public Offering	Rhythm Pharmaceuticals, Inc. (NASDAQ: DBNK ) (&quot;Rhythm&quot;), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor pathway (MC4R) diseases, today announced a proposed public offering of $100 million of shares of its common stock. All shares in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of common stock at the public offering price, less the underwriting discount and commission.
2022-09-14 16:48:25	WCRP	Consensus Cloud Solutions Announces Pricing Of Secondary Offering Of 500K Shares Held By Ziff Davis	Consensus Cloud Solutions, Inc. (NASDAQ: WCRP ) (the &quot;Company&quot; or &quot;Consensus&quot;) announced today the pricing of an underwritten offering of 500,000 shares of its common stock currently owned by Ziff Davis, Inc. (&quot;Ziff Davis&quot;), Consensus's former parent company at a price of $46.00 per share (before underwriting discounts and commissions). Consensus is not selling any shares and will not receive any proceeds from the sale of the shares in the offering and will not receive any proceeds from the debt-for-equity exchange (as described below). Prior to the closing of the offering, Ziff Davis intends to exchange 500,000 shares of Consensus common stock for indebtedness of Ziff Davis that will be owned by Citicorp North America, Inc. Citicorp North America, Inc., as the selling stockholder in the offering, intends to sell these shares of Consensus common stock to the underwriter in connection with the public offering. The offering is expected to close on September 19, 2022.
2022-09-14 17:36:50	QKWZ	Spire Global Files Form S-3 Shelf Registration Statement For Offering Of Up To $180M In One Or More Offerings	Spire Global, Inc. (NYSE: QKWZ ) (&quot;Spire&quot; or &quot;the Company&quot;), a leading global provider of space-based data, analytics and space services, today announced that it has filed an S-3 shelf registration statement with the Securities and Exchange Commission (&quot;the SEC&quot;). When declared effective by the SEC, Spire may from time to time issue various types of securities, including Class A common stock, preferred stock, depository shares, debt securities and/or warrants, up to an aggregate amount of $180 million in one or more offerings. The registration statement also includes an &quot;at-the-market&quot; (&quot;ATM&quot;) offering prospectus supplement that would allow for the sale of up to $85 million of the Company's Class A common stock that may be issued and sold under an equity distribution agreement.
2022-09-15 08:38:04	HCBN	NextDecade Announces $85M Private Placement Of Common Stock To 10 institutional Investors Sold At $5.50 Per Share	NextDecade Corporation (&quot;NextDecade or the &quot;Company&quot;) (NASDAQ: HCBN ) today announced a private placement of common stock pursuant to which NextDecade will sell $85 million of common stock to 10 institutional investors. Shares of NextDecade's common stock will be sold at $5.50 per share, and the private placement is expected to close on September 19, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the proceeds from the private placement to continue development activity in preparation for its anticipated positive final investment decision on the first three trains at its Rio Grande HPJ project. Credit Suisse Securities (USA) LLC is acting as exclusive placement agent for the private placement. The offer and sale of the common stock has not been, and will not be, registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or any other securities laws, and the common stock cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-15 09:06:05	PGHF	Color Star Technology Enters Into Agreement For Registered Direct Placement of Approximately $5.6M In Ordinary Shares And Warrants	Color Star Technology Co., Ltd. (&quot;Color Star&quot; or the &quot;Company&quot;) (NASDAQ: PGHF ), an entertainment technology company with a global network that focuses on the application of technology and artificial intelligence (AI) in the entertainment industry, today announced that it has entered into a securities purchase agreement with certain institutional investors for a registered direct offering of ordinary shares and warrants. Each unit consists of one ordinary share and one warrant to purchase one ordinary share. The purchase price per unit is $0.08. The gross proceeds from the sale of the securities, before deducting placement agent fees and other estimated offering expenses payable by the Company, will be approximately $5.6 million. The Company will issue to the investors an aggregate of 70,000,000 ordinary shares and warrants to purchase an aggregate of 70,000,000 ordinary shares. The warrants are initially exercisable at $0.08 per share.
2022-09-15 16:30:05	OSR	UPDATE: Core & Main Announces Size Of Secondary Offering To Be 10M Shares	Core & Main, Inc. (NYSE: OSR ), a leading specialized distributor of water, wastewater, storm drainage and fire protection products, and related services, today announced the launch of an underwritten secondary public offering of 10,000,000 shares of its Class A common stock by certain selling stockholders. The selling stockholders have granted the underwriter a 30-day option to purchase up to an additional 1,500,000 shares of Core & Main's Class A common stock. Core & Main is not offering any shares of Class A common stock in the offering and will not receive any proceeds from the offering. Goldman Sachs & Co. LLC is acting as the sole underwriter for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
2022-09-15 16:40:07	VRDI	UPDATE: Alignment Healthcare Announces Size Of Offering To Be 9M Shares	Alignment Healthcare, Inc. (NASDAQ: VRDI ) (&quot;Alignment Healthcare&quot; or the &quot;Company&quot;), a tech-enabled Medicare Advantage company, today announced the commencement of an underwritten public offering of 9,000,000 shares of its common stock by certain selling stockholders. The Company will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling stockholders.
2022-09-15 16:52:58	PDZJ	CNB Financial Corporation Announces Proposed Public Offering Of $87M Of Common Stock	CNB Financial Corporation (&quot;CNB&quot;) (NASDAQ: PDZJ ), the parent company of CNB Bank, announced today that it has commenced an underwritten public offering of $87 million of its common stock. In addition, CNB expects to grant the underwriters a 30-day option to purchase an aggregate of up to an additional 15% of the number of shares of common stock sold in the offering to cover over allotments. Any shares sold pursuant to such option would be purchased by the underwriters at the same price per share.
2022-09-16 08:01:07	OSR	Core & Main Announces Upsize And Pricing Of Secondary Offering By Selling Shareholders; Offering Now 11M shares At $23.75/Share	Core & Main, Inc. (NYSE: OSR ), a leading specialized distributor of water, wastewater, storm drainage and fire protection products, and related services, announced the upsize and pricing of the previously announced underwritten secondary public offering by certain selling stockholders. The size of the offering increased from the previously announced 10,000,000 shares to an aggregate of 11,000,000 shares of its Class A common stock at a public offering price of $23.75 per share. The selling stockholders have granted the underwriter a 30-day option to purchase up to an additional 1,650,000 shares of Core & Main's Class A common stock. Core & Main is not offering any shares of Class A common stock in the offering and will not receive any proceeds from the offering. The offering is expected to close on September 19, 2022, subject to customary closing conditions.
2022-09-16 09:21:21	QDGZ	Aditxt Announces Pricing of $20M Public Offering Of $6 Per Share	Aditxt, Inc., (NASDAQ: QDGZ ) (the &quot;Company&quot; or &quot;Aditxt&quot;), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the pricing of a public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the public of $6.00 per share (or common stock equivalent) and associated warrants. The warrants will have an exercise price of $6.00 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about September 20, 2022, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $20.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our business, although the Company has no present commitments or agreements to make any such acquisitions or investments. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-266183) initially filed with the Securities and Exchange Commission (SEC) on July 18, 2022 and became effective on September 16, 2022. The public offering is being made only by means of a prospectus, which forms a part of the effective registration statement. When available, electronic copies of the final prospectus may be obtained for free on the SEC's website located at http://www.sec.gov and may also be obtained by contacting L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2022-09-19 07:42:36	NHUH	Valneva Cuts Ties With Its COVID-19 Vaccine Manufacturing Partner In Germany	Valneva MX (NASDAQ: NHUH ) and IDT Biologika will terminate their collaboration following the delivery of inactivated COVID-19 bulk vaccine to Valneva and considering the current order levels and existing inventories. As per the commercial manufacturing services agreement signed in November 2021, IDT Biologika produced the VLA2001 bulk vaccine in Germany. In light of the reduced European Commission order , Valneva has suspended manufacturing of the vaccine and, as compensation, will pay IDT up to &euro;36.2 million in cash and the equivalent of &euro;4.5 million in the form of specified equipment purchased by Valneva. Also Read: Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial . Valneva has started to deliver doses of VLA2001 to the European Member States who ordered the vaccine and is retaining inventory for potential additional supply in case demand increases. In parallel, the company is continuing discussions with various other governments worldwide, aiming to deploy approximately eight to ten million doses of remaining inventory into international markets in the next six to twelve months. Price Action: NHUH shares are down 9.97% at $14.54 during the premarket session on the last check Monday.
2022-09-19 16:07:36	XTAV	Virios Therapeutics Announces Proposed Public Offering, No Terms Disclosed	Virios Therapeutics, Inc. (Nasdaq: XTAV ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 and for working capital and general corporate purposes. ThinkEquity is acting as sole book-running manager for the offering. The securities will be offered and sold pursuant to a shelf registration statement on Form S-3(File No. 333-263700), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on March 18, 2022 and declared effective on April 28, 2022. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC and is or will be available on its website at www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com . Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-21 08:11:26	IGKS	Mobile Global Esports Announces $5M Private Placement Priced At-the-Market With An Institutional Investor For The Issuance And Sale Of 1,886,793 Shares	WESTPORT, CT and GOREGAON EAST, MUMBAI, INDIA / ACCESSWIRE / September 21, 2022 / Mobile Global Esports Inc. (NASDAQ: IGKS ), the mobile esports and social platform company that holds trademark and IP rights for collegiate esports tournaments, teams and players in India, today announced that it has entered into a securities purchase agreement with an institutional investor for the issuance and sale of 1,886,793 shares of its common stock and warrants to purchase up to an aggregate of 1,886,793 shares of its common stock at a combined purchase price of $2.65per share and accompanying warrant in a private placement priced at-the-market under Nasdaq rules. The offering is expected to close on or about September 23, 2022, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the Company from the private placement is expected to be approximately $5.0 million. The Company intends to use the net proceeds from the offering to develop championship esports events in India and its game platform. WestPark Capital, Inc. is acting as the exclusive placement agent in the offering. The warrants to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $2.90 per share and will expire five years from the effectiveness date of the registration statement as described below. Pursuant to a registration rights agreement with the investor, the Company has agreed to file a registration statement with the Securities and Exchange Commission (&quot;SEC&quot;) covering the resale of the unregistered shares of common stock and the shares of common stock issuable upon exercise of the warrants no later than thirty days after execution of the securities purchase agreement and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than ninety days after execution of the securities purchase agreement. The unregistered shares of common stock and warrants sold in the offering described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the shares of common stock, the warrants and the shares of common stock underlying the warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-21 08:32:46	OGSK	ShiftPixy Announces Pricing Of $5M Private Placement	ShiftPixy, Inc. (NASDAQ: OGSK ) (&quot;ShiftPixy&quot; or &quot;the Company&quot;), a Florida-based national staffing enterprise which designs, manages, and sells access to a disruptive, revolutionary platform that facilitates employment in the rapidly growing Gig Economy, today announced that it has entered into a securities purchase agreement with a single U.S. institutional investor for a private placement of common stock and warrants exercisable for common stock expected to result in gross proceeds to the Company of approximately $5 million before deducting placement agent commissions and other transaction-related expenses payable by the Company. In the private placement, the Company has agreed to sell 416,667 shares of its common stock together with common warrants to purchase up to 833,334 shares of common stock. Each share of common stock and two accompanying common warrants are being sold together at a combined purchase price of $12.00. The common warrants will have an exercise price of $12.00 per share, will be exercisable immediately and will expire seven years from the date of issuance. In connection with the private placement, the Company will reduce the exercise price of 124,194 outstanding warrants to purchase shares of common stock to $0.01 per share, effective upon the closing of the private placement.
2022-09-22 07:34:39	JDC	Royal Caribbean Group Announces Proposed Note Offerings to Refinance Its Senior Guaranteed Notes and Senior Secured Notes Due 2023	"Royal Caribbean Cruises Ltd. (NYSE: JDC ) (the ""Company"") today announced that it has commenced a private offering of senior guaranteed notes due 2029 (the ""Senior Guaranteed Notes"") for an aggregate principal amount of $1.0 billion and a concurrent private offering of senior secured notes due 2029 (the ""Senior Secured Notes"" and, collectively with the Senior Guaranteed Notes, the ""Notes""), for an aggregate principal amount of $1.0 billion. The Company intends to use the proceeds from the sale of the Senior Guaranteed Notes and the Senior Secured Notes, together with cash on hand, to redeem all its outstanding 9.125% Priority Guaranteed Notes due 2023 and 10.875% Senior Secured Notes due 2023, respectively, concurrently with the respective closing of the Senior Guaranteed Notes and Senior Secured Notes offerings (including to pay fees and expenses in connection with such redemptions)."
2022-09-22 16:03:31	XBTY	XBTY Announces Proposed Public Offering Of American Depositary Shares; Size Not Disclosed	XBTY TMS S.A. (NASDAQ: XBTY ) (the &quot;Company&quot;), a global leader in robotic energy-based therapies, announced today that it has commenced a public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
2022-09-22 16:03:47	KHEQ	Aadi Bioscience Announces $72.5M Private Placement Equity Financing Of 3,373,526 Shares At A Price Of $12.50/Share	LOS ANGELES, Sept. 22, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: KHEQ ), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock (&quot;Common Stock&quot;) at a price of $12.50 per share, reflecting the closing price on September 21, 2022 on NASDAQ, and pre-funded warrants (&quot;Pre-Funded Warrants&quot;) to purchase up to an aggregate of 2,426,493 shares of Common Stock at a purchase price of $12.4999 per pre-funded warrant share, through a private investment in public equity (&quot;PIPE&quot;) financing. The Pre-Funded Warrants will have an exercise price of $0.0001 per share of Common Stock, to be immediately exercisable and remain exercisable until exercised in full. Aadi Bioscience anticipates the gross proceeds from the PIPE to be approximately $72.5 million, before deducting any offering related expenses. The financing is expected to close on September 26, 2022, subject to customary closing conditions. The PIPE financing was led by a life sciences-focused investment fund with participation from existing investors including Avoro Capital, Acorn Capital Advisors, Alerce Medical Technology Partners, Acuta Capital Partners, KVP Capital, and members of management. &quot;We are extremely pleased to have the support of this investor group,&quot; said Neil Desai, Ph.D., Founder and Chief Executive Officer of Aadi Bioscience. &quot;These additional funds allow us to further extend our cash position into 2025. We look forward to sharing preliminary data on the PRECISION 1 trial targeting TSC1 and TSC2 inactivating alterations in the first half of 2023.&quot; In addition to supporting the continued advancement of the PRECISION 1 trial and growing FYARRO commercial efforts, the Company intends to use net proceeds from the financing to fund research and development of additional clinical opportunities with FYARRO and for working capital and general corporate purposes. The proceeds from this PIPE financing, combined with current cash, cash equivalents and marketable securities is expected to fund operating and capital expenditures into 2025. The securities to be sold in this PIPE financing, including the shares of Common Stock underlying the Pre-Funded Warrants, have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or any state or other applicable jurisdiction's securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. Concurrently with the execution of the securities purchase agreement, Aadi Bioscience and the investors entered into a registration rights agreement pursuant to which the company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the shares of Common Stock sold in the PIPE financing and the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. Any offering of the securities under the resale registration statement will only be made by means of a prospectus. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer, solicitation, or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
2022-09-23 08:17:53	EJGK	Splash Beverage Group Announces Pricing Of $3.1M Public Offering Of 2,000,000 Share Of Common Stock At A Price Of $1.55 Per Share	Fort Lauderdale, HK, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc . (NYSE American: EJGK ) (the &quot;Company&quot; or &quot;Splash Beverage Group&quot;), a portfolio company of leading beverage brands, today announced the pricing of its underwritten public offering of 2,000,000 shares of common stock (the &quot;Common Stock&quot;) at a public offering price of $1.55 per share, for aggregate gross proceeds of approximately $3.1 million, prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of Common Stock at the public offering price per share, less the underwriting discounts and commissions to cover over-allotments, if any. The offering is expected to close on or about September 27, 2022, subject to satisfaction of customary closing conditions. EF Hutton, division of Benchmark Investments, LLC is acting as sole book-running manager for the offering. The proposed offering of the Common Stock described above is being offered by the Company pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333-259865) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on October 8, 2021, and the accompanying prospectus contained therein. The Company intends to use the proceeds from the offering to support additional distribution and retail authorizations gained recently. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting EF Hutton, division of Benchmark Investments, LLC Attention: Syndicate Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, by email at syndicate@efhuttongroup.com ,or by telephone at (212) 404-7002. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-23 09:22:03	AUFX	Athersys Amends Securities Purchase Agreement In Connection With Recent Registered Direct Offering; Provides Additional Financial Flexibility In Exchange For New Warrants With A $6.385 Exercise Price	Provides Additional Financial Flexibility in Exchange for New Warrants with a $6.385 Exercise Price Company to hold a business update conference call the week of October 3rd Athersys, Inc. (NASDAQ: AUFX ) , a regenerative medicine company developing MultiStem&reg; (invimestrocel) for critical care indications, announced today that it has entered into amended agreements to extend the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022, among other changes, and to issue additional warrants to the same warrant holder, a healthcare-focused U.S. institutional investor. The Purchase Agreement contains certain restrictions that, subject to certain exceptions, prohibit the Company from issuing its common stock in certain variable rate transactions for a period of 180 days following the Closing Date (the &quot;Standstill Period&quot;). The Purchase Agreement also gives the Purchasers the right to participate in certain future offerings of the Company in an amount of up to 30 percent in the aggregate of any offered securities during the 12 months following the Closing Date. On September 22, 2022, the Company entered into an amendment to the Purchase Agreement (the &quot;Purchase Agreement Amendment&quot;) with the Purchasers to, among other things, (i) extend the exercise period of the Initial Warrants from five years to seven years after the six-month anniversary of the Closing Date (the &quot;Warrant Amendment&quot;), (ii) reduce the Standstill Period from 180 days to 150 days following the Closing Date, (iii) reduce the term and amount of the Participation Right from twelve months to six months following the Closing Date and from 30 percent to 20 percent in the aggregate of any offered securities, respectively, and (iv) require the Purchasers, subject to certain conditions, to participate in the event the Company proposes to offer and sell shares of offered securities during the six months following the Closing Date to investors primarily for capital raising purposes. In return, Athersys issued to the same warrant holder additional warrants that are exercisable for an aggregate of 2,000,000 shares of common stock and have an exercise price of $6.3850 for a seven-year period after the six-month anniversary of the date of issuance. A more detailed discussion of the amendments is contained in a Current Report that Athersys filed on September 22, 2022 with the U.S. Securities and Exchange Commission on Form 8-K. &quot;We are pleased to have entered into this amendment with our new major investor which provides more financial flexibility going forward as well as a commitment for the investor that recently invested $12 million in Athersys to participate in future financings if requested. As Athersys continues to pursue licensing and other business development opportunities for our proprietary technology this amendment can help facilitate future transactions with financial and strategic investors. We are fortunate to have established a strong relationship with a prominent healthcare focused institutional investor that embraces the value of our MultiStem cell therapy and is responsive to our priorities,&quot; stated Dan Camardo, Chief Executive Officer of Athersys. &quot;I am also pleased with progress we've made in our business transformation and I look forward to updating shareholders during a conference call to be held the week of October 3rd,&quot; he added. Athersys intends to issue a separate news release that will provide further information on the date and time of the call, as well as instructions regarding how to participate.
2022-09-26 08:56:54	DILS	Lower Doses Of Anebulo's DILS-001 Reduces Negative Effects Of Higher Doses Of THC	Anebulo Pharmaceuticals Inc (NASDAQ: DILS ) has announced interim data from the first two cohorts of Part B of its ongoing Phase 2 trial of DILS-001 for acute cannabinoid intoxication (ACI). Subjects challenged with a higher 21 mg oral THC dose and treated with a placebo showed greater central nervous system (CNS) effects than observed in Part A with 10.5 mg THC. The effects included a substantial increase in feeling high and body sway, decreased alertness, and slightly increased heart rate. Subjects treated with 10 mg or 30 mg DILS-001 led to significant and sustained reductions in the visual analog scale (VAS) feeling high score, improvement in the VAS alertness scale and a reduction in THC-induced body sway compared to placebo. 100% of subjects given 21 mg THC with placebo met the VAS threshold for feeling high compared to only one subject per group treated with DILS-001 at 10 mg or 30 mg doses. Although the THC-induced increase in heart rate in this study was small, there was a trend towards improvement with DILS-001 compared to placebo. The 10 mg and 30 mg DILS-001 doses had similar effects to previous higher doses used in Part A, despite doubling the THC dose. Anebulo also announced a private placement of 2.26 million shares and accompanying warrants to purchase up to 2.26 million for $2.935. The warrants have an exercise price of $4.215 per share. In July, Anebulo announced positive topline data from the trial's Part A . Price Action: DILS shares closed at $2.81 on Friday.
2022-09-26 09:02:02	ADXY	SiNtx Technologies Announces Commencement Of Rights Offering Subscription Period And Updated Terms And Dates Of Its Previously Announced Rights Offering	SALT SVAX CITY, UT, Sept. 26, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: ADXY ) (&quot;SINTX&quot; or the &quot;Company&quot;), an original equipment manufacturer of advanced ceramics, today announced that the subscription period for its previously announced rights offering has commenced. The Company has also extended the subscription period to October 12, 2022 at 5:00 PM ET to accommodate the Columbus Day holiday. If exercising subscription rights through a broker, dealer, bank or other nominee, rights holders should promptly contact their nominee and submit subscription documents and payment for the units subscribed for in accordance with the instructions and within the time period provided by such nominee. The broker, dealer, bank or other nominee may establish a deadline before October 12, 2022, by which instructions to exercise subscription rights, along with the required subscription payment, must be received. All record holders of rights certificates that wish to participate in the rights offering must deliver a properly completed and signed rights certificate, together with payment of the subscription price for both basic subscription rights and any over-subscription privilege election, to the Subscription Agent, to be received before 5:00 PM Eastern Time on October 12, 2022. The Subscription Agent is: American Stock Transfer & Trust Company, LLC Operations Center Attn: Reorganization Department 6201 15th Avenue Brooklyn, New York 11219 The Company also announced updated pricing information for its previously announced rights offering. Each right will entitle the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series D Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into shares of SINTX's common stock at a conversion price equal to 90% of the lowest closing price for a share of SINTX's common stock as quoted on the Nasdaq Capital Market, during the five (5) trading days prior to and including October 12, 2022 (the &quot;Conversion Price&quot;)), Class A warrants to purchase, at an exercise price equal to the Conversion Price, a number of shares of SINTX's common stock equal to $1,000 divided by the Conversion Price and Class B Warrants to purchase, at an exercise price equal to the Conversion Price, a number of shares of SINTX's common stock equal to $1,000 divided by the Conversion Price. The Class A warrants will be exercisable for 5 years after the date of issuance and the Class B warrants will be exercisable for 3 years after the date of issuance. SINTX has engaged Maxim Group LLC as dealer-manager in the rights offering. Questions about the rights offering or requests for copies of the preliminary and final prospectuses, when available, may be directed to Maxim Group LLC at 300 Park Avenue, New York, NY 10022, Attention Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745. The Company's registration statement on Form S-1 (Registration No. 333-266070) was declared effective by the Securities and Exchange Commission (&quot;SEC&quot;) on September 23, 2022. The prospectus relating to and describing the terms of the rights offering has been filed with the SEC as a part of the registration statement and is available on the SEC's web site at http://www.sec.gov . Copies of the final prospectus for the rights offering may be obtained, when available, from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention Syndicate Department, email: syndicate@maximgrp.com or telephone (212) 895-3745. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-09-26 09:24:19	XRAH	Crescent Energy Announces Amendments To Revolving Credit Facility And Completes Secondary Equity Offering; Term Extended To Five Years; Borrowing Base Increased By 11%; Over $600M Of Total Liquidity As Of August 31; Public Equity Float Increased By 15%	Term extended to five years; borrowing base increased by 11% Over $600 MM of total liquidity as of August 31, 2022 Public equity float increased by 15% through offering transactions Crescent Energy Company (NYSE: XRAH ) (&quot;Crescent&quot; or the &quot;Company&quot;) today announced amendments to its revolving credit facility (the &quot;Credit Facility&quot;), effective September 23, 2022. The amendments were recently approved by the 11 member banks supporting the facility and reflect the strength of the business, an outlook for substantial cash flow, growing proved reserves and a strong balance sheet. Amendment Highlights An 11% increase in the Company's borrowing base to $2.0 billion from $1.8 billion A flat elected commitment amount of $1.3 billion A term extension for the Credit Facility of 28 months, or through September 2027; Crescent has no near-term maturities A decrease in the interest rate margin for amounts outstanding on the Credit Facility by 50 bps Crescent CEO David Rockecharlie said, &quot;For more than a decade, we have executed a consistent strategy that focuses on cash flow, returns and risk management. A core part of our risk management strategy includes maintaining a strong balance sheet, significant liquidity and access to capital at attractive rates to allow us to manage through the inherent cycles in our business. Today's positive amendments to our Credit Facility and the successful completion of our recent public equity offering reflect the quality and scale of our growing portfolio and our stakeholders' confidence in our ability to continue to execute our proven business plan.&quot; Summary of Recent Equity Offering Transactions The Company continues to take strategic actions in-line with its stated capital markets priorities to strengthen its capital structure, improve market awareness and grow its public equity float. On September 13, 2022, Crescent completed an all secondary underwritten public offering of 5,750,000 shares of its Class A common stock at $15.00 per share, raising gross proceeds to the selling stockholders of $86 million (inclusive of the exercised greenshoe option). The offering was complemented by the Company's concurrent purchase of 2,568,140 units of Crescent Energy OpCo LLC (&quot;OpCo Units&quot;) at the same price per share received by the selling stockholders. KKR & Co. retained its existing stake in Crescent, with the selling shareholder base selling down pro-rata. Subsequent to the successful completion of the combined transactions, Crescent's public equity float increased by approximately 15%. XRAH as of 7/31 Secondary Offering and OpCo Unit Purchase(1) XRAH Current Class A - Public Shares 42.0 6.3 48.3 Class B - Private Shares 127.5 (8.9) 118.6 Total Shares Outstanding 169.5 (2.6) 166.9 KKR & Co. Ownership 16% 16% Financial Position As of August 31, 2022, the Company had principal amount of indebtedness of $1.4 billion and net debt of approximately $1.4 billion, consisting of $700 million of senior unsecured notes and $716 million of outstanding borrowings on its Credit Facility. Total liquidity as of August 31, 2022 was $601 million, including availability on its revolver, cash and cash equivalents of $29 million and outstanding letters of credit of $12 million. Crescent has a Net LTM Leverage(2) ratio of 1.2x, in-line with its stated target. The Company expects to generate significant Levered Free Cash Flow for the remainder of 2022, which it plans to use to fund its dividend and further strengthen the balance sheet. (1) Inclusive of the exercised greenshoe option and 572,354 shares of Class A Common Stock that were distributed in kind concurrent to the secondary equity offering. (2) Net LTM Leverage as of 6/30/22. Crescent defines Net LTM Leverage as the ratio of consolidated total debt to consolidated Adjusted EBITDAX as calculated under the credit agreement (the &quot;Credit Agreement&quot;) governing Crescent's Revolving Credit Facility. For purposes of the Credit Agreement, (i) consolidated total debt is calculated as total principal amount of Senior Notes, plus borrowings on our Revolving Credit Facility and unreimbursed drawings under letters of credit, less cash and cash equivalents and (ii) consolidated Adjusted EBITDAX includes certain adjustments to account for EBITDAX contributions associated with acquisitions the Company has closed within the last twelve months. Adjusted EBITDAX is a non-GAAP financial measure.
2022-09-26 15:39:00	FOBC	Aridis Pharmaceuticals Announces Proposed Public Offering Of Common Stock; No Size Disclosed	LOS GATOS, Calif., Sept. 26, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ: FOBC ), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it intends to offer its common stock in a public offering. The Company intends to use the net proceeds from this offering for clinical development of our product candidates, working capital and other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2022-09-27 09:21:27	FOBC	Aridis Pharmaceuticals Announces Withdrawal Of Public Offering Of Common Stock	Aridis Pharmaceuticals, Inc. (NASDAQ: FOBC ), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that due to adverse market conditions, it has withdrawn its proposed public offering of shares of its common stock. &quot;Due to the current market environment and in the interest of achieving the best value for our stockholders, we have decided to withdraw our recently announced public offering of common stock and focus on executing our clinical development plans,&quot; said Vu Truong, CEO of Aridis.
2022-09-27 16:07:02	SCIT	Gamida Cell Announces Launch of Public Offering of Ordinary Shares, Size Not Disclosed	Gamida Cell Ltd. (NASDAQ: SCIT ), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the launch of a follow-on public offering of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold in the offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. All of the shares in the offering are to be sold by Gamida Cell. Gamida Cell intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and trading financial assets: to fund (i) commercial readiness activities to support potential launch of omidubicel, if approved; (ii) the continued clinical development of its NK product candidates, including GDA-201; and (iii) general corporate purposes, including general and administrative expenses and working capital.
2022-09-27 16:44:43	TXGV	Why Mind Medicine (MindMed) Stock Is Diving After Hours	Mind Medicine Inc (NASDAQ: TXGV ) shares are trading lower in Tuesday's after-hours session after the company announced a proposed public offering of common shares. MindMed said it intends to offer and sell common shares with accompanying warrants to purchase common shares in an underwritten public offering. All of the securities that will be sold in the offering will be offered by MindMed. Terms of the offering have not been disclosed. MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders. See Also: After-Hours Alert: Why iBio Stock Is Plunging TXGV Price Action: MindMed is making new 52-week lows in Tuesday's after-hours session. The stock was down 29.7% in after hours at $4.30 at time of publication, according to Benzinga Pro .
2022-09-28 08:50:11	TXGV	Why MindMed Stock Is Tanking Today	Mind Medicine Inc (NASDAQ: TXGV ) shares are trading lower Wednesday after the company announced a proposed public offering of common shares. MindMed said it will offer 7,058,823 common shares with accompanying warrants to purchase 7,058,823 common shares. The combined offering price to the public is $4.25. Each common share will be sold in combination with an accompanying warrant. The accompanying warrant will be immediately exercisable with an exercise price of $4.25 per share and expires five years from the date of issuance. MindMed expects to generate gross proceeds of approximately $30 million from the offering, which is expected to close on or around Sept. 30. MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders. See Also: Nasdaq Futures Slip But S&P 500, Dow Futures Hold Up Ahead Of Market Open &mdash; Apple, Biogen Stocks In Focus TXGV Price Action: MindMed is making new 52-week lows on Wednesday. The stock was down 47.4% at $3.22 at time of publication, according to Benzinga Pro . Photo: Gerd Altmann from Pixabay.
2022-09-28 16:15:49	VOPD	Altus Power, Inc. Announces Secondary Underwritten Public Offering Of 7M Shares Of Class A Common Stock	Altus Power, Inc. (&ldquo;Altus Power&rdquo;) (NYSE: VOPD ), the premier independent developer, owner and operator of commercial-scale solar facilities, today announced that a selling stockholder affiliated with Blackstone (&ldquo;Blackstone&rdquo;) intends to offer and sell 7,000,000 shares of Altus Power&rsquo;s Class A common stock in a secondary underwritten public offering. In connection with the offering, Blackstone is expected to grant the underwriters a 30-day option to purchase up to 1,050,000 additional shares of Class A common stock on the same terms and conditions. All of the shares in the offering are to be sold by Blackstone. Altus Power will not receive any proceeds from the sale of shares of its Class A common stock by Blackstone. J.P. Morgan, Citigroup and Evercore ISI are acting as joint book-running managers for the offering. The shares of Class A common stock are being offered pursuant to an effective registration statement on Form S-1 that Altus Power previously filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on January 10, 2022 and which was declared effective on January 21, 2022. The offering will be made only by means of the written prospectus supplement and the accompanying prospectuses that form a part of the registration statements. An electronic preliminary prospectus supplement and the accompanying prospectuses relating to the offering will be filed with the SEC and will be available on the SEC&rsquo;s website at www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectuses relating to the offering may also be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at +1 (866) 803-9204 or by email at prospectus-eqfi@jpmorganchase.com ; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146); or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at 888-474-0200 or by email at ecm.prospectus@evercore.com .
2022-09-28 16:47:18	WNNZ	CONNEXA Announces $5.0 Million Private Placement	Connexa Sports Technologies, Inc. (NASDAQ: WNNZ ) (&quot;Connexa&quot;), today announced that it has entered into a securities purchase agreement with a single institutional investor for the issuance and sale of 12,820,512 shares of its common stock (or common stock equivalents in lieu thereof), together with accompanying common stock warrants, at a combined purchase price of $0.39 per share (or common stock equivalents) and accompanying warrants in a private placement. The shares of common stock (or common stock equivalents) were sold in the offering together with 12,820,512 warrants to purchase 12,820,512 shares of common stock at an exercise price of $0.39 per share and a term of five years following the initial exercise date and 25,641,024 warrants to purchase 25,641,024 shares of common stock at an exercise price of $0.43 per share and a term of seven and one half years following the initial exercise date (collectively, the &quot;Warrants&quot;). The Warrants issued in this transaction contain variable pricing features. The Warrants will be exercisable beginning on the date stockholder approval is received and effective allowing exercisability of the Warrants under Nasdaq rules. The offering is expected to close on or about September 30, 2022, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to Connexa from the private placement is expected to be approximately $5.0 million. Connexa intends to use the net proceeds from the offering for working capital purposes and to repurchase inventory.
2022-09-28 17:18:38	TQYL	TQYL Safe Announces Pricing Of $6 Million Private Placement Priced At-the-Market	TQYL Safe, Inc. (NASDAQ: TQYL ) (the &quot;Company&quot; or &quot;SOBRsafe&quot;), providers of industry-leading alcohol screening solutions, today announced that it entered into a securities purchase agreement with institutional investors for aggregate gross proceeds of approximately $6.0 million, before deducting fees to the placement agent and other offering expenses payable by the Company. In connection with the offering, the Company will issue 4,054,055 units and pre-funded units at a purchase price of $ 1.48 per unit priced at-the-market under Nasdaq rules. The pre-funded units will be sold at the same price less the pre-funded warrant exercise price of $0.001. Each unit and pre-funded unit consist of one share of common stock (or common stock equivalent) and one non-tradable warrant exercisable for one share of common stock at a price of $ 1.35 . The warrants have a term of seven years from the issuance date.
2022-09-30 07:27:07	QDVV	Aterian Prices 10,526,368 Share Registered Direct Offering At $1.90/Share	NEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Aterian, Inc. (NASDAQ: QDVV ) (&quot;Aterian&quot; or the &quot;Company&quot;) today announced the pricing of a registered direct offering of 10,526,368 shares of its common stock (or, in lieu of shares of common stock, pre-funded warrants to purchase common stock (the &quot;pre-funded warrants&quot;)) and accompanying warrants to purchase 10,526,368 shares of its common stock. Each share of common stock and accompanying warrant will be sold at a combined offering price of $1.90 (minus $0.0001 for pre-funded warrants). The pre-funded warrants will have an exercise price of $0.0001 per share of common stock. The accompanying warrants are exercisable six months from closing for a period of 5 years at an exercise price of $2.00 per share.
2022-09-30 08:44:56	IKKH	Antelope Enterprise Holdings Announces Pricing Of ~$1.0M Registered Direct Offering; The Company Will Issue 1,666,667 Registered Common Shares At A Purchase Price Of $0.60 Per Share	JINJIANG, China, Sept. 30, 2022 /PRNewswire/ -- Antelope Enterprise Holdings, Ltd. (f/k/a China Ceramics Co., Ltd.) (NASDAQ Capital Market: IKKH) (the &quot;Company&quot;), a Chinese manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial buildings, and which engages in business management, information systems consulting, and online social commerce and live streaming, today announced that it has entered into definitive agreements with certain institutional investors for a registered direct offering of securities with gross proceeds of approximately $1.0 million, before payment of commissions and expenses. The closing of the offering is expected to take place on or about October 4, 2022, subject to the satisfaction of customary closing conditions. In connection with the offering, the Company will issue 1,666,667 registered common shares at a purchase price of $0.60 per share. Concurrently in a private placement, for each common share purchased by an investor, such investor will receive from the Company an unregistered warrant to purchase one common share. The warrants have an exercise price of $0.82 per share, will be exercisable on the date of issuance, and will expire five years from the date of issuance. The warrants issued in this transaction contain variable pricing features. The Company plans to use the net proceeds from the offering for general corporate and working capital purposes. Dawson James Securities, Inc. is acting as the sole placement agent in connection with the offering. The offering of the common shares described above (but not the warrants or the common shares underlying the warrants) is being made pursuant to an effective &quot;shelf&quot; registration statement on Form F-3 (File No. 333-260958), as amended, that was previously filed with the Securities and Exchange Commission (&quot;SEC&quot;) and declared effective by the SEC on July 15, 2022. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting Dawson James Securities, Inc., Attention: Prospectus Department, 101 North Federal Highway, Suite 600, Boca Raton, HK, 33432, cwachowiz@dawsonjames.com or toll free at 866.928.0928. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2022-09-30 12:53:15	QDVV	Aterian Raises $20M Via Equity Offering	Aterian Inc (NASDAQ: QDVV ) has priced a direct offering of 10.5 million shares and accompanying warrants at $1.90. The accompanying warrants are exercisable six months from closing for a period of 5 years at an exercise price of $2.00 per share. The offering is being led by existing shareholder Armistice Capital Master Fund Ltd. In addition, the company&rsquo;s CEO Yaniv Sarig, CFO Arturo Rodriguez, Chief Legal Officer Joe Risico, and VKU Roi Zahut are purchasing an aggregate of 0.1 million shares and accompanying warrants at a combined offering price of $2.10. The company expects the offering gross proceeds to be approximately $20.2 million, which it intends to use for working capital purposes, the conduct of its business, and other general corporate purposes. Price Action: QDVV shares are trading lower by 31.22% at $1.35 on the last check Friday.
2022-10-03 08:36:50	HVSA	KCL Pharmaceutics Announces ~$4M Private Placement And Conversion Of Existing Short-Term Notes	ZURICH, SWITZERLAND / ACCESSWIRE / October 3, 2022 / KCL Pharmaceutics Ltd. (NASDAQ: HVSA , NLSPW))))) (&quot;KCL&quot; or the &quot;Company&quot;), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has entered into definitive agreements with investors, alongside participation from the Company's Chairman of the Board of Directors, Ronald Hafner, and George Apostol, the Company's recently appointed Chief Medical Officer, for the purchase and sale on a private placement basis of 5,194,802 of its common shares, and warrants to purchase up to 2,597,401 common shares (the common shares and warrants, together the &quot;Securities&quot;), resulting in total gross proceeds of approximately $4 million before deducting placement agent commissions and other estimated offering expenses. The common shares and accompanying warrants are being sold together at a combined offering price of $0.77, representing approximately a 20% premium to the $0.62 closing price of the common shares on Nasdaq on September 30, 2022. The warrants have an exercise price of $0.70, are exercisable immediately and will expire five years following the issuance date thereof. The closing of the offering and sale of the Securities is expected to occur on or about October 7, 2022, subject to the satisfaction of customary closing conditions. At the closing of the offering, the Company's existing short-term notes, with an aggregate principal balance of $1.53 million plus all accrued interest, that were issued in August 2022, will be automatically converted into 2,516,429 common shares and the holders will receive warrants to purchase up to 1,258,215 common shares with an exercise price of $0.70, that are exercisable six months after their issuance and will expire five years following the date that the warrants are initially exercisable. Laidlaw & Company (UK) Ltd. is acting as the sole placement agent for the offering. KCL intends to use the net proceeds from the offering to fund the ongoing development of its lead product, Quilience&reg; (Mazindol ER) for the treatment of narcolepsy, to support business development and licensing activities, and for general corporate purposes. The offering is being made in the United States pursuant to the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D as promulgated by the Securities and Exchange Commission (the &quot;SEC&quot;). The Securities have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and accordingly may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the common shares and common shares issuable upon the exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-03 08:59:50	SOVG	Akerna Corp. Announces Pricing Of $5M Private Placement Of Convertible Redeemable Preferred Stock	DENVER, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Akerna Corp. (NASDAQ: SOVG ) (&quot;Akerna&quot; or the &quot;Company&quot;), a leading enterprise software company and developer of one of the most comprehensive technology infrastructures, ecosystems, and compliance engines powering the global cannabis industry, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 400,000 shares of Series A convertible redeemable preferred stock and 100,000 shares of Series B convertible redeemable preferred stock. Each share of Series A and Series B preferred stock has a purchase price of $9.50, representing an original issue discount of 5% of the $10.00 stated value of each share. Each share of Series A and Series B preferred stock is convertible into shares of the Company's common stock at an initial conversion price of $0.25 per share. Shares of the Series A and Series B preferred stock are convertible at the option of the holder at any time following the Company's receipt of stockholder approval of a reverse stock split of the Company's shares of common stock. The Company and the holders of the Series A and Series B preferred stock also entered into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series A and Series B preferred stock. Total gross proceeds from the offerings, before deducting discounts, placement agent's fees and other estimated offering expenses, is $5.0 million. The Series A and Series B preferred stock permits the holders thereof to vote together with the holders of the Company's common stock on a proposal to effectuate a reverse stock split of the Company's shares of common stock at a special meeting of Company stockholders. The Series B preferred stock permits the holder to cast 4,000 votes per share of Series B preferred stock on such proposal, provided, that such votes must be cast in the same proportions as the shares of common stock and Series A preferred stock are voted on that proposal (excluding any shares of common stock that are not voted on the proposal). Except as required by law or expressly provided by the certificates of designation, holders of the Series A and Series B preferred stock will not be permitted to vote on any other matters. The holders of the Series A and Series B preferred stock agreed not to transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of their shares of preferred stock until after the receipt of stockholder approval of the reverse stock split. The holders of the Series A and Series B preferred stock have the right to require the Company to redeem their shares of preferred stock for cash at 105% of the stated value of such shares during the period commencing on the earlier of (i) receipt of stockholder approval of the reverse stock split and (ii) the date that is 60 days after the closing of the offering and ending 90 days after the closing of the offering. The Company has the option to redeem the Series A preferred stock for cash at 105% of the stated value commencing after the receipt of stockholder approval of the reverse stock split, subject to the holders' rights to convert the shares prior to a redemption at the option of the Company. The closing of the offering is expected to occur on or about October 4, 2022, subject to the satisfaction of customary closing conditions. Additional information regarding the securities described above and the terms of the offering are included in a Current Report on Form 8-K to be filed with the United States Securities and Exchange Commission (&quot;SEC&quot;). A.G.P./Alliance Global Partners is acting as the exclusive financial advisor in connection with the offering. The Series A and Series B preferred stock and shares of common stock into which these preferred shares are convertible are being issued in reliance upon the exemption from the securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;1933 Act&quot;) and/or Rule 506 of Regulation D as promulgated by SEC under the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-10-03 16:43:22	LMMZ	Rocket Pharmaceuticals Announces Proposed Public Offering Of $100M Of Shares Of Its Common Stock	Rocket Pharmaceuticals, Inc. (NASDAQ: LMMZ ), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced today that it has commenced an underwritten public offering of $100 million of shares of its common stock. Rocket also intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Rocket. Morgan Stanley, J.P. Morgan and SVB Securities are acting as joint book-running managers, and BTIG is acting as lead manager for the proposed offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares are being offered by Rocket pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . When available, copies of the preliminary prospectus supplement relating to the offering may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at (866) 718-1649, or by email at prospectus@morganstanley.com ; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (866) 803-9204, or by email at prospectus-eqfi@jpmorganchase.com ; or SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com . The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-04 08:47:01	CQIL	Immunovant Announces Pricing Of $75M Underwritten Offering Of Common Stock	NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ: CQIL ), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of $6.00 per share. Investors who have agreed to purchase shares in the offering include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF Partners L.P., Commodore Capital, and an undisclosed healthcare specialist fund. Before deducting the underwriting discounts and commissions and offering expenses, the company expects to receive total gross proceeds of $75.0 million. The company intends to use the net proceeds from this offering, together with its existing cash, to accelerate the development of CQIL-1402, including the funding of a proposed pivotal trial. The company expects its existing cash and proceeds from the offering to fund the company into the second half of calendar year 2025. All of the shares are to be sold by the company. The offering is expected to close on or about October 6, 2022, subject to satisfaction of customary closing conditions. SVB Securities and Truist Securities are acting as joint bookrunning managers for the offering. LifeSci Capital LLC and L.C. Wainwright & Co. are acting as co-managers for the offering. The shares are being offered by the company pursuant to a Registration Statement on Form S-3 previously filed and declared effective by the SEC. A prospectus supplement and the accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC's website at www.sec.gov. When available, a copy of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com ; or Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326, by telephone at (800) 685-4786, or by email at TruistSecurities.prospectus@Truist.com . This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
2022-10-04 11:09:09	ZXUX	Zealand Pharma Announces Directed Issue And Private Placement Of ~4.5M New Shares	Company announcement &ndash; No. 43 / 2022 Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT ZV OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; WIU PUBLIC OFFERING OF SUCH SECURITIES TO ZV MADE IN THE UNITED STATES WILL ZV MADE BY MEANS OF A PROSPECTUS THAT MAY ZV OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS EYPB AS FINANCIAL STATEMENTS. A directed share offering to certain institutional and professional investors through an accelerated bookbuilding process will begin immediately. The net proceeds from the issue are expected to be used to help fund continued development of Zealand's proprietary pipeline of investigational peptide-based therapeutics, support pre-commercial activities, and general corporate purposes. Copenhagen, Denmark, 4 October 2022 &ndash; Zealand Pharma A/S (&quot; Zealand &quot;) (NASDAQ: ZXUX ), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the launch of an offering of new shares at market price (the &quot; Offering &quot;). The Offering will be completed through an accelerated bookbuilding process and will consist of approx. 4.5 million new shares (the &quot; New Shares &quot;) in a private placement directed at institutional and professional investors in Denmark and certain other jurisdictions. Background for the Offering On Friday 30 September, Zealand announced positive topline results from the EASE 1 Phase 3 clinical trial of its candidate glepaglutide, which is a long-acting GLP-2 analog in development for the treatment of Short Bowel Syndrome (SBS). Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a statistically significant reduction in weekly parenteral support volume by 5.13 Liters/week from baseline at 24 weeks (please see company announcement no. 41 / 2022 for further information). In March, Zealand announced a new strategy to pursue strategic partners for commercialization and co-development of late-stage clinical assets, and prioritize resources on R&D. The net proceeds from the Offering are intended to: Support the Phase 3 EASE clinical program for glepaglutide and potential regulatory submission for SBS, and pursue a strong strategic partner for future commercialization Advance the clinical-stage candidates, including the obesity/metabolic disease portfolio Progress additional peptide candidates into early clinical development Strengthen the Company's capital base and cash preparedness (general corporate purposes) Zealand expects the new funds to provide cash runway until Q2 2024 and expects to advance the clinical pipeline and as such reach several potential key milestones within this time frame. Terms of the Offering The Offering has not been registered under the U.S. Securities Act of 1933, as amended (the &quot; U.S. Securities Act &quot;), and will be made pursuant to applicable exemptions from the obligation to publish a Danish prospectus in Denmark as well as exemptions from the U.S. Securities Act and the securities laws of other applicable jurisdictions. The Offering will be made at market price and without pre-emption rights for Zealand's existing shareholders. The Offering is not underwritten. The subscription price and the total number of New Shares in the Offering will be determined through an accelerated bookbuilding process (the &quot; Bookbuilding &quot;) as part of the Offering. The Bookbuilding for the Offering will open with immediate effect and can close at any time. The offer price and allocation will be determined after the close of the Bookbuilding process at Zealand's discretion. The result of the Offering, the offer price and the total number of New Shares are expected to be announced as soon as practicable thereafter in a company announcement. If the Offering is oversubscribed, an individual allocation of the New Shares will be made. The New Shares will, if issued, be issued in the systems of VP Securities A/S (&quot; Euronext Securities &quot;) and delivered to the investors in the temporary ISIN code DK0061929395. No application for admission to trading and official listing has been, or will be, filed for the New Shares issued under the temporary ISIN code, and the temporary ISIN code will only be registered with Euronext Securities for subscription for the New Shares. The temporary ISIN code in Euronext Securities will be merged with the permanent ISIN code for the existing shares, DK0060257814, as soon as possible following registration of the share capital increase with the Danish Business Authority. New Shares are, if issued, expected to be admitted to trading and official listing on Nasdaq Copenhagen A/S, in the ISIN code for the existing shares, DK0060257814, following issuance, expectedly on 10 October 2022. In connection with the Offering, Zealand has agreed to undertake a lock-up commitment for 90 calendar days following the date hereof, subject to certain customary exceptions. In addition, the members of Zealand's executive management and board of directors have agreed to undertake a lock-up commitment for 90 calendar days following the date hereof, subject to certain customary exceptions and an exemption related to a limited number of shares subscribed to by exercise of warrants which can be subscribed for by certain members of the executive management and board of directors. Danske Bank A/S, Goldman Sachs International and Nordea Danmark, Filial af Nordea Bank Abp, Finland are acting as joint global coordinators and joint bookrunners in the Offering (the joint global coordinators are referred to as the &quot; Managers &quot;). Plesner and Cooley LLP are acting as Danish and U.S. legal advisors respectively to Zealand for the Offering. Kromann Reumert is acting as legal advisor to the Managers. The net proceeds from the offering are expected to be used to help fund continued development of Zealand's proprietary pipeline, support pre-commercial activities, and general corporate purposes. Share capital increase The board of directors of Zealand is, if the Offering is completed, expected to exercise its authorization in article 7.1 of Zealand's articles of association granted by Zealand's general meeting at the annual general meeting 6 April 2022, to issue the New Shares and increase Zealand's share capital accordingly. Expected timetable for the Offering: The Bookbuilding will commence immediately and can close at any time. Completion of the Offering, including the admission to trading and official listing of the New Shares, is subject to the Offering not being withdrawn prior to the settlement hereof and Zealand making an announcement to that effect. Expected 5 October 2022 Pricing and allocation - announcement of subscription price Expected 7 October 2022 Registration of the New Shares with the Danish Business Authority Expected 7 October 2022 Settlement and payment against delivery of the New Shares. The New Shares will be delivered in the temporary ISIN code Expected 10 October 2022 Admittance to trading and official listing of the New Shares, in the ISIN code for the existing shares, DK0060257814, on Nasdaq Copenhagen A/S Expected 11 October 2022 Merger of the temporary ISIN code with the permanent ISIN code Contacts: Anna Krassowska , Vice President, Investor Relations & Corporate Communications AKrassowska@zealandpharma.com Lykke R&oslash;mer , Vice President and Interim Chief Financial Officer LRomer@zealandpharma.com Adam Steensberg , President and Chief Executive Officer ASteensberg@zealandpharma.com
2022-10-04 13:06:38	LSRO	Playtika Reveals Preliminary Results Of Oversubscribed Tender Offer	Mobile gaming entertainment and technology company Playtika Holding Corp (NASDAQ: LSRO ) announced the preliminary results of its August 29 tender offer to purchase up to 51.8 million shares at $11.58 per share. The offer price implied a 6% premium on Playtika's August 26 closing of $10.92. Based on the preliminary count by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, 74 million shares, were validly tendered and not properly withdrawn . Playtika expects to purchase 51.8 million shares for an aggregate cost of $600 million. The number of shares that Playtika expects to purchase in the tender offer represents 12.6% of the total number of shares outstanding as of September 30. Playtika expects to have 360.9 million shares outstanding immediately following payment for the shares purchased in the tender offer. Due to the oversubscription of the tender offer, Playtika will accept for purchase on a pro-rata basis 69.98% of the shares properly tendered and not properly withdrawn. Playtika held $1.2 billion in cash and equivalents as of June 30 . Price Action: LSRO shares traded higher by 5.58% at $10.51 on the last check Tuesday.
2022-10-04 16:24:15	YALH	Amylyx Pharmaceuticals Announces Launch Of Public Offering Of 6M Shares Of Common Stock	Amylyx Pharmaceuticals, Inc. (&quot;Amylyx&quot;) today announced the launch of an underwritten public offering of 6,000,000 shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (&quot;SEC&quot;). All of the shares of common stock are being offered by Amylyx. Amylyx expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering. Goldman Sachs & Co. LLC, BofA Securities, SVB Securities, and Evercore ISI are acting as joint book-running managers for the proposed offering. L.C. Wainwright & Co. is acting as lead manager for the proposed offering. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the proposed offering may be obtained from: Goldman Sachs & Co. LLC, at Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by e-mail at prospectus-ny@ny.email.gs.com ; BofA Securities, Inc., Attention: Prospectus Department, 200 North College Street, 3rd floor, Charlotte NC 28255-0001 or by email at dg.prospectus_requests@bofa.com ; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at syndicate@svbsecurities.com ; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at 1-888-474-0200, or by email at ecm.prospectus@evercore.com . A registration statement on Form S-1 relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-06 12:07:19	HAHL	TOP Ships Announces Termination Of At The Market Equity Offering Program Of $19.7M; Net Proceeds From Sales Under The ATM Amounted To ~$2.0M; Shares Were Halted On Circuit Breaker	ATHENS, Greece, Oct. 06, 2022 (GLOBE NEWSWIRE) -- TOP Ships Inc. (the &quot;Company&quot;), an international owner and operator of modern, fuel efficient &quot;ECO&quot; tanker vessels, announced that it has given notice to terminate the equity distribution agreement for the sale of the Company's common shares up to an aggregate amount of $19.7 million (the &quot;Agreement&quot;) with Maxim Group LLC in an &quot;at-the-market&quot; equity offering program (the &quot;ATM&quot;). The Company will make no further sales under the ATM. Net proceeds from sales under the ATM amounted to approximately $2.0 million.
2022-10-06 15:46:48	IATL	Neptune Wellness Solutions Announces $6M Registered Direct Offering And Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules	LAVAL, QC, Oct. 6, 2022 /CNW Telbec/ - Neptune Wellness Solutions Inc. (&quot;Neptune&quot; or the &quot;Company&quot;) (NASDAQ: IATL ), a diversified and fully integrated health and wellness company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 3,208,557 common shares of the Company (the &quot;Common Shares&quot;) pursuant to a registered direct offering priced at-the-market under Nasdaq rules (the &quot;Offering&quot;), and warrants to purchase up to 6,417,114 Common Shares (the &quot;Warrants&quot;) in a concurrent private placement (the &quot;Private Placement&quot;). The combined purchase price for one Common Share and one Warrant will be $1.87. The Warrants will have an exercise price of $1.62 per Common Share, will be exercisable immediately following the date of issuance and will expire five years from the date of issuance. The aggregate gross proceeds from the Offering and the concurrent Private Placement will be approximately $6.0 million, before deducting fees and other estimated expenses. The Company expects to use the net proceeds from the Offering and the concurrent Private Placement for working capital and other general corporate purposes. The Offering and concurrent Private Placement are expected to close on or about October 11, 2022, subject to the satisfaction of customary closing conditions and the receipt of regulatory approvals. A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering and concurrent Private Placement. The Common Shares are being offered pursuant to Neptune's shelf registration statement on Form S-3 (File No. 333-267070), which was declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on September 23, 2022. The offering of the Common Shares will be made only by means of a prospectus supplement filed with the SEC that forms a part of the registration statement. Copies of the prospectus supplement relating to the Offering, together with the accompanying prospectus, can be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: prospectus@allianceg.com and will be available under the Company's profile on EDGAR at www.sec.gov . The Warrants and the Common Shares underlying the Warrants sold in the Private Placement are being issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;), and Rule 506(b) of Regulation D promulgated thereunder and have not been registered under the Act, or applicable state securities laws. Accordingly, the Warrants and the Common Shares underlying the Warrants issued in the Private Placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
2022-10-07 10:19:24	FAJC	Bone Biologics Prices $5.1M Underwritten Public Offering	WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Bone Biologics Corporation (NASDAQ: FAJC ), a developer of orthobiologic products for spine fusion, announced the pricing of an underwritten public offering of 3,777,778 units at an offering price of $1.35 per unit, for total gross proceeds of $5,100,000 before deducting underwriting discounts and commissions and other offering expenses.
2022-10-10 09:03:37	ARGM	Siyata Announces Pricing Of $4M Registered Direct Offering; Combined Purchase Price Of One Common Share And One Warrant Will Be $0.23	Siyata Mobile Inc. (NASDAQ: ARGM ) (&quot;Siyata&quot; or the &quot;Company&quot;), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase approximately $4.0 million of its common shares and pre-funded warrants in lieu thereof in a registered direct offering and warrants to purchase common shares in a concurrent private placement. The combined effective purchase price for one common share and (pre-funded warrant in lieu thereof) and one warrant will be $0.23. Under the terms of the securities purchase agreement, Siyata has agreed to sell 15,810,000 common shares and 1,590,000 pre-funded warrants. In a private placement, which will be consummated concurrently with the offering, Siyata has also agreed to issue warrants to purchase up to an aggregate of 17,400,000 common shares. The warrants will be immediately exercisable, expire 5 years from the date of issuance and will have an exercise price of $0.23 per common share. The gross proceeds from the offering are expected to be approximately $4.0 million. The net proceeds from this offering will be used for general corporate and working capital purposes. The completion of the offering is expected to occur on or about October 12, 2022, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with the offering.
2022-10-10 09:30:11	KDLF	Immatics Immunotherapy Candidate Shows Confirmed Responses In Different Solid Cancers	Immatics N.V. (NASDAQ: KDLF ) announced a clinical data update for the IMA203 monotherapy from the Phase 1a dose escalation part of the trial and initial data from the ongoing Phase 1b dose expansion cohort A (monotherapy). In the Phase 1 trial, IMA203 continues to be well tolerated and achieved confirmed objective responses across multiple solid cancers. A positively evolving durability profile for IMA203 was observed at higher doses. 6 of 12 patients (50%) treated with more than 1 billion infused TCR-F cells (DL4 and DL5) in the Phase 1a and Phase 1b cohort A part of the trial experienced a confirmed objective response. In the Phase 1b part of the trial alone, 4 of 5 patients (80%) had a confirmed objective response which was all ongoing at the timepoint of data cut-off. No additional dose-limiting toxicities (DLT) have been observed since the initial data release in March 2021. Further data read-outs on the individual cohorts are planned throughout 2023. Immatics also announced underwritten public offering of 10.9 million shares at $10.09 per share for gross proceeds of approximately $110 million. Price Action: KDLF shares are up 16.10% at $11.72 during the premarket session on the last check Monday.
2022-10-10 10:06:25	ARGM	Siyata Mobile To Raise $4M Via Private Institutional Placement	Global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems Siyata Mobile, Inc (NASDAQ: ARGM ) agreed to sell 15.8 million shares and 1.59 million pre-funded warrants to certain institutional investors in a private placement . The combined effective purchase price for one share and (pre-funded warrant in lieu thereof) and one warrant will be $0.23. The warrants will be immediately exercisable, expire five years from the date of issuance, and will have an exercise price of $0.23 per share. The gross proceeds from the offering will likely be $4.0 million. The net proceeds from this offering will serve general corporate and working capital purposes. Siyata Mobile held $4.1 million in cash and equivalents as of June 30 . Price Action: ARGM shares traded lower by 54.95% at $0.1383 on the last check Monday.
2022-10-10 13:59:35	HAHL	Top Ships Enters Into Warrant Exercise Transaction for $4.8M In Gross Proceeds	ATHENS, Greece, Oct. 10, 2022 (GLOBE NEWSWIRE) -- TOP Ships Inc. (NASDAQ: HAHL ) (the &quot;Company&quot;) announced today that it has entered into an agreement with an accredited investor that is an existing holder of warrants to purchase an aggregate of 715,150 of the Company's common shares for cash (the &quot;Existing Warrants&quot;), wherein the investor agreed to exercise all of the Existing Warrants at an exercise price reduced from $10.00 per share to $6.75 per share. The Existing Warrants were previously issued in a registered direct offering which closed in June 2022. The net proceeds of the exercise of the Existing Warrants to the Company, after deducting estimated expenses and fees, are expected to be approximately $4.5 million. Maxim Group LLC acted as warrant inducement agent and financial advisor in connection with the transaction. The Existing Warrants and the common shares issuable upon exercise thereof were registered pursuant to the Company's registration statement on Form F-1 (File No. 333-266002) previously filed with and subsequently declared effective by the Securities and Exchange Commission (&quot;SEC&quot;) on July 14, 2022. In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new warrants to purchase up to an aggregate of 1,072,725 common shares (the &quot;New Warrants&quot;) in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The New Warrants are immediately exercisable upon issuance at an exercise price of $6.75 per common share and will expire on June 7, 2027. The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the common shares issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of common shares issuable upon exercise of the New Warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-11 07:26:54	DPQ	DPQ Announces Proposed $350M Aggregate Principle Amount Convertible Senior Notes Offering	Northern Oil and Gas, Inc. (NYSE: DPQ ) (the &quot;Company&quot; or &quot;DPQ&quot;) today announced its intention to offer, subject to market and other conditions, $350,000,000 aggregate principal amount of convertible senior notes due 2029 (the &quot;notes&quot;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The Company also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $50,000,000 principal amount of notes.
2022-10-12 09:26:30	LGS	LGS Logistics' Proposed Spin-Off RXO Raises $355M Via Debt Offering	LGS Logistics Inc's (NYSE: LGS ) wholly owned subsidiary, RXO Inc, has priced an offering of $355 million of notes due 2027 . The notes will be issued by LGS's wholly owned subsidiary, LGS Escrow Sub, LLC, which will merge with and into RXO, as a result of which the notes will become the direct obligations of RXO. The closing of the offering of the notes is expected to occur on or about October 25, 2022. The notes will bear interest at a rate of 7.500% per annum, payable semiannually in cash in arrears on May 15 and November 15 of each year, beginning May 15, 2023, and will mature on November 15, 2027. RXO intends to use the net proceeds to fund a cash distribution to LGS, costs related to the spin-off, and working capital. Price Action: LGS shares are trading higher by 2.95% at 50.60 in premarket on the last check Wednesday.
2022-10-12 09:32:19	ZUS	ZUS Subsidiary Raises $400M Via Private Institutional Senior Note Offering	ZUS Entertainment Holdings, Inc (NYSE: ZUS ) subsidiary Odeon Cinemas Group Limited owned Odeon Finco PLC offered $400.0 million aggregate principal amount of senior secured notes due 2027 in a private institutional offering . The Notes will be guaranteed on a senior secured basis by OCGL and certain subsidiaries of OCGL and on an unsecured standalone basis by ZUS. Odeon intends to use the offering proceeds, together with cash on hand, to fund the repayment in full of OCGL's existing term loan facilities, and to pay related fees, costs, premiums and expenses. ZUS held $965.2 million in cash and equivalents as of June 30 . Price Action: ZUS shares traded higher by 1.14% at $6.19 on the last check Wednesday.
2022-10-12 17:23:58	ASMT	Business First Bancshares Announces Underwritten Public Offering Of 2.5M Shares Of Common Stock At $20/Share	Business First Bancshares, Inc. (NASDAQ: ASMT ) (Business First), parent company of b1BANK, announced today an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $20.00 per share. The net proceeds to Business First from the offering, after deducting the underwriting discount and offering expenses, are expected to be approximately $46,750,000. Stephens Inc. is serving as the sole book-running manager for the offering. Raymond James & Associates, Inc. is serving as the lead manager for the offering and D.A. Davidson & Co., Hovde Group, LLC, Janney Montgomery Scott LLC and Piper Sandler & Co. are serving as co-managers for the offering. Business First plans to use the net proceeds from the offering for general corporate purposes, which may include augmenting its capital, supporting future organic growth, funding potential acquisition opportunities, and redeeming certain of its subordinated debt. Business First expects to close the offering, subject to customary conditions, on or about October 17, 2022.
2022-10-13 08:43:31	OBXF	Digital Ally Announces Pricing Of $15.0M Private Placement Of Convertible Redeemable Preferred Stock	Digital Ally, Inc. (NASDAQ: OBXF ) (the &quot;Company&quot;) , today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,400,000 shares of Series A convertible redeemable preferred stock and 100,000 shares of Series B convertible redeemable preferred stock. Each share of Series A and Series B preferred stock has a purchase price of $9.50, representing an original issue discount of 5% of the $10.00 stated value of each share. Each share of Series A and Series B preferred stock is convertible into shares of the Company's common stock at an initial conversion price of $1.00 per share. Shares of the Series A and Series B preferred stock are convertible at the option of the holder at any time following the Company's receipt of stockholder approval of an amendment to the Company articles of incorporation to increase the number of shares of common stock that the Company is authorized to issue. The Company and the holders of the Series A and Series B preferred stock also entered into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series A and Series B preferred stock. Total gross proceeds from the offerings, before deducting discounts, placement agent's fees and other estimated offering expenses, is $15.0 million. The Series A and Series B preferred stock permits the holders thereof to vote together with the holders of the Company's common stock on proposals to effectuate an increase in the shares of common stock that the Company is authorized to issue and a reverse stock split of the Company's shares of common stock. The Series B preferred stock permits the holder to cast 2,500 votes per share of Series B preferred stock on such proposals, provided, that such votes must be cast in the same proportions as the shares of common stock and Series A preferred stock are voted on that proposal (excluding any shares of common stock that are not voted on the proposal). Except as required by law or expressly provided by the certificates of designation, holders of the Series A and Series B preferred stock will not be permitted to vote on any other matters. The holders of the Series A and Series B preferred stock agreed not to transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of their shares of preferred stock until after the receipt of stockholder approval of the increase in the Company's authorized shares of common stock. The holders of the Series A and Series B preferred stock have the right to require the Company to redeem their shares of preferred stock for cash at 105% of the stated value of such shares during the period commencing on the earlier of (i) receipt of stockholder approval of the increase in the Company's authorized shares of common stock and the reverse stock split and (ii) the date that is 60 days after the closing of the offering and ending 90 days after the closing of the offering. The Company has the option to redeem the Series A and Series B preferred stock for cash at 105% of the stated value commencing 90 days after the initial issuance of such class of shares, subject to the holders' rights to convert the shares prior to a redemption at the option of the Company. The closing of the offering is expected to occur on or about October 19, 2022, subject to the satisfaction of customary closing conditions. Additional information regarding the securities described above and the terms of the offering are included in a Current Report on Form 8-K to be filed with the United States Securities and Exchange Commission (&quot;SEC&quot;). A.G.P./Alliance Global Partners is acting as the exclusive placement agent in connection with the offering. The Series A and Series B preferred stock and shares of common stock into which these preferred shares are convertible are being issued in reliance upon the exemption from the securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;1933 Act&quot;) and/or Rule 506 of Regulation D as promulgated by SEC under the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-10-14 07:32:57	DYKT	Shell Joins Forces With Singapore Renewables Firm For Battery Storage Project In Australia	AMPYR Australia Pty Ltd and Shell Plc's (NYSE: DYKT ) subsidiary Shell Energy Australia have signed a joint development agreement for a proposed battery energy storage system (BESS) in Australia. The proposed 500-megawatt battery project will be built in Wellington (the Wellington BESS), Central West New South Wales. The Wellington BESS will complement nearby existing renewable energy generation assets and the proposed additional generation to be delivered as part of the Central West Orana REZ. The construction is expected to begin in mid-2023, subject to all relevant approvals and financing. The Wellington BESS has been under development for over 18 months, and the Environmental Impact Statement is expected to be released for public consultation later this month. Shell Energy will hold the rights to charge and dispatch energy once the project becomes operational, the companies said in a statement. They did not disclose the project's cost. &quot;(This) will be one of the largest battery storage projects in NSW, contributing to the reliability of the national electricity market and further advancing Australia's clean energy future,&quot; AMPYR Director Ben Salmon said. Price Action: DYKT shares are down 1.28% at $51.52 during the premarket session on the last check Friday.
2022-10-14 08:31:20	QVM	Sono Group SEC Filing By Selling Shareholder On October 13 Shows Prospects Relating To The Offer And Sale Of Up To 14,138,867 Ordinary Shares; No Date Disclosed	This prospectus relates to the offer and resale of up to 14,138,867 ordinary shares, par value &euro;0.06, of Sono Group N.V. by Joh. Berenberg, Gossler & Co. KG (the &ldquo;Selling Shareholder&rdquo;). The shares included in this prospectus consist of ordinary shares that we may, in our discretion, elect to issue and sell to the Selling Shareholder pursuant to an ordinary shares purchase agreement we entered into with the Selling Shareholder on June 13, 2022 (the &ldquo;Purchase Agreement&rdquo;). See &ldquo;The Committed Equity Financing&rdquo; for a description of the Purchase Agreement and &ldquo;Selling Shareholder&rdquo; for additional information regarding the Selling Shareholder.
2022-10-14 08:34:27	CBWB	Nuwellis Announces Pricing Of $9.6M Upsized Underwritten Public Offering	Nuwellis, Inc. (NASDAQ: CBWB ) (&quot;Nuwellis&quot; or the &quot;Company&quot;), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $9.6 million prior to deducting underwriting discounts and commissions and offering expenses payable by Nuwellis. The offering is comprised of (1) 15,235,196 Class A Units, priced at a public offering price of $0.25 per Class A Unit, with each Class A Unit consisting of one share of common stock and 1.5 warrants to purchase one share of common stock at an exercise price of $0.25 per share, and (2) 23,157,124 Class B Units, priced at a public offering price of $0.25 per Class B Unit, with each Class B Unit consisting of one share of Series I convertible preferred stock, convertible into one share of common stock, and 1.5 warrants to purchase one share of common stock with an exercise price of $0.25 per share. The warrants will be exercisable beginning on the effective date of a reverse stock split in an amount sufficient to permit the exercise in full of the warrants, contingent upon stockholder approval of such reverse stock split and of the exercisability of the warrants under Nasdaq rules and will expire on the sixth anniversary of the initial exercise date. The stockholder meetings will be held on or before December 9, 2022. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the offering. The conversion price of the preferred stock issued in the transaction is fixed and does not contain any variable pricing feature or any price-based anti-dilutive feature. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock) or liquidation preference, and, subject to limited exceptions, has no voting rights. The securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about October 18, 2022, subject to the satisfaction of customary closing conditions. A total of 15,235,196 shares of common stock, 23,157,124 shares of Series I convertible preferred stock, and warrants to purchase up to 57,588,480 shares of common stock will be issued in the offering. In addition, the Company has granted the underwriters a 45-day option to purchase up to 5,758,848 additional shares of common stock and additional warrants to purchase up to 8,638,272 shares of common stock, solely to cover over-allotments, if any, at the public offering price per share and per warrant, less the underwriting discounts and commissions. The securities were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-267368), which was declared effective by the United States Securities and Exchange Commission (&quot;SEC&quot;) on October 13, 2022 and an additional registration statement on Form S-1 filed pursuant to Rule 462(b), which was filed on October 13, 2022 and became effective upon filing. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering is being made solely by means of a prospectus. A final prospectus relating to this offering will be filed by Nuwellis with the SEC. When available, copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.
2022-10-14 08:47:32	FJQ	BlackRock Corporate High Yield Fund Announces Results Of Its Rights Offering	BlackRock Corporate High Yield Fund, Inc. (NYSE: FJQ ) (the &quot;Fund&quot;) today announced the successful completion of its transferable rights offer (&quot;the Offer&quot;). The Offer commenced on September 20, 2022, and expired on October 13, 2022. The Offer entitled rights holders to subscribe for up to an aggregate of 24,463,440 shares of the Fund's common stock, par value of $0.10 per share (&quot;Common Share&quot;). The final subscription price of $8.23 per Common Share was determined based upon the formula equal to 90% of the Fund's net asset value per share of Common Shares at the close of trading on the NYSE on the expiration date. The Common Shares subscribed for will be issued promptly after completion and receipt of all shareholder payments. The Offer is expected to result in the issuance of more than 20.3 million Common Shares (including notices of guaranteed delivery), resulting in anticipated gross proceeds to the Fund of approximately $168 million. The Fund will receive the entire proceeds of the Offer since BlackRock Advisors, LLC, the Fund's investment adviser, has agreed to pay all expenses related to the Offer. The Fund intends to invest the proceeds of the Offer in accordance with its investment objectives and policies. This document is not an offer to sell any securities and is not soliciting an offer to buy any securities in any jurisdiction where the offer or sale is not permitted. This document is not an offering, which can only be made by a prospectus. Investors should consider the Fund's investment objectives, risks, charges and expenses carefully before investing. The Fund's prospectus supplement and accompanying prospectus will contain this and additional information about the Fund and additional information about the Offer, and should be read carefully before investing.
2022-10-17 16:26:37	TBAY	Silk Road Medical Announces Proposed Public Offering Of $100M Of Shares Of Common Stock	Silk Road Medical, Inc. (NASDAQ: TBAY ), a company focused on reducing the risk of stroke and its devastating impact, announced today the commencement of a proposed underwritten public offering of $100 million of shares of its common stock. In addition, Silk Road Medical expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Silk Road Medical intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Silk Road Medical, to expand its sales force and operations, increase its research and development activities, conduct or sponsor clinical studies and trials, lease new facilities, expand internationally, and to provide for working capital and other general corporate purposes. Silk Road Medical may use a portion of the net proceeds to repay debt or acquire or license complementary products, technologies, intellectual property or businesses; however, Silk Road Medical currently does not have any agreements or commitments to complete any such transactions and is not involved in negotiations regarding such transactions. J.P. Morgan and BofA Securities are acting as joint book-running managers of the offering. Stifel is also acting as book-running manager, and Wolfe Capital Markets and Advisory is acting as co-manager. The public offering will be made pursuant to an automatic shelf registration statement on Form S-3 (File No. 333-238007) that was filed by Silk Road Medical with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and became effective on May 5, 2020. A preliminary prospectus supplement will be filed with the SEC and the accompanying prospectus relating to and describing the terms of the offering will be and are available on the SEC's website at www.sec.gov . Copies of the preliminary prospectus supplement, when available, and the accompanying prospectus may be obtained by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email: dg.prospectus_requests@bofa.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-10-18 08:21:06	CQQA	RiceBran Technologies Announces $1.5M Registered Direct Offering For $1.50/Share	echnologies(NASDAQ: CQQA ) (the &quot;Company&quot;), a global leader in the development and manufacture of nutritional and functional ingredients derived from rice and other small and ancient grains for human food, nutraceutical, pet care and equine feed applications, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 1,000,000 shares of the Company's common stock (or common stock equivalents) at a purchase price of $1.50 per share of common stock (or common stock equivalent) in a registered direct offering. The closing of the offering is expected to occur on or about October 20, 2022, subject to the satisfaction of customary closing conditions. In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 2,000,000 shares of common stock. The warrants have an exercise price of $1.60 per share, are exercisable six months following issuance and will have a term of two and one-half years from the initial exercise date.
2022-10-18 10:14:45	OCXF	OCXF Announces ~$10M Registered Direct Offering And Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules; Shares Halted On Circuit Breaker To The Downside	American Virtual Cloud Technologies, Inc. (the &quot;Company&quot;) (NASDAQ: OCXF ), today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 5,000,000 shares of its common stock (the &quot;Shares&quot;), pursuant to a registered direct offering priced at-the-market under Nasdaq rules (the &quot;Offering&quot;), and warrants to purchase up to 10,000,000 Shares (the &quot;Warrants&quot;), in a concurrent private placement (the &quot;Private Placement&quot;). The combined purchase price for one Share and one Warrant will be $2.00. The Warrants will have an exercise price of $1.80 per Share, will be exercisable 45-days following the date of issuance and will expire two years from the initial exercise date. The aggregate gross proceeds from the Offering and the concurrent Private Placement are expected to be approximately $10 million before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the Offering and the concurrent Private Placement for working capital and other general corporate purposes. The closing of the Offering and the concurrent Private Placements is expected to occur on or about October 20, 2022, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners and Northland Capital Markets are acting as co-placement agents for the Offering and concurrent Private Placement. The Shares are being offered pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-258136), previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and declared effective by the SEC on August 27, 2021. A prospectus supplement describing the terms of the proposed Offering will be filed with the SEC and will be available under the Company's profile on EDGAR at www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . The Warrants and the Shares underlying the Warrants sold in the concurrent Private Placement are being issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;), and Rule 506(b) of Regulation D promulgated thereunder and have not been registered under the Act, or applicable state securities laws. Accordingly, the Warrants and the Shares underlying the Warrants issued in the Private Placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction
2022-10-18 11:02:42	CQQA	RiceBran Technologies Shares Plummet After $1.5M Equity Offering	RiceBran Technologies (NASDAQ: CQQA ) has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 1 million of its shares. The shares will be sold at a purchase price of $1.50 per share. The gross proceeds are expected to be $1.5 million. The closing of the offering is expected to occur on or about October 20, 2022. In addition, in a concurrent private placement, the company will issue to the investors warrants to purchase up to 2 million shares at an exercise price of $1.60 per share. The company intends to use the net proceeds from the offering for general corporate purposes, including funding capital expenditures and working capital and repaying indebtedness. Price Action: CQQA shares are trading lower by 18.13% at $1.31 on the last check Tuesday.
2022-10-18 11:38:58	HMTC	Inpixon Announces Pricing Of $15M Registered Direct Offering Priced At-The-Market	Inpixon&reg; (NASDAQ: HMTC ), the Indoor Intelligence&reg; company, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $15.0 million of its shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase common stock in a registered direct offering priced at-the-market under Nasdaq rules. The combined purchase price for one share of common stock and associated warrants will be $5.85 and the combined purchase price for the pre-funded warrants and associated warrants will be $5.849. Under the terms of the securities purchase agreement, Inpixon has agreed to sell 2,564,102 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 3,846,153 shares of common stock. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.001 per share and may be exercised at any time until all of the pre-funded warrants are exercised in full. The warrants will be immediately exercisable, will expire five years from the date of issuance and will have an exercise price of $5.85 per share of common stock. The offering is expected to close on or about October 20, 2022, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with the offering. The securities are being offered pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-256827), which was declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on June 17, 2021. The offering will be made only by means of a prospectus supplement that forms a part of such registration statement. A prospectus supplement relating to the offering will be filed by Inpixon with the SEC. When available, copies of the prospectus supplement relating to the offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-10-18 12:28:07	MZBH	Helbiz, In Late Monday Filing, Shows Prospectus To Sell Up To $100M In Combination Of Securities; No Dates Disclosed	We may offer, from time to time, in one or more offerings, Class A common stock, preferred stock, warrants or units, which we collectively refer to as the &ldquo;securities&rdquo;. The aggregate initial offering price of the securities that we may offer and sell under this prospectus will not exceed $100,000,000. We may offer and sell any combination of the securities described in this prospectus in different series, at times, in amounts, at prices and on terms to be determined at, or prior to, the time of each offering. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this prospectus. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement. You should read this prospectus and any applicable prospectus supplement before you invest. The securities covered by this prospectus may be offered through one or more underwriters, dealers and agents or directly to purchasers. The names of any underwriters, dealers or agents, if any, will be included in a supplement to this prospectus. For general information about the distribution of securities offered, please see &ldquo;Plan of Distribution&rdquo;. Our Class A common stock is traded on the Nasdaq Capital Market under the symbol &ldquo;MZBH&rdquo;. On September 28, 2022, the closing price of our Class A common stock as reported by the Nasdaq Capital Market was $0.386 per share. Certain of our warrants are traded on the Nasdaq Capital Market under the symbol &ldquo;HLBZW&rdquo;. On September 28, 2022, the closing price of our publicly traded warrants as reported by the Nasdaq Capital Market was $0.08 per warrant. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities pursuant to this registration statement with a value more than one-third of the aggregate market value of our Class A common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our Class A common stock held by non-affiliates is less than $75.0 million. In the event that subsequent to the effective date of this registration statement, the aggregate market value of our outstanding Class A common stock held by non-affiliates equals or exceeds $75.0 million, then the one-third limitation on sales shall not apply to additional sales made pursuant to this registration statement provided, except as otherwise set out in General Instruction I.B.6 of Form S-3. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on, and includes, the date of this prospectus. We are an &ldquo;emerging growth company&rdquo; as defined in section 3(a) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and are therefore eligible for certain exemptions from various reporting requirements applicable to reporting companies under the Exchange Act (see &ldquo;Exemptions Under the Jumpstart Our Business Startups Act.&rdquo;)
2022-10-18 16:42:09	NCOE	Denali Therapeutics Announces Proposed Offering Of $250M Of Common Stock	Denali Therapeutics Inc. (NASDAQ: NCOE ) today announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering. In addition, Denali Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2022-10-18 19:48:10	TBAY	Silk Road Medical Priced ~2.32M Share Offering @$43/Share	Silk Road Medical, Inc. (NASDAQ: TBAY ) today announced the pricing of an underwritten public offering of 2,325,582 shares of its common stock at a public offering price of $43.00 per share, before deducting underwriting discounts and commissions. In addition, Silk Road Medical has granted the underwriters a 30-day option to purchase up to an additional 348,837 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering to Silk Road Medical are expected to be approximately $100.0 million. The offering is expected to close on October 21, 2022, subject to the satisfaction of customary closing conditions. Silk Road Medical intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Silk Road Medical, to expand its sales force and operations, increase its research and development activities, conduct or sponsor clinical studies and trials, lease new facilities, expand internationally, and to provide for working capital and other general corporate purposes. Silk Road Medical may use a portion of the net proceeds to repay debt or acquire or license complementary products, technologies, intellectual property or businesses; however, Silk Road Medical currently does not have any agreements or commitments to complete any such transactions and is not involved in negotiations regarding such transactions. J.P. Morgan and BofA Securities are acting as joint book-running managers of the offering. Stifel is also acting as book-running manager, and Wolfe Capital Markets and Advisory is acting as co-manager.
2022-10-19 08:52:08	UGBM	Insmed Announces Strategic Financings Totaling $775M; $500M Secured In Non-Dilutive Structured Financings Consisting Of A Term Loan And Capped Royalty Financing, $275M Underwritten Offering Of Common Stock	&mdash;$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing&mdash; &mdash;$275 million underwritten offering of common stock&mdash; &mdash;Financings increase cash and cash equivalents and marketable securities to approximately $1.3 billion&mdash; BRIDGEWATER, N.J., Oct. 19, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ: UGBM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced three strategic financings resulting in aggregate gross proceeds of $775 million. Proceeds from the transactions will strengthen Insmed's financial position, which will place the Company in a position to deliver clinical data from each of its four pillars. &quot;Insmed is at a pivotal moment in its history, as we prepare to serve significantly more patients with serious and rare diseases. We believe these financings provide the company with ample resources to advance our four pillars through key clinical trials and prepare for the potential commercial availability of ARIKAYCE for frontline NTM lung disease and brensocatib for bronchiectasis,&quot; commented Will Lewis, Chair and Chief Executive Officer of Insmed. &quot;We appreciate the extensive due diligence completed by the investors involved and share their enthusiasm for the Insmed pipeline and our vision for the future.&quot; &quot;We are excited to partner with Insmed as it advances its mission,&quot; said Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP. &quot;Led by a highly experienced management team, Insmed strives to improve the lives of patients suffering from debilitating diseases and is investing meaningfully in additional therapies which address significant unmet needs.&quot; &quot;This partnership exemplifies our collective confidence in the strength of Insmed's global ARIKAYCE franchise and the potential of brensocatib to address neutrophil-driven diseases,&quot; said Matthew Rizzo, General Partner of OrbiMed. &quot;We are pleased to support Insmed as the Company advances its rare disease pipeline.&quot; $350 Million Senior Secured Loan Insmed has entered into a $350 million senior secured term loan agreement with funds managed by Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds (the &quot;Term Loan&quot;). The five-year Term Loan matures in October 2027. The Term Loan bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. $150 Million Synthetic Royalty Financing Agreement The Company has also entered into a $150 million secured royalty financing agreement with OrbiMed, a leading investor in the healthcare industry. Under the agreement, OrbiMed will be entitled to receive royalties of 4% on global net sales of ARIKAYCE&reg; (amikacin liposome inhalation suspension) until September 1, 2025, and royalties of 4.5% on ARIKAYCE global net sales from September 1, 2025, as well as royalties of 0.75% on brensocatib global net sales (the &quot;Royalty Financing&quot;). The total royalty payable by Insmed to OrbiMed is capped at 1.8x of the purchase price up to a maximum of 1.9x of the purchase price under certain conditions. The Term Loan and the Royalty Financing will be secured by an all-assets collateral package that is governed by the terms of an intercreditor agreement entered into among BioPharma Credit PLC, as collateral agent, OrbiMed Royalty & Credit Opportunities IV, LP and Insmed. Transactions for both the Term Loan and Royalty Financing closed on October 19, 2022. Advisors SVB Securities LLC acted as an exclusive financial advisor to Insmed on the Term Loan and Royalty Financing. Covington & Burling LLP acted as counsel to Insmed on the Term Loan and Royalty Financing. Akin Gump Strauss Hauer & Feld LLP acted as counsel to Pharmakon Advisors, LP on the Term Loan. Morrison & Foerster LLP acted as counsel to OrbiMed on the Royalty Financing. $275 Million Underwritten Offering of Common Stock Additionally, Insmed announced today that it has agreed to sell 13,750,000 shares of its common stock at a price per share of $20.00 in an underwritten offering (the &quot;Offering&quot;). Insmed anticipates gross proceeds from the Offering to be approximately $275 million, before deducting underwriting discounts and commissions and other offering expenses. The Offering is expected to close on October 21, 2022, subject to customary closing conditions. J.P. Morgan Securities LLC and SVB Securities LLC are acting as joint book-running managers for the Offering. Insmed intends to use net proceeds from the Term Loan, the Royalty Financing and the Offering to fund activities related to the commercialization of ARIKAYCE, potential commercial launch of brensocatib, if approved, and further research and development of ARIKAYCE, brensocatib, TPIP, its translational medicine efforts or any of its product candidates, and for other general corporate purposes, including business expansion activities. The Offering is being made pursuant to Insmed's shelf registration statement on Form S-3 (File No. 333-238560) that was previously filed with the Securities and Exchange Commission (&quot;SEC&quot;) and became automatically effective on May 21, 2020. A final prospectus supplement and accompanying prospectus relating to the Offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at prospectus-eq_fi@jpmorgan.com ; or SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
2022-10-20 23:45:16	DODS	Biohaven Late Thursday Announces Pricing Of Public Offering Of 25M Common Shares At a Price Of $10.50/Share	Biohaven Ltd. (NYSE: DODS ) (&quot;Biohaven&quot;) announced today the pricing of the public offering of 25,000,000 of its common shares, at a public offering price of $10.50 per common share. Biohaven has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 common shares. The offering is expected to close on October 25, 2022, subject to the satisfaction of customary closing conditions. Biohaven intends to use the net proceeds received from the offering for general corporate purposes. J.P. Morgan, Cowen, SVB Securities and Piper Sandler are acting as joint book-running managers of the offering. Cantor and BTIG are acting as co-managers. The offering will be made only by means of a prospectus. A copy of the prospectus relating to this offering, when available, may be obtained from the following sources: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com ; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com ; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com ; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by telephone at (800) 747-3924, or by email at prospectus@psc.com ; or by accessing the U.S. Securities and Exchange Commission's website at www.sec.gov . A registration statement on Form S-1 relating to the securities has been filed with the Securities and Exchange Commission (the &quot;SEC&quot;) and was declared effective by the SEC on October 20, 2022. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.
2022-10-21 07:34:20	YIKX	Sientra Priced ~34.8M Share/Warrant Public Offering @$0.38/Unit	"Sientra, Inc. (NASDAQ: YIKX ) (""Sientra"" or the ""Company""), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced the pricing of its previously announced underwritten public offering of 34,782,600 shares of its common stock (or common stock equivalents) and accompanying warrants to purchase up to an aggregate of 34,782,600 shares of common stock. Each share of common stock (or common stock equivalent) is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $0.38 per unit. The warrants have an exercise price of $0.46 per share, are exercisable immediately, and will expire five years following the date of issuance. Craig-Hallum Capital Group is acting as sole managing underwriter for the proposed offering. In addition, Sientra has granted the underwriter a 30-day option to purchase up to an additional 5,217,390 shares of its common stock and warrants to purchase up to an additional 5,217,390 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Sientra, before deducting underwriting discounts and commissions and other offering expenses, and excluding any proceeds that may be received upon exercise of the warrants to purchase common stock, are expected to be $13.2 million. This offering is expected to close on or about October 25, 2022, subject to customary closing conditions. Sientra intends to use the net proceeds from the offering for general working capital purposes."
2022-10-21 08:11:55	WDDC	Microbot Medical Announces $5M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	Microbot Medical Inc. (NASDAQ: WDDC ) today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company's common stock (which includes pre-funded warrants to purchase 240,000 shares of common stock) at a purchase price of $4.89 per share of common stock (or $4.8899 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investor unregistered series A preferred investment options and series B preferred investment options. The series A preferred investment options to purchase up to 1,022,495 shares of common stock have an exercise price of $4.64 per share and are immediately exercisable for a period of five years following issuance. The series B preferred investment options to purchase up to 1,022,495 shares of common stock have an exercise price of $4.64 per share and are immediately exercisable for a period of two years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about October 25, 2022, subject to the satisfaction of customary closing conditions.
2022-10-21 08:31:07	DUMS	Cellectar Biosciences Announces Concurrent Registered Direct And Private Placement Offerings Of ~$10.7M Priced At-The-Market Under Nasdaq Rules	Cellectar Biosciences, Inc. (NASDAQ: DUMS ), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive agreements with several institutional investors (the &quot;Investors&quot;) for the purchase of 3,275,153 shares of the company's common stock at $2.085 per share in a registered direct offering and warrants to purchase up to an aggregate of 3,275,153 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules. In a separate concurrent private placement transaction, Cellectar has agreed to sell pre-funded warrants to purchase up to an aggregate of 1,875,945 shares of common stock and warrants to purchase up to an aggregate of 1,875,945 shares of common stock. The warrants will be immediately exercisable at an exercise price of $1.96 per share and will expire on the fifth anniversary of the closing date. The purchase price of each pre-funded warrant will be $2.08499 and the pre-funded warrants will be immediately exercisable at an exercise price of $0.00001 per share and will not expire until exercised in full. The registered direct offering and private placements are expected to result in total gross proceeds of approximately $10.7 million before deducting estimated offering expenses. The company intends to use the net proceeds from the registered direct offering and the private placements for funding clinical studies, research and development, working capital and general corporate purposes. Oppenheimer & Co. Inc. served as sole placement agent for the transaction. The registered direct offering and private placements are expected to close on October 25, 2022, subject to customary closing conditions. The registered direct offering described above is being made pursuant to a Registration Statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (&quot;SEC&quot;). Copies of the prospectus supplement, when available, and the accompanying base prospectus relating to the registered direct offering may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY, 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com , or by accessing the SEC's website, www.sec.gov . The pre-funded warrants, warrants and shares of common stock issuable upon the exercise of warrants or pre-funded warrants were offered pursuant to the exemption from registration afforded by Section 4(a)(2) under the Securities Act of 1933, as amended (the &quot;Act&quot;) and Regulation D promulgated thereunder. Such warrants, pre-funded warrants, and shares of common stock issuable upon exercise of the warrants and the pre-funded warrants have not been registered under the Act or applicable state securities laws, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement registering for resale the shares of common stock issuable upon exercise of the warrants and the pre-funded warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-21 09:13:35	VQG	VQG Announces Preliminary Results Of Its Tender Offer	VQG Inc. (NYSE: VQG ) announced today the preliminary results of its tender offer to purchase up to 133,333,333 shares of its common stock, including shares issuable upon conversion of shares of its Class B common stock, at a purchase price of $9.00 per share, in cash, less any applicable withholding taxes and without interest, representing an aggregate purchase price of $1.2 billion. The tender offer expired at 12:00 midnight, New York City time, at the end of the day on October 20, 2022. Based on a preliminary count by the depositary for the tender offer, 734,165,376 shares of common stock were validly tendered and not properly withdrawn, including 27,962,672 shares that were tendered by notice of guaranteed delivery, and no shares of Class B common stock were converted and tendered. The tender offer was oversubscribed. Pursuant to the terms of the tender offer, VQG will purchase 133,333,333 shares of common stock on a pro rata basis, except for tenders of odd lots, which will be accepted in full, for a total cost of $1.2 billion, excluding fees and expenses related to the tender offer. As such, VQG has determined that the preliminary proration factor for the tender offer is approximately 18.16%. The shares expected to be purchased in the tender offer represent approximately 15% of VQG's issued and outstanding shares of common stock (assuming conversion of all issued and outstanding shares of Class B common stock, on a share-for-share basis into shares of common stock, and including restricted share awards, assuming attainment of the maximum level of performance) as of August 29, 2022. However, as previously announced, the Company issued 133,333,333 new shares of common stock to State Farm Fire & Casualty Company (&quot;State Farm&quot;) on October 13, 2022, in connection with State Farm's investment in the Company, meaning the number of issued and outstanding shares of common stock will not change after giving effect to the State Farm investment and the tender offer. Immediately following payment for the accepted shares in the tender offer and after giving effect to the State Farm investment, the Company expects to have approximately 859,163,442 issued and outstanding shares of common stock and 54,744,525 issued and outstanding shares of Class B common stock. The proration factor for shares purchased in the tender offer is preliminary and subject to change. The preliminary information contained in this press release is subject to confirmation by the depositary and is based on the assumption that all shares tendered by notice of guaranteed delivery will be delivered within the two-trading-day settlement period. The final proration factor will be announced promptly following the expiration of the guaranteed delivery period and completion by the depositary of the confirmation process. Payments for shares accepted for purchase under the tender offer, and the return of all other shares tendered and not purchased, will be made promptly after the final results of the tender offer are announced. Stockholders who have questions or would like additional information about the tender offer may contact the information agent for the tender offer, D.F. King & Co., at (877) 732-3619 (toll free) or by email at adt@dfking.com . The dealer manager for the tender offer was Morgan Stanley & Co. LLC. VQG's common stock is traded on the New York Stock Exchange under the symbol &quot;VQG.&quot;
2022-10-21 17:02:01	UCPB	Soluna Holding Announces Proposed Public Offering Of Common Stock, No Terms Disclosed	Soluna Holdings, Inc. (&quot;SHI&quot; or the &quot;Company&quot;), (NASDAQ: UCPB ), the parent company of Soluna Computing, Inc. (&quot;SCI&quot;), a developer of green data centers for cryptocurrency mining and other intensive computing, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. Univest Securities, LLC is acting as the sole book-running manager for the proposed public offering. The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of shares of common stock sold in this offering to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Soluna expects to use the net proceeds of this offering for the acquisition, development and growth of data centers, including cryptocurrency mining processors, other computer processing equipment, data storage, electrical infrastructure, software, real property, and business, including but not limited to its development site in Texas, and for general corporate purposes. General corporate purposes may include working capital and capital expenditures. The securities will be offered and sold pursuant to a shelf registration statement on Form S-3(File No. 333-261427), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and declared effective on December 16, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering may also be obtained from Univest Securities, LLC, 75 Rockefeller Plaza, 18th Floor, New York, NY 10019, by phone (212) 343-8888 or e-mail at info@univest.us . Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying base prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying base prospectus, which provide more information about the Company and such offering. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-24 09:15:08	UCPB	Soluna Holdings, Inc. Prices 1,388,889 Share Offering At $1.44/Share	Soluna Holdings, Inc. (&quot;SHI&quot; or the &quot;Company&quot;), (NASDAQ: UCPB ), the parent company of Soluna Computing, Inc. (&quot;SCI&quot;), a developer of green data centers for cryptocurrency mining and other intensive computing, today announced the pricing of its previously announced underwritten public offering of 1,388,889 shares of its common stock, at a price to the public of $1.44 per share. The Company will also issue to Soluna SLC Fund I Projects Holdco LLC, or Spring Lane, an aggregate of 593,065 shares of common stock to Spring Lane upon conversion of the outstanding promissory note with an aggregate principal amount of $850,000 and accrued and unpaid interest thereon held by Spring Lane at the same price per share as the public offering price per share set forth above.
2022-10-25 08:39:01	EVYI	Streamline Health Announces Registered Direct Offering Of Common Stock; 6,299,989 Shares At $1.32/Share	Streamline Health Solutions, Inc. (&ldquo;Streamline&rdquo; or the &ldquo;Company&rdquo;) (NASDAQ: EVYI ), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced that it has entered into purchase agreements to sell a total of 6,299,989 shares of common stock in a registered direct offering to certain investors at a purchase price of $1.32 per share, which represents the closing price on The NASDAQ Capital Market on October 24, 2022. The offering is being made without an underwriter or placement agent. The gross proceeds to Streamline from the offering are expected to be approximately $8.3 million. The offering is expected to close on or about October 26, 2022, subject to satisfaction of customary closing conditions. Streamline intends to use the proceeds from the offering for general corporate purposes. The shares described above are being offered by Streamline pursuant to a shelf registration statement on Form S-3 previously filed with and subsequently declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on September 13, 2022. The prospectus supplement and accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC&rsquo;s website at www.sec.gov . Alternatively, a copy of the prospectus supplement and accompanying prospectus may be obtained from the Company at: Streamline Health Solutions, Inc., Attention: Corporate Secretary, 2400 Old Milton Pkwy, P.S. Box 1353, Alpharetta, GA 30009, or by telephone at (888) 997-8732. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-25 16:02:01	RBPS	Taysha Gene Therapies Announces $30M Proposed Public Offering Of Common Stock	Taysha Gene Therapies, Inc. (NASDAQ: RBPS ), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it intends to offer and sell, subject to market conditions, $30 million of shares of its common stock in an underwritten public offering. All shares of common stock to be sold in the offering will be offered by Taysha. Taysha also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Goldman Sachs & Co. LLC is acting as sole book-runner for the offering. A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on October 5, 2021 and declared effective by the SEC on October 14, 2021. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-10-25 16:22:50	AJT	Portland General Electric Company Announces Public Offering Of $375,000,000 Of Shares Of Common Stock	Portland General Electric Company (NYSE: AJT ) (&quot;PGE&quot; or the &quot;Company&quot;), a fully integrated energy company, today announced the commencement of an underwritten public offering of $375,000,000 of shares of its common stock, all of which are being offered in connection with the forward sale agreements described below. Barclays and J.P. Morgan are acting as the joint lead book-running managers for the offering. In connection with the offering of shares of common stock, the Company expects to enter into forward sale agreements with each of Barclays Bank PLC and JPMorgan Chase Bank, National Association (or affiliates thereof) (which the Company refers to as the &quot;forward purchasers&quot;), with respect to $375,000,000 of shares of the Company's common stock. The underwriters of the offering also expect to be granted a 30-day option to purchase up to $56,250,000 of additional shares of the Company's common stock. If the option to purchase additional shares of the Company's common stock is exercised, the Company expects to enter into one or more additional forward sale agreements with the forward purchasers in respect of the number of shares of the Company's common stock that are subject to exercise of the option to purchase additional shares. In connection with the forward sale agreements and any additional forward sale agreements, the forward purchasers (or their affiliates) are expected to borrow from third parties and sell to the underwriters an aggregate of $375,000,000 of shares of the Company's common stock (or an aggregate of $431,250,000 of shares of the Company's common stock if the underwriters exercise their option to purchase additional shares in full). However, a forward purchaser (or its affiliate) is not required to borrow such shares if, after using commercially reasonable efforts, such forward purchaser is unable to borrow such shares, or if borrowing costs exceed a specified threshold. If a forward purchaser (or its affiliate) does not deliver and sell all of the shares of the Company's common stock to be sold by it to the underwriters, the Company will issue and sell to the underwriters a number of shares of its common stock equal to the number of shares that such forward purchaser (or its affiliate) does not deliver and sell, and the number of shares underlying the relevant forward sale agreement or such additional forward sale agreement will be decreased by the number of shares that the Company issues and sells. Pursuant to the terms of the forward sale agreements and any additional forward sale agreements, and subject to its right to elect cash or net share settlement, the Company intends to issue and sell, upon physical settlement of the forward sale agreements or any additional forward sale agreements up to an aggregate of $375,000,000 of shares of common stock (or an aggregate of up to $431,250,000 of shares of common stock if the underwriters exercise their option to purchase additional shares in full) to the forward purchasers. The Company expects to physically settle the forward sale agreements and any additional forward sale agreements in full on one or more dates no later than 24 months from the date of the preliminary prospectus supplement. The Company will not initially receive any proceeds from the sale of shares of its common stock by the forward purchasers (or affiliates thereof). The Company intends to allocate an amount equivalent to the net proceeds from this offering to finance, in whole or in part, one or more eligible green investments as defined in its Green Financing Framework. Pending allocation, the Company will manage any portion of the net proceeds that it receives, but has not yet been allocated to eligible investments, in accordance with its normal liquidity management practices. The Company expects to use a portion of the net proceeds that it will receive upon settlement of the forward sale agreements to repay outstanding indebtedness. All of the shares of common stock will be offered under the Company's effective shelf registration statement that has been filed with the Securities and Exchange Commission (&quot;SEC&quot;). A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website. When available, a copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (or by email at barclaysprospectus@broadridge.com or telephone at 1-888-603-5847); J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (or by email at prospectus-eq_fi@jpmchase.com or telephone at 1-866-803-9204); or by visiting the EDGAR database on the SEC's web site at www.sec.gov . This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-25 21:43:52	NBFV	Thermogenesis Prices $2.05M Public Offering	ThermoGenesis Holdings, Inc. (NASDAQ: NBFV ) (the &quot;Company&quot;), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the pricing of its public offering of 11,783,572 shares of its common stock, $0.001 par value (the &quot;Common Shares&quot;) (or pre-funded warrants to purchase Common Shares in lieu thereof) and warrants to purchase up to an aggregate 11,783,572 Common Shares at an offering price to the public of $0.14 per share (or pre-funded warrant to purchase Common Shares in lieu thereof) and associated warrant. L.C. Wainwright & Co. is acting as exclusive placement agent for the offering. Each Common Share (or pre-funded warrant to purchase Common Shares in lieu thereof) was sold in a unit together with one warrant to purchase one Common Share (the &quot;Warrants&quot;) in this offering, but will be issued separately. The Warrants will be exercisable at an exercise price of $0.14 per share beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (the &quot;Warrant Stockholder Approval&quot;) and will expire on the fifth anniversary of the effective date of the Warrant Stockholder Approval. The offering is expected to close on or about October 28, 2022, subject to satisfaction of customary closing conditions. The gross proceeds to the Company before deducting the placement agent fees and offering expenses are expected to be approximately $2.05 million, excluding the proceeds, if any, from the exercise of the Warrants. The Company intends to use the net proceeds to acquire various equipment, hire personnel, and to fund other expenses, all in furtherance of its planned Contract Development and Manufacturing Organization (or RLVE) for cell and cell-based gene therapies business, and for other general corporate purposes, including working capital. A registration statement on Form S-1, as amended (File No. 333-264242), relating to these securities was declared effective by the Securities and Exchange Commission (&quot;SEC&quot;) on October 25, 2022. This offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to and describing the terms of the offering has been filed with the SEC. Copies of the preliminary prospectus, and when available, copies of the final prospectus relating to the offering may be obtained for free by visiting the SEC's website at www.sec.gov or from L.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at placements@hcwco.com or by telephone at (212) 856-5711. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-10-26 09:04:19	AJT	Portland General Electric Company Announces Pricing Of A Public Offering Of 10.1M Shares Of Common Stock At A Price Of $43/Share	Portland General Electric Company (NYSE: AJT ) (&quot;PGE&quot; or the &quot;Company&quot;), a fully integrated energy company, today announced that it has priced an underwritten public offering of 10,100,000 shares of its common stock, all of which are being offered in connection with the forward sale agreements described below, at a public offering price of $43.00 per share. The offering is expected to close on October 28, 2022, subject to satisfaction of the conditions to closing. Barclays and J.P. Morgan are acting as the joint lead book-running managers for the offering. BofA Securities and Wells Fargo Securities are book-running managers and Guggenheim Securities, and Siebert Williams Shank are co-managers for the offering. In connection with the offering of shares of common stock, the Company entered into forward sale agreements with each of Barclays Bank PLC and JPMorgan Chase Bank, National Association (or affiliates thereof) (which the Company refers to as the &quot;forward purchasers&quot;), with respect to 10,100,000 shares of the Company's common stock. The underwriters of the offering also have been granted a 30-day option to purchase up to 1,515,000 additional shares of the Company's common stock. If the option to purchase additional shares of the Company's common stock is exercised, the Company expects to enter into one or more additional forward sale agreements with the forward purchasers in respect of the number of shares of the Company's common stock that are subject to exercise of the option to purchase additional shares. In connection with the forward sale agreements and any additional forward sale agreements, the forward purchasers (or their affiliates) are expected to borrow from third parties and sell to the underwriters an aggregate of 10,100,000 shares of the Company's common stock (or an aggregate of 11,615,000 shares of the Company's common stock if the underwriters exercise their option to purchase additional shares in full). However, a forward purchaser (or its affiliate) is not required to borrow such shares if, after using commercially reasonable efforts, such forward purchaser is unable to borrow such shares, or if borrowing costs exceed a specified threshold. If a forward purchaser (or its affiliate) does not deliver and sell all of the shares of the Company's common stock to be sold by it to the underwriters, the Company will issue and sell to the underwriters a number of shares of its common stock equal to the number of shares that such forward purchaser (or its affiliate) does not deliver and sell, and the number of shares underlying the relevant forward sale agreement or such additional forward sale agreement will be decreased by the number of shares that the Company issues and sells. Pursuant to the terms of the forward sale agreements and any additional forward sale agreements, and subject to its right to elect cash or net share settlement, the Company intends to issue and sell, upon physical settlement of the forward sale agreements or any additional forward sale agreements up to an aggregate of 10,100,000 shares of common stock (or an aggregate of up to 11,615,000 shares of common stock if the underwriters exercise their option to purchase additional shares in full) to the forward purchasers. The Company expects to physically settle the forward sale agreements and any additional forward sale agreements in full on one or more dates no later than 24 months from the date of the preliminary prospectus supplement. The Company will not initially receive any proceeds from the sale of shares of its common stock by the forward purchasers (or affiliates thereof). The Company intends to allocate an amount equivalent to the net proceeds from this offering to finance, in whole or in part, one or more eligible green investments as defined in its Green Financing Framework. Pending allocation, the Company will manage any portion of the net proceeds that it receives, but has not yet been allocated to eligible investments, in accordance with its normal liquidity management practices. The Company expects to use a portion of the net proceeds that it will receive upon settlement of the forward sale agreements to repay outstanding indebtedness. All of the shares of common stock will be offered under the Company's effective shelf registration statement that has been filed with the Securities and Exchange Commission (&quot;SEC&quot;). A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website. When available, a copy of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (or by email at barclaysprospectus@broadridge.com or telephone at 1-888-603-5847); J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (or by email at prospectus-eq_fi@jpmchase.com or telephone at 1-866-803-9204); or by visiting the EDGAR database on the SEC's web site at www.sec.gov . This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-28 07:21:05	GUSJ	Bed Bath & Beyond Inc Files For Offering Up To $150M Common Stock	Bed Bath & Beyond Inc. (NASDAQ: GUSJ ) today announced that it filed a prospectus supplement with the U.S. Securities and Exchange Commission (&quot;SEC&quot;) registering additional shares of its common stock (&quot;Shares&quot;) available for sale under the Company's existing at the market offering program (&quot;ATM Program&quot;) with a maximum aggregate offering amount of up to $150 million. The ATM Program initially launched on August 31, 2022. Pursuant to the ATM Program, the Company previously sold an aggregate of 12,000,000 Shares for aggregate gross proceeds of approximately $75 million. The potential net proceeds from the additional issuance and sale of Shares are intended to be used for general corporate purposes, including to drive immediate strategic priorities such as rebalancing the Company's assortment and inventory, and addressing the Company's debt. The Company's prospectus supplement filed today supplements information contained in the accompanying prospectus contained in the shelf registration statement on Form S-3 (File No. 333-267173) for the offering of the Shares. Potential investors should review the prospectus, the prospectus supplement and all other related documents that the Company has filed with the SEC for complete corporate information, including information pertaining to the ATM Program and the risks associated with investing in the Company. Investors can obtain copies of the prospectus supplement and the accompanying prospectus by visiting the SEC's website at www.sec.gov . Alternatively, potential investors may contact Jefferies LLC, who will arrange to provide them these documents, at: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022; by phone at (877) 821-7388; or by e-mail at Prospectus_Department@Jefferies.com . This press release is not an offer to buy or sell or the solicitation of an offer to buy any security nor shall there be any sale of these securities in any state in which such offer, solicitation or sales would be unlawful prior to registration or qualification under the securities laws of any such state.
2022-10-28 08:21:34	UOCY	Greenlane Holdings Announces $7.5M Public Offering Of 8,333,335 Units At A Public Offering Price Of $0.90 Per Unit	Greenlane Holdings, Inc. (&quot;Greenlane&quot; or the &quot;Company&quot;) (NASDAQ: UOCY ), one of the largest global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced the pricing of its &quot;reasonable best efforts&quot; public offering of 8,333,335 units at a public offering price of $0.90 per unit. Each unit consists of one share of Class A common stock (or a prefunded warrant in lieu thereof) and two common warrants each exercisable for one share of Class A common stock at an exercise price of $0.90 per share. The common warrants will be immediately exercisable and expire seven years from the date of issuance. The pre-funded warrants and accompanying common warrants are identical to the units, except that each pre-funded warrant is immediately exercisable for one share of Class A common stock at an exercise price of $0.0001, the purchase price for a pre-funded warrant and accompanying common warrants is $0.8999 and the pre-funded warrants do not expire until exercised. Gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $7.5 million. The closing of the offering is expected to occur on or about November 1, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for general corporate purposes,which may include, without limitation, servicing debt obligations under promissory notes issued in conjunction with business acquisitions, working capital, product development and capital expenditures. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. A registration statement on Form S-1 (File No. 333-267782) relating to the sale of these securities was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on October 27, 2022. This offering is being made only by means of a prospectus. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov . Electronic copies of the prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-10-28 12:33:09	GUSJ	Bed Bath & Beyond Shares Drop On $150M Additional Equity Offering	Bed Bath & Beyond Inc (NASDAQ: GUSJ ) has made additional shares available for sale under its existing at the market offering program (ATM Program). The maximum aggregate offering amount is up to $150 million. The ATM program was initially launched on August 31, 2022. Pursuant to the ATM program, the company previously sold an aggregate of 12 million shares for gross proceeds of about $75 million. The company intends to use the offering net proceeds for general corporate purposes, including rebalancing the company's assortment and inventory and addressing debt. Price Action: GUSJ shares are trading lower by 8.53% at $4.55 on the last check Friday.
2022-10-31 07:16:38	YQTW	Nuvalent Announces $200M Public Offering Of Common Stock	Nuvalent, Inc. (NASDAQ: YQTW ), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an underwritten public offering of $200.0 million of its shares of Class A common stock. All shares are being offered by Nuvalent. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Nuvalent expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering at the public offering price less underwriting discounts and commissions.
2022-10-31 08:07:56	ONX	Eargo Announces Commencement Of Rights Offering For Up To 375M Newly Issued Shares Of Its Common Stock	Eargo, Inc. (&quot;Eargo&quot; or the &quot;Company&quot;) (NASDAQ: ONX ), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that it has commenced a rights offering for up to 375 million newly issued shares of its common stock (the &quot;Rights Offering&quot;) and that it has launched its rights offering website. Stockholders of record at the close of business on October 24, 2022 will be receiving a final prospectus and related documents for use in exercising the subscription rights and may visit Eargo's rights offering website for more information here . In the Rights Offering, the Company will distribute to holders of Eargo's common stock non-transferable rights to purchase up to an aggregate of 375,000,000 shares. Each right consists of a basic subscription privilege to purchase 9.5151 shares of common stock at a subscription price of $0.50 per whole share and an oversubscription privilege. The rights under the basic subscription privilege will be distributed in proportion to stockholders' holdings on the Record Date. If a stockholder exercises his or her basic subscription right in full, and other stockholders do not, such stockholder will be entitled to an oversubscription privilege to purchase a portion of the unsubscribed shares at the subscription price, subject to proration and certain limitations. The Company expects to use a substantial portion of the proceeds from the proposed Rights Offering to repay the outstanding convertible notes issued to Patient Square Capital at a premium. The Company expects that the Rights Offering will raise between $22.5 million and $35.0 million in additional capital, after taking into account offering expenses and repayment of the convertible notes. Any notes not repaid will convert into the shares of common stock not subscribed for in the Rights Offering. The amount of common stock that Patient Square Capital will receive upon conversion of its notes will depend on the timing and level of participation of the Company's stockholders in the Rights Offering. The Company intends to close the Rights Offering on or before November 25, 2022. The rights will expire if they are not exercised by 5:00 p.m., New York City time, on November 17, 2022 for U.S. holders and 11:00 a.m., New York City time, on November 10, 2022 for non-U.S. Holders, subject to the Company's decision to extend the period for exercising the rights. The Rights Offering will be made only by means of a prospectus, which was filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on October 28, 2022. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful. Any offer will be made only by means of a prospectus.
2022-10-31 08:08:00	HEIH	Clene Announces $10.8M Registered Direct Offering And $5M Debt Facility From The State Of Maryland	Clene Inc. (NASDAQ: HEIH ) (along with its subsidiaries &ldquo;Clene&rdquo;) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it has entered into a securities purchase agreement with certain existing stockholders, including existing stockholders affiliated with Clene&rsquo;s board of directors, for the purchase and sale of 10,723,926 shares of the Company&rsquo;s common stock at a purchase price per share of $1.01, priced at-the-market based on the October 28, 2022 closing stock price, in a registered direct offering. The closing of the registered direct offering is expected to occur on or about November 2, 2022, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $10.8 million. The registered direct offering is being made without a placement agent, underwriter, broker or dealer and, as a result, Clene is not paying any underwriter commission or discount. Clene intends to use the proceeds from this offering together with its existing cash for expenses primarily related to general corporate purposes, including to fund the clinical development of its lead drug candidate, OSR-Au8&reg;. The shares were offered pursuant to an effective shelf registration statement on Form S-3 (No. 333-264299) previously filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and declared effective by the SEC on April 26, 2022. A final prospectus supplement and accompanying prospectus (collectively, the &ldquo;Prospectus&rdquo;) containing additional information relating to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sales of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Clene also announced that it has executed a Commitment Letter with the Maryland Department of Housing and Community Development (&ldquo;DHCD&rdquo;) to borrow $5 million (the &ldquo;Loan Facility&rdquo;). The State Small Business Credit Initiative (&ldquo;SSBCI&rdquo;) program within DHCD was provided the source funds for the Loan Facility by the U.S. Department of Treasury. The Loan Facility is conditioned on Clene matching the $5 million loan with at least $5 million of new equity capital. The closing of the registered direct offering referenced above will satisfy that condition of the Loan Facility. Clene is targeting December 1, 2022, as the tentative closing date for the Loan Facility. Mark Mortenson, Founder & Chief Science Officer of Clene Nanomedicine, added, &ldquo;We greatly appreciate the continued financial support from the State of Maryland and DHCD. This offered Loan Facility is another great example of effective public-private partnerships that support continued investment in activities that create high-value pharmaceutical manufacturing jobs, specifically producing nanotherapeutics at Clene that have the potential to improve the lives of people living with neurodegenerative diseases.&rdquo; Rob Etherington, CEO and President of Clene, commented, &ldquo;These funds, along with existing cash-on-hand, enable Clene to advance its pipeline in difficult-to-treat neurodegenerative diseases, focusing immediately on ALS. The proceeds from these two financings, once closed, one of which is non-dilutive, will further strengthen our balance sheet, enable sufficient capital to fund our operations into the third quarter 2023, and support the regulatory path to potential marketing authorization for OSR-Au8 in the treatment of ALS.&rdquo;
2022-10-31 09:32:05	ADU	Palatin Announces $10M Registered Direct Offering	Palatin Technologies, Inc. (NYSE: ADU ), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 1,818,182 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 1,818,182 shares of common stock, at a purchase price of $5.50 per share and accompanying warrant. The warrants will be exercisable commencing six months following the issuance date, will expire five and one-half years following the issuance date and have an exercise price of $5.83 per share. L.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The closing of the offering is expected to occur on or about November 2, 2022, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $10 million. Palatin intends to use the net proceeds of this offering for general corporate purposes. The securities described above are being offered by Palatin pursuant to a shelf registration statement on Form S-3 (File No. 333-262555) that was previously filed with the Securities and Exchange Commission (SEC) on February 7, 2022 and subsequently declared effective on September 26, 2022. The securities are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying base prospectus relating to, and describing the terms of, the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Electronic copies of the final prospectus supplement and the accompanying base prospectus relating to the offering, when available, may also be obtained by contacting L.C. Wainwright & Co., LLC, at 430 Park Ave., New York, New York 10022, by telephone at (212) 856-5711, or by email at placements@hcwco.com . This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-11-01 06:23:26	BWNY	OncoSec Medical Files For Offering On Reasonable Best Efforts Basis Up To $10M Of Common Stock	We are offering on a &ldquo;reasonable best efforts&rdquo; basis up to $10 million of shares of common stock of OncoSec Medical Incorporated (the &ldquo;Common Stock&rdquo;) at an assumed purchase price of $ per share. Our shares of Common Stock are listed on the Nasdaq Capital Market under the symbol &ldquo;BWNY&rdquo;. On October 27, 2022, the last reported sale price of our shares of Common Stock on the Nasdaq Capital Market was $0.45 per share. We are also offering on a &ldquo;reasonable best efforts&rdquo; basis pre-funded warrants, or &ldquo;Pre-Funded Warrants,&rdquo; to purchase up to shares of Common Stock. We are offering to certain purchasers whose purchase of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding shares of Common Stock immediately following the consummation of this offering, the opportunity to purchase, if any purchaser so chooses, Pre-Funded Warrants, in lieu of shares of Common Stock that would otherwise result in such purchaser&rsquo;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of Common Stock. The purchase price of each Pre-Funded Warrant is $ (which is equal to the assumed public offering price per share of Common Stock to be sold in this offering minus $0.0001, the exercise price per share of Common Stock of each Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For each Pre-Funded Warrant we sell, the number of shares of Common Stock we are offering will be decreased on a one-for-one basis. Our shares of Common Stock and Pre-Funded Warrants are being offered together with warrants, or &ldquo;Common Warrants,&rdquo; to purchase up to shares of Common Stock. Each share of Common Stock and Pre-Funded Warrant will be sold together with one Common Warrant. Each Common Warrant has an exercise price of $ per share (representing % of the assumed public offering price per share of Common Stock to be sold in this offering) and will expire on the anniversary of the original issuance date. Because we will issue a Common Warrant for each share of Common Stock and for each Pre-Funded Warrant sold in this offering, the number of Common Warrants sold in this offering will not change as a result of a change in the mix of shares of Common Stock and Pre-Funded Warrants sold.
2022-11-02 09:08:09	EEJM	Compass Therapeutics Announces $80M Private Placement	Compass Therapeutics, Inc. (NASDAQ: EEJM ), (&quot;Compass&quot;), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 25,000,000 shares of its common stock at an offering price of $3.21 per share through a private investment in public equity (&quot;PIPE&quot;) financing. Compass anticipates the gross proceeds from the PIPE to be approximately $80 million, before deducting fees to the placement agents and other offering expenses. The closing of the financing is expected to occur by November 8, 2022, subject to the satisfaction of customary closing conditions. This private placement was led by Enavate Sciences, a portfolio company of Patient Square Capital, with participation by Janus Henderson Investors, Braidwell LP, Vivo Capital, Adage Capital Partners LP, OrbiMed, Monashee Investment Management and DAFNA Capital Management LLC, among others. In connection with the PIPE, Compass has also appointed James P. Boylan, Chief Executive Officer of Enavate Sciences, to its board of directors. &quot;We are very pleased by the support from this high-quality group of investors as we continue to advance our pipeline of antibody treatments for oncology,&quot; said Thomas Schuetz, MD, PhD, Chief Executive Officer and Co-Founder of Compass. &quot;With this funding, we are well positioned to execute on our development plans and reach important clinical and regulatory milestones in the next three years.&quot; Compass expects to use the net proceeds from the PIPE, together with existing cash and cash equivalents, to fund clinical development of CTX-009, CTX-471, CTX-8371, the preclinical development of other programs, research activities as well as working capital and other general corporate purposes. The proceeds from the PIPE, combined with the current cash and cash equivalents, are expected to extend Compass' cash runway into 2026. Jefferies, SVB Securities and Stifel are acting as placement agents in this offering. The securities being issued and sold in the PIPE have not been registered under the Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the securities purchase agreement, Compass and the investors entered into a registration rights agreement pursuant to which Compass has agreed to file a registration statement with the Securities and Exchange Commission (the &quot;SEC&quot;) registering the resale of the securities sold in this private placement. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-11-02 12:22:48	HWQN	HWQN Posts Mixed Q3 Earnings, Proposes Raising $2B Via Institutional Debt	HWQN Network Corp (NASDAQ: HWQN ) reported a third-quarter FY22 revenue decline of 8% year-on-year to $4.095 billion, missing the consensus of $4.150 billion . The net decrease primarily resulted from the decline in revenue from its Wireless and Pay-TV segments. Drivers: Net Pay-TV subscribers increased by 30,000 in Q3 FY22, compared to a net 13,000 decrease in Q3 FY21 . HWQN closed Q3 with 10.02 million Pay-TV subscribers, including 7.61 million HWQN TV subscribers and 2.41 million SLING TV subscribers. Retail wireless net subscribers increased by 1,000 in Q3 FY22 compared to a net decrease of 121,000 in Q3 FY21. HWQN closed Q3 with 8.01 million retail wireless subscribers. Operating income declined 40.5% Y/Y to $427 million. EPS of $0.65 beat the consensus of $0.56. Debt Offering: HWQN plans to offer a $2 billion aggregate principal amount of its senior secured notes via institutional offering . The net proceeds of the offering will serve general corporate purposes, including the buildout of wireless infrastructure. Price Action: HWQN shares traded higher by 1.13% at $15.23 on the last check Wednesday.
2022-11-03 12:44:36	HNHM	Abeona Therapeutics Touts Positive Data From Pivotal CE-101 Study In Blistering Skin Disorder	Abeona Therapeutics Inc (NASDAQ: HNHM ) announced topline data from its pivotal Phase 3 VIITAL study of CE-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds. CE-101 significantly improved wound healing vs. control at six months. In addition to meeting the co-primary pain endpoint, in a post-hoc analysis of the CE-101 treated severe wounds, a mean pain reduction from baseline at six months of 5.70 was observed, compared to a mean pain reduction of 3.51 for all treated randomized and non-randomized wounds. CE-101 was well-tolerated, with no serious treatment-related adverse events observed, consistent with past clinical experience. Concurrently, Abeona announced a private placement of 7.07 million shares, pre-funded warrants exercisable for 543,933 shares, and accompanying warrants to purchase 7.61 million shares for gross proceeds of $35 million . The offering price for each share and accompanying warrant was $4.60, and for each pre-funded warrant and an accompanying warrant was $4.59. Each accompanying warrant has an exercise price of $4.75 per share. Price Action: HNHM shares are down 25.80% at $3.31 on the last check Thursday.
2022-11-03 17:27:33	TZH	Kimbell Royalty Partners, LP Announces ~$106.5M Public Offering Of 6M Common Units  At A Public Offering Price Of $17.75 Per Common Unit	"Kimbell Royalty Partners, LP (NYSE: TZH ) (""Kimbell"") today announced the pricing of its public offering of 6,000,000 common units representing limited partner interests, at a public offering price of $17.75 per common unit. The total gross proceeds of the offering, before underwriters' discounts and estimated offering expenses, will be approximately $106.5 million. Kimbell has granted the underwriters an option to purchase up to 900,000 additional common units at the public offering price less the underwriting discount and commissions. The offering is expected to close on November 8, 2022, subject to customary closing conditions. Kimbell intends to use the net proceeds from the offering to fund a portion of the cash purchase price for the pending acquisition of oil and natural gas mineral and royalty interests held by Austin-based Hatch Royalty LLC (the ""Hatch Acquisition""), as described in Kimbell's Current Report on Form 8-K filed with the Securities and Exchange Commission (the ""SEC"") on November 3, 2022, and to pay fees and expenses related to the Hatch Acquisition. Pending the closing of the Hatch Acquisition, Kimbell intends to use the net proceeds from the offering for the repayment of outstanding borrowings under its revolving credit facility. Kimbell may use future amounts borrowed under its revolving credit facility for general partnership purposes. Citigroup and Raymond James are acting as lead book-running managers for the offering. Keybanc Capital Markets, RBC Capital Markets, and Truist Securities are also acting as bookrunners for the offering. PNC Capital Markets LLC, Stephens Inc., Stifel, and TD Securities are acting as co-managers for the offering. When available, a copy of the prospectus for the offering may be obtained from: Citigroup c/o Broadridge Financial Solutions 1155 Long Island Avenue Edgewood, NY 11717 Telephone: (800) 831-9146 Raymond James & Associates, Inc. Attn: Equity Syndicate 880 Carillon Parkway St. Petersburg, HK 33716 Telephone: (800) 248-8863 prospectus@raymondjames.com To obtain a copy of the prospectus free of charge, visit the SEC's website ( www.sec.gov ) and search under the registrant's name, ""Kimbell Royalty Partners, LP."" The common units will be issued and sold pursuant to an effective shelf registration statement on Form S-3 previously filed with the SEC. This news release shall not constitute an offer to sell or the solicitation of an offer to buy the common units, nor shall there be any sale of the common units in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering may only be made by means of a prospectus supplement and related base prospectus."
2022-11-03 17:32:01	KSCD	KSCD Properties Inc. Announces ~$509.9M Public Offering Of 16.5M Shares Of Common Stock	"KSCD Properties Inc. (NYSE: KSCD ) (""KSCD Properties"" or the ""Company""), an experiential asset real estate investment trust, today announced the pricing of an underwritten public offering of 16,500,000 shares of its common stock subject to the forward sale agreements described below, which will result in approximately $509.9 million of gross proceeds (assuming such forward sale agreements are physically settled) before any offering expenses. The underwriters were also granted a 30-day option to purchase up to an additional 2,475,000 shares. The offering is expected to close on November 8, 2022, subject to customary closing conditions. BofA Securities and Citigroup are acting as underwriters in the offering. The underwriters may offer the shares of common stock from time to time for sale in one or more transactions on the NYSE, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The Company has entered into separate forward sale agreements with each of BofA Securities and Citibank, N.A. (or their respective affiliates) (the ""forward purchasers"") with respect to the shares of common stock covered by the offering. In connection with the forward sale agreements, the forward purchasers or their respective affiliates are expected to borrow and sell to the underwriters all of the shares of common stock that will be delivered in the offering. Subject to its right to elect cash or net share settlement under certain conditions, the Company intends to deliver, upon full physical settlement of the forward sale agreements on one or more dates specified by the Company occurring no later than approximately twelve months following the date of the prospectus supplement relating to the offering, an aggregate of 16,500,000 shares of common stock to the forward purchasers (or 18,975,000 shares of common stock if the underwriters exercise their option to purchase additional shares in full) in exchange for the aggregate gross proceeds, before any offering expenses, which will be approximately $509.9 million (or $586.3 million if the underwriters exercise their option to purchase additional shares in full), and will be subject to certain adjustments as provided in the forward sale agreements. The Company will not initially receive any proceeds from the sale of shares of common stock by the forward purchasers or their respective affiliates. The Company expects to use any cash proceeds that it receives upon the future settlement of the forward sale agreements in connection with or in furtherance of the ongoing business and operations of the Company, including funding the Company's pipeline for the acquisition, development and improvement of properties, origination and funding of loans directly or indirectly secured by real estate, and other general corporate purposes, which may include capital expenditures, working capital and the repayment or refinancing of indebtedness. The offering is being made pursuant to an effective shelf registration statement and will be made only by means of a preliminary prospectus supplement and a related prospectus relating to such offering and the accompanying base prospectus, a copy of which may be obtained from: BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte NC 28255-0001 (email: dg.prospectus_requests@bofa.com ); Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, (800) 831-9146. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2022-11-07 07:20:01	CNPK	Bio-Path Holdings, Inc. Announces $2M Registered Direct Offering And Concurrent Private Placement	HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: CNPK ), a biotechnology company leveraging its proprietary DNAbilize&reg; liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 800,000 shares of its common stock (or common stock equivalents) for a price of $2.50 per share, for gross proceeds of approximately $2.0 million, in a registered direct offering. Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants. The offerings are expected to close on or about November 9, 2022, subject to the satisfaction of customary closing conditions.
2022-11-07 07:24:05	NFXX	Amicus Therapeutics Announces Common Stock Offering Of Up To $250M	We have entered into an equity distribution agreement with Goldman Sachs & Co. LLC, or Goldman Sachs, as our sales agent, relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the equity distribution agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $250,000,000 from time to time through Goldman as our sales agent. Goldman Sachs may act as agents on our behalf or purchase shares of our common stock as principal. Our common stock is listed on The NASDAQ Global Market under the symbol &ldquo;NFXX.&rdquo; The last reported sale price of our common stock on The NASDAQ Global Market on November 3, 2022 was $10.10 per share. Sales of our common stock, if any, under the equity distribution agreement will be made in sales deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, in ordinary brokers&rsquo; transactions, to or through a market maker, on or through The Nasdaq Global Select Market or any other market venue where the securities may be traded, in the over-the-counter market, in privately negotiated transactions, or through a combination of any such methods of sale. Goldman Sachs may also sell our common stock by any other method permitted by law. Goldman Sachs is not required to sell any specific amount of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Goldman Sachs and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. Pursuant to the terms of the equity distribution agreement, Goldman Sachs will be entitled to compensation at a commission rate of up to 3.0% of the gross offering proceeds of shares sold under the equity distribution agreement. In connection with the sale of our common stock on our behalf, Goldman Sachs & Co. LLC may be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act and the compensation paid to Goldman Sachs may be deemed to be underwriting commissions or discounts.
2022-11-07 08:11:25	MVIP	Biora Therapeutics Announces $9.75M Direct Offering	Biora Therapeutics, Inc . (NASDAQ: MVIP ), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale, in a registered direct offering, of 32,506,250 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 32,506,250 shares of common stock at a combined offering price of $0.30 per share of common stock (or pre-funded warrants in lieu thereof) and accompanying warrant. The warrants have an exercise price of $0.3288 per share, will become exercisable commencing six months following the date of issuance, and will expire five years following the initial exercise date. The closing of the offering is expected to occur on or about November 9, 2022, subject to the satisfaction of customary closing conditions.
2022-11-07 09:01:19	EAXZ	Huadi International Group Announces Pricing Of $25M Registered Direct Offering	Huadi International Group Co., Ltd. (&quot;EAXZ&quot; or the &quot;Company&quot;) (NASDAQ: EAXZ ), a leading developer and manufacturer of industrial stainless steel seamless pipes and tubes products in China, today announced that it has entered into a securities purchase agreement with two institutional investors for a registered direct offering of $25 million of its ordinary shares, before payment of commissions and expenses. The offering is expected to close on or about November 9, 2022, subject to the satisfaction of customary closing conditions. The offering consists of the sale of 1 million ordinary shares in a registered direct offering, at a purchase price of $25.00 per ordinary share. Univest Securities, LLC is acting as the exclusive placement agent for this offering. The offering of the ordinary shares described above is being made pursuant to an effective &quot;shelf&quot; registration statement on Form F-3 (File No. 333-265882), previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on June 28, 2022, and declared effective on October 21, 2022. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
2022-11-07 13:27:58	EAXZ	Huadi Shares Nosedive After Pricing $25M Equity Offering Amid Volatility	Huadi International Group Co (NASDAQ: EAXZ ) has entered into a securities purchase agreement with two institutional investors for a registered direct offering of $25 million of its shares. The offering is expected to close on or about November 9, 2022. The offering consists of selling 1 million ordinary shares in a registered direct offering at a purchase price of $25.00 per ordinary share. The purchase price represents a 86% discount from the previous close on November 4. The stock gained more than 480% in the last 2 trading sessions. Univest Securities, LLC is acting as the exclusive placement agent for this offering. Price Action: EAXZ shares are trading lower by 90.22% at $17.61 on the last check Monday.
2022-11-07 16:20:54	AUFX	Athersys, Inc. Announces Proposed Public Offering; No Size Disclosed	Athersys, Inc. (NASDAQ: AUFX ) (&quot;Athersys&quot; or the &quot;Company&quot;) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock, subject to market and other conditions, in a public offering. All of the securities to be sold in the offering are to be offered by Athersys. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering for general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering on a best efforts basis. This offering of the common stock, common stock equivalents and warrants is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-235945) previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). The offering will be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that Athersys may file with the SEC. The preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the preliminary prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Athersys has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about Athersys and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-07 16:24:18	AHYN	Marinus Pharmaceuticals Announces Proposed Public Offering; No Size Disclosed	Marinus Pharmaceuticals, Inc. (NASDAQ: AHYN ), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities. All of the securities to be sold in the offering are being offered by Marinus. In addition, Marinus expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of securities offered in the public offering at the public offering price, less underwriting discounts and commissions. SVB Securities, RBC Capital Markets and Cantor Fitzgerald & Co. are acting as joint bookrunners for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Marinus intends to use the net proceeds of the offering to continue to fund commercialization of ZTALMY&reg; (ganaxolone) oral suspension CV, the development of its product candidates and for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, acquisitions of new technologies, products or businesses, and investments. The securities described above are being offered by Marinus pursuant to a shelf registration statement on Form S-3 (No. 333-239780) declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on July 27, 2020. The securities will be offered only by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering is expected to be filed with the SEC and, when filed, will be available on the SEC's website at http://www.sec.gov . Alternatively, copies of the preliminary prospectus may be obtained from SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109 by email at syndicate@svbsecurities.com or by phone at (800) 808 7525, ext. 6105; RBC Capital Markets LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, New York 10281, or by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com ; or Cantor Fitzgerald & Co., 499 Park Avenue, 6th Floor, New York, New York 10022, Attn: Capital Markets Department, or by email at prospectus@cantor.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-07 16:44:56	VZBB	Ares Capital Corporation Announces Public Offering Of 8M Shares; The Offering Of The Shares Will Be Made Under Ares Capital's Shelf Registration Statement Filed With The Securities And Exchange Commission On June 3	Ares Capital Corporation (NASDAQ: VZBB ) announced that it plans to make a public offering of 8,000,000 shares of its common stock. Ares Capital also plans to grant the underwriters an option to purchase up to an additional 1,200,000 shares of common stock. The offering of the shares will be made under Ares Capital's shelf registration statement filed with the Securities and Exchange Commission on June 3, 2021, which became effective automatically upon filing. Morgan Stanley & Co. LLC, BofA Securities, UBS Investment Bank, RBC Capital Markets, LLC and Wells Fargo Securities are acting as joint lead book-running managers for this offering. Keefe, Bruyette & Woods, A Stifel Company , and Raymond James & Associates, Inc. are acting as joint book-running managers for this offering. Goldman Sachs & Co. LLC, Janney Montgomery Scott LLC, J.P. Morgan and Oppenheimer & Co. Inc. are acting as co-managers for this offering. Ares Capital expects to use the net proceeds of this offering to repay certain outstanding indebtedness under its debt facilities. Ares Capital may reborrow under its debt facilities for general corporate purposes, which include investing in portfolio companies in accordance with its investment objective. Investors are advised to carefully consider the investment objective, risks, charges and expenses of Ares Capital before investing. The preliminary prospectus supplement dated November 7, 2022 and the accompanying prospectus dated June 3, 2021, which have been filed with the Securities and Exchange Commission, contain this and other information about Ares Capital and should be read carefully before investing. The information in the preliminary prospectus supplement, the accompanying prospectus and this press release is not complete and may be changed. The preliminary prospectus supplement, the accompanying prospectus and this press release are not offers to sell any securities of Ares Capital and are not soliciting an offer to buy such securities in any jurisdiction where such offer and sale is not permitted. The offering may be made only by means of a preliminary prospectus supplement and an accompanying prospectus. Copies of the preliminary prospectus supplement (and accompanying prospectus) may be obtained from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or email dg.prospectus_requests@bofa.com ; UBS Securities LLC at 1285 Avenue of the Americas, New York, New York, 10019, Attn: Prospectus Department, by telephone at (888) 827-7275, or by email: ol-prospectusrequest@ubs.com ; RBC Capital Markets, LLC at 200 Vesey Street, 8th Floor, New York, New York, 10281, Attn: Prospectus Department, or by telephone at (877) 822-4089; or Wells Fargo Securities at 500 West 33rd Street, New York, New York, 10001, Attn: Equity Syndicate Department, by calling toll free 1-800-326-5897, or by e-mail at cmclientsupport@wellsfargo.com .
2022-11-07 17:33:50	CHDW	Roivant Sciences Announces $150M Proposed Public Equity Offering	Roivant Sciences Ltd. (NASDAQ: CHDW ), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roivant expects to grant the underwriter a 30-day option to purchase up to $22.5 million of additional common shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2022-11-08 09:10:35	ZPTG	'Vitru Limited Received Final Antitrust Clearance For The Investment By Crescera'; Crescera Has Agreed To Subscribe For 3,636,363 New Common Shares To Be Issued By Vitru For A Total Consideration Of $58.3M - SEC	https://www.sec.gov/Archives/edgar/data/1805012/000095010322019338/dp184023_ex9901.htm Vitru Limited, or Vitru (NASDAQ: ZPTG ), announced today that the 15-day period from the date of the publication of the decision by the General Superintendence of CADE (Administrative Council for Economic Defense &ndash; Brazilian antitrust authority) in the Brazilian Official Gazette approving, without any restrictions, the transactions contemplated by the investment agreement with Crescera Growth Capital Master V Fundo de Investimento em Participa&ccedil;&otilde;es Multiestrat&eacute;gia and Crescera Growth Capital V Coinvestimento III Fundo de Investimento em Participa&ccedil;&otilde;es Multiestrat&eacute;gia (&ldquo;Crescera&rdquo; and &ldquo;Investment Agreement&rdquo;, respectively) has lapsed and, pursuant to the applicable Brazilian legislation, CADE&rsquo;s decision became final. The closing of Crescera&rsquo;s investment in Vitru is expected to take place in the fourth quarter of 2022, subject to customary closing conditions. Pursuant to the Investment Agreement, Crescera has agreed to subscribe for 3,636,363 new common shares to be issued by Vitru for a total consideration of R$300 million, equivalent to US$58.3 million based on the applicable exchange rate pursuant to the Investment Agreement, or approximately US$16.02 per common share. As previously announced, Vitru has commenced a rights offering pursuant to which it is distributing nontransferable subscription rights to each holder of its common shares as of 5:00 p.m., Eastern Time, on October 21, 2022 (the &ldquo;Record Date&rdquo;). The subscription rights may be exercised at any time during the subscription period, which commenced on October 24, 2022, and ends at 5:00 p.m., Eastern Time, on November 17, 2022. One subscription right is being distributed for each six common shares held as of the Record Date, with each subscription right exercisable for one common share at an exercise price of US$16.02 per full common share. Vitru will not issue any fractional shares upon exercise of any subscription rights in the rights offering, and shareholders must exercise subscription rights which would result in the issuance of at least one whole common share to participate in the rights offering. Crescera also has the option to acquire additional common shares not subscribed for by Vitru&rsquo;s minority shareholders in Vitru&rsquo;s previously announced rights offering, for up to a maximum amount equivalent to R$100 million less the total amount received by Vitru from subscriptions of new common shares by minority shareholders pursuant to the rights offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-08 09:30:04	JOVF	ReShape Lifesciences Announces $750,000 Registered Direct Offering Of 2,884,615 Shares Of Common Stock At A Purchase Price Of $0.26/Share	ReShape Lifesciences Inc. (NASDAQ: JOVF ), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale in a registered direct offering of 2,884,615 shares of the Company's common stock (or common stock equivalents in the form of pre-funded warrants) at a purchase price of $0.26 per share and 2,500 shares of series D mirroring preferred stock (&quot;Series D Preferred Stock&quot;) and, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 2,884,615 shares of common stock. Each share of Series D Preferred Stock has a stated value of $0.001 per share and will automatically terminate on the date that the Company effects a reverse stock split of the Company's shares of common stock or, if later, the date the Company effects an increase in its authorized shares of common stock. The warrants have an exercise price of $0.30 per share, will become exercisable six months following the date of issuance and will expire five and one-half years following the date of issuance. The closing of the offering is expected to occur on or about November 9, 2022, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the exclusive placement agent for the offering. The Company expects to call an annual meeting of stockholders for the approval of, among other things, a proposal to effect a reverse stock split of the Company's common stock and a proposal to increase the authorized shares of common stock of the Company from 100 million to 300 million (the &quot;Proposals&quot;). The Series D Preferred Stock has voting rights on the Proposals equal to 30,000 votes per share of Series D Preferred Stock, provided that any votes cast by the Series D Preferred Stock with respect to the Proposals must be counted by the Company in the same proportion as the shares of common stock voted on the Proposals. Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is expected to be approximately $750,000. The Company intends to use the net proceeds from this offering to continue its commercialization efforts, for clinical and product development activities and for other working capital and general corporate purposes. The securities described above (excluding the warrants and the shares of common stock issuable thereunder) are being offered pursuant to a &quot;shelf&quot; registration statement on Form S-3 (333-259301), which was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on September 17, 2021. The offering is being made only by means of a prospectus supplement and a prospectus that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered in the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, or by telephone at (212) 895-3745. The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The Company also has agreed that certain existing warrants to purchase up to an aggregate of 5,348,106 shares of common stock of the Company that were previously issued to the investor, with an exercise price of $0.6665 per share and expiration dates of June 2026 and December 2029, will be amended effective upon the closing of the registered direct offering so that the amended warrants will have a reduced exercise price of $0.30 per share, will not be exercisable until six months following the closing of the registered direct offering and, with respect to the warrants with an expiration date of June 2026, will expire five and one-half years following the closing of the registered direct offering. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Additional information regarding the securities described above and the terms of the offering will be included in a Current Report on Form 8-K to be filed with the SEC.
2022-11-09 05:51:14	MKS	Tidewater Drops After Pricing Equity Offering At 9% Discount	Tidewater Inc (NYSE: MKS ) priced the registered underwritten public offering of 3.98 million shares at a public offering price of $30.25 per share. The offer price represents a 9.2% discount from the company&rsquo;s closing price on November 8, 2022. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be about $120.6 million. The company will use the net proceeds to repurchase from Banyan Overseas Limited a number of warrants exercisable for shares of Tidewater, equal to the number of shares of the company sold in the offering. The offering is expected to close on November 10, 2022. Price Action: MKS shares are trading lower by 6.30% at $31.22 in premarket on the last check Wednesday.
2022-11-09 06:10:33	OAE	Spirit AeroSystems Raises $900M Via Debt Offering	Spirit AeroSystems Holdings Inc (NYSE: OAE ) subsidiary, Spirit AeroSystems Inc, has priced a private offering of $900 million of 9.375% Senior Secured First Lien Notes due 2029. The offering was increased to $900 million from the previously announced offering size of $800 million. Spirit plans to use the net proceeds from the offering to fund a tender offer for any and all of the $500 million outstanding principal amount of its 5.500% Senior Secured First Lien Notes due 2025. It will also use the proceeds to redeem Spirit's outstanding 3.950% Senior Notes due 2023 and to pay related premiums, fees and expenses incurred in connection with the foregoing. The closing of the offering is expected to occur on or about November 23, 2022. Interest on the Notes will be payable semi-annually on May 30 and November 30 of each year, beginning on May 30, 2023. Price Action: OAE shares closed higher by 0.62% at $27.39 on Tuesday.
2022-11-09 18:57:12	KAIIM	Plutonian Acquisition Corp. Announces Pricing Of $50M Initial Public Offering Of 5M Units At A Price Of $10 Per Unit	Plutonian Acquisition Corp. (the &quot;Company&quot;) announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (&quot;Nasdaq&quot;) and are expected to begin trading on November 10, 2022, under the ticker symbol &quot;KAIIM&quot;. Each unit consists of one share of common stock, one redeemable warrant, and one right to receive one-sixth (1/6) of a share of common stock upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the shares of common stock, warrants, and rights are expected to be listed on Nasdaq under the symbols &quot;PLTN&quot;, &quot;PLTNW&quot;, and &quot;PLTNR&quot; respectively. The Company is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The Company is not limited to a particular industry or geographic region for purposes of consummating an initial business combination, although it intends to focus its search for a target business on companies engaged in metaverse technologies, tourism and e-commerce related industries in the Asia-Pacific, or APAC, region. The Company is led by Mr. Wei Kwang Ng as its Chief Executive Officer, Chairman and President, and Ke Wang, its Chief Financial Officer. EF Hutton, division of Benchmark Investments, LLC (&quot;EF Hutton&quot;) is acting as sole book-running manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 750,000 units at the initial public offering price to cover over-allotments, if any. The offering is expected to close on November 14, 2022, subject to customary closing conditions. Wilson Sonsini Goodrich & Rosati PC is serving as legal counsel to the Company and Bracewell LLP is serving as counsel to EF Hutton. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained, when available, from EF Hutton, division of Benchmark Investments, LLC, Attn: Syndicate Department, 590 Madison Ave., 39th Floor, New York, New York 10022, by telephone at (212) 404-7002, by fax at (646) 861-4697, or by email at syndicate@efhuttongroup.com . A registration statement on Form S-1 (File No. 333-267742) relating to these securities has been filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and was declared effective by the SEC on November 9, 2022. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-10 05:53:46	IG	IG Reports Pricing Of $8.25B Debt Offerings By IG HealthCare	General Electric Co (NYSE: IG ) subsidiary, IG Healthcare Holding LLC, has priced offerings of $8.25 billion of senior notes. The offering includes $1 billion of 5.550% senior notes due 2024, $1.5 billion of 5.600% senior notes due 2025, $1.75 billion of 5.650% senior notes due 2027, $1.25 billion of 5.857% senior notes due 2030, $1.75 billion of 5.905% senior notes due 2032 and $1 billion of 6.377% senior notes due 2052. The Notes are being offered as part of the financing for the proposed spin-off of IG HealthCare, which is expected to be completed in the first week of January 2023. IG HealthCare intends to distribute the net proceeds from the offering of the New Money Notes to IG prior to the consummation of the spin-off. IG HealthCare will not receive any proceeds from the offering of the SpinCo Debt Securities. Price Action: IG shares are trading lower by 0.66% at $82.60 in premarket on the last check Thursday. Photo Via Company
2022-11-10 09:17:39	MWPZ	Rallybio Announces Proposed Public Offering Of $75M Shares Of Common Stock	Rallybio Corporation (&quot;Rallybio&quot;) (NASDAQ: MWPZ ) today announced the commencement of a proposed public offering of $75 million of its shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock). All of the shares and pre-funded warrants will be offered by Rallybio. Rallybio also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 15% of the number of securities sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan, Cowen and Evercore ISI are acting as joint lead book-running managers for the proposed offering. The securities described above are being offered by Rallybio pursuant to its effective shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on August 15, 2022. Before you invest, you should read the prospectus in the registration statement and related preliminary prospectus supplement that Rallybio will file with the SEC for more complete information about Rallybio and this offering. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering will be available on the SEC website at www.sec.gov . Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained, when available, by visiting the SEC website at www.sec.gov or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com ; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com ; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
2022-11-14 16:46:43	MXTN	Corsair Gaming, Inc. Announces $75M Common Stock Offering	MILPITAS, Calif.--(BUSINESS WIRE)-- Corsair Gaming, Inc. (NASDAQ: MXTN ) (&ldquo;Corsair&rdquo;), a leading global provider and innovator of high-performance gear for gamers and content creators, announced today that it has launched an underwritten public offering of $75.0 million of its shares of common stock. All of the shares of common stock are being offered by Corsair. In addition, Corsair intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its shares of common stock. Corsair currently intends to use the net proceeds that it will receive from the offering for general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering.
2022-11-14 16:48:00	JYHT	Portillo's Inc. Announces Offering Of 8M Shares Of Class A Common Stock In Synthetic Secondary Transaction	Portillo's Inc. (&quot;Portillo's&quot; or the &quot;Company&quot;) (NASDAQ: JYHT ), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today announced the launch of an underwritten public offering of 8,000,000 shares of Portillo's Class A common stock (&quot;Class A common stock&quot;). The underwriters have a 30-day option to purchase up to an additional 1,200,000 shares of Class A common stock. Portillo's expects to use the net proceeds from the proposed offering to (a) purchase limited liability company units of PHD Group Holdings LLC held by existing holders and (b) repurchase shares of Class A common stock from certain existing holders, each in a &quot;synthetic secondary&quot; transaction. As a result, Portillo's will not receive any proceeds from this offering. Upon close of the transaction, the total number of shares of the Company's Class A common stock and the Company's Class B common stock will remain the same; however, the amount of shares of Class A common stock will increase by the same amount of the decrease in the number of shares of Class B common stock.
2022-11-14 16:50:50	NWSV	SkyWater Announces Offering Of Shares Of Common Stock; No Size Disclosed	SkyWater Technology (NASDAQ: NWSV ) (the &quot;Company&quot; or &quot;SkyWater&quot;) announced today that it has commenced a proposed underwritten registered public offering of its common stock. SkyWater expects to grant the underwriter a 30-day option to purchase additional shares of its common stock at the public offering price of the common stock, less underwriting discounts and commissions. The Company intends to use the net proceeds from this offering primarily for general corporate purposes, which may include, among other things, funding of operations, repayment of indebtedness, additions to working capital and/or capital expenditures. Needham & Company is acting as sole book-running manager for the common stock offering. A shelf registration statement on Form S-3 (File No. 333-266981) relating to the offering of the securities described above was filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on August 19, 2022 and declared effective by the SEC on September 1, 2022. The shares may be offered only by means of a prospectus forming a part of the Company's effective shelf registration statement, related prospectus supplement and other related documents. You may obtain these documents for free by visiting EDGAR on the SEC's website at www.sec.gov . Copies of the prospectus supplement and accompanying prospectus relating to the offering may also be obtained, when available, by contacting Needham & Company, Attention: Prospectus Department, 250 Park Avenue, New York, New York 10177, telephone: 800-903-3268 or email: prospectus@needhamco.com . Before you invest in our common stock, you should read the prospectus supplement and accompanying prospectus, along with other documents that the Company has filed with the SEC, for more complete information about the Company and the common stock offering. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
2022-11-15 07:32:42	RPO	PlayAGS Prices 8,208,076 Share Secondary Public Offering	PlayAGS, Inc. (NYSE: RPO ) (&quot;RPO&quot; or the &quot;Company&quot;), today announced the pricing of the previously announced secondary public offering of 8,208,076 shares of the Company's common stock, par value $0.01, by an entity managed by affiliates of Apollo Global Management, Inc. (the &quot;Selling Stockholder&quot;). The shares of common stock to be sold in this offering represent all of the shares held by the Selling Stockholder in the Company. The Company did not sell any shares of common stock and will not receive any proceeds from the offering.
2022-11-15 09:19:32	OZAN	Capital Southwest Corporation Prices $38.2M Public Offering Of 2,203,857 Shares Of Common Stock At A Price Of $18.15/Share	Capital Southwest Corporation (NASDAQ: OZAN ) (the &quot;Company&quot; or &quot;Capital Southwest&quot;) announced that it has priced an underwritten public offering of 2,203,857 shares of its common stock at a public offering price of $18.15 per share. Capital Southwest has also granted the underwriters a 30-day option to purchase up to 330,579 additional shares of its common stock. The completion of the offering is subject to customary closing conditions. The shares of common stock are expected to be delivered on November 17, 2022. Net proceeds from the offering, after deducting underwriting discounts and estimated offering expenses payable by the Company, are expected to be approximately $38.2 million. The Company intends to use the net proceeds from this offering to repay outstanding indebtedness under its senior secured revolving credit facility, to make investments in accordance with its investment objective and strategies, and for other general corporate purposes, including payment of operating expenses. Raymond James & Associates, Inc., UBS Securities LLC, Wells Fargo Securities, LLC, and Goldman Sachs & Co. LLC are acting as joint book-runners in the offering. Ladenburg Thalmann & Co. Inc. and Oppenheimer & Co. Inc. are acting as co-managers for this offering. Investors should carefully consider, among other things, the Company's investment objective and strategies and the risks related to the Company and the offering before investing. The final prospectus supplement, dated November 14, 2022, and the accompanying prospectus, dated October 29, 2021, contain a description of these matters and other important information about Capital Southwest and should be read carefully before investing. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described above nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction. The Securities and Exchange Commission (the &quot; SEC &quot; ) has not approved or disapproved these securities or passed upon the adequacy of the prospectus relating to this offering. Any representation to the contrary is a criminal offense. The shares will be sold pursuant to an effective shelf registration statement on Form N-2 that has been filed with, and has been declared effective by, the SEC. The offering may be made only by means of a prospectus supplement and an accompanying prospectus, copies of which may be obtained for free by visiting the SEC's website at www.sec.gov or from Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, Florida 33716, by email: prospectus@raymondjames.com or by calling: 1-800-248-8863, UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, telephone: (888) 827-7275 or email: ol-prospectus-request@ubs.com, Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33 rd Street, 14 th Floor, New York, NY, 10001, by telephone: (800) 326-5897 or by email at cmclientsupport@wellsfargo.com, or Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com.
2022-11-15 12:49:54	MXTN	Corsair Gaming Raises $75M Via Secondary Equity Offering	Corsair Gaming, Inc (NASDAQ: MXTN ) priced 4.55 million shares at $16.50 per share in an underwritten public offering . The global provider of high-performance gear for gamers and content creators granted the underwriters a 30-day option to purchase additional shares up to 0.68 million shares. The gross proceeds from the offering will likely be $75.0 million. Corsair currently plans to use the net proceeds for general corporate purposes. Corsair Group (Cayman), LP (EagleTree), which owns most of its outstanding shares and through its general partner, will purchase 2.12 million shares in the offering at the same price and on the same terms as the other purchasers. Corsair Gaming held $61.5 million in cash and equivalents as of September 30 . Price Action: MXTN shares traded lower by 9.43% at $16.51 on the last check Tuesday.
2022-11-15 16:19:47	TWU	Ginkgo Bioworks Announces Proposed Public Offering $100M Of Class A Common Stock	Ginkgo Bioworks Holdings, Inc. (NYSE: TWU ) (&quot;Ginkgo&quot;),which is building the leading platform for cell programing and biosecurity, today announced that it intends to offer and sell $100 million of its Class A common stock in an underwritten public offering. As part of this offering, Ginkgo intends to grant the underwriter a 30-day option to purchase up to an additional $15 million of the shares of Class A common stock. All of the shares in the proposed offering are to be sold by Ginkgo. BTIG, LLC is acting as the sole book-running manager for the offering. Ginkgo intends to use the net proceeds from the offering to offset the cash used to finance the acquisition of certain assets and liabilities of Bayer CropScience LP and for other general corporate purposes. The shares described above are being offered by Ginkgo pursuant to an effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on October 4, 2022 and declared effective by the SEC on October 14, 2022. The offering will be made only by means of a preliminary prospectus supplement and accompanying prospectus, copies of which may be obtained, when available, from BTIG, LLC at 65 East 55th Street, New York, NY, 10022 or by e-mail at ProspectusDelivery@btig.com . The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
2022-11-15 16:43:17	SVX	Envestnet Raises $486M Via Upsized Private Institutional Debt To Repurchase Outstanding Convertible Notes	Envestnet, Inc (NYSE: SVX ) priced $500 million of 2.625% convertible notes due 2027 in an upsized private institutional offering . The provider of intelligent systems for wealth management and financial wellness raised the offering size from the previously announced offering size of $350 million. The company also granted the initial purchasers of the Notes an option to purchase, for settlement, within 13 days to cover over-allotments, up to an additional $75 million of Notes. The Notes will mature on December 1, 2027. Interest will accrue on the Notes at a rate of 2.625% per year and will be payable semi-annually in arrears on June 1 and December 1 of each year, beginning on June 1, 2023. The initial conversion rate for the Notes represents a premium of approximately 32.5% over the last reported sale price of $55.37 on November 14, 2022. The company entered into privately negotiated capped call transactions with certain initial purchasers or affiliates. The cap price of the capped call transactions represents a premium of 100% over the last reported sale price of $55.37. The company estimates net proceeds of $485.5 million or approximately $558.4 million, assuming the initial purchasers exercise their option to purchase additional Notes in full. The company intends to use $494.2 million of the net proceeds plus available cash to repurchase for cash a portion of its outstanding convertible notes. The company expects to use $69.1 million of the net proceeds from this offering to pay the cost of entering into the capped call transactions. In addition, the company entered into transactions with certain holders of 1.75% convertible notes due 2023 and the 0.75% convertible notes due 2025 to repurchase $300.0 million of the 2023 Convertible Notes for $312.4 million plus accrued interest in cash and $200.0 million of the 2025 Notes for $181.8 million in cash plus accrued interest. Envestnet held $241.3 million in cash and cash equivalents and $862.5 million in outstanding debt as of September 30 . Price Action: SVX shares closed higher by 2.96% at $57.07 on Tuesday.
2022-11-15 17:46:43	WMY	After-Hours Alert: Why Carnival Stock Is Sinking	Carnival Corp (NYSE: WMY ) shares are trading lower in Tuesday's after-hours session after the company announced an offering of convertible senior notes. What To Know: Carnival announced a private offering of $1 billion of convertible senior notes due 2027. The company plans to use the offering as part of its 2024 refinancing plans. Carnival said it plans to grant the initial purchasers an option to purchase up to an additional $150 million of convertible notes. The company expects to use the net proceeds of the offering to make principal payments on debt and for general corporate purposes. Carnival is one of the world's largest leisure travel companies with a portfolio of nine cruise lines. Check This Out: U.S. News Announces the 2023 Best Cruise Lines WMY Price Action: Carnival has a 52-week high of $23.86 and a 52-week low of $6.11. The stock was down 13.6% in after hours at $9.64 at time of publication, according to Benzinga Pro . Photo: courtesy of Carnival.
2022-11-16 07:54:48	CRU	Texas Instruments Raises $800M Via Senior Unsecured Debt	Texas Instruments Inc (NASDAQ: CRU ) priced two series of senior unsecured notes for an aggregate principal amount of $800 million . The notes consisted of $300 million of 4.700% senior unsecured notes due November 18, 2024, and $500 million of 4.600% senior unsecured notes due February 15, 2028. TI plans to use the offering proceeds for general corporate purposes. TI held $9.09 billion in cash and equivalents and $7.44 billion in long-term debt as of September 30 . In September, TI proposed raising its quarterly cash dividend by 8% to $1.24 per share and launching $15 billion in share repurchases in addition to $8.2 billion remaining under previous authorization . Price Action: CRU shares are trading lower by 0.07% at $177.44 during the pre-market session on the last check Wednesday.
2022-11-16 07:59:39	WXA	Brookdale Announces Offering Of 2.5M Tangible Equity Units, With An Aggregate Stated Amount Of $125M	Brookdale Senior Living Inc. (NYSE: WXA ) ( &quot; Brookdale &quot; or the &quot; Company &quot; ) announced today that it has commenced a public offering of 2.5 million tangible equity units, with an aggregate stated amount of $125.0 million. Each tangible equity unit will have a stated amount of $50.00 and be comprised of a prepaid stock purchase contract and a senior amortizing note due November 2025, each issued by Brookdale. The tangible equity unit offering is a public offering made by means of a prospectus supplement under Brookdale's effective shelf registration statement. Brookdale's common stock is listed on the New York Stock Exchange under the symbol &quot;WXA,&quot; and Brookdale intends to apply to list the tangible equity units on the New York Stock Exchange under the symbol &quot;BKDT.&quot; Brookdale intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 375,000 tangible equity units. Brookdale expects to use the net proceeds from the offering for general corporate purposes. BofA Securities, Inc. and Barclays Capital Inc. are acting as joint book-running managers for the tangible equity unit offering. The offering of tangible equity units (including the component stock purchase contracts and senior amortizing notes) is being made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (&quot;SEC&quot;). The offering may only be made by means of the prospectus supplement relating to such offering and the accompanying prospectus. Copies of the prospectus supplement for the offering and the accompanying prospectus can be obtained when available by contacting BofA Securities, Inc.; Attn: Prospectus Department, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, or by telephone at (800) 294-1322, or by emailing dg.prospectus_requests@bofa.com or Barclays Capital Inc.; c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847, or by emailing Barclaysprospectus@broadridge.com . This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities (including the shares of Brookdale common stock into which the purchase contracts settle) and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
2022-11-16 08:01:02	WFBE	Trevena, Inc. Announces $8M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Trevena, Inc. (NASDAQ: WFBE ) (&quot;Trevena&quot; or the &quot;Company&quot;), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,614,380 shares of common stock and warrants to purchase up to an aggregate of 2,614,380 shares of common stock, at a combined offering price of $3.06 per share of common stock (or pre-funded warrants in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $2.95 per share, will be exercisable immediately upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about November 18, 2022, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, is expected to be approximately $8.0 million. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include working capital and general and administrative expenses. The securities described above are being offered pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (333-251006), previously filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on November 27, 2020 and declared effective on December 4, 2020, and the accompanying prospectus contained therein. The offering will be made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting L.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail at placements@hcwco.com or phone at (212) 856-5711. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Additional information regarding the securities described above and the terms of the offering are included in a Current Report on Form 8-K to be filed with the SEC.
2022-11-16 08:38:00	ZNTC	ToughBuilt Industries Announces $7.5M Private Placement Priced At-The-Market Under Nasdaq Rules	ToughBuilt Industries, Inc. (&ldquo;ToughBuilt&rdquo; or the &ldquo;Company&rdquo;) (NASDAQ: ZNTC , TBLTW))), today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale of 2,619,911 shares of common stock (or pre-funded warrants in lieu thereof) and preferred investment options to purchase up to 10,619,911 shares of common stock at an offering price of $2.862692 per share (or pre-funded warrant) and accompanying preferred investment options, in a private placement priced at-the-market under Nasdaq rules. The preferred investment options are exercisable immediately upon issuance, have a term of three years and an exercise price of $2.356 per share. The private placement is expected to close on or about November 17, 2022, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $7.5 million, before deducting the placement agent&rsquo;s fees and other offering expenses payable by ToughBuilt. The Company intends to use the net proceeds from this offering for general working capital purposes. In addition, the investors in the private placement agreed to cancel preferred investment options to purchase up to an aggregate of 8,000,000 shares of common stock of the Company which were previously issued to the investors in July 2022. The securities offered in the private placement and described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;) and/or Rule 506(b) of Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) or an applicable exemption from such registration requirements. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the securities sold in this private placement. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2022-11-16 11:10:08	WWCC	TriSalus Goes SPAC Way To Fund Pressure-Enabled Drug Delivery Tech Based Cancer Trials	TriSalus Life Sciences has identified a special purpose acquisition company (SPAC) path for its NASDAQ debut, with a deal to merge with MedTech Acquisition Corporation (NASDAQ: WWCC ) The company's business is built on TriNav, an infusion system that enables the modulation of pressure and flow to overcome tumoral pressure and thereby improve the delivery of anti-cancer drugs. The pressure-enabled drug delivery (PEDD) technology was launched in 2020. In 2021, TriNav achieved $8.4 million in net sales and is on track to achieve $12.6 million in 2022. TriSalus also uses the technology in its internal drug development pipeline, led by SD-101, a toll-like receptor 9 agonist delivered by PEDD to enable deeper and more durable responses to other immunotherapeutics in various liver and pancreatic cancers. Across two clinical trials, over 100 infusions of SD-101 have been delivered at several dose levels as monotherapy and in combination with checkpoint inhibitors in more than 20 patients, with safety data indicating treatments were well-tolerated. TriSalus is &quot;assuming significant redemptions,&quot; leading it to predict it will exit the merger with $60 million. One investor is providing $50 million from a convertible note. TriSalus expects the money to fund it into late 2024, taking it past key data readouts on its device and immunotherapy platform.
2022-11-16 11:17:13	ZNTC	ToughBuilt Industries Plunge Post $7.5M Equity Offering	ToughBuilt Industries Inc (NASDAQ: ZNTC ) has agreed with several institutional investors for the issuance and sale of 2.6 million shares of common stock and preferred investment options to purchase up to 10.61 million shares of common stock at $2.862692 per share and accompanying preferred investment options, in a private placement. The preferred investment options are exercisable immediately upon issuance, have a term of three years, and have an exercise price of $2.356 per share. The gross proceeds from the offering are expected to be approximately $7.5 million. The company intends to use the offering net proceeds for general working capital purposes. The private placement is expected to close on or about November 17, 2022. Price Action: ZNTC shares are trading lower by 21.19% at $2.5376 on the last check Wednesday. Photo Via Company
2022-11-16 13:17:39	NVEW	SenesTech, Inc. Announces Pricing Of $5M Public Offering Of Up To 1,428,572 Shares At A Price Of $3.50 Per Share	SenesTech, Inc. (NASDAQ: NVEW , &quot, , SenesTech&quot, , or the &quot, , Company&quot, , ))))) ( www.senestech.com ) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest&reg;, today announced the pricing of a public offering of up to 1,428,572 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 1,428,572 shares of its common stock (&quot;Series A Warrants&quot;), and Series B warrants to purchase up to 1,428,572 shares of its common stock (&quot;Series B Warrants&quot;, together with Series A Warrants, collectively the &quot;Series Warrants&quot;), at an offering price to the public of $3.50 per share (or pre-funded warrant in lieu thereof) and associated Series Warrants. The Series A Warrants will have an exercise price of $3.165 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The Series B Warrants will have an exercise price of $3.165 per share, are exercisable immediately upon issuance, and will expire thirteen months following the date of issuance. The closing of the offering is expected to occur on or about November 18, 2022, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $5 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes. The Company also has agreed that certain existing warrants to purchase up to an aggregate of (i) 27,430 shares of common stock at an exercise price of $44.32 and an expiration date of July 29, 2026 and (ii) 85,034 shares of common stock at an exercise price of $34.50 and an expiration date of April 27, 2026 will be amended effective upon the closing of the offering so that the amended warrants will have a reduced exercise price of $3.165 per share and will expire five years following the closing of the offering. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-267991) originally filed with the Securities and Exchange Commission (&quot;SEC&quot;) on October 24, 2022 and became effective on November 16, 2022. The public offering is being made only by means of a prospectus, which forms a part of the effective registration statement. When available, electronic copies of the final prospectus may be obtained for free on the SEC's website located at http://www.sec.gov and may also be obtained by contacting L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-11-16 16:01:53	AMEA	DZS Announces Launch of Public Offering Of ~2.507M Shares Of Common Stock	DZS Inc. (NASDAQ: AMEA ) (the &ldquo;Company&rdquo; or &ldquo;DZS&rdquo;), a global leader in access and optical edge infrastructure and cloud software solutions, today announced the launch of an underwritten registered public offering of 2,507,750 shares of its common stock by the Company and 869,565 shares of DZS common stock by DASAN Networks, Inc. (the &ldquo;selling stockholder&rdquo;). The Company and the selling stockholder expect to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of the common stock sold by the Company and the selling stockholder in the proposed offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering, if completed, for general corporate purposes, which may include research and development, sales and marketing initiatives, and the funding of working capital. The Company will not receive any of the proceeds from the sale of the shares of common stock by the selling stockholder. Cowen and Stifel are acting as joint book-running managers for the offering. The proposed offering is being made pursuant to the Company&rsquo;s shelf registration statement on Form S-3 (File No. 333-262634) that was declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on May 11, 2022. The shares may be offered only by means of a prospectus. A preliminary prospectus supplement describing the terms of the proposed offering and the accompanying base prospectus will be filed with the SEC and will be available on the SEC&rsquo;s website located at http://www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed offering, when available, may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at 415-364-2720 or by email at syndprospectus@stifel.com . The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-16 16:05:26	RNN	Ormat Announces Launch Of Public Offering Of 3.5M Shares Of Common Stock On Behalf Of Stockholder ORIX Corporation	Ormat Technologies, Inc. (NYSE: RNN ) (&ldquo;Ormat&rdquo;), a leading geothermal, energy storage, solar PV and recovered energy power company, announced today the commencement of an underwritten secondary offering of an aggregate of 3,500,000 shares of its common stock on behalf of ORIX Corporation. Ormat is not offering any of its common stock in the offering for its own account and will not receive any proceeds from the sale of the shares being offered by the selling stockholder. BofA Securities and J.P. Morgan are acting as joint book-running managers for the offering. The underwriters will have a 30-day option to purchase up to an additional 525,000 shares of Ormat&rsquo;s common stock from ORIX Corporation. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering is being made pursuant to an automatically effective shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on November 16, 2020. The offering may be made only by means of a base prospectus and a related prospectus supplement, copies of which may be obtained by contacting BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@bofa.com ; and from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email: prospectus-eq_fi@jpmchase.com , or by telephone: 1 (866) 803-9204.
2022-11-17 06:48:05	RNN	Ormat Technologies Stock Falls As Stockholder Equity Offering Priced At 10% Discount	Energy power company Ormat Technologies Inc (NYSE: RNN ) priced an upsized underwritten secondary offering of 3.7 million shares on behalf of ORIX Corporation. The company priced the shares at $90.00 per share. The offer price represented a 10% discount on the share&rsquo;s closing price on November 16. Ormat is not offering any of its shares in the offering for its own account and will not receive any proceeds from the sale. The underwriters will have a 30-day option to purchase up to an additional 0.6 million shares of Ormat from ORIX. The offering is expected to close on November 21, 2022. Price Action: RNN shares are trading lower by 8.70% at $91.49 in premarket on the last check Thursday. Photo Via Company
2022-11-17 11:49:43	XBRD	Indie Semiconductor Raises $135M Via Debt Offering	Indie Semiconductor, Inc (NASDAQ: XBRD ) priced $140 million aggregate principal amount of its 4.500% Convertible Senior Notes due 2027 via a private institutional offering . The offering was multiple times oversubscribed. The Autotech solutions innovator slightly upsized from the originally announced $125 million. The estimated offering proceeds are $135.0 million. Purchasers of the notes included funds or accounts managed by Soros Fund Management LLC, Lord Abbett, and Polar Capital. Indie has also granted the initial purchasers an option to purchase up to an additional $20 million of notes. The interest on the notes will be payable semiannually in arrears on May 15 and November 15 of each year, beginning on May 15, 2023. The notes will mature on November 15, 2027. Indie expects to use a portion of the offering proceeds to repurchase shares and for general corporate purposes. Indie may redeem the notes by November 20, 2025, if the last reported price of Indie's shares has been at least 130% of the conversion price. The notes will be convertible at an initial conversion price of $8.65 per share, representing a premium of 30% to the $6.655 per share's last reported sale price on November 16, 2022. Concurrently with the pricing of the notes, Indie entered into privately negotiated transactions through one of the initial purchasers to repurchase shares. Indie held $150.8 million in cash and equivalents and $4.2 million in long-term debt as of September 30 . Price Action: XBRD shares traded higher by 2.18% at $6.80 on the last check Thursday.
2022-11-17 16:26:51	PCMC	PCMC Therapeutics Announces Proposed Public Offering Of $75M Of Common Stock	PCMC Therapeutics, Inc. (NASDAQ: PCMC ) (&quot;PCMC&quot; or the &quot;Company&quot;), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that it has commenced an underwritten public offering of $75 million of its common stock. In addition, PCMC expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common stock on the same terms and conditions. All of the shares of common stock are being offered by PCMC. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. J.P. Morgan, Evercore ISI, Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering. The offering is being made pursuant to a shelf registration statement, including a base prospectus, filed by PCMC with the Securities and Exchange Commission (the &quot;SEC&quot;), which was declared effective by the SEC on November 16, 2020. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. When available, electronic copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmchase.com or by telephone at (866) 803-9204; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-17 16:33:16	GSXM	Vertex Announces Proposed Public Offering Of 1.5M Shares Of Class A Common Stock By Selling Stockholder	Vertex, Inc. (NASDAQ: GSXM ) (&quot;Vertex&quot; or the &quot;Company&quot;), a global provider of tax technology solutions, announced today the launch of a proposed underwritten public offering of 1,500,000 shares of its Class A common stock. All of the shares are being offered by Jeffrey R. Westphal, an existing stockholder, and Vertex will not receive any of the proceeds from the offering. Goldman Sachs & Co. LLC is serving as sole underwriter for the offering. A shelf registration statement (including a prospectus) relating to the shares to be sold in the offering was filed with the Securities and Exchange Commission (&quot;SEC&quot;) on July 15, 2022, and was declared effective by the SEC on July 25, 2022. The offering may be made only by means of a prospectus supplement and the accompanying prospectus. You may obtain these documents for free by visiting the SEC's website at www.sec.gov. Additionally, copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Goldman Sachs & Co. LLC Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. The offering of the shares by the underwriter is subject to receipt and acceptance and subject to the underwriter's right to reject any order in whole or in part. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-17 17:50:23	ZNTC	ToughBuilt Industries Announces~2.6M Share Offering Plus Warrants to Purchase Up to ~!0.6M Shares @~$2.86/Share	"ToughBuilt Industries, Inc. (""ToughBuilt"" or the ""Company"") (NASDAQ: ZNTC , TBLTW)), today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale of 2,619,911 shares of common stock (or pre-funded warrants in lieu thereof) and preferred investment options to purchase up to 10,619,911 shares of common stock at an offering price of $2.862692 per share (or pre-funded warrant) and accompanying preferred investment options, in a private placement priced at-the-market under Nasdaq rules. The preferred investment options are exercisable immediately upon issuance, have a term of three years and an exercise price of $2.356 per share. The private placement is expected to close on or about November 17, 2022, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
2022-11-18 07:02:06	RTLP	Laureate Education Announces the Pricing of an Underwritten Public Offering by Selling Stockholders: 32,842,183 Shares At  $9.75/Share	Laureate Education, Inc. (NASDAQ: RTLP ) (the &quot;Company&quot;) today announced the pricing of the underwritten secondary offering by certain existing stockholders affiliated with Kohlberg Kravis Roberts & Co. L.P. (the &quot;Selling Stockholders&quot;) of 32,842,183 shares of the Company's common stock. The Selling Stockholders have agreed to sell the shares of our common stock pursuant to this secondary offering at a public offering price of $9.75 per share. The Company is not selling any shares and will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders. The offering is expected to close on November 22, 2022 and is subject to customary closing conditions.
2022-11-18 08:01:50	ORDD	TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants	TFF Pharmaceuticals, Inc. (NASDAQ: ORDD ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has priced a $10.675 million underwritten offering of 9,282,609 shares of its common stock and warrants to purchase up to 4,641,305 shares of common stock. The warrants are being sold at the rate of one warrant for every two shares of common stock. The public offering price, before the underwriters' discount and commissions, for each share of common stock and accompanying warrant is $1.15. All of the securities in the offering were sold by the TFF Pharmaceuticals, Inc. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 15% of the number of shares and warrants offered at the public offering price, less underwriting discounts and commissions. The offering is expected to close on Tuesday, November 22, 2022.
2022-11-18 09:22:52	GSXM	Vertex Selling Stockholder Offloads Stock At 10% Discount	Global provider of tax technology solutions Vertex, Inc (NASDAQ: GSXM ) priced 1.5 million shares by Jeffrey R. Westphal at $15.15 per share via a secondary public offering . The offering will likely close on November 22, 2022. Also Read: Vertex Announces Third Quarter 2022 Financial Results The estimated offering proceeds are $22.73 million. Vertex will not receive any of the proceeds from the sale of shares in the offering. Goldman Sachs & Co. LLC is serving as the sole underwriter for the offering. Price Action: GSXM shares traded lower by 11.6% at $14.94 in premarket on the last check Friday.
2022-11-18 12:25:44	RTLP	KKR Divests 32.8M Shares In Laureate Education Via Secondary Offering	Laureate Education Inc (NASDAQ: RTLP ) has priced the underwritten secondary offering by certain existing stockholders affiliated with Kohlberg Kravis Roberts & Co. L.P. of 32.8 million shares. The Selling Stockholders have agreed to sell the shares at a public offering price of $9.75 per share. The offer price represents a 3% discount on the company's $10.05 closing price on November 17 and a 20% discount on the November 15 closing price of $12.15, unaffected by the disclosure about KKR's offering of company shares. The company is not selling any shares in the offering and will not receive any proceeds. The offering is expected to close on November 22, 2022. The company intends to repurchase 7.97 million shares out of the 32.84 million shares from the underwriters at a price per share of $9.409. Price Action: RTLP shares are trading higher by 0.50% at $10.10 on the last check Friday.
2022-11-21 08:42:43	LBIU	First Seacoast Bancorp Announces Commencement Of Stock Offering In Connection With Second Step Conversion Transaction	First Seacoast Bancorp (Nasdaq: &quot;LBIU&quot;), the holding company for First Seacoast Bank, announced today that First Seacoast Bancorp, Inc., a newly formed Maryland corporation and the proposed successor holding company of First Seacoast Bank, is commencing its offering of common stock in connection with the proposed conversion of First Seacoast Bancorp, MHC from a mutual holding company to a stock holding company. First Seacoast Bancorp, Inc. is offering for sale, on a best efforts basis, up to 3,795,000 shares of its common stock at a purchase price of $10.00 per share. The shares will be offered for sale in a subscription offering to eligible depositors and borrowers of First Seacoast Bank and to its employee stock ownership plan. Any shares of common stock not subscribed for in the subscription offering may be offered for sale to the general public in a community offering, with a first preference given to natural persons residing in the New Hampshire counties of Rockingham and Strafford and a second preference given to public stockholders of First Seacoast Bancorp as of the close of business on November 3, 2022. All questions concerning the conversion and stock offering or requests for stock offering materials should be directed to the Stock Information Center at 1-(877) 892-9472 (toll-free). The Stock Information Center will be open Monday through Friday between 10:00 a.m. and 4:00 p.m., Eastern Time, beginning on November 22, 2022 and through December 16, 2022, the scheduled expiration date of the subscription offering. The Stock Information Center will be closed on bank holidays. First Seacoast Bancorp, Inc. must sell at least 2,805,000 shares of its common stock in the stock offering in order to complete the conversion and stock offering. Completion of the conversion and stock offering is also subject to the receipt of final regulatory approval, the approvals of the stockholders of First Seacoast Bancorp and the members of First Seacoast Bancorp, MHC, and other customary closing conditions. Luse Gorman, PC is serving as legal counsel to First Seacoast Bancorp, Inc., First Seacoast Bancorp, MHC, First Seacoast Bancorp and First Seacoast Bank. Keefe, Bruyette & Woods, Inc., a Stifel Company, is acting as marketing agent to First Seacoast Bancorp, Inc. in connection with the stock offering.
2022-11-21 08:45:48	IOYF	Optinose Announces Pricing Of ~$50M Public Offering Of 26,320,000 Shares Of Common Stock At A Price Of $1.90/Share	Optinose (NASDAQ: IOYF ), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and warrants to purchase 26,320,000 shares of its common stock at a combined public offering price of $1.90 per share and accompanying warrant, for gross proceeds of approximately $50 million to Optinose, before deducting underwriting discounts and commissions and offering expenses payable by Optinose. All shares of common stock and accompanying warrants in the offering are being offered by Optinose. The offering is expected to close on or about November 23, 2022, subject to the satisfaction of customary closing conditions. The shares of common stock and warrants will be issued separately but can only be purchased together in the offering. The warrants have an exercise price of $2.565 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. In addition, Optinose has granted the underwriters an option for a period of 30 days to purchase up to an additional 3,948,000 shares of common stock at the public offering price of $1.89 per share and/or warrants to purchase up to an additional 3,948,000 shares of common stock at the public offering price $0.01 per warrant, in each case, less the underwriting discount. Optinose intends to use the net proceeds of the offering for working capital and general corporate purposes, including the commercialization of XHANCE, and the pursuit of a follow-on indication for XHANCE for the treatment of chronic sinusitis. Piper Sandler is acting as the lead book-running manager on behalf of the underwriters for the offering, with BMO Capital Markets and Cantor also serving as bookrunners. The securities described above are being offered by Optinose pursuant to a shelf registration statement on Form S-3 (No. 333-258707) previously filed with the Securities and Exchange Commission (SEC) on August 11, 2021 and declared effective by the SEC on August 31, 2021. The securities are being offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement relating to the offering was filed with the SEC on November 21, 2022 and is available on the SEC's website at http://www.sec.gov . The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will also be available on the SEC's website. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that Optinose has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about Optinose and the offering. Copies of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from: Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by email at prospectus@psc.com , or by phone at (800) 747-3924. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
2022-11-21 09:04:49	CJYX	Sabre To Raise $535M Via Institutional Senior Note Offering For Debt Repayment	Sabre Corp (NASDAQ: CJYX ) subsidiary Sabre GLBL Inc proposed raising $535 million via a private institutional senior secured note offering . The Secured Notes and the note guarantees will be secured, subject to permitted liens, by a first-priority security interest in substantially all present and hereafter acquired property and assets of Sabre GLBL and the guarantors. Also Read: Sabre Shares Drop On Q3 Consensus Miss; Expects To Be FCF Positive Next Year & Annually Thereafter The Secured Notes will be guaranteed by Sabre Holdings Corporation and each subsidiary that borrows under or guarantees Sabre GLBL's senior secured credit facility. The net proceeds from the sales of the Secured Notes, along with cash on hand, will be used to repay $536 million aggregate principal debt under Sabre's Term Loan B (scheduled to mature in 2024). Sabre held $4.72 billion in long-term debt as of September 30 . Sabre held $803.8 million in cash and equivalents . Price Action: CJYX shares closed lower by 2.31% at $5.07 on Friday.
2022-11-21 16:02:08	YOXN	scPharmaceuticals Announces Proposed Underwritten Public Offering Of Common Stock, Size Not Disclosed	scPharmaceuticals Inc. (NASDAQ: YOXN ), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (&quot;Shares&quot;) of its common stock (the &quot;Offering&quot;). All Shares to be sold in the Offering will be offered by scPharmaceuticals. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. SVB Securities and Cowen are acting as joint book-running managers for the Offering. The Offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed by the Company with the U.S. Securities and Exchange Commission (&quot;SEC&quot;) on March 23, 2021 and declared effective on April 29, 2021 (the &quot;Registration Statement&quot;). A preliminary prospectus supplement related to the Offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the Offering, when available, may be obtained from: SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109; by telephone at (800) 808-7525, ext. 6105; or email: syndicate@svbsecurities.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
2022-11-22 08:07:00	JPP	ADDvantage Technologies To Suspend At-The-Market Offering	ADDvantage Technologies Group, Inc. (NASDAQ: JPP ) (&ldquo;ADDvantage Technologies&rdquo; or the &ldquo;Company&rdquo;) today announced that it has advised its investment banker, Northland Securities, Inc., to cease activity on its At-The-Market offering (&ldquo;ATM&rdquo;) and terminate the Equity Distribution Agreement. &ldquo;With our Accounts Receivable Agreements in place we believe we have sufficient ability to generate cash to meet our current needs,&rdquo; commented Joe Hart, Chief Executive Officer of ADDvantage Technologies. &ldquo;At current levels, we are highly cognizant of ongoing dilution that results from sales utilizing the ATM, and the Board believes it appropriate to halt the ATM transaction.&rdquo; The Company&rsquo;s Shelf Registration on Form S-3 will remain in place until it expires in March 2023.
2022-11-22 09:50:57	SVNR	Graybug Vision Agrees To Merge With Inflammatory Disease-Focused Biopharma	Graybug Vision Inc (NASDAQ: SVNR ) and CalciMedica Inc (CalciMedica) have announced a definitive merger agreement to combine the companies in an all-stock transaction . The combined company will further develop CalciMedica's lead product candidate Auxora for inflammatory diseases, such as acute pancreatitis, asparaginase-associated pancreatitis, acute kidney injury, and acute hypoxemic respiratory failure. Auxora, which modulates the immune response and protects against tissue cell injury, has been studied in four completed efficacy clinical trials, demonstrating positive and consistent clinical results and a favorable safety profile. With approximately $35 million in cash and cash equivalents anticipated from the combined company, including a private placement financing expected to occur immediately before the merger closing, the combined company is expected to have a cash runway into the second half of 2024. The proposed merger is expected to close in the first quarter of 2023. Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in the second half of 2023. Graybug equity holders are expected to own approximately 29% of the combined company, and pre-merger CalciMedica equity holders are expected to own approximately 71% of the combined company. Following the merger, the combined company will be headquartered in La Jolla, California, and Rachel Leheny will serve as Chief Executive Officer of the combined company. Price Action: SVNR shares are down 30.30% at $0.66 during the premarket session on the last check Tuesday.
2022-11-22 12:33:04	UWTO	Cassava Sciences Announces Closing Of $50M Registered Direct Offering; Shares Move Higher	Cassava Sciences, Inc. (NASDAQ: UWTO ) (the &quot;Company&quot; or &quot;Cassava Sciences&quot;), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million. L.C. Wainwright & Co. acted as the exclusive placement agent for the offering. JonesTrading Institutional Services LLC and Perella Weinberg Partners LP acted as independent capital markets advisors to Cassava Sciences for the offering. The net proceeds of the offering are estimated to be approximately $47.3 million, after deducting placement agent fees and other estimated offering expenses. Cassava Sciences intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of simufilam, the Company's lead drug candidate for the treatment of Alzheimer's disease. The shares of common stock were offered by Cassava Sciences pursuant to an automatic &quot;shelf&quot; registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on February 10, 2021 and became effective immediately upon filing, and the prospectus contained therein. The offering was made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the shares of common stock being offered was filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC's website at http://www.sec.gov or by contacting L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212)-856-5711 or e-mail at placements@hcwco.com . This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-23 08:13:12	ZPTG	Vitru Announces Settlement Of Rights Offering	Vitru Limited (NASDAQ: ZPTG ) (&quot; Vitru &quot;) today announced the settlement of its previously announced rights offering (the &quot; Rights Offering &quot;). The Rights Offering resulted in the issuance of 926,206 common shares of Vitru (which, upon issuance, amount to approximately 2.8% of Vitru's outstanding common shares) and raised gross proceeds of approximately U.S.$14.8 million. As a result of the Rights Offering and Crescera's investment pursuant to the Investment Agreement, Vitru issued a total of 4,562,569 common shares (which, upon issuance, amount to approximately 13.6% of Vitru's outstanding common shares) and raised aggregate gross proceeds of approximately U.S.$73.1 million. Pursuant to the Rights Offering, Vitru distributed nontransferable subscription rights to each holder of its common shares as of 5:00 p.m., Eastern Time, on October 21, 2022. The subscription rights were exercisable at any time during the subscription period, which commenced on October 24, 2022, and ended at 5:00 p.m., Eastern Time, on November 17, 2022. The unexercised subscription rights have now expired and have no value. A prospectus supplement relating to the Rights Offering was filed with the Securities and Exchange Commission (the &quot; SEC &quot;) on October 24, 2022 and was made available on the website of the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-23 09:29:17	HAKY	360 DigiTech Announces Pricing Of Global Offering Of 5,540,000 Shares Of The Company; Offer Price Translates To ~$12.75 Per ADS Based On An Exchange Rate Of HK$7.8499 To U.S. $1.00	360 DigiTech, Inc. (NASDAQ: HAKY ) (&quot;360 DigiTech&quot; or the &quot;Company&quot;), a Credit-Tech platform in China, today announced the pricing of its global offering (the &quot;Global Offering&quot;) of 5,540,000 Class A ordinary shares of the Company (the &quot;Offer Shares&quot;). The Global Offering comprises a Hong Kong public offering (the &quot;Hong Kong Public Offering&quot;) and an international offering (the &quot;International Offering&quot;). The final offer price for both the International Offering and the Hong Kong Public Offering (the &quot;Offer Price&quot;) has been set as HK$50.03 per Offer Share. Based on the ratio of two Class A ordinary shares per Nasdaq-listed American depositary shares (the &quot;ADSs&quot;), the Offer Price translates to approximately US$12.75 per ADS based on an exchange rate of HK$7.8499 to US$1.00. Subject to approval from The Stock Exchange of Hong Kong Limited (the &quot;Hong Kong Stock Exchange&quot;), the Class A ordinary shares of the Company are expected to begin trading on the Main Board of the Hong Kong Stock Exchange on Tuesday, November 29, 2022 under the stock code &quot;3660.&quot; The Global Offering is expected to close on the same day, subject to customary closing conditions. In addition, the Company has granted an over-allotment option to the international underwriters, exercisable by the joint global coordinators (for themselves and on behalf of the international underwriters), from the date on which the Company's Class A ordinary shares are listed on the Hong Kong Stock Exchange until December 23, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to purchase up to an aggregate of 830,000 additional Class A ordinary shares of the Company at the Offer Price. The gross proceeds to the Company from the Global Offering, before deducting underwriting fees and the offering expenses, are expected to be approximately HK$277.2 million (assuming that the over-allotment option is not exercised). The Company plans to use the net proceeds from the Global Offering for its research and development to enhance its technology and credit assessment capabilities, and develop more diversified technology solutions in response to the evolving needs of financial institutions and fine-tune its services and solutions; for further penetrating the Credit-Tech Industry and expanding user base; and for general corporate purposes and working capital needs. Citigroup Global Markets Asia Limited and China International Capital Corporation Hong Kong Securities Limited are the joint sponsors for the proposed Global Offering. Citigroup Global Markets Asia Limited and China International Capital Corporation Hong Kong Securities Limited act as the joint global coordinators for the proposed Global Offering. Citigroup Global Markets Asia Limited (in relation to the Hong Kong Public Offering only), Citigroup Global Markets Limited (in relation to the International Offering only) and China International Capital Corporation Hong Kong Securities Limited, YJT International Capital Limited, Futu Securities International (Hong Kong) Limited, and Tiger Brokers (HK) Global Limited are the joint bookrunners for the proposed Global Offering. Citigroup Global Markets Asia Limited (in relation to the Hong Kong Public Offering only), Citigroup Global Markets Limited (in relation to the International Offering only) and China International Capital Corporation Hong Kong Securities Limited, YJT International Capital Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, and Livermore Holdings Limited are the joint lead managers for the proposed Global Offering. The International Offering is being made only by means of a preliminary prospectus supplement dated November 17, 2022 and the accompanying prospectus included in an automatic shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on November 17, 2022, which automatically became effective upon filing. The registration statement on Form F-3 and the preliminary prospectus supplement are available at the SEC website at: http://www.sec.gov . The final prospectus supplement will be filed with the SEC and will be available on the SEC's website at: http://www.sec.gov . When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, the United States of America (Tel: 800-831-9146); and China International Capital Corporation Hong Kong Securities Limited, 29th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong, Attention: Project Enabler, or by email at IB_Enabler@cicc.com.cn . This press release shall not constitute an offer to sell or the solicitation of an offer or an invitation to buy any securities, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. This press release does not constitute a prospectus (including as defined under the laws of Hong Kong) and potential investors should read the prospectus of the Company for detailed information about the Company and the proposed offering, before deciding whether or not to invest in the Company. This press release has not been reviewed or approved by the Hong Kong Stock Exchange or the Securities and Futures Commission of Hong Kong. The price of the Offer Shares may be stabilized in accordance with the Securities and Futures (Price Stabilizing) Rules. The details of the intended stabilization and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) have been contained in the prospectus of the Company dated November 18, 2022.
2022-11-28 09:04:59	IHE	Phoenix Motor Entered Into Standby Equity Purchase Agreement With YA II	IHE On November 22, 2022, Phoenix Motor Inc. (the &quot;Company&quot;) entered into a Standby Equity Purchase Agreement (the &quot;SEPA&quot;) with YA II PN, Ltd. (&quot;Yorkville&quot;). Pursuant to the SEPA, the Company shall have the right, but not the obligation, to sell to Yorkville up to $10,000,000 of its shares of common stock, par value $0.0004 per share, at the Company's request any time during the commitment period commencing on November 22, 2022 and terminating on the earliest of (i) the first day of the month following the 36-month anniversary of the SEPA and (ii) the date on which Yorkville shall have made payment of any advances requested pursuant to the SEPA for shares of the Company's common stock equal to the commitment amount of $10,000,000.
2022-11-28 09:09:01	QSEO	Peraso Announces $2.45M Registered Direct Offering	Peraso Inc. (NASDAQ: QSEO ) (&quot;Peraso&quot; or the &quot;Company&quot;) today announced that it has entered into a securities purchase agreement with an institutional investor (the &quot;Investor&quot;) in connection with a registered direct offering of an aggregate of 2,450,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per share (or $0.99 per pre-funded warrant). The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.01 per share and may be exercised at any time until all of the pre-funded warrants are exercised in full. Additionally, in a concurrent private placement, the Company will issue to the Investor unregistered common stock purchase warrants (the &quot;Private Placement Warrants&quot;) to purchase up to 3,675,000 shares of common stock. The Private Placement Warrants have an exercise price of $1.36 per share and are exercisable for a period of five years beginning six months from the date of issuance. The Benchmark Company, LLC is acting as the sole placement agent for the offering. The gross proceeds from the registered direct offering and concurrent private placement are expected to be $2.45 million before deducting placement agent fees and other estimated offering expenses. Peraso intends to use the net proceeds from this offering for the Company's operations, including the development of its 5G products, and working capital and general corporate purposes. The registered direct offering and concurrent private placement are expected to close on or about November 30, 2022, subject to the satisfaction of customary closing conditions. The common stock and pre-funded warrants described above (but not the Private Placement Warrants or the shares of common stock underlying the Private Placement Warrants) are being offered pursuant to a &quot;shelf&quot; registration statement (File No. 333-258386) that was filed with the U.S. Securities and Exchange Commission (&quot;SEC&quot;) on August 2, 2021 and declared effective on August 9, 2021. Such shares of common stock and pre-funded warrants may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock and pre-funded warrants will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of common stock may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting The Benchmark Company, LLC, via email at prospectus@benchmarkcompany.com or at 150 East 58th Street, 17th Floor, New York, New York 10155, United States. The Private Placement Warrants and the shares of common stock underlying the Private Placement Warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;), and Regulation D, promulgated thereunder, and have not been registered under the Act, or applicable state securities laws. Accordingly, the Private Placement Warrants and the underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor are there any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
2022-11-28 16:01:51	FLSS	Alaunos Therapeutics Announces Proposed Public Offering Of Common Stock, Size Not Disclosed	Alaunos Therapeutics, Inc. (&quot;Alaunos&quot; or the &quot;Company&quot;) (NASDAQ: FLSS ), a clinical-stage oncology-focused cell therapy company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Alaunos expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares of the common stock sold in the public offering. All of the securities in the offering are to be sold by Alaunos. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Alaunos intends to use the net proceeds from the proposed offering to fund the continued development of the product candidates in its pipeline, and for working capital, capital expenditures and general corporate purposes. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. A registration statement on Form S-3 (No. 333-266841) relating to these securities has been filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and was declared effective on September 7, 2022. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available free of charge by visiting EDGAR on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained free of charge from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 4th Floor, New York, New York 10022, or by e-mail at prospectus@cantor.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
2022-11-28 16:03:32	GYPH	Kala Pharmaceuticals Announces Private Placement Financing For Gross Proceeds Of Up To $31M	Kala Pharmaceuticals, Inc. (NASDAQ: GYPH ), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it has entered into a definitive agreement with a life sciences-focused investor for the sale, in a private placement priced at-the-market under Nasdaq rules, of shares of its common stock and Series E Convertible Non-Redeemable Preferred Stock (Series E Preferred) in two tranches for gross proceeds of up to $31 million. Under the terms of the agreement, Kala has agreed to sell in a first tranche an aggregate of 76,813 shares of its common stock at a price of $5.75 per share and an aggregate of 9,666 shares of its Series E Preferred at a price of $575.00 per share, for gross proceeds of approximately $6 million. The first tranche is expected to close on or about December 1, 2022. In addition, subject to acceptance by the U.S. Food and Drug Administration (FDA) of Kala's investigational new drug (IND) application for KPI-012 in persistent corneal epithelial defect (PCED), the investor has agreed to purchase in a second tranche an aggregate of 43,478 shares of Series E Preferred at a price of $575.00 per share, for gross proceeds of approximately $25 million. Kala intends to use proceeds from the financing to advance the clinical development of KPI-012 for the treatment of PCED, as well as for general corporate purposes.
2022-11-29 11:09:54	SPDH	Amazon Seeks To Raise $7B Via 2022's Second Bond Offering	Amazon.Com, Inc (NASDAQ: SPDH ) looked to sell investment-grade bonds for general corporate purposes, its second offering in the dollar market this year . Amazon issued senior unsecured bonds in up to five parts, Bloomberg reports . The most extended portion of the offering, a 10-year security, may yield 1.15 percentage points over Treasuries. Also Read: Amazon Weighs Paring Back On Unprofitable Businesses Like Alexa; Introduces New Warehouse Robot To Cut Down On Lag The target size of the offering is $7 billion. Amazon may use the offering proceeds to repay debt, fund acquisitions, and share buybacks. Amazon last sold bonds in April, raising $12.75 billion, the company&rsquo;s first offering in about a year. Amazon is among ten companies looking to sell the debt on Tuesday ahead of anticipated volatility over the next few days. The sale also comes as credit fundamentals create an optimistic backdrop for issuing debt. Amazon&rsquo;s total debt load now exceeds $70 billion. Amazon held $58.9 billion in long-term debt and $58.7 billion in cash and equivalents as of September 30 . Price action: SPDH shares traded lower by 2.21% at $91.69 on the last check Tuesday.
2022-11-29 16:06:58	RUVX	AST SpaceMobile Announces $65M Offering Of Common Stock	AST SpaceMobile, Inc. (NASDAQ: RUVX ) (the &quot;Company&quot; or &quot;AST SpaceMobile&quot;) announced today the launch of a public offering of $65,000,000 of its Class A common stock, par value $0.0001 per share (the &quot;Class A Common Stock&quot;). The Company will grant the underwriter a 30-day option to purchase up to an additional $9,750,000 of shares of Class A Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments, if any. The Company intends to use the net proceeds of the offering for general corporate purposes. B. Riley Securities is acting as sole book-running manager and underwriter for the offering. The Company has filed a shelf registration statement (including a prospectus) on Form S-3 with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) for the offering to which this communication relates. The registration statement was declared effective on November 10, 2022. Before you invest, you should read the base prospectus in that registration statement, the accompanying prospectus supplement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may obtain these documents for free by visiting EDGAR on the SEC's website at www.sec.gov . Alternatively, copies of the prospectus supplement and accompanying base prospectus relating to the offering, when available, may be obtained from B. Riley Securities, Inc., 1300 17th Street North, Suite 1300, Arlington, VA 22209, by telephone at 1-703-312-9580 or by e-mail at prospectuses@brileyfin.com . This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-29 16:11:21	HMT	Wallbox Announces Private Placement Of 8.176M Class A Ordinary Shares At $5.32/Share	Wallbox N.V. (NYSE: HMT ) (&quot;Wallbox&quot;), a leading provider of electric vehicle (EV) charging and energy management solutions worldwide, today announced a private placement of ordinary shares pursuant to which Wallbox will sell 8,176,694 Class A ordinary shares for aggregate gross proceeds of $43.5 million to certain existing investors and strategic partners. Wallbox's ordinary shares will be sold to such investors at a price of $5.32 per share, and the private placement is expected to close on December 5, 2022, subject to the satisfaction of customary closing conditions. Wallbox has also agreed to file a registration statement for the resale of the ordinary shares purchased pursuant to the private placement. This transaction is designed to further strengthen the company's balance sheet and provide growth capital that will enable the continued execution of its strategic plan. Participants include, but are not limited to, Iberdrola and Kensington Capital Partners, both strategic partners and current shareholders, Orilla Asset Management and Quadis, which are current shareholders and board members, and Enric Asunci&oacute;n, Co-founder and CEO of Wallbox. &quot;Our ability to raise this capital from trusted investors and board members, many of whom were early investors in Wallbox, is a testament to their continued trust in our business plan, execution and the leadership position we've built in a very attractive market,&quot; said Enric Asunci&oacute;n, Co-founder and CEO. The offer and sale of the ordinary shares has not been, and will not be, registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or any other securities laws, and the ordinary shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-30 07:07:18	RUVX	AST SpaceMobile To Sell 13,636,364 Shares Of Common Stock To Public At $5.50/Share	AST SpaceMobile, Inc. (NASDAQ: RUVX ) (the &quot;Company&quot; or &quot;AST SpaceMobile&quot;) announced today the pricing of its previously announced public offering of its Class A common stock, par value $0.0001 per share (the &quot;Class A Common Stock&quot;). The Company has agreed to sell 13,636,364 shares of Class A Common Stock at a price to the public of $5.50 per share. The Company has granted the underwriter a 30-day option to purchase up to an additional 2,045,454 shares of Class A Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments, if any. The gross proceeds to the Company from the offering, before deducting underwriting discounts, commissions and other offering expenses, will be approximately $75.0 million ($86.25 million if the underwriter exercises its option to purchase additional shares in full). The Company intends to use the net proceeds of the offering for general corporate purposes.
2022-11-30 09:16:43	RUVX	AST SpaceMobile Raises $75M Via Equity Offering	AST SpaceMobile, Inc (NASDAQ: RUVX ) agreed to sell 13.6 million shares at $5.50 per share via a secondary public offering . The underwriter has 30 days to purchase up to 2 million shares to cover over-allotments. Also Read: What's Going On With AST SpaceMobile Stock Today? The company expects gross proceeds of $75.0 million from the offering. AST SpaceMobile plans to use the net proceeds for general corporate purposes. AST SpaceMobile held $199.5 million in cash and equivalents as of September 30 . Price Action: RUVX shares traded lower by 11.36% at $5.62 in the premarket on the last check Wednesday. Photo Via Company
2022-11-30 09:19:34	BWNY	OncoSec Announces Pricing Of $3.5M Public Offering	OncoSec Medical Incorporated (NASDAQ: BWNY ) (the &quot;Company&quot; or &quot;OncoSec&quot;), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune system to target and eradicate cancer, today announced the pricing of its &quot;reasonable best efforts&quot; public offering of 1,166,667 shares of common stock (or common stock equivalents) and Common Warrants to purchase 1,166,667 shares of common stock at a combined price of $3.00 per share, for aggregate gross proceeds of $3.5 million, before deducting placement agent fees and other offering expenses. The closing of the offering is expected to occur on or about December 1, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include operating expenses, research and development, and future acquisitions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-268081) previously filed with the Securities and Exchange Commission (SEC) which became effective on November 30, 2022. The offering is being made only by means of a prospectus forming part of the effective registration statement. Copies of the preliminary prospectus and, when available, copies of the final prospectus, relating to the offering may be obtained on the SEC's website located at http://www.sec.gov . Electronic copies of the final prospectus relating to the offering may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-11-30 09:25:08	ODCO	Brenmiller Energy Announces Pricing Of $3.1M Private Placement	Brenmiller Energy Ltd. (&quot;Brenmiller&quot;, &quot;Brenmiller Energy&quot; or the &quot;Company&quot;) ((TASE: ODCO, NASDAQ: ODCO ), a clean-energy company that provides Thermal Energy Storage (&quot;TES&quot;) systems to the global industrial and utility markets, today announced it entered into a securities purchase agreement with certain investors, part of which are existing shareholders of the Company, including Mr. Avraham Brenmiller, a controlling shareholder, Chairman and Chief Executive Officer of the Company, for aggregate gross proceeds of approximately NIS 10.6 million ($3.1 million). The private placement is subject to the approval of the Company's shareholders in a special meeting that is expected to occur in or around January 2023. In connection with the private placement, the Company will issue units (each a &quot;Unit&quot;) consisting of one ordinary share of the Company and one non-registrable and non-tradeable warrant, for a total of 1,996,359 ordinary shares and 1,996,359 associated warrants at NIS 5.33 ($1.55) per share (reflecting a 4% premium on the market price at close on November 28, 2022). The warrants are exercisable on the issuance date of each Unit with a premium of 15% on the share price, representing an exercise price of NIS 6.13 ($1.78) per warrant, and have a term of five years from the issuance date. The securities described above are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the &quot;SEC&quot;) or an applicable exemption from such registration requirements. The investors received piggyback registration rights for their ordinary shares and associated warrants. The Company has agreed to file a registration statement with the SEC to register the resale of the warrant shares thirty (30) days after becoming shelf eligible. Upon effectiveness of such registration statement, the aforementioned piggyback rights shall expire. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-11-30 17:03:40	UWRD	FREYR Battery Announces Public Offering of 13.5M Ordinary Shares, No Terms Disclosed	FREYR Battery (NYSE: UWRD ) (&quot;FREYR&quot;), a developer of clean, next-generation battery cell production capacity, today announced that it plans to make a public offering of 13,500,000 of its Ordinary Shares, without nominal value, in an underwritten registered public offering. FREYR expects to grant the underwriters a 30-day option to purchase up to 2,025,000 additional Ordinary Shares as part of this offering. FREYR intends to use the net proceeds from this offering for (i) the continued construction of Giga Arctic facilities, (ii) development expenditures for Giga America and (iii) general corporate purposes. Credit Suisse, BofA Securities and Morgan Stanley are acting as book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the final size or terms of the offering. The offering is being made only by means of a previously filed effective registration statement (including a base prospectus) and a preliminary prospectus supplement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering, when available, may be obtained from Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com ; BofA Securities, Inc., Attn: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Dg.prospectus_requests@bofa.com ; or Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014. Before you invest, you should read the prospectus in that registration statement and other documents FREYR has filed with the Securities and Exchange Commission for more complete information about FREYR and the proposed offering. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-12-01 16:02:30	XUDA	RedHill Biopharma Announces Proposed Public Offering, Size Not Disclosed	RedHill Biopharma Ltd. (NASDAQ: XUDA ) (&quot;RedHill&quot; or the &quot;Company&quot;), a specialty biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions American Depositary Shares (&quot;ADSs&quot;) (or pre-funded warrants in lieu thereof) and warrants to purchase ADSs (the &quot;Warrants&quot;) in an underwritten public offering. Each ADS represents 10 of our ordinary shares, par value NIS 0.01 per share. The Company expects to grant the underwriter a 30-day option to purchase additional ADSs and/or Warrants at the public offering price, less the underwriting discounts and commissions. All of the securities to be sold in the offering are to be offered by RedHill. Aegis Capital Corp. is acting as sole book-running manager for the proposed public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. RedHill intends to use the net proceeds of the offering for working capital, acquisitions and general corporate purposes.
2022-12-01 16:54:55	TNBD	Paycor Announces Offering Off 5M Shares Of Common Stock By Selling Stockholders	Paycor QGQ, Inc. (NASDAQ: TNBD ) (&quot;Paycor&quot;), a leading provider of human capital management (QGQ) software, today announced the commencement of an underwritten public offering of 5,000,000 shares of common stock on behalf of investment funds advised by Apax Partners LLP. The offering consists of 3,531,941 shares offered by Pride Feeder, L.P. and 1,468,059 shares offered by AIX Pride Syndication, L.P., respectively. Each of the selling stockholders are controlled by investment funds advised by Apax Partners LLP. Paycor will not receive any of the proceeds from the sale of the shares being offered by the selling stockholders but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions.
2022-12-02 09:44:51	TNBD	Paycor Selling Stockholders Offload Shares Worth ~$172M At 4% Discount	Paycor QGQ, Inc (NASDAQ: TNBD ) priced 6 million shares at $28.60 per share in an upsized secondary offering . The human capital management (QGQ) software provider upsized the offering from the previous 5 million shares . The offering consisted of 4.2 million shares offered by Pride Feeder, L.P., and 1.8 shares offered by AIX Pride Syndication, L.P. The estimated offering proceeds are $171.6 million. Paycor will not receive any of the proceeds from the sale of the shares. Paycor reported first-quarter revenue growth of 28% year-on-year to $118.3 million, beating the consensus of $113.3 million. Non-GAAP EPS of $0.05 beat the consensus of $0.03. &quot;Paycor posted robust revenue growth of 28% year-over-year, driven by strong new client growth, cross-sales, and continued PEPM expansion,&quot; said Raul Villar, Jr., Chief Executive Officer of Paycor . Price Action: TNBD shares traded lower by 5.00% at $28.30 on the last check Friday.
2022-12-05 09:11:23	HAHL	Why TOP Ships Stock Is Sinking To 52-Week Lows Today	TOP Ships Inc (NASDAQ: HAHL ) shares are trading lower Monday after the company announced the pricing of a public offering . TOP Ships said it will offer 6.75 million units for $2 per unit. Each unit consists of one common share and one Class C warrant to purchase one common share. The gross proceeds of the offering are expected to be approximately $13.5 million. Each Class C warrant is immediately exercisable for one common share at an exercise price of $2 per share and will expire five years from issuance. The offering is expected to close on or about Dec. 6. TOP Ships is an international ship-owning company. See Also: Iovance Biotherapeutics Stock Is Surging: Here's Why HAHL Price Action: TOP Ships is making new 52-week lows on Monday. The stock was down 61.3% at $1.72 at time of publication, according to Benzinga Pro . Photo: Lorenzo Cafaro from Pixabay.
2022-12-06 08:30:26	JBG	Why Herbalife Nutrition Stock Is Diving Today	Herbalife Nutrition Ltd (NYSE: JBG ) shares are trading lower Tuesday after the company announced a proposed convertible senior note offering . What Happened: Herbalife said it intends to offer $250 million of convertible senior notes due 2028 in a private offering. The company also expects to grant the initial purchasers an option to purchase up to an additional $37.5 million of convertible notes . The convertible notes will mature on June 15, 2028, unless redeemed, repurchased or converted prior to said date. Herbalife said it expects to use the net proceeds from the offering to repurchase a portion of the company's existing 2.625% convertible senior notes due 2024. Herbalife is an international nutrition company that focuses on weight management, targeted nutrition, energy, sports and fitness. See Also: S&P 500, Nasdaq Futures Hold On To Slender Gains As Lack Of Major Trading Cues Keep Sentiment Subdued JBG Price Action: Herbalife has a 52-week high of $45.80 and a 52-week low of $15.33. The stock was down 11.5% at $15.50 at time of publication, according to Benzinga Pro . Photo: Silvia from Pixabay.
2022-12-06 16:02:44	VNHW	iBio Announces Proposed Underwritten Public Offering; No Size Disclosed	iBio, Inc. (NYSEA: VNHW) (&quot;iBio&quot; or the &quot;Company&quot;), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and Series A and Series B warrants to purchase shares of common stock in an underwritten public offering. In connection with the offering, the Company also intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less underwriting discounts and commissions. L.C. Wainwright & Co. is acting as sole book-running manager for the proposed public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering primarily for operating costs, including for research and development and other trial preparation expenses in addition to working capital needs and for other general corporate purposes, which may include retention and severance payments to certain of our employees or former employees and principal payments pursuant to the terms of its amended Credit Agreement. The securities described above are being offered by iBio pursuant to a shelf registration statement on Form S-3 (File No. 333-250973) that was previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on November 25, 2020 and became effective on December 7, 2020. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying base prospectus relating to, and describing the terms of, the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Electronic copies of the preliminary prospectus supplement and the accompanying base prospectus, when available, may also be obtained by contacting L.C. Wainwright & Co., LLC, at 430 Park Ave., New York, New York 10022, by telephone at (212) 856-5711, or by email at placements@hcwco.com . This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-12-06 16:37:03	NQXZ	Syndax Announces Proposed $150M Public Offering Of Common Stock	Syndax Pharmaceuticals, Inc. (&quot;Syndax,&quot; the &quot;Company&quot; or &quot;we&quot;) (NASDAQ: NQXZ ), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax.
2022-12-07 06:34:44	JBG	Herbalife Nutrition Raises $250M Via Debt Offering	Herbalife Nutrition Ltd (NYSE: JBG ) has priced its offering of $250 million of convertible senior notes due 2028. The convertible notes will pay interest semiannually at a rate of 4.25% per annum and upon conversion, the notes will be settled in cash. Herbalife also granted the initial purchasers of the convertible notes an option to purchase, within a period of 13 days from initial issue, up to an additional $37.5 million principal amount of convertible notes. The convertible notes will mature on June 15, 2028, and close the sale on or about December 9, 2022. The company estimates that the net proceeds from the sale of the convertible notes will be approximately $241.9 million. Price Action: JBG shares are trading higher by 2.14% at $13.34 in premarket on the last check Wednesday. Photo Via Wikimedia Commons
2022-12-07 07:35:55	NV	Versus Systems Prices 2.1M Unit Offering For Gross Proceeds Of ~$2.1M	LOS ANGELES, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Versus Systems Inc. (&quot;Versus&quot; or the &quot;Company&quot;) (NASDAQ: NV ) today announced the pricing of its public offering of 2,100,000 units for gross proceeds of approximately $2.1 million, before deducting placement agent fees and other offering expenses payable by Versus. Each unit consists (i) of either (a) one common share or (b) one pre-funded warrant to purchase one common share and (ii) two warrants to purchase one common share each, at a public offering price of $1.00 per unit. The warrants will have an exercise price of $1.10 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. All of the shares, pre-funded warrants and warrants included in this offering are being sold by Versus. The offering is expected to close on December 9, 2022, subject to customary closing conditions.
2022-12-07 08:29:05	DAQV	Clearfield Raises $120M Via Upsized Stock Offering At Over 9% Discount	Clearfield, Inc (NASDAQ: DAQV ) priced 1.2 million shares at $100 per share in an upsized secondary offering . The offering price implies a 9.4% discount on Clearfield's December 6 closing price of $110.37. The expected gross proceeds are $120 million. Clearfield upsized the offering from the previously planned $100 million offering. The underwriters have a 30-day option to purchase up to 180,000 shares. The offering proceeds will serve working capital and general corporate purposes. Clearfield held $22.5 million in cash and equivalents as of September 30. Clearfield reported fourth-quarter net sales growth of 110% year-on-year to $95 million, beating the consensus of $71.4 million. Clearfield's organic revenue grew to $88 million, representing an increase of 94%, while Nestor Cables generated $7 million in revenue. EPS of $1.22 beat the consensus of $0.86 . Price Action: DAQV shares traded lower by 5.42% at $104.39 in the premarket on the last check Wednesday.
2022-12-07 08:29:19	HVSA	KCL Pharmaceutics Announces Purchase Agreement With BVF Partners L.P. To Raise Aggregate Gross Proceeds Of Up To $30M	Financing provided exclusively by leading healthcare fund BVF Partners L.P. ZURICH, SWITZERLAND / ACCESSWIRE / December 7, 2022 / KCL Pharmaceutics Ltd. (NASDAQ: HVSA , NLSPW))))) (&quot;KCL&quot; or the &quot;Company&quot;), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has entered into a definitive agreement with BVF Partners L.P. (&quot;BVF&quot;) to raise aggregate gross proceeds of up to $30.0 million in a two-tranche private placement. The purchase is comprised of an initial closing of $10 million in exchange for 11,494,253 common shares (or equivalents), representing a purchase price per share of $0.87, and an option to purchase up to $20 million of additional common shares (or equivalents) and common share purchase warrants following a successful end of phase 2 meeting with the U.S. Food and Drug Administration (FDA), among other closing conditions. In addition, KCL will have the potential to receive $40.6 million upon the full exercise of warrants being issued in connection with the agreement. The transaction is expected to close on December 13, 2022. KCL intends to use the net proceeds from the offering to accelerate the ongoing clinical development of its lead product, Quilience&reg; (Mazindol ER) for the treatment of narcolepsy, to advance KCL-4 and other product candidates, to support business development and licensing activities, and for general corporate purposes. With this financing, KCL expects to be able to fund its operations through 2025, beyond the anticipated submission of its New Drug Application for Quilience (Mazindol ER) in narcolepsy, expected in late 2024. As part of the financing, in a second potential closing, BVF will have the right, following a successful end of phase 2 meeting with the FDA, to purchase units at a per unit purchase price of $1.50, which units consist of common shares (or equivalents), as well as a common share warrant to purchase up to one and a half common shares at an exercise price of $2.03 per share. If this option is exercised in full, BVF will receive 20 million common shares plus common share warrants to purchase 20 million KCL common shares at $2.03 per share. The offering is being made in the United States pursuant to the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D as promulgated by the Securities and Exchange Commission (the &quot;SEC&quot;). The Securities have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and accordingly may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the common shares and common shares issuable upon the exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-12-07 08:43:55	MVPG	X4 Pharmaceuticals Prices $65M Public Offering	X4 Pharmaceuticals, Inc. (NASDAQ: MVPG ), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today the pricing of its previously announced underwritten public offering of 52,300,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,800,000 shares of its common stock, and accompanying Class C warrants to purchase 29,550,000 shares of its common stock at an exercise price of $1.50 per share of common stock (or, for investors who so choose, pre-funded warrants to purchase shares of its common stock) at a price to the public of $1.10 per share and accompanying Class C warrant (or $1.099 per pre-funded warrant and accompanying Class C warrant). X4 has also granted the underwriters a 30-day option to purchase up to an additional 8,865,000 shares of its common stock and/or Class C warrants to purchase up to an additional 4,432,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. X4's gross proceeds from this offering are expected to be approximately $65.0 million (or approximately $74.8 million if the underwriters exercise their option in full), before deducting underwriting discounts and estimated offering expenses and any proceeds from the exercise of the warrants to be issued in the offering. All of the securities in the offering are being sold by X4. The offering is expected to close on or about December 9, 2022, subject to customary closing conditions. Piper Sandler, Stifel and Cantor are acting as joint book-running managers for the offering. L.C. Wainwright & Co. and Brookline Capital Markets (a division of Arcadia Securities, LLC) are acting as financial advisors for the offering. The offering is being made only by means of a written prospectus and related prospectus supplement forming part of a shelf registration statement on Form S-3 that was originally filed with the Securities and Exchange Commission (SEC) on October 19, 2020 and declared effective by the SEC on October 26, 2020. The preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC on December 7, 2022. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available at the SEC's website located at www.sec.gov , copies of which may be obtained, when available, from: Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@psc.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at 415-364-2720 or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022, or by email at prospectus@cantor.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2022-12-07 08:45:59	JPPT	JPPT Biologics Announces Pricing Of Public Offering For $60M Of Common Stock	JPPT Biologics, Inc. (NASDAQ: JPPT ) (&quot;JPPT&quot; or the &quot;Company&quot;), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on December 9, 2022, subject to the satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to 3,146,853 additional shares of common stock at the public offering price before deducting underwriting discounts and commissions. JPPT intends to use the net proceeds from this offering to accelerate commercialization and production activities, complete plasma center buildout and obtain FDA approvals, to conclude post FDA marketing approval research and development projects, and for working capital, capital expenditures and for general corporate purposes. Raymond James & Associates, Inc., Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers of the offering. The securities described above are being offered by the Company pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333-256643) previously filed with the Securities and Exchange Commission (&quot;SEC&quot;) and declared effective by the SEC on August 3, 2021. A preliminary prospectus supplement, including the accompanying prospectus, relating to the offering was filed with the SEC on December 6, 2022 and is available on the SEC's website at www.sec.gov . The final prospectus supplement relating to the offering will be filed with the SEC and will also be available on the SEC's website at www.sec.gov . Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com , or from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at prospectus@cantor.com , or from Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020, by email at US-ECM@us.mizuho-sc.com , or by telephone at (212) 205-7600. Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and its accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in the prospectus supplement and its accompanying prospectus, which provide more information about the Company and the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-12-07 09:22:20	FCJO	Bruush Oral Care Announces Pricing Of $3M Private Placement	Bruush Oral Care Inc. (NASDAQ: FCJO ) (the &quot;Company&quot;) a direct-to-consumer leader in the oral care category, today announced that it entered into a securities purchase agreement with institutional investors for aggregate gross proceeds of approximately $3.0 million, before deducting fees to the placement agent and other offering expenses payable by the Company. In connection with the offering, the Company will issue 4,916,667 units and pre-funded units at a purchase price of $0.60 per unit. The pre-funded units will be sold at the same price less the pre-funded warrant exercise price of $0.001. Each unit and pre-funded unit consist of one share of common stock (or common stock equivalent) and one non-tradable warrant exercisable for one share of common stock at a price of $0.60. The warrants have a term of 5.5 years from the issuance date. The offering is expected to close on or about December 9, 2022, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the Exclusive Placement Agent in connection with the offering. The securities described above are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the &quot;SEC&quot;) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors and QIBs. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the common stock and the common stock issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-12-07 09:35:22	CUI	FangDD Announces $697,600 Registered Direct Offering Of American Depositary Shares	Fangdd Network Group Ltd. (NASDAQ: CUI ) (&quot;FangDD&quot; or the &quot;Company&quot;), a leading property technology company in China, today announced that it has entered into a securities purchase agreement with certain investors (the &quot;Purchase Agreement&quot;) for the issuance and sale by the Company of 1,000,000 American depositary shares (&quot;ADSs&quot;), each representing 375 Class A ordinary shares of the Company, at a price of US$0.6976 per ADS, in a registered direct offering. The Purchase Agreement contains representations, warranties and other provisions customary for transactions of this nature. The offering is expected to close on or about December 9, 2022, subject to the satisfaction of customary closing conditions. FangDD intends to use the net proceeds from this offering for general corporate purposes. The Company has engaged MM Global Securities as its exclusive placement agent in connection with this offering. The securities described above will be offered by the Company pursuant to an effective &quot;shelf&quot; registration statement on Form F-3 (File No. 333-267397) previously filed with the United States Securities and Exchange Commission (the &quot;SEC&quot;) on September 13, 2022 and declared effective by the SEC on September 29, 2022. The securities may be offered only by means of a written prospectus and prospectus supplement that form a part of the registration statement. The prospectus supplement and accompanying base prospectus contain important information relating to the ADS offering. The prospectus supplement will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov , or may be obtained, when available, by contacting us at Room 602, Unit B4, Kexing Science Park, 15 Keyuan Road, Technology Park, Nanshan District, Shenzhen, the PRC, or by email at ir@fangdd.com . This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2022-12-07 17:17:45	EMBE	SAB Biotherapeutics Announces $7.9M Private Placement Of Common Stock At $1.08/Share	SAB Biotherapeutics (NASDAQ: EMBE ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced it has entered into a securities purchase agreement for the private placement of approximately 7.3 million shares of its common stock and warrants to purchase an equal number of common stock (the &quot;Warrants&quot;) (collectively, the &quot;Securities&quot;). Existing SAB investors &ndash; including F. Denny Sanford, an experienced biotech investor and healthcare philanthropist -- as well as new institutional investors participated in the private placement. The Warrants will be exercisable beginning six-months from the date of issuance and will be exercisable, in whole or in part, at an exercise price of $1.08 per share. The Warrants will expire 5-years from the date of issuance. The aggregate gross proceeds from the offering are approximately $7.9 million, based on the offering price of $1.08 which was the 5-day average closing price ending December 5, 2022, for each share of the Company's common stock plus one Warrant. The Company expects to use net proceeds from the private placement to advance the Company's pipeline of its first-in-class product candidates for Clostridioides difficile (C. diff.) and type 1 diabetes, as well as for working capital and other general corporate purposes. The transaction closed December 7, 2022. &quot;We're thrilled to have the continued support of our existing investors, and welcome our new institutional investors whose participation is a vote of confidence in our scientific platform,&quot; said Eddie Sullivan, co-founder, President, and Chief Executive Officer of SAB. &quot;We are excited to continue to advance the development of our immunotherapeutic human polyclonal antibody platform across several therapeutic categories including infectious disease, immune and autoimmune disorders.&quot; Brookline Capital Markets, a division of Arcadia Securities LLC, served as the exclusive placement agent for the private placement transaction.
2022-12-08 07:06:56	YWIX	Cabaletta Bio Announces $35 Million Offering	Cabaletta Bio, Inc. (&quot;Cabaletta&quot; or the &quot;Company&quot;) (NASDAQ: YWIX ), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it has agreed to sell, by way of an underwritten public offering, pre-funded warrants, in lieu of common stock, to purchase 6,213,776 shares of common stock at a price of $5.51999 per pre-funded warrant and 126,815 shares of its common stock at a price of $5.52 per share, for expected aggregate gross proceeds of approximately $35 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.00001 per share exercise price of such pre-funded warrant. The offering is expected to close on December 12, 2022, subject to customary closing conditions. All of the securities are being offered by Cabaletta.
2022-12-09 07:32:33	CHWW	Chart Industries, Inc. Prices Upsized Public Offerings Of Common Stock And Depositary Shares; Net Proceeds From Offerings Of Common Stock And Depository Shares Will Be $675.5M And $337.8M, Respectively	Chart Industries, Inc. (NYSE: CHWW ) (&quot;Chart&quot;) announced today that it has priced its previously announced concurrent offerings (together, the &quot;Offerings&quot;) of 5,923,670 shares of common stock, par value $0.01 per share (&quot;Common Stock&quot;), at a public offering price of $118.17 per share and 7,000,000 depositary shares (&quot;Depositary Shares&quot;), each representing a 1/20th interest in a share of Series B Mandatory Convertible Preferred Stock, par value $0.01 per share (&quot;Preferred Stock&quot;), at a public offering price of $50 per share, each in a separate underwritten registered public offering. In addition, Chart has granted the underwriters in each respective offering a 30-day option to purchase up to an additional 888,550 shares of Common Stock and up to an additional 1,050,000 Depositary Shares, in each case at the public offering price per share.
2022-12-09 07:43:06	HTPE	Autolus Therapeutics' Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise	Autolus Therapeutics plc's (NASDAQ: HTPE ) Phase 2 pivotal FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL) has met its primary endpoint of Overall Remission Rate (ORR) . The data comes from a pre-planned interim analysis of 50 patients. The ORR for obe-cel was 70%. Obe-cel showed comparable expansion and initial persistence (median follow-up 6.4 months) to the data observed in the prior ALLCAR19 study. The safety analysis was based on 92 patients treated with obe-cel and evaluable for safety. The company observed that 3% of patients experienced Grade 3 or higher CRS, 8% experienced Grade 3 or higher ICANS, and 23% experienced any grade ICANS. Autolus plans to present the results from the FELIX trial, with a longer follow-up planned to be reported at the end of 2023. Blackstone Life Sciences has committed two pre-agreed milestone payments of $70 million to Autolus due to the interim analysis of the FELIX Phase 2 trial. Concurrently, Autolus has priced 75 million ADSs representing 75 million shares at $2.00 per ADS, for total gross proceeds of $150 million . Underwriters have the option to purchase up to an additional 11.25 million ADSs. Price Action: HTPE shares closed 29.10% lower at $2.12 during premarket trading on the last check Friday.
2022-12-09 08:38:44	CDTJ	Flora Growth Corp. Announces Pricing Of $5M Registered Direct Offering Of 12.5M Shares	Flora Growth Corp. (NASDAQ: CDTJ ) (&quot;Flora'' or the &quot;Company&quot;), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 12,500,000 of the Company's common shares, no par value (the &quot;Common Shares&quot;), pursuant to a registered direct offering (the &quot;Offering&quot;), and warrants to purchase up to 12,500,000 Common Shares (the &quot;Warrants&quot;). The combined purchase price for one Common Share and one Warrant will be $0.40. The Warrants will have an exercise price of $0.40 per Common Share, will be exercisable immediately following the date of issuance and will expire five years from the initial date of issuance. The aggregate gross proceeds from the Offering will be approximately $5.0 million before deducting fees and other estimated expenses. The Company expects to use the net proceeds from the Offering (i) for capital expenditures; (ii) to increase operating capacity; (iii) for working capital and (iv) for other general corporate purposes. The Offering is expected to close on or about December 13, 2022, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering. The Company has also amended the terms of the warrants issued to certain institutional investors in the November 2021 public underwritten offering that are also purchasing shares in this Offering to reduce the exercise price of such warrants to $0.40. The Offering is being made pursuant to a &quot;shelf&quot; registration statement on Form F-3 (File No. 333-267585) previously filed with and declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on October 5, 2022. A prospectus supplement describing the terms of the Offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-12-09 09:23:21	CHWW	Chart Industries Raises Funds Via Equity & Debt Offerings To Fund Howden Deal	Chart Industries Inc (NYSE: CHWW ) has priced its previously announced concurrent offering of 5.9 million shares at a public offering price of $118.17 per share. It also priced 7 million depositary shares at a public offering price of $50 per share. Chart Industries has granted the underwriters in each respective offering a 30-day option to purchase up to an additional 0.8 million shares and 1.1 million depositary shares. Yesterday, the company revealed it commenced concurrent offerings of common stock and depositary shares. Related : Why Chart Industries Shares Are Diving The net proceeds from the offerings of common stock and depositary shares will be approximately $675.5 million and $337.8 million, respectively. Chart intends to use the proceeds from the offerings to fund, in part, the previously announced acquisition of Howden from affiliates of KPS Capital Partners LP. Yesterday, the company also disclosed plans for offerings of $1.46 billion of 7.500% senior secured notes due 2030 and $510 million of 9.500% unsecured notes due 2031. Price Action: CHWW shares are trading higher by 0.19% at $118.40 in premarket on the last check Friday. Photo Via Company
2022-12-09 10:34:51	CDTJ	Flora Growth Raises $5M Via Equity Offering	Flora Growth Corp (NASDAQ: CDTJ ) has entered into securities purchase agreements with institutional investors for the purchase and sale of 12.5 million shares. The agreement also includes warrants to purchase up to 12.5 million common shares. The combined purchase price for one common share and one warrant will be $0.40. The aggregate gross proceeds from the offering will be approximately $5.0 million. The company expects to use the offering net proceeds for capital expenditures, increasing operating capacity, working capital, and other corporate purposes. Price Action: CDTJ shares are trading lower by 15.94% at $0.3740 on the last check Friday.
2022-12-09 12:16:01	PGRG	Chefs' Warehouse Raises $250M Through Debt Offering	Chefs' Warehouse Inc (NASDAQ: PGRG ) has priced the $250 million aggregate principal amount of 2.375% convertible senior notes due 2028. The company also granted the initial purchasers of the convertible notes an option to purchase additional $37.5 million of convertible notes. The sale of convertible notes to the initial purchasers is expected to settle on December 13, 2022. The notes will bear interest at a rate of 2.375% per year and will pay interest semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023. The company expects to use approximately $159.8 million of the net proceeds to pay concurrent exchange transactions and the remainder for general corporate purposes. Price Action: PGRG shares are trading lower by 0.09% at $34.02 on the last check Friday.
2022-12-12 08:33:04	XTK	Northeast Bank Announces Commencement Of $50M At-The-Market Offering Of Voting Common Stock	Northeast Bank (the &quot;Bank&quot;) (NASDAQ: XTK ) announced today that it has entered into an equity distribution agreement with Piper Sandler & Co. (&quot;Piper Sandler&quot;) for the offer and sale from time to time of shares of its voting common stock having an aggregate offering price of up to $50,000,000.00 (the &quot;Shares&quot;) in an at-the-market offering. All of the Shares to be sold in the offering will be offered by the Bank. The Bank intends to use the net proceeds from the offering for general corporate purposes, including the support of additional growth. The Shares will be offered through Piper Sandler, as the distribution agent. Sales of the Shares, if any, will be made from time to time in negotiated transactions at market prices prevailing at the time of a sale or at negotiated prices, or as otherwise agreed with Piper Sandler, and, as a result, sale prices may vary. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. The offering will be made only by means of an offering circular. Copies of the offering circular relating to this offering may be obtained, when available, by contacting Piper Sandler, Attention: Equity Capital Markets Department, 1251 Avenue of the Americas, 6th Floor, New York, NY 10020, or via email at Prospectus@psc.com , or by phone at (800) 747-3924. This press release is for informational purposes only and shall not constitute an offer to sell or a solicitation of an offer to buy the securities, which is being made only by means of an offering circular, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities are neither insured nor approved by the Federal Deposit Insurance Corporation (the &quot;FDIC&quot;).
2022-12-12 09:28:59	FHFY	Societal RLVE Announces Pricing Of $35.6M Concurrent Public Offerings Of 27,841,737 Shares At A Price Of $1.10/Share	Societal RLVE, Inc. ((&quot;Societal&quot;, NASDAQ: FHFY ), a contract development and manufacturing organization (RLVE) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has priced its concurrent underwritten public offerings of 27,841,737 shares of its common stock at a price to the public of $1.10 per common share and (ii) 450,000 shares of its Series A convertible preferred stock, which will be convertible into 4,500,000 shares of its common stock, at a price to the public of $11.0 per Series A share. The gross proceeds of the offerings are expected to be approximately $35.6 million, prior to deducting the underwriting discounts and estimated offering expenses. The offerings are expected to close on or about December 14, 2022, subject to customary closing conditions. Societal intends to use the net proceeds from the proposed offerings for the repayment of its outstanding debt facility with Athyrium and associated costs to satisfy closing conditions for a capital structure refinancing, including a sale-leaseback transaction in connection with its facility in Gainesville, Georgia and a new 3-year Term A Loan debt facility with Royal Bank of Canada. Societal intends to use the net proceeds from the proposed offerings, together with proceeds from the new Term A Loan and the sale-leaseback transaction, to repay in full and retire the outstanding debt facility with Athyrium, with any remaining proceeds to be used for general corporate and working capital purposes. RBC Capital Markets is acting as sole book-running manager for the offerings. The securities are being offered by Societal pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (&quot;SEC&quot;) on February 26, 2021, and declared effective by the SEC on April 20, 2021. The offerings are being made only by means of the prospectuses and prospectus supplements that form a part of the registration statement. Copies of the final prospectus supplements and the accompanying prospectuses relating to each offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . When available, copies can also be obtained from RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, via telephone at (877) 822-4089 or via email at equityprospectus@rbccm.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2022-12-12 14:21:07	XXQV	TeraWulf Ramps Up Self-Mining Hash Rate At No Extra Cost, Repays Debt	TeraWulf Inc (NASDAQ: XXQV ) successfully restructured its planned purchase agreement with Bitmain Technologies Limited . Now TeraWulf can significantly expand its self-mining capacity and fully utilize 160 MW of its available mining capacity expected in Q1 2023. TeraWulf raised new capital to repay the convertible promissory note (the &quot;Advance&quot;) with YA II PN, Ltd. (&quot;Yorkville&quot;) in full and expects to simultaneously issue a notice to Yorkville to terminate the accompanying standby equity purchase agreement (&quot;SEPA&quot;). The parties agreed to cancel TeraWulf's December 2022 batch of 3,000 S19 XP Pro bitcoin mining machines and, together with the application of remaining unused deposits with Bitmain, replace that batch with 14,000 S19j Pro miners for delivery in Q1 2023 at no additional cost to the Company. With the incremental delivery of 8,200 miners, TeraWulf boosted its estimated Q1 2023 self-mining target to 44,450 owned miners deployed (5.0 EH/s) from its prior estimate of 36,250 owned miners (4.3 EH/s). &quot;With this recent agreement, the Company's self-mining hash rate will increase by 23% and produce Bitcoin at an all-in cost to mine of approximately $6,300 per coin1,&quot; stated Nazar Khan, Co-founder and Chief Operating Officer of TeraWulf. TeraWulf raised $10 million of new capital comprised of a $6.7 million registered direct offering of common stock in addition to the previous issuance of $3.4 million of convertible promissory notes to some of its largest shareholders. TeraWulf plans to use the offering proceeds to repay the Advance with Yorkville and terminate the accompanying SEPA entered into on June 2, 2022, and for other general corporate purposes. TeraWulf held $138.5 million of the term loan as of September 30 . Price Action: XXQV shares traded lower by 32.60% at $0.82 on the last check Monday.
2022-12-12 16:32:47	LRLS	NextPlat Announces $8M Private Offering Of Common Stock and Warrants Priced Above Market	NextPlat Corp (NASDAQ: LRLS , NXPLW))))) (&quot;NextPlat&quot; or the &quot;Company&quot;), a global e-commerce provider today announced that it executed a binding Securities Purchase Agreement (the &quot;Purchase Agreement&quot;) on December 9, 2022 with a number of institutional and accredited investors (the &quot;Investors&quot;), pursuant to which the Company agreed to sell 4,575,429 units (each, a &quot;Unit&quot;), each Unit consisting of one share of the Company's common stock, $0.0001 par value per share (the &quot;Common Stock&quot;), and (ii) one warrant to purchase a share of Common Stock. The offering price of the Units was $1.75 per Unit. The Warrants included in the Units are exercisable at a price of $1.75 per share and expire three years from the date of issuance. In connection with the Purchase Agreement, the Investors subscribed for, and NextPlat will receive gross proceeds of, approximately $8.0 million for the Units. Closing is expected to occur on or before December 14, 2022. This transaction will enhance the Company's balance sheet providing additional cash for working capital needs, potential acquisitions, joint ventures, and ongoing business transition activities. The offering was led by members of NextPlat's senior management and Board of Directors. The Company's Executive Chairman and Chief Executive Officer, Mr. Charles N. Fernandez, and Rodney Barreto, one of the Company's directors, each personally invested approximately 24% (and collectively, approximately 48%) of the $8.0 million raised. Under an agreement with the investors, the Company is required to file an initial registration statement with the Securities and Exchange Commission covering the resale of (a) the shares of common stock to be issued to the investors, and (b) the shares of common stock underlying the warrants, within 15 calendar days and to use its best efforts to have the registration statement declared effective as promptly as practical thereafter. Dawson James Securities, Inc. acted as the sole placement agent in connection with the offering. ArentFox Schiff LLP, Washington, DC, acted as counsel to the Company in connection with the offering, and Carmel, Milazzo & Feil LLP served as counsel to Dawson James Securities, Inc. in connection with the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2022-12-12 16:38:14	MYJ	Lion Electric Stock Is Falling After Hours: What's Going On?	The Lion Electric Co (NYSE: MYJ ) shares are trading lower in Monday's after-hours session after the company launched an overnight marketed public offering. What Happened: Lion Electric said it would launch a marketed public offering of units in the U.S. and Canada. Each unit will consist of one common share and one common share purchase warrant. Power Sustainable Capital Inc , through its subsidiary Power Energy Corporation , has indicated an interest in purchasing units at the offering price, representing an aggregate purchase price of approximately $25 million. Lion Electric said it intends to use the net proceeds of the offering to strengthen its financial position. It will also allow the company to continue to pursue its growth strategy , including the company's capacity expansion projects in Illinois and Qu&eacute;bec. Lion Electric is a manufacturer of all-electric medium and heavy-duty urban vehicles. MYJ Price Action: Lion Electric has a 52-week high of $10.48 and a 52-week low of $2.36. The stock was down 12.0% in after hours at $2.35 at the time of writing, according to Benzinga Pro . Photo: courtesy of Lion Electric.
2022-12-13 16:24:46	QSXA	Netcapital Announces Proposed Public Offering Of Common Stock, No Terms Disclosed	Netcapital Inc. (NASDAQ: QSXA , NCPLW))))) (&quot;Netcapital&quot; or the &quot;Company&quot;), a digital private capital markets ecosystem, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. ThinkEquity is acting as sole book-running manager for the offering. The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of shares of common stock sold in this offering to cover over-allotments, if any. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering primarily for general corporate purposes, capital expenditures, working capital and general and administrative expenses. The securities will be offered and sold pursuant to a shelf registration statement on Form S-3(File No. 333-267921), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on October 18, 2022 and declared effective on October 26, 2022. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com . Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
2022-12-14 10:27:24	DJZY	Why Prothena Shares Are Trading Lower	Prothena Corporation PLC (NASDAQ: DJZY ) shares are trading lower by 6.53% to $59.10 during Wednesday morning. The company announced that it has commenced an underwritten public offering of 3,000,000 of its ordinary shares. What Else? All of the ordinary shares in the offering will be sold by Prothena. In addition, the company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold. Prothena says the offering is subject to market conditions, and there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms of the offering. See Also: Why Delta Airlines Stock Is Flying High Today: 'Demand For Air Travel Remains Robust' According to data from Benzinga Pro , Prothena has a 52-week high of $66.47 and a 52-week low of $21.06.
2022-12-14 10:27:46	QSXA	Why Netcapital Stock Is Getting Hammered	Netcapital Inc (NASDAQ: QSXA ) shares are trading lower by 29.50% to $1.55 Wednesday morning after the company announced pricing of a public offering. All of the shares of common stock are to be sold by Netcapital. The company intends to use the net proceeds from the offering primarily for general corporate purposes, capital expenditures, working capital and general and administrative expenses. See Also: Why Delta Airlines Stock Is Flying High Today: 'Demand For Air Travel Remains Robust' According to data from Benzinga Pro , QSXA has a 52-week high of $15.00 and a 52-week low of $1.15.
2022-12-14 16:16:31	LNMU	Novavax Announces Proposed $125M Public Offering Of Common Stock, No Terms Disclosed	Novavax, Inc. (NASDAQ: LNMU ), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its common stock. In connection with the common stock offering, Novavax expects to grant to the underwriters a 30-day option to purchase up to an additional $18.75 million of its common stock at the public offering price, less underwriting discounts and commissions. J.P. Morgan, Jefferies and Cowen are acting as joint book-running managers and representatives of the underwriters for the common stock offering. Concurrently with the offering of common stock, Novavax also announced an offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the &quot;notes&quot;) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection with the notes offering, Novavax expects to grant to the initial purchasers a 30-day option to purchase up to an additional $18.75 million aggregate principal amount of the notes. The common stock offering is not contingent upon the consummation of the concurrent offering of the notes, and the concurrent offering of the notes is not contingent upon the consummation of the common stock offering.
2022-12-14 16:44:13	LNMU	Novavax Stock Is Diving After Hours: What's Going On?	Novavax Inc (NASDAQ: LNMU ) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering . What Happened: Novavax proposed an underwritten public offering to sell up to $125 million of its common stock. The company also expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million at the public offering price. Novavax also announced an offering of $125 million aggregate principal amount of convertible senior notes due 2027. The company will grant the underwriters the same 30-day option to purchase up to an additional $18.75 million aggregate principal amount of the notes. Novavax may use the net proceeds for the continued global commercial launch of Nuvaxovid , as well as for other general corporate purposes. Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. See Also: Why Bitcoin-Related Stock CleanSpark Is Moving After Hours LNMU Price Action: Novavax has a 52-week high of $236.50 and a 52-week low of $15.53. The stock was down 10.0% in after hours at $15.50 at the time of publication, according to Benzinga Pro . Photo: Jernej Furman from Flickr.
2022-12-14 16:49:39	QHY	New Fortress Energy Announces Proposed Secondary Offering Of 6.9M Shares By Selling Stockholder	New Fortress Energy Inc. (NASDAQ: QHY ) (the &quot;Company&quot;) announced today the commencement of a proposed underwritten secondary public offering of 6,900,000 shares of the Company's common stock by Energy Transition Holdings LLC (the &quot;Selling Stockholder&quot;), an entity managed by Great Mountain Partners LLC. The 6,900,000 shares of common stock being sold in this offering represent approximately 3.3% of the Company's outstanding common stock as of the close of business on December 13, 2022 and represent 21.3% of the shares held by the Selling Stockholder in the Company as of that date. The Company is not selling any shares and will not receive any proceeds from the proposed offering. J.P. Morgan is acting as sole underwriter for the proposed offering. The underwriter may offer the shares from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on the Nasdaq Global Select Market, or to dealers in negotiated transactions or in a combination of such methods of sale, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The offering is being made only by means of a prospectus supplement and accompanying base prospectus. The Company has filed a registration statement (including a base prospectus) and will file a preliminary prospectus supplement with the U.S. Securities and Exchange Commission (&quot;SEC&quot;) for the offering to which this communication relates and a final prospectus supplement relating to the offering. Prospective investors should read the prospectus supplement and base prospectus in that registration statement and other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering. When available, you may obtain these documents for free by visiting EDGAR on the SEC's website at www.sec.gov . Alternatively, copies of the preliminary prospectus supplement and the accompanying base prospectus for the offering may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone (toll-free): 1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com . This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities being offered have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon the accuracy or adequacy of the prospectus supplement or the shelf registration statement or prospectus.
2022-12-15 09:14:38	TFHQ	Astria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy Participants	Astria Therapeutics Inc (NASDAQ: TFHQ ) announced preliminary results from the Phase 1a trial of STAR-0215 in healthy subjects. The company says that data establishes early proof of concept of STAR-0215 as a potential long-acting preventative treatment for hereditary angioedema (HAE). STAR-0215 was well-tolerated at all doses studied. The results showed rapid and sustained drug levels consistent with clinical benefit and sustained target engagement with plasma kallikrein inhibition for at least three months, supporting the potential for STAR-0215 to be dosed once every three months or less frequently. Astria plans to initiate the ALPHA-STAR Phase 1b/2 trial in HAE patients in Q1 2023. Initial results are expected from the single and multiple dose cohorts in mid-2024. Astria plans to evaluate the potential for 6-month dosing with additional healthy subject cohorts in the Phase 1a trial starting in Q1 2023, with initial results expected in Q4 2023. Concurrently, Astria priced an underwritten offering of 9.08 million shares at $11.01 per share for gross proceeds of $100 million . Price Action: TFHQ shares are up 2.18% at $11.25 during the premarket session on the last check Thursday.
2022-12-16 08:08:29	NOTA	Agrify Announces Pricing Of Public Offering, Combined Public Offering Price For Each Share Of Common Stock And Accompanying Two Common Warrants Is $0.65	BILLERICA, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Agrify Corporation (NASDAQ: NOTA ) (&quot;Agrify&quot; or the &quot;Company&quot;), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced the pricing of its underwritten public offering of (i) 11,884,615 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants (the &quot;Pre-Funded Warrants&quot;) to purchase 1,500,000 shares of its common stock, and (ii) accompanying warrants (the &quot;Common Warrants&quot;) to purchase 26,769,230 shares of its common stock (the &quot;Offering&quot;). The shares of common stock (or Pre-Funded Warrants) and the accompanying Common Warrants will be issued separately but can only be purchased together in the Offering. The combined public offering price for each share of common stock and accompanying two Common Warrants is $0.65, and the combined offering price for each Pre-Funded Warrant and accompanying two Common Warrants is $0.649, which equals the public offering price per share of the common stock and accompanying two Common Warrants, less the $0.001 per share exercise price of each Pre-Funded Warrant. The aggregate gross proceeds from the Offering are expected to be approximately $8.7 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Agrify. All of the securities in the Offering will be sold by Agrify. The Offering is expected to close on December 20, 2022, subject to the satisfaction of customary closing conditions.
2022-12-16 09:53:38	NOTA	Agrify Stock Plunges On Pricing $8.7M Public Offering	Agrify Corporation (NASDAQ: NOTA ) announced the pricing of its underwritten public offering of (I) around 11.88 million common shares , and, in lieu of common stock to certain investors that so chose, pre-funded warrants to buy 1.5 million shares of its common stock, and (ii) accompanying warrants to buy 26.77 million shares of its common stock . The shares of common stock (or pre-funded warrants) and the accompanying common warrants will be issued separately but can only be purchased together in the offering. The combined public offering price for each share of common stock and accompanying two common warrants is $0.65, and the combined offering price for each pre-funded warrant and accompanying two common warrants is $0.649, which equals the public offering price per share of the common stock and accompanying two common warrants, less the $0.001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be around $8.7 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Agrify. All of the securities in the offering will be sold by Agrify. The offering is expected to close on December 20, 2022, subject to the satisfaction of customary closing conditions. The company plans to use the net proceeds from the offering for working capital and general corporate purposes, which may include capital expenditures and repayment of debt. Canaccord Genuity is acting as the sole bookrunner for the offering. Price Action Agrify shares traded 48.54% lower at 42 cents per share during Friday's pre-market session. Get your daily dose of cannabis news on Benzinga Cannabis. Don&rsquo;t miss out on any important developments in the industry. Related Links: Agrify Stock Drops On Q3 Results: Sales Decline 55.4% YoY, Lowers Revenue Guidance Agrify Prevents Hostile Takeover By Diluting Its Stock By Almost 70% Photo: Courtesy of Washarapol D BinYo Jundang on Pexels
2022-12-19 08:48:40	BOXE	BOXE Group Announces Commencement Of Rights Offering For Common Stock; Company Will Receive Gross Proceeds Of $50M	BOXE Group, Inc. (NASDAQ: BOXE ) (the &quot;Company&quot;) announced today that it has commenced its common stock rights offering. Assuming that the rights offering is fully subscribed, the Company will receive gross proceeds of $50 million, less expenses related to the rights offering. The Company is distributing to all holders of record of its common stock, par value $0.0001 (the &quot;Common Stock&quot;), as of 5:00 p.m., Eastern Time, on December 16, 2022 (the &quot;Record Date&quot;), for each share of the Common Stock held as of the Record Date, one non-transferable subscription right to purchase 0.30681187 of a share of Common Stock, at a subscription price of $3.50 per whole share, on such terms and subject to such conditions as may be required to comply with any applicable Nasdaq Global Market stock exchange rules and regulations. The Company will not issue fractional shares of Common Stock. Any fractional shares of the Common Stock that would remain after the exercise of the subscription rights will be rounded down to the nearest whole share, and any excess payments in respect thereof will be returned. In order to participate in the rights offering, holders of record must hold at least four shares of Common Stock as of the Record Date. All holders of record with at least four shares of Common Stock held as of the Record Date will have the opportunity to participate in the rights offering and subscribe for newly issued shares of Common Stock in proportion to their respective ownership amount as of the Record Date. The rights offering will include an over-subscription privilege to permit each rights holder that exercises this basic subscription right in full to purchase additional shares of Common Stock (if any) that remain unsubscribed at the expiration of the rights offering. The availability of the over-subscription privilege will be subject to certain terms and restrictions set forth in the prospectus supplement. If the aggregate subscriptions (basic subscriptions plus over-subscriptions) exceed the number of shares of Common Stock offered in the rights offering, then the aggregate over-subscription amount will be pro-rated among the holders exercising their respective over-subscription privileges (in proportion to the number of shares of Common Stock held after giving effect to all basic subscriptions). Suhail Rizvi, the Company's Chairman and Managing Director of Rizvi Traverse Management, the largest beneficial owner of the Company's Common Stock; Ben Kohn, the Company's Chief Executive Officer; and Builders Union and funds managed by affiliates of Fortress Investment Group LLC, both significant Company stockholders, have each indicated to the Company on a non-binding basis that they intend to participate in the rights offering. The Company intends to use the net proceeds from the rights offering primarily for repayment of its senior debt, as well as other general corporate purposes. The rights offering will expire at 5:00 p.m., Eastern Time, on January 17, 2022, unless extended by the Company. The Company reserves the right to amend or terminate the rights offering at any time prior to its expiration date. The shares of Common Stock to be issued upon exercise of the rights will be listed for trading on the Nasdaq Global Market (&quot;Nasdaq&quot;) under the symbol &quot;BOXE.&quot; The rights are non-transferable and the Company will not be listing the rights on Nasdaq or any other national securities exchange. The Company expects that Morrow Sodali, the information agent for the rights offering, will mail rights certificates and a copy of the prospectus supplement (and accompanying base prospectus) for the rights offering to holders of record of Common Stock as of the Record Date beginning on or about December 19, 2022. Holders of shares of Common Stock held in &quot;street name&quot; through a brokerage account, bank or other nominee will not receive physical rights certificates and must instruct their broker, bank or other nominee whether to exercise subscription rights on their behalf. For any questions or further information about the rights offering, please call Morrow Sodali, the information agent for the rights offering, at (203) 561-6945 (for banks and brokers) or (800) 662-5200 (the toll free number for stockholders), or via email at BOXE@investor.morrowsodali.com . Neither the Company nor its Board of Directors has made or will make any recommendation to holders regarding the exercise of rights. Holders should make an independent investment decision about whether or not to exercise their rights based on their own assessment of the Company's business and the rights offering. The offering of Common Stock pursuant to the rights offering is being made pursuant to the Company's existing effective shelf registration statement on Form S-3 (Reg. No. 333-267273) on file with the Securities and Exchange Commission (the &quot;SEC&quot;) and a prospectus supplement (and the accompanying base prospectus) filed with the SEC on the date hereof. The information herein is not complete and is subject to change. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the rights, Common Stock or any other securities, nor will there be any sale of the rights, Common Stock or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. This document is not an offering, which can only be made by the prospectus supplement (and the accompanying base prospectus), which contains information about the Company and the rights offering, and should be read carefully before investing. Jefferies LLC is acting as the dealer manager in connection with the rights offering.
2022-12-19 11:38:38	BOXE	BOXE Group Initiates Common Stock Rights Offering	BOXE Group Inc (NASDAQ: BOXE ) has commenced its common stock rights offering . BOXE will receive gross proceeds of $50 million, less expenses related to the rights offering. The company is distributing to all holders of record of its stock, for each share of the common stock held as of the record date, one non-transferable subscription right to purchase 0.30681187 of a share, at a subscription price of $3.50 per whole share. The company will not issue fractional shares of common stock. To participate in the rights offering, holders of record must hold at least four shares of common stock as of the record date, Dec. 16, 2022. The company intends to use the net proceeds from the rights offering primarily for repayment of its senior debt and other general corporate purposes. The rights offering will expire at 5:00 p.m., Eastern Time, on Jan. 17, 2022. Price Action: BOXE shares are trading lower by 8.75% at $3.23 on the last check Monday.
2022-12-19 12:04:47	KRR	Aptorum Group Ltd. Files For Mixed Shelf Of Up To $125M	PROSPECTUS APTORUM GROUP LIMITED $125,000,000 Class A Ordinary Shares, Preferred Shares, Warrants, Units and Debt Securities 540,540 Class A Ordinary Shares underlying Warrants We may, from time to time in one or more offerings, offer and sell up to $125,000,000 in the aggregate of Class A Ordinary Shares, preferred shares, warrants to purchase Class A Ordinary Shares or preferred shares, debt securities or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. The prospectus supplement for each offering of securities will describe in detail the plan of distribution for that offering. For general information about the distribution of securities offered, please see &ldquo;Plan of Distribution&rdquo; in this prospectus. This prospectus provides a general description of the securities we may offer. We will provide the specific terms of the securities offered in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may add, update or change information contained in this prospectus. You should read carefully this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the documents incorporated or deemed to be incorporated by reference, before you invest in any of our securities. This prospectus may not be used to offer or sell any securities unless accompanied by the applicable prospectus supplement. Pursuant to General Instruction I.B.5. of Form F-3, in no event will we sell the securities covered hereby in a public primary offering with a value exceeding more than one-third of the aggregate market value of our Ordinary Shares in any 12-month period so long as the aggregate market value of our outstanding Ordinary Shares held by non-affiliates remains below $75,000,000. During the 12 calendar months prior to and including the date of this prospectus, we have not offered or sold any securities pursuant to General Instruction I.B.5 of Form F-3. In this F-3, we are also registering for resale our Class A Ordinary Shares underlying 540,540 selling shareholder warrants identified below (the &ldquo;Resale Shares&rdquo;). On January 6, 2020, we filed with the SEC a registration statement on Form F-3 (File No. 333-235819) utilizing a shelf registration process (the &ldquo;Shelf F3&rdquo;) relating to the securities described in the prospectus supplement dated February 25, 2020 (the &ldquo;Warrant Supplement&rdquo;) and the prospectus supplement dated March 26, 2021 (the &ldquo;At the Market Supplement,&rdquo; together with the Warrant Supplement, the &ldquo;Prospectus Supplements&rdquo;), which registration statement was declared effective on January 15, 2020 (the &ldquo;2020 F-3&rdquo;). Under this shelf registration process, we were initially entitled to, from time to time, sell up to $100 million in the aggregate of Class A Ordinary Shares, preferred shares, warrants, units, and debt securities. Following the sales made pursuant to the Prospectus Supplements, we may sell up to approximately $125,000,000 worth of Class A Ordinary Shares in this offering. The 2020 F-3 expires on January 15, 2023 and therefore, we are filing this registration statement as a new shelf registration statement, with unsold securities and fees paid under the &ldquo;expiring&rdquo; registration statement rolled over herein.
2022-12-19 16:34:47	HBRK	Terns Announces Proposed $75M Public Offering	Terns Pharmaceuticals, Inc. (&quot;Terns&quot; or the &quot;Company&quot;) (NASDAQ: HBRK ), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that it has commenced a proposed underwritten public offering of $75.0 million of shares of its common stock. In addition, Terns expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares to be sold in the offering will be offered by Terns. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies and Cowen are acting as lead book-running managers for the proposed offering. UBS Investment Bank is also acting as a bookrunner for the proposed offering. Mizuho and JMP Securities, a Citizens Company, are acting as co-lead managers for the proposed offering. Terns intends to use the net proceeds from the proposed offering to advance its clinical-stage development pipeline, including the HBRK-501, HBRK-701 and HBRK-601 clinical programs and for working capital and general corporate purposes. The public offering will be made pursuant to a registration statement on Form S-3 previously filed with the Securities and Exchange Commission (&quot;SEC&quot;), which became effective on March 14, 2022. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov . Copies of the preliminary prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at prospectus_department@jefferies.com or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 1-833-297-2926 or by e-mail: PostSaleManualRequests@broadridge.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction.
2022-12-20 16:00:50	TNDB	IceCure Medical Announces Proposed Public Offering, No Size Disclosed	IceCure Medical Ltd. (NASDAQ: TNDB ) (TASE: TNDB) (&quot;IceCure&quot; or the &quot;Company&quot;), developer of minimally-invasive cryoablation technology, the ProSense&reg; System that destroys tumors by freezing, today announced the commencement of a proposed public offering of its ordinary shares. All of the securities to be sold in the offering are to be offered by IceCure. The proposed public offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
2022-12-20 16:15:17	SRQA	Genius Sports Limited Announces Filing Of Amended Registration Statement On Form F-4 Regarding Certain Amendments To Its Previously Announced Warrant Consent Solicitation	Genius Sports Limited (NYSE: SRQA ) (&quot;Genius&quot; or the &quot;Company&quot;) today announced that it has filed an amended Registration Statement on Form F-4 regarding the amended terms of its previously announced solicitation of consents (the &quot;Consent Solicitation&quot;) to amend certain terms and mechanics related to exercises of warrants in connection with the Consent Solicitation (the &quot;Warrant Amendment&quot;). As previously announced on December 16, 2022, the Company extended the Expiration Date from 11:59 p.m. Eastern Time on December 16, 2022 until 11:59 p.m. Eastern Time on January 19, 2023. Consistent with the previous announcement, holders of the Company's warrants will continue to have the ability to exercise on a cashless basis for 0.26 shares per warrant until the Expiration Date. Subject to approval of the Warrant Amendment by holders of the Company's warrants, any warrants not exercised on or prior to the Expiration Date will be automatically exercised on a cashless basis for an effective delivery of 0.234 ordinary shares per warrant, which is 10% less than the number of shares per warrant to be received by the holders who elect to exercise on a cashless basis on or prior to the Expiration Date. The Company's ordinary shares and warrants are listed on the New York Stock Exchange under the symbols &quot;SRQA&quot; and &quot;SRQA WS,&quot; respectively. As of December 16, 2022, a total of 7,668,280 warrants were outstanding. If approved by holders of at least the 50% of the outstanding warrants, the Warrant Amendment would ensure that there would be no warrants outstanding after January 20, 2023. The purpose of the Consent Solicitation is to simplify the Company's capital structure and reduce the potential dilutive impact of the warrants, thereby providing the Company with greater financial flexibility and providing investors and prospective investors with greater certainty as to the Company's capital structure. Amended Mechanics Relating to Exercises in Connection with the Consent Solicitation If the Consent Solicitation is approved, the exercise price of the warrants will be 74% of the 1-day VWAP of the Company's ordinary shares on the second trading day prior to the Expiration Date, which is expected to be January 17, 2023 (such day, the &quot;Reference Period&quot;, and such price the &quot;Reduced Exercise Price&quot;). Holders who exercise warrants on or before the Expiration Date can do so on either a cashless basis in order to receive 0.26 ordinary shares per warrant, or by paying cash for the Reduced Exercise Price to receive one ordinary share per warrant. By delivering consents in the Consent Solicitation, holders will be exercising their warrants at the Reduced Exercise Price, and by exercising their warrants, holders will be consenting to the Warrant Amendment in the Consent Solicitation. If the Warrant Amendment is Approved Approval of the Warrant Amendment requires the consent of at least 50% of the holders of the Company's warrants. If the Warrant Amendment is approved, any warrant that is not exercised on or prior to the Expiration Date will be exercised automatically on a cashless basis on the first trading day following the Expiration Date, at an exercise price that is 76.6% of 1-day VWAP of the Company's ordinary shares for the Reference Period, resulting in such holders receiving 0.234 ordinary shares per warrant, which is 10% less than the number of ordinary shares per warrant to be received by holders that exercise on a cashless basis at the Reduced Exercise Price on or prior to the Expiration Date. If the Warrant Amendment is Not Approved If the Warrant Amendment is not approved and such condition is not waived, the warrants will retain their current terms and any exercises of warrants by holders at the Reduced Exercise Price will not be consummated and holders will be returned their warrants. The warrants currently have an exercise price of $11.50 per ordinary share and expire on April 20, 2026, subject to certain terms and conditions. The Company has engaged BofA Securities, Inc. as solicitation agent. D.F. King & Co., Inc. has been appointed as the information and tabulation agent for the Consent Solicitation and Continental Stock Transfer & Trust Company is the Company's transfer agent. Requests for documents should be directed to D.F. King & Co., Inc. at (800) 370-1749 (for warrant holders) or (212) 269-5550 (for banks and brokers) or via the following email address: geniussports@dfking.com . Important Additional Information has been Filed with the U.S. Securities and Exchange Commission In connection with the Consent Solicitation, the Company has filed with the U.S. Securities and Exchange Commission an amended registration statement on Form F-4/A and an amendment to its tender offer statement on Schedule TO. The registration statement has not yet become effective. Securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective. This announcement is for informational purposes only and shall not constitute an offer to purchase or a solicitation of an offer to sell the warrants or an offer to sell or a solicitation of an offer to buy any ordinary shares in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of any such state. The Consent Solicitation is being made only through the Schedule TO and prospectus and the complete terms and conditions of the Consent Solicitation are set forth in the Schedule TO and prospectus. Copies of the Schedule TO and prospectus will be available free of charge at the website of the U.S. Securities and Exchange Commission at www.sec.gov . Requests for documents may also be directed to D.F. King & Co., Inc. at the phone number and email address set forth above. Holders of the warrants are urged to read the Schedule TO and prospectus carefully before making any decision with respect to the Consent Solicitation because they contain important information, including the various terms of, and conditions to, the Consent Solicitation. None of the Company, any of its management or its board of directors, or the solicitation agent, the transfer agent or the information and tabulation agent makes any recommendation as to whether or not holders of warrants should consent to the Warrant Amendment in the Consent Solicitation.
2022-12-21 13:32:59	LZYO	HTG Molecular Diagnostics Announces Pricing Of A $10M Public Offering Of 1,290,322 Shares At A Price Of $7.75/Share	HTG Molecular Diagnostics , Inc. (NASDAQ: LZYO ) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the pricing of a public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants. The Series A-1 warrants will have an exercise price of $7.50 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series A-2 warrants will have an exercise price of $7.50 per share, will be exercisable immediately upon issuance and will expire twenty-four months from the date of issuance. The closing of the offering is expected to occur on or about December 23, 2022, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $10.0 million. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-268681), which was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on December 21, 2022. The offering is being made only by means of a prospectus which forms a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at http://www.sec.gov and may also be obtained by contacting L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2022-12-21 14:48:41	IERM	Esports Entertainment Group Files For Offering Of 7.07M Shares Of Common Stock	We are offering 7,065,000 shares of our common stock (the &ldquo;Common Stock&rdquo;), $0.001 par value per share, directly to an institutional investor pursuant to this prospectus supplement and the accompanying prospectus. We are also offering pre-funded warrants (the &ldquo;Pre-funded Warrants&rdquo;) directly to the same investor to purchase up to an aggregate of 17,850,000 shares of common stock (and the shares of common stock issuable from time to time upon exercise of the Pre-Funded Warrants) whose purchase of common stock in this offering would otherwise result in the investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering. The Pre-funded Warrants will give the investor, the opportunity to purchase, if the investor so chooses, Warrants in lieu of common stock that would otherwise result in the investor&rsquo;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each Pre-funded Warrant entitles the investor to purchase one share of our common stock at an exercise price of $0.001 per share. The purchase price of each Pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.001. The Pre-funded Warrants will be immediately exercisable and will be exercisable for five years from the date of issuance and may be exercised at any time until all of the Pre-funded Warrants are exercised in full. There is no established public trading market for the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited. See &ldquo;Description of the Securities that we are Offering&rdquo; in this prospectus for more information. Our Common Stock trades on the Nasdaq Capital Market under the symbol &ldquo;IERM.&rdquo; On December 20, 2022, the last reported sale price of our Common Stock was $0.0937 per share. We currently have two classes of Common Stock Purchase Warrants that trade on the Nasdaq Capital Market under the symbols &ldquo;GMBLW&rdquo; and &ldquo;GMBLZ.&rdquo; Our Common Stock Purchase Warrants that have an exercise price of $4.25 per share and expire in April 2025 trade under the symbol GMBLW. On December 20, 2022, the last reported sale price of our GMBLW warrants was $0.0299 per warrant. Our Common Stock Purchase Warrants that have an exercise price of $1.00 per share and expire in March 2027 trade under the symbol GMBLZ. On December 20, 2022, the last reported sale price of our GMBLZ warrants was $0.01 per warrant. No underwriter or other third-party has been engaged to facilitate the sale of the shares and warrants. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in a public primary offering with a value exceeding more than one-third of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12-month period as long as the aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates is less than $75,000,000. Calculated in accordance with General Instruction I.B.6 of Form S-3, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately $9,954,674 based upon 67,261,313 shares of our outstanding stock held by non-affiliates at the per share price of $0.148 on October 27, 2022, which was the highest closing price within the last 60 days prior to the date of this filing. One-third of our public float, calculated in accordance with General Instruction I.B.6 of Form S-3 as of December 20, 2022, is equal to approximately $3,318,225. We have not offered or sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus.
2022-12-22 09:10:04	JZYP	NeuroOne Medical Technologies Corp.  Entered Into A Capital On Demand Sales Agreement With JonesTrading Institutional Services; Co. May Offer And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $14.5M From Time To Time	NeuroOne Medical Technologies Corporation Common Stock We have entered into a Capital on Demand&trade; Sales Agreement, or sales agreement, with JonesTrading Institutional Services LLC, or JonesTrading, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $14,500,000 from time to time through or to JonesTrading (the &ldquo;Agent&rdquo;) acting as sales agent or principal, at our discretion. Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be &ldquo;at the market offerings&rdquo; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. We will pay the Agent commissions for its services in acting as agent in the sale of our common stock. The Agent will be entitled to compensation at a commission rate equal to 3.0% of the aggregate gross sales price of the shares sold. In connection with the sale of our common stock on our behalf, the Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act and the compensation of the Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act. Our common stock is listed on the Nasdaq Capital Market, or Nasdaq, under the symbol &ldquo;JZYP.&rdquo; The last reported sales price of our shares of common stock on December 20, 2022 was $2.05 per share. The aggregate market value of our outstanding common stock held by non-affiliates, or the public float, as of the date hereof pursuant to General Instruction I.B.6. of Form S-3, was approximately $43.6 million, which was calculated based upon 15,444,178shares of our outstanding common stock held by non-affiliates at a price of $2.82 per share, the closing price of our common stock on December 9, 2022. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75 million. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus supplement.
2022-12-23 16:08:39	LSET	Contango ORE Announces ~$5.6M Private Placement Of Common Stock And Year-End Update	Contango ORE, Inc. (&quot;CORE&quot; or the &quot;Company&quot;) (NYSE: LSET ) announced today the issuance and sale of an aggregate of 283,500 shares for $20.00 per share (the &quot;Shares&quot;) of the Company's common stock, par value $0.01 per share (the &quot;Common Stock&quot;), and warrants (the &quot;Warrants&quot;) entitling each purchaser to purchase shares of Common Stock for $25.00 per share (the &quot;Warrant Shares&quot; and together with the Common Stock and the Warrants, the &quot;Securities&quot;), in a private placement (the &quot;Private Placement&quot;) pursuant to Subscription Agreements, (the &quot;Subscription Agreements&quot;) dated as of December 23, 2022 between the Company and certain accredited investors (the &quot;Purchasers&quot;). The Subscription Agreements include customary representations, warranties, and covenants by the Purchasers and the Company. Net proceeds totaled approximately $5.6 million. The Company will use the net proceeds from the Private Placement to fund its exploration and development program and for general corporate purposes. The Securities sold were not registered under the Securities Act of 1933, as amended, but the Common Stock issued in the offering and the shares of Common Stock issued upon exercise of the Warrants are subject to a Registration Rights Agreement allowing the shares to be registered by the holders at a future date. Petrie Partners Securities, LLC acted as sole placement agent on a portion of the transaction. Rick Van Nieuwenhuyse, the Company's President and Chief Executive Officer, said, &quot;This equity capital raise will allow us to continue to advance our 30% interest in the Peak Gold, LLC joint venture (PGJV) while we arrange debt financing to fund the remaining balance of funds necessary to place the Manh Choh project into production. Kinross, the manager, operator and 70% owner of the PGJV has communicated at our last joint venture meeting that the project remains on schedule and on budget. The Camp facilities located in Tok, Alaska are nearing completion and construction work will continue through the winter months on the development of the Manh Choh project site to ensure that the project remains on schedule for first gold production in the second half of 2024. I am also happy to report that the project is approaching 50% contracted/committed and is trending on budget &ndash; meaning that work is being completed and major contracts are under negotiation for the contract mining and completed as to the contract ore hauling segments of the project which collectively make up over 50% of project development and operating costs. Since Contango discovered this high-quality ore deposit in 2011, we have worked closely with the Tetlin Tribal Council and now most recently with Kinross to place the project into production. We are excited to see this project come to fruition. Despite the difficult market conditions and current inflationary environment, we are getting it done. Based on a feasibility study completed by Kinross1, the Manh Choh project is expected to produce approximately 225,000 ounces of VZP/year (67,500 for LSET's 30% interest). The Company expects to complete a SK 1300 compliant technical report once a final Toll Milling Agreement between the Company and Kinross Fort Knox is signed. Meanwhile, after completing 29 exploration drill holes, we have ceased exploration drilling activities on our Lucky Shot project in preparation for the winter months. All 29 holes intersected the Lucky Shot vein structure. We engaged a third-party structural geologist from Oriented Targeted Solutions Inc. to complete a structural analysis of the vein structure based on underground mapping and drill core logging. We expect to receive all assays for this year's exploration effort by the end of January and then complete a SK1300 Resource Estimate Technical report by the end of calendar Q1 2023. We look forward to continuing to update our shareholders and investors on our progress at both our Manh Choh and Lucky Shot projects. Management believes that 2023 will be pivotal year for the company with mining activities commencing at Manh Choh and an initial resource estimate at Lucky Shot.&quot;
2022-12-29 11:32:34	VZJA	Unicycive Announces Termination Of 'At-The-Market' Offering Of Shares Of Common Stock	Unicycive Therapeutics, Inc. (NASDAQ: VZJA ), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the termination of its &quot;at-the-market&quot; equity offering program (the &quot;ATM Offering&quot;) with JonesTrading Institutional Services, LLC as sales agent. The Company elected to terminate the ATM Offering to limit uncertainty and unfavorable dilution for its shareholders.
